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OST opioid substitution therapy
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RR residential rehabilitation
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Glossary
a
The use of bold with upper case indicates a term that is also defined in this glossary.
Abuse liability
The propensity of a particular Psychoactive substance to be susceptible to abuse. 
It is defined in terms of the relative probability that use of the substance will lead to
social, physical or psychological problems for an individual or society.
See also Dependence potential, Drug abuse and Harmful use. 
Addiction
Repeated use of a Psychoactive substance or substances, to the extent that the user
(referred to as an addict) is periodically or chronically intoxicated, shows a compulsion 
to take the preferred substance (or substances), has great difficulty in voluntarily ceasing
or modifying Substance use, and exhibits determination to obtain psychoactive
substances by almost any means. Typically, Tolerance is prominent and a Withdrawal
syndrome frequently occurs when substance use is interrupted. The life of the addict
may be dominated by substance use to the virtual exclusion of all other activities and
responsibilities. The term addiction also conveys the sense that such substance use 
has a detrimental effect on society, as well as on the individual. Addiction is a term of
long-standing and variable usage. It is regarded by many as a discrete disease entity, a
debilitating disorder rooted in the pharmacological effects of the Drug, which is often
progressive. Addiction is not a diagnostic term in the International Classification of
Diseases 10th revision (ICD-10), but continues to be very widely employed by
professionals and the general public.
The term is often used interchangeably with Dependence.
Addictive
Causing, or tending to cause, Addiction. Different Psychoactive drugs have different
levels of addictiveness (or Dependence potential); these are outlined in Appendix 2.
Alcoholics Anonymous, AA
A Mutual-help movement for individuals who are dependent on, or are recovering
from dependence on, alcohol. Participants support each other in recovering from, or
maintaining recovery from, their dependence. It uses a 12-step programme based on a
non-denominational spiritual approach, with an emphasis on mutual aid and support.
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a Adapted from World Health Organization (2004) Lexicon of alcohol and drug terms. Geneva: World Health Organization; 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Online glossary (www.emcdda.europa.eu, accessed 
1 October 2012) and the United Nations Office on Drugs and Crime (UNODC) (www.unodc.org, accessed 1 October 2012). 
Controlled substances
Psychoactive substances, and their precursors, whose distribution is forbidden by law
or limited to medical and pharmaceutical channels. The substances actually subject to
this control differ between countries. The term is often used to refer to Psychoactive
drugs and precursors covered by international drug conventions. At international and
national levels, controlled Drugs are commonly classified according to a hierarchy of
schedules, reflecting different degrees of restriction of availability.
Craving
A psychological urge to self-administer a Drug. Craving is often associated with
Dependence and a desire to obtain repeated doses of a drug in order to feel 
good or avoid feeling bad. It may also be associated with a physiological
dependence or Tolerance.
Decriminalisation
A process in which the seriousness of a crime or of the penalties the crime attracts is
reduced. More specifically, it refers to the move from a criminal sanction to the use 
of civil or administrative sanctions. An example in relation to Illicit drugs would be 
where possession of cannabis is downgraded from a crime that warrants arrest,
prosecution and a criminal record to an infraction to be punished with a warning or
fine. Decriminalisation is often distinguished from Legalisation, which involves the
complete repeal of any legal definition as a crime, often coupled with a governmental
effort to control or influence the market for the affected behaviour or product.
A distinction is also made between de jure decriminalisation, which involves specific
reforms to the legal framework, and de facto decriminalisation, which involves a similar
outcome, but is achieved through ‘turning a blind eye’ to tolerant policing – effectively
non-enforcement of criminal laws that technically remain in force.
Depenalisation
Depenalisation refers to reforms of Illicit drug control provisions (to either the letter or
practice of the law) that reduce the severity of the penalties imposed upon the offender.
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Dependence
As a general term, dependence is the state of needing or depending on something or
someone for support or to function or survive. As applied to alcohol and other Drugs,
the term includes psychological and physiological aspects. Psychological dependence
involves impaired control over Drug use and a need (Craving) for repeated doses of
the drug, to feel good or avoid feeling bad. Physiological, or physical, dependence is
associated with Tolerance, where increased doses of the drug are required to produce
the effects originally produced by lower doses, and development of Withdrawal
syndrome when the drug is withdrawn. The Diagnostic and Statistical Manual of
Mental Disorders, 4th edition revised (DSM-IV) defines it as:
‘When an individual persists in use of alcohol or other drugs
despite problems related to use of the substance, substance
dependence may be diagnosed. Compulsive and repetitive use
may result in tolerance to the effect of the drug and withdrawal
symptoms when use is reduced or stopped.’
The DSM-IV definition is roughly equivalent to the Dependence syndrome of the 
ICD-10. In the ICD-10 context, the term dependence could refer generally to any of 
the elements in the syndrome.
The term can be used generally with reference to the whole range of Psychoactive
drugs (drug dependence, chemical dependence, substance use dependence), or with
specific reference to a particular drug or class of drugs (eg opioid dependence). While
the ICD-10 describes dependence in terms that are applicable across drug classes,
there are differences in the characteristic dependence symptoms for different drugs.
In biologically oriented discussion, dependence is often used to refer only to 
physical dependence. Dependence or physical dependence is also used in the
Psychopharmacological context in a still narrower sense, referring solely to the
development of withdrawal symptoms on cessation of drug use.
The term is often used interchangeably with Addiction.
See also Dependence syndrome.
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Dependence potential
The propensity of a substance, as a consequence of its pharmacological effects on
physiological or psychological functions, to give rise to Dependence on that substance.
Dependence potential is determined by those intrinsic pharmacological properties that
can be measured in animal and human Drug-testing procedures. It is a term used in
applying international drug treaties.
Dependence syndrome
A cluster of behavioural, cognitive, and physiological phenomena that may develop
after repeated Substance use. Typically, these phenomena include a strong desire 
to take the Drug, impaired control over its use, persistent use despite harmful
consequences, a higher priority given to drug use than to other activities and
obligations, increased Tolerance, and a physical withdrawal reaction when 
Drug use is discontinued (Withdrawal syndrome). In ICD-10, the diagnosis of
dependence syndrome is made if three or more of six specified criteria have been
experienced within a year (see Section 1.1.2, Box 1). Dependence syndrome may
relate to a specific substance (eg heroin), a class of substances (eg opioids), or a
wider range of pharmacologically different substances.
See also Dependence and Tolerance.
Detoxification
A controlled process of providing symptomatic relief to assist patients to complete
withdrawal from a Drug, while minimising the associated adverse effects. In the
context of Illicit drug use, the aim of detoxification is to reverse or reduce
Dependence on and Tolerance to a Psychoactive drug.
Diversion
From a medical perspective, diversion is the inappropriate use of a Drug by those for
whom it has been prescribed, or use by a person for whom the medication was not
prescribed. The term may be used to describe diversion of a shipment of drugs out of
legal channels at wholesale level or, for example, to describe the sale of prescription
methadone to, and use by, an individual for whom it was not prescribed.
The term diversion is also used in a criminal justice context to refer to measures that
take an arrestee out of the criminal justice system and into education, medical
management or another type of intervention.
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Drug
A term of varied usage. In medicine, it refers to any substance with the potential to
prevent or cure disease or enhance physical or mental welfare, and in pharmacology it
refers to any chemical agent that alters the biochemical or physiological processes of
tissues or organisms. Hence, a drug is a substance that is, or could be, listed in a
pharmacopoeia. In common usage, the term often refers specifically to Psychoactive
drugs, and often, even more specifically, to Illicit drugs, of which there is non-medical
use in addition to any medical use. Professional formulations (eg ‘alcohol and other
drugs’) often seek to make the point that caffeine, tobacco, alcohol and other
substances in common non-medical use are also drugs in the sense of being taken, 
at least in part, for their psychoactive effects.
Drug abuse
A term in wide use but of varying meaning. The DSM-IV defines ‘Psychoactive
substance abuse’ as:
‘A maladaptive pattern of substance use leading to clinically
significant impairment or distress, as manifested by one (or
more) of the following, occurring within a 12-month period: 
(1) Recurrent substance use resulting in a failure to fulfil major
role obligations at work, school, or home (eg repeated absences
or poor work performance related to substance use; substance-
related absences, suspensions or expulsions from school; neglect
of children or household); (2) Recurrent substance use in
situations in which it is physically hazardous (eg driving an
automobile or operating a machine when impaired by substance
use); (3) Recurrent substance-related legal problems (eg arrests
for substance-related disorderly conduct); (4) Continued
substance use despite having persistent or recurrent social or
interpersonal problems caused or exacerbated by the effects of
the substance (eg arguments with spouse about consequences
of intoxication, physical fights).’
The term ‘abuse’ is sometimes used disapprovingly to refer to any use at all,
particularly of Illicit drugs. The term is not used in ICD-10 because of its ambiguity
and to avoid including social consequences in the definition of a diagnosis. 
Harmful use is the closest equivalent in ICD-10. In other contexts, abuse has referred
to non-medical or unsanctioned patterns of use, irrespective of consequences. Thus
the definition published in 1969 by the WHO Expert Committee on Drug Dependence
was ‘persistent or sporadic excessive drug use inconsistent with or unrelated to
acceptable medical practice’.
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The term Drug use is often preferred as it is non-judgemental; it has been used
throughout this report. See also Drug misuse.
Drug control
The regulation, by a system of laws and agencies, of the production, distribution, sale
and use of specific Psychoactive drugs (Controlled substances) locally, nationally or
internationally. This is the legal aspect of Drug policy.
Drug misuse
Use of a substance for a purpose that is not consistent with legal or medical guidelines,
as in the non-medical use of prescription medications. This term is often preferred to
Drug abuse, as it is perceived to be less judgemental.
The term Drug use is often preferred as it is even more non-judgemental. This is the
term used throughout this report.
Drug poisoning
A state of major disturbance of consciousness level, vital functions, and behaviour
following the administration in excessive dosage (deliberately or accidentally) of a
Psychoactive substance. In the field of toxicology, the term poisoning is used more
broadly to denote a state resulting from the administration of excessive amounts of any
pharmacological agent, psychoactive or not. In the context of Illicit drug use,
poisoning may occur as a result of adulterants in the drug.
Drug policy
In the context of Psychoactive drugs, the aggregate of policies designed to affect the
supply and/or demand for Illicit drugs, locally or nationally, including education,
treatment, control and other programmes and polices to reduce the harms related to
illicit drug use. In this context, ‘drug policy’ often does not include pharmaceutical
policy (except with regard to diversion to non-medical use), or tobacco or alcohol policy.
In the context of the WHO’s Action Programme on Essential Drugs, ‘national drug
policy’ refers to a national pharmaceutical policy concerning the marketing, availability
and therapeutic use of medicines.
Drug-related problem
Any of the range of adverse accompaniments of Drug use, particularly Illicit drug use.
‘Related’ does not necessarily imply causality. The term was coined by analogy with
alcohol-related problems but is less used, since it is Drug use itself, rather than the
consequence, that tends to be defined as the problem. It can be used to refer to
problems at an individual or societal level. In international Drug control, drug-related
problems are taken into account in setting a level of control for a Controlled
substance through a WHO assessment of the drug’s Dependence potential and
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Abuse liability. ‘Drug problems’ is a possible cognate term, but can be confused with
‘the drug problem’, meaning Illicit drugs as a policy issue.
Drug use
Self-administration of a psychoactive substance. This term has been used throughout
this book rather than Drug abuse or Drug misuse, as it is non-judgemental.
Gateway drug
An Illicit or Licit drug, use of which is regarded as opening the way to the use of
another drug, usually one that is viewed as more problematic.
Harmful use
A pattern of Psychoactive Substance use that is causing damage to health. 
The damage may be physical (eg hepatitis following injection of drugs) or mental 
(eg depressive episodes secondary to heroin use). Harmful use commonly, but not
invariably, has adverse social consequences but social consequences are not necessary
to justify a diagnosis of harmful use. The term was introduced in ICD-10 and
supplanted ‘non-dependent use’ as a diagnostic term. The closest equivalent in other
diagnostic systems (eg DSM-IV) is Substance abuse, which usually includes social
consequences.
Harm reduction
In the context of alcohol or other drugs, harm reduction describes policies or
programmes that focus directly on reducing the harm resulting from the use of alcohol
or other drugs. The term is used particularly of policies or programmes that aim to
reduce the harm without necessarily affecting the underlying Drug use; examples
include Maintenance treatment in Opioid Dependence and needle/syringe
exchanges to counteract needle sharing among heroin users. Harm reduction can be
used either to refer to goals (focusing on the harm rather than on use per se) or to
means (eg needle exchanges, Opioid Substitution Therapy etc); in the latter sense, 
it is often contrasted to the dichotomy of supply reduction and demand reduction.
Hazardous use
A pattern of substance use that increases the risk of harmful consequences for the user.
Some would limit the consequences to physical and mental health (as in Harmful use);
some would also include social consequences. In contrast to Harmful use, hazardous
use refers to patterns of use that are of public health significance, despite the absence
of any current disorder in the individual user. The term is currently used by the WHO but
is not a diagnostic term in ICD-10. It is also commonly used for Licit drugs, such as
alcohol, which allows comparison between the pattern of use of these drugs and the
harm related to their use.
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High
An intense feeling of pleasure experienced when using some Psychoactive drugs.
These substances cause dopamine to be released rapidly and in huge quantities when
compared to usual brain levels, which leads to the intense feelings of pleasure.
Illicit drug
A Psychoactive substance, the possession, production, sale or use of which is
prohibited. Strictly speaking, it is not the Drug that is illicit, but its possession,
production, sale or use in particular circumstances in a given jurisdiction. Illicit drug
market, a more exact term, refers to the production, distribution, and sale of any
drug outside legally sanctioned channels.
Intoxication
Defined in the ICD-10 as ‘a transient condition following the administration of alcohol
or other Psychoactive substance, resulting in disturbances in level of consciousness,
cognition, perception, affect or behaviour, or other psychophysiological functions and
responses’. The term ‘acute intoxication’ is used for intoxication of clinical significance.
Complications may include trauma, inhalation of vomitus, delirium, coma, and
convulsions, depending on the substance and method of administration.
Keyworking
A system of providing individualised care though a specific keyworker, who provides a
consistent means of contact with medical and social care. It is used for Rehabilitation
of Dependence on Illicit drugs and enables support to be tailored to individual need
by creating a strong partnership between the individual requiring rehabilitation and the
keyworker.
Legalisation
Legalisation is a process of repealing a prohibition (in criminal law) on a given
behaviour or product – in this context, supply, possession or use of an Illicit drug.
The process is often coupled with a governmental effort to control or influence the
market for the affected behaviour or product. The term should be distinguished from
Decriminalisation, which refers to a reduction in the seriousness of an offence or
of the penalties it attracts, and specifically the move from a criminal sanction to a
civil or administrative one.
Licit drug
A drug that is legally available, either to purchase, or by medical prescription. Examples
of licit Psychoactive drugs that are available to purchase are alcohol and tobacco.
See also Illicit drug.
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Maintenance treatment
A method of medical management that involves prescribing and administration of a
pharmaceutical Drug as a ‘substitute’ for an Illicit drug, to patients who have become
dependent. It is most commonly used for Opioid Dependence (eg treatment with
methadone or buprenorphine – commonly called Opioid Substitution treatment). 
The aim is to attenuate withdrawal symptoms, diminish opioid Craving and arrive at 
a Tolerance threshold, while preventing euphoria and sedation from overmedication.
Multiple drug use
See Polydrug use.
Mutual-help movement
Voluntary associations, usually led by former drug users who now use their experiences
to help others cease drug use and improve their coping skills.
See also Alcoholics Anonymous and Narcotics Anonymous.
Narcotics Anonymous, NA
A Mutual-help movement for individuals who are dependent on, or are recovering
from dependence on, narcotics (chemical agents (such as opiates or opioids) that induce
stupor, coma, or insensibility to pain, but also a term used imprecisely to mean illicit
drugs, irrespective of their pharmacology). Participants support each other in recovering
from, or maintaining recovery from, their dependence. It uses a 12-step programme
based on a non-denominational spiritual approach, with an emphasis on mutual aid
and support.
Opiate
An opiate is an Addictive drug, derived from the opium poppy, which reduces pain,
induces sleep and may alter mood or behaviour (see Opioids). This term excludes
synthetic Opioids.
Opioid
A generic term applied to alkaloids from the opium poppy (Opiates), their synthetic
analogues and compounds synthesised in the body that interact with specific
Receptors in the brain and reduce pain, induce sleep and may alter mood or
behaviour. In high doses they can cause stupor, coma and respiratory depression.
Opium alkaloids and their semi-synthetic analogues include morphine,
diacetylmorphine (diamorphine, heroin), hydromorphine, codeine and oxycodone.
Synthetic opioids include buprenoprhine, methadone, pethidine, pentazocine and
tramadol. More information is available in Appendix 3.
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Overdose
The use of any Drug in such an amount that acute adverse physical or mental effects
are produced. It usually implies an amount that constitutes a mortal risk. Deliberate
overdose is a common means of suicide and attempted suicide. In absolute numbers,
overdoses of Licit drugs are usually more common than those of Illicit drugs.
Overdose may produce transient or lasting effects, or death; the lethal dose of a
particular drug varies with the individual and with circumstances. Poisoning is a 
near-synonym in external-cause diagnostic codes.
Polydrug use
The use of more than one Psychoactive drug or type of Drug by an individual, 
often at the same time or sequentially, and usually with the intention of enhancing,
potentiating, or counteracting the effects of another drug. The term is also used more
loosely, to include the unconnected use of two or more drugs by the same person. 
It carries the connotation of Illicit drug use, though alcohol, nicotine, and caffeine are
the substances most frequently used in combination with others in industrialised
societies (Polysubstance use). Multiple drug use disorder is one of the ‘Mental and
behavioural disorders due to psychoactive substance use’ in the ICD-10, diagnosed only
when two or more substances are known to be involved and it is impossible to assess
which substance is contributing most to the disorder. The category is also used when
the exact identity of some or even all of the substances being used is uncertain or
unknown, since many multiple drug users often do not know themselves what they are
taking. The term Multiple drug use is also commonly used.
Polysubstance use
The concurrent use of an Illicit drug or Drugs and alcohol, tobacco (nicotine) 
or caffeine.
Problem drug use
There are varying definitions for problem drug use. In its broadest sense, according to
the United Nations Office on Drugs and Crime (UNODC), problem drug use is used to
describe individuals who inject Drugs and/or are considered dependent, facing serious
social and health consequences as a result. For statistical purposes, the definitions and
methods of calculation differ from country to country. The European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA) defines problem drug use as ‘injecting drug
use or long duration/regular use of opioids, cocaine and/or amphetamines’.
Prohibition
Policy under which the cultivation, manufacture, and/or sale (and sometimes the use) of
a Psychoactive drug are prohibited under criminal law (although pharmaceutical sales
are usually permitted).
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Psychoactive drug or substance
A substance that, when ingested, affects mental processes (eg cognition, mood,
sensation and behaviour). This term and its equivalent, Psychotropic drug, are the
most neutral and descriptive terms for the whole class of substances, licit and illicit, 
of interest to Drug policy. ‘Psychoactive’ does not necessarily imply Dependence
producing, and in common parlance the term is often left unstated, as in Drug
use/Drug abuse or Substance abuse/Substance use.
Psychoactive substance use disorders
A shortened version of the term used in ICD-10 – mental and behavioural disorders
associated with Psychoactive Substance use. The term encompasses acute
Intoxication, Harmful use, Dependence syndrome, withdrawal state, withdrawal
state with delirium, psychotic disorder, and amnesic syndrome. For a particular
substance, these conditions may be grouped together as, for example, cannabis use
disorders, stimulant use disorders. Psychoactive substance use disorders are defined as
being of clinical relevance; the term ‘psychoactive substance use problems’ is a broader
one, which includes conditions and events not necessarily of clinical relevance.
Psychopharmacology
The actions of Drugs, and their effects on mood, sensation, cognition and behaviour.
Psychotropic drug
See Psychoactive drug.
Receptor
A structure or site on the surface of a cell that can bind a chemical substance that will
then induce a change in the cell. In the context of Psychoactive drugs, binding of a
drug to a specific receptor on nerves in the brain can induce a psychological effect by
either mimicking or blocking the action of a specific natural neurotransmitter. 
See also Psychoactive drug or substance.
Recreational use
Use of a Drug, usually an Illicit drug, in sociable or relaxing circumstances, by
implication without Dependence or other problems. The term is not favoured 
by those seeking to define all Illicit drug use as a problem.
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Recovery
In the context of Drug Dependence, recovery involves achievement of the individual
user’s goals for making positive changes in their life. This usually includes improved
family and social relationships, living in appropriate housing and being gainfully
employed. It is likely to be achieved by treatment to reduce or eliminate dependence 
on Illicit drugs.
Recovery capital
The ‘breadth and depth of internal and external resources that can be drawn upon to
initiate and sustain Recovery’ from Substance use.a
Regulation/Regulated market
A range of regulatory controls are deployed, covering drug production and trade,
products, gatekeepers of supply and users. Some drugs, preparations and activities
remain prohibited. Examples of regulated products are over-the-counter drugs,
prescription drugs, alcohol and tobacco.
Rehabilitation
In the field of Substance use, the process by which an individual with a substance use
disorder achieves an optimal state of health, psychological functioning, and social
wellbeing. Rehabilitation follows the initial phase of treatment (which may involve
Detoxification and medical and psychiatric treatment). It encompasses a variety of
approaches, including group therapy, specific behaviour therapies to prevent relapse,
involvement with a mutual-help group, residence in a therapeutic community or half-
way house, vocational training, and work experience. There is an expectation of social
reintegration into the wider community.
Relapse
A return to drug use after a period, of abstinence or controlled use, often accompanied
by reinstatement of Dependence symptoms. Some distinguish between relapse and
lapse (‘slip’), with the latter denoting an isolated occasion of alcohol or drug use.
Relapse prevention
Techniques to prevent relapse into drug use. This can be pharmacological 
(eg naltrexone-maintained abstinence from opioid use), or a psychosocial intervention
such as cognitive-behavioural therapy, which focuses on helping users to identify
situations where they are most vulnerable to drug use and to develop coping skills to
deal with these situations.
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a Granfield R & Cloud W (1999) Coming clean: overcoming addiction without treatment. New York: New York University Press.
Remission
A symptom-free period. In the context of Illicit drug use, it can refer to a period of
abstinence or controlled use, or to a period of freedom from the Craving associated
with Dependence.
Residential rehabilitation
Prolonged residential treatment in a home, hostel or hospital unit, for Dependence,
usually on a Psychoactive drug. There is a positive and highly structured drug-free
environment with strict rules, where residents are expected to participate in a
programme of Rehabilitation, based on self-help and mutual support. 
See also Therapeutic community.
Substance abuse/Substance use
See Drug abuse and Drug use.
Substitution treatment
Treatment of Dependence on a Psychoactive drug with a substitute drug with 
cross-dependence and cross-Tolerance. The goal is to reduce or eliminate use of the
original drug and/or to reduce harm from a particular method of administration.
See also Harm reduction. 
Therapeutic community
A structured environment where individuals with Substance use disorders live, 
to achieve Rehabilitation. Such communities are often specifically designed for
individuals with Dependence on Psychoactive drugs, are run according to strict rules,
based on self-help and mutual support, and are often geographically isolated. They use
a hierarchical model with treatment stages that reflect increased levels of personal and
social responsibility. Peer influence, mediated through a variety of group processes, is
used to help individuals learn and assimilate social norms and develop more effective
social skills.
See also Residential rehabilitation.
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Tolerance
A decrease in response to a Drug dose that occurs with continued use. Increased doses
of alcohol or other drugs are required to achieve the effects originally produced by
lower doses. Physiological and psychosocial factors may contribute to the development
of tolerance, which may be physical, behavioural or psychological. With respect to
physiological factors, both metabolic and/or functional tolerance may develop. 
By increasing the rate of metabolism of the substance, the body may be able to
eliminate the substance more readily. Functional tolerance is defined as a decrease in
sensitivity of the central nervous system to the substance. Behavioural tolerance is a
change in the effect of a drug as a result of learning or alteration of environmental
constraints. Acute tolerance is rapid, temporary accommodation to the effect of a
substance following a single dose. Reverse tolerance, also known as sensitisation, 
refers to a condition in which the response to a substance increases with repeated use.
Tolerance is one of the criteria for the Dependence syndrome.
Withdrawal syndrome
A group of symptoms of variable clustering and degree of severity that occur on
cessation or reduction of use of a Psychoactive substance that has been taken
repeatedly, usually for a prolonged period and/or in high doses. The syndrome may be
accompanied by signs of physiological disturbance. A withdrawal syndrome is one of
the indicators of a Dependence syndrome. It is also the defining characteristic of the
narrower Psychopharmacologicalmeaning of Dependence. The onset and course of
the withdrawal syndrome are time limited and are related to the type of substance and
dose being taken immediately before cessation or reduction of use. Typically, the
features of a withdrawal syndrome are the opposite of those of acute Intoxication.
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Foreword
In this report, the BMA, through its Board of Science, seeks to open and refocus 
the debate on drug treatment and drug policy through the eyes of the medical
profession. The first step in such a debate is to ensure that the facts are presented,
along with the evidence to support them. For this reason, we have set out to
establish the evidence and seek to draw conclusions from it. We do not have a
predetermined medical position on the ways in which policy might be changed,
rather a desire to start from a secure baseline of knowledge. As with so many other
medical conditions, we believe that there is no ‘one size fits all’ solution to the
problem of drug misuse, and the medical profession’s familiarity with the need for
advocacy for each individual patient should be at the forefront of this debate.
There will inevitably be differences of opinion and of interpretation. Individuals have
experiences that affect their views. They have different ethical, moral and religious
persuasions; identifying a common, agreed pathway may prove to be difficult. Taking
into account the myriad differences in approach across the world, this is no doubt an
understatement.
As a surgeon, I have had limited contact with the medical problems associated with
drug use but it has become clear to me that the present approach is not satisfactory.
My understanding has been greatly enhanced by the superb team of contributors to
this report. Their contributions have been reviewed by all of the main committees of
the BMA. We believe that this report is an up-to-date resource that will provide the
factual foundation for informed debate.
The medical profession would never condone drug taking. Individuals, who press
others into experimenting with the use of drugs, may deserve punishment. But those
who fall into drug dependence become a medical problem from which we, as a
society, cannot escape and they badly need our help.
In this country, we are beginning to see evidence of a reduction in the use of hard
drugs but they remain a major hazard for those who try them and the dependence
that may follow is a lifelong problem for many.
So we acknowledge that, while some progress has been made, this should not lull us
into the false belief that we can put this problem out of our minds in the hope that it
might go away.
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The medical profession should look squarely at the issue and debate it as a medical
problem. We have vast expertise to call upon and compassionate understanding to
offer. Our involvement, indeed our leadership, in this debate will ensure that the
medical issues become central to the national debate and the criminal justice aspects
are put into a more accurate context. 
We have the special opportunity to listen to patients’ views and concerns and to
guide them, as individuals, through the various treatment options. We owe it to the
patients, their families and those around them to get actively involved in the national
debate and so to ensure that the medical aspects are at the heart of the discussions.
Professor Averil Mansfield
Chairman, BMA Board of Science
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Executive summary
Objectives
The objectives of this report are to:
• encourage debate on the most effective approach to preventing and
reducing the harms associated with illicit drug use and illicit drug-control
policies, based on an independent and objective review of the evidence
• examine the role of the medical profession in preventing and reducing 
the harms associated with illicit drug use and policies for control of illicit
drug use
• encourage debate and dialogue between the medical profession and
policy makers, legislators, the police, service providers and academics who
have knowledge and expertise in this area.
The report starts by examining the scale of the problem, the harms associated with
drug use – for both the individual and society – and influences on illicit drug use. 
The development of drug policy in Britain is then presented, followed by a chapter
discussing the particular harms to the individual and society that are associated with
the prohibitionist legal framework controlling drug use. This chapter also presents
the options for an alternative legal framework. Interventions to reduce the harms
associated with illicit drug use are then discussed, followed by three chapters that
examine the doctor’s role in the medical management of drug dependence and the
ethical challenges of working within the criminal justice system.
Medical practitioners are ideally placed to encourage a refocusing of debate on
policies for supporting and treating the physical and mental health needs of illicit
drug users. The final chapter examines their role, both as individuals and as a
profession, in relation to illicit drug use. 
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Key points from each chapter are summarised next.
1. Introduction
• Substance use describes a wide range of different patterns of use, from
harmless recreational use to life-threatening dependence.
• There is evidence of a neurobiological underpinning to dependence, and an
association between biological, psychological and social factors. These factors
create a framework within which an individual’s predisposing, precipitating,
perpetuating and protective elements can be used to plan the most effective
treatments.
• Drugs of dependence, such as alcohol and tobacco, are at least as harmful as
some illicit drugs, and their use in the UK is subject to a regulatory framework
that covers various aspects of production, supply and consumption.
• The Misuse of Drugs Act 1971 in the UK and the three international
conventions on international drug policy, to which the UK is a party, classify
illicit drugs according to their perceived level of harm, and regulate their
control and supply. Possession, purchase or cultivation of illicit drugs is illegal
and thus a criminal offence in the UK.
• The priority of the medical profession is to support and treat the physical and
mental health needs of drug users and those affected by others’ drug use.
• Medical professionals are ideally placed to encourage a refocusing of debate
on issues relating to dependent drug use and to influence national and global
drug policy.
2. The scale of the problem: illicit drug use in the UK
• There has been a long-term downward trend in illicit drug use in the UK,
although use of cocaine has increased slightly. In 2009-2010, 5 per cent of 
16 to 59 year olds in the UK population were current drug users (had used
drugs in the last month).
• Men are more likely than women to report drug use and current use is
highest in the under-25 age group.
• International evidence suggests 10 to 13 per cent of all people who use drugs
worldwide are problem drug users. Problem drug use affects approximately
10 per cent of all UK drug users, with the highest levels in the 25 to 34 years
age group.
• Cannabis is the most commonly used drug, followed by cocaine powder,
ecstasy and amphetamines.
• After North America, Europe is the next largest cocaine market and the UK is
the largest market in Europe.
• In Europe, UK teenagers are among the most likely to report recent and
current cannabis use, and are above the European average reported level for
lifetime use of other illicit drugs.
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• There are few reliable data on novel psychoactive substances (gamma-
butyrolactone (GBL), 1-benzylpiperazine (BZP), mephedrone, oripavine,
anabolic steroids, Spice, etc), which have only been controlled under the
Misuse of Drugs Act 1971 since 2009, but they appear to be used more by
younger age groups and as an alternative to ecstasy.
• Around half the UK population surveyed considers drug use is a serious
problem; and slightly more believe drug users should be treated as individuals
needing medical treatment or other support.
• A majority of those interviewed in the British Social Attitudes survey in 2011
believed cannabis should remain illegal and is harmful; this has increased
since 2009.
• A majority interviewed for the Scottish Social Attitudes survey thought
illegal drug use should not be accepted as a normal part of some people’s
lives and the proportion has also increased from 2001 to 2009; this is
particularly noticeable in the 18 to 24 years age group. Less than 10 per cent
of pupils interviewed in England in 2010 thought use of any illicit drugs 
was acceptable.
• Over half the UK population interviewed in 2011 believed the Government’s
approach to illicit drug use is totally ineffective.
3. The burden of illicit drug use
• The use of illicit drugs is associated with a range of physical, psychological
and social harms. These are affected by the dosage of drug, the pattern of
drug use and the mode of administration.
• Most drug-related deaths in the UK are related to the use of opioid drugs,
followed by cocaine. The vast majority of these deaths are in men and many
are associated with polydrug or polysubstance use. Ecstasy-related deaths are
very rare and deaths from cannabis overdose do not occur.
• The risk of death from accidental drug overdose, and from suicide, is
associated with poverty, homelessness, polydrug or polysubstance use,
impaired physical health and depression.
• While dependence per se is not necessarily significantly harmful, the risk of
harm is intrinsically raised as a result of chronic drug use. The following are
associated with physical and psychological dependence: cannabis, cocaine,
gamma-hydroxybutyrate (GHB), heroin, methamphetamine and other opioid
drugs. Amphetamine and ecstasy are associated with psychological
dependence only, and there is limited evidence for dependence with
ketamine and phencyclidine (PCP). Dependence is rare with hallucinogens.
• Fetal development can be adversely impacted by maternal drug use.
• Adverse health impacts and drug-related deaths may also be associated 
with adulterants.
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• Social harms of drug use include deprivation and family adversity/neglect;
criminality associated with drug intoxication or with the need to obtain drugs;
and drug-impaired performance at work or when driving. These can result
from the illegality of the drugs, or from factors such as the
psychopharmacological effects of the drug. They have associated costs for the
individual related to loss of earnings, reduced educational attainment and
damage to personal relationships. High levels of drug use in a community are
linked to unsafe communities because of the associated social problems.
• Studies of the level of harm associated with use of different drugs in the UK
scored heroin, crack cocaine and methamphetamine as most harmful to
individuals; alcohol, heroin, crack cocaine and cannabis as most harmful to
others; and alcohol as most harmful overall, followed by heroin, crack
cocaine, methamphetamine and cocaine. The relative levels of harm for the
different drugs correlate poorly with the legal classification of drugs.
• Economic and social costs of drug use are related to health and social care
costs and criminality; 99 per cent of costs are linked to Class A drug use
(cocaine, crack cocaine, ecstasy, heroin, methadone, lysergic acid
diethylamide (LSD) and psilocybin (magic mushrooms)) and a large proportion
is linked to crime, including crimes of illegality. The economic and social costs
of Class A drug use in 2003-2004 in England and Wales were estimated to be
£15.4 billion, which equates to £44,231 per year per problematic Class A
drug user.
4. Influences on illicit drug use
• Drug use is widely held to be a multifaceted biopsychosocial phenomenon.
No single biological, psychological or social factor is exclusively responsible for
drug use.
• Family-based, adoption and twin studies have shown a substantial genetic
component to drug use. Comorbid psychiatric illness and personality type
have also been shown to be strongly linked to drug use.
• The rewarding potential of drugs, such as sensations of pleasure or relief
from pain, may play a role in reinforcing the continued use of drugs. 
The use of drugs activates the mesolimbic dopamine system in the brain,
strengthening neural connections, which influences the repetition of 
drug-related behaviours.
• A drug’s potential to lead to tolerance and withdrawal may influence its
continued use.
• The environmental or social factors commonly attributed to problematic drug
use include family composition, behaviour and relationships, peer influence,
social inequalities and being a member of a stigmatised group.
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• Positive family relationships and communication may guard against future use
of drugs. Living in a single-parent or step-family, substance use among family
members, family conflict and poor parental supervision are all indicators for
drug use in young people.
• Stigmatised groups are at increased risk of drug use; these include young
people in care institutions, sex workers (particularly those who work
outdoors), homeless populations and victims of traumatic experiences.
• Evidence shows price has an impact on drug use but the effect is not the
same for all types of drugs.
• Evidence of the effect of portrayals of drug use in popular media on drug use
are limited and difficult to interpret. There is some evidence that portrayals of
drug use in film have an impact on drug use in the UK. Notable celebrities
may have a role in either reducing or increasing drug use.
5. Drug policy in the UK: from the 19th century to the
present day
• Purchase of psychoactive drugs such as opium and laudanum was
unregulated in the UK until 1868, when the Pharmacy Act was passed,
restricting opium sales to pharmacists’ shops, with a requirement on
pharmacists to keep a record of purchasers.
• In 1916, an Army Council order, and the Defence of the Realm Act later the
same year, made it an offence for anyone except a physician, pharmacist or
vet to possess, sell or give cocaine, and the drug and its preparations could
only be supplied on prescription.
• The first Dangerous Drugs Act passed in 1920, and a further Act in 1923,
passed to conform to the 1912 International Opium Convention at The
Hague to which Britain was a signatory, imposed stricter controls on doctors
and pharmacists in relation to dangerous drugs, in a climate with a penal
emphasis on policy.
• It was not clear from these Acts or the Convention whether prescribing drugs
to addicts constituted legal medical work. The Rolleston Report in 1926
affirmed the right of doctors to prescribe controlled drugs to addicts in
defined circumstances and set the scene for a balanced medical approach
within a penal framework.
• The second Geneva Convention in 1925 brought cannabis under
international control, and restrictions were implemented in the 1928
Dangerous Drugs Act.
• As a result of increasing use of heroin, the 1967 Dangerous Drugs Act
restricted prescribing of heroin to doctors licensed by the Home Office, 
and set up new drug treatment centres within the NHS hospital system. 
A notification system for addiction was also introduced.
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• Introduction of other drugs to the illicit market, such as amphetamines and
LSD, led to the Drugs (Prevention of Misuse) Act 1967, and recommendations
that penalties for possession of cannabis should be reduced, with no custodial
sentencing for casual use, were implemented.
• The 1961 United Nations Single Convention on Narcotic Drugs introduced
four schedules of controlled drugs and was followed in the UK by the Misuse
of Drugs Act 1971, with drugs categorised in classes according to perceived
harm and therapeutic value. This Act also set up the Advisory Council on the
Misuse of Drugs, to keep the drug situation under review and advise the
Government.
• With increasing illicit drug use, Government strategies in the 1980s began to
focus on the social and economic problems of drug users, in addition to their
medical problems, and GPs became involved with the more general
healthcare needs of drug users, leaving specialists to deal with more difficult
drug users.
• The spread of HIV and AIDS generated ‘harm-minimisation’ policies in relation
to drug use, by modification of using behaviours, from injecting to oral use
where possible.
• The 1995 Drug Strategy moved away from this approach to one encouraging
users to enter treatment, with the aim of moving users towards abstinence
and achievement of a drug-free state and of reducing criminal behaviour.
• Later strategies (2002, 2004, 2008) continued to emphasise the need to
move drug users into treatment and focused on the links between drugs and
crime; they also aimed to move drug treatment away from the NHS into the
community and voluntary sector.
• The 2008 strategy maintained a focus on drugs and crime but placed
greater emphasis on the impact of problematic drug use on children and
families of users.
• With the 2010 strategy, policy continues to move away from drug-crime links
and towards a focus on wider social and economic factors that drive
problematic drug use. The emphasis is on people in drug treatment achieving
recovery, rather than aiming to simply engage and retain them in treatment.
• The international policy framework means that all possession or marketing of
illicit drugs remains a criminal activity.
6. Controlling illicit drug use
• For the last half century, prohibition and criminalisation has been the
dominant policy for drug control, both nationally and internationally.
• It is very difficult to separate the impact of drug policy from the wider effects
of social policy and environmental factors on drug-using behaviour.
• Levels of drug consumption do not necessarily follow predictable economic
patterns in a linear way, where an increase in price leads to decreased use.
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• It is difficult to predict supply and demand of illicit drugs, as all trade is illegal;
decreased availability of one drug may result in users turning to other drugs
that are more readily available.
• Illegally sourced drugs are of variable quality and purity, with clear adverse
health implications for users.
• Criminalisation increases the health risks of illicit drugs by encouraging use in
unsafe environments and through dangerous methods of administration. 
It also deters users from approaching health professionals for treatment.
• A prohibitionist approach creates a lucrative opportunity for criminality and
leads to high levels of acquisitive crime among dependent users.
• The stigmatisation of vulnerable populations of drug users also has significant
public health implications.
• The illicit drug trade has deleterious effects on development and security in
many of the world’s most fragile regions and states.
• The national budget required for law enforcement, the criminal justice system
and dealing with the costs of drug-related crime is several times higher than
the amount spent on drug-related health interventions.
• The existing legal framework directly impacts on the ability of medical
professionals to gain access to and treat problematic drug users.
• Debate on liberalisation of drug policy is contentious, with strong feelings on
both sides of the argument.
• There is widespread confusion about the use of terms such as
‘decriminalisation’ and an insufficient understanding that criminalisation can
operate in tandem with other forms of regulation, supervision and
intervention.
• Alternative legal frameworks include decriminalisation (eg sentencing reform),
regulation (within a legislative framework), and free market legalisation.
• There is a shortage of robust evidence relating to the benefits of the present
prohibitionist framework in terms of deterring use or reducing availability.
• The evidence suggests that the costs of enforcement are high and that
prohibition has created a range of unintended health, social and 
economic costs.
• While some commentators argue that the benefits of the UK’s current system
are questionable, and that there is a pressing need to explore whether a new
and/or modified legal and policy framework is required, other commentators
have been more cautious. Among this latter group of commentators, the lack
of research into the effects of criminalising illicit drug use and possession does
not, in itself, lead to the position that new or amended regulations are required.
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7. Delaying initiation and minimising the use of illicit drugs
• Current prevention strategies aim to reduce drug use by influencing attitudes
and behaviour, in order to prevent or delay the initiation of drug use.
• Primary prevention aims to avert or delay initial use, while secondary
prevention aims to minimise the harms in those already using drugs.
Secondary prevention interventions, such as harm-prevention strategies, are
yet to receive much in the way of attention.
• There is no clear evidence that drug education and prevention strategies have
an effect on reducing total drug use in the UK. Drug treatment programmes
are more cost effective.
• All schools in the UK are required to have a drug education programme.
These programmes improve young people’s knowledge about drug use, and
have a small impact, notably in delaying the onset of use.
• There is evidence that most pupils recall the content of their drug-education
lessons and report that it helps them to make decisions about what to do if
offered drugs. Those who had taken drugs said lessons helped them
understand why people take drugs and that not as many people as they
thought take drugs.
• Programmes that also address classroom behaviour management have been
shown to reduce lifetime drug use in boys but not girls in the USA.
• Drug testing in schools does not appear to affect the use of illicit drugs;
random testing in schools may have a negative effect.
• There is insufficient research on interventions outside the school setting to
prevent drug use to provide evidence on their effectiveness.
• The use of mass media can improve knowledge but is not effective at
reducing illicit drug use; social marketing may be a useful way of increasing
the efficacy of mass media campaigns.
• Selective prevention strategies target at-risk groups and often address
multiple and complex risk factors. There is conflicting evidence about their
efficacy in reducing drug use among vulnerable groups, and there is a risk
that they further stigmatise already marginalised individuals. The age range
11 to 13 years has been identified as a crucial period for effective
intervention.
• Groups that are most susceptible to drug harm should be identified. Taking
action on preventing the underlying causes of drug harm rather than
preventing drug harm directly may be more effective.
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8. Medical management of drug dependence: the doctor’s
role in managing heroin addiction
• Medical management of drug dependence is more difficult and challenging
than for other chronic disorders. Many users who present for treatment are
socially marginalised, lead chaotic lifestyles and have little to motivate them
towards recovery.
• Stigma and staff attitudes may also complicate management.
• Traditional methods for treating opioid addiction were based on two
approaches – encouraging abstinence and a change of attitude on the part of
the user.
• Although some individuals do recover spontaneously from opioid
dependence, it is usually a chronic relapsing–remitting condition.
• The principle of opioid substitution therapy (OST) is to prescribe and
administer a pharmaceutical opioid as a substitute for heroin. This attenuates
the symptoms of withdrawal from heroin and allows the user to gain control
over other aspects of their life, thereby creating the necessary preconditions
to cease drug seeking and use.
• Opioid substitution therapy provides a structured routine through daily
attendance for administration in a safe non-punitive and non-judgemental
treatment space, which may benefit users in restructuring a chaotic lifestyle.
• The basis of effective OST is suppression of opioid withdrawal.
• High-dose methadone is more effective than a low dose, because it
progressively increases the patient’s tolerance to opioids, making heroin less
reinforcing and cessation of use more likely.
• For some users, the respite from withdrawal offered by methadone is
insufficient to allow them to move away from heroin use; treatment with
diamorphine is more reinforcing and successful in these individuals.
• Long-term studies suggest OST may reduce use of opioid drugs (in a
relapsing–remitting manner), but seldom results in long-term abstinence from
all drugs. Continued alcohol misuse and cannabis use are common.
• Opioid substitution has been shown to reduce deaths from opioid overdose
and the risk of blood-borne viruses.
• Evidence on the effects of OST on mental health and quality of life is limited
and equivocal.
• The National Treatment Outcome Research Study (NTORS) demonstrated that
for every pound spent on treatment in the UK, a reduction of £3 in public
costs was observed. Economic benefits were largely accounted for by reduced
costs of crime.
• Opioid substitution has been shown to reduce rates of acquisitive crime and
there is some evidence that it contributes to social reintegration.
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• There has been little research on the effectiveness of supervised
administration of OST, but limited evidence suggests it is more effective at
reducing heroin use than non-supervised treatment.
• Randomised trials have shown no benefit overall of additional psychological
interventions in terms of retention, non-prescribed opioid use, psychiatric
symptoms, compliance or depression. There is substantial evidence that good-
quality staff interactions are of benefit for recovery.
• Opioid substitution is associated with a risk of diversion of methadone to
other individuals, as well as an increased risk of death during the first 
two weeks of treatment and in the month after leaving treatment. Overall,
the risk of death is reduced by entering OST.
• Subtherapeutic dosing is a serious limitation on the effectiveness of OST.
9. Medical management of drug dependence: reducing
secondary health harms
• Consistent evidence shows that doctors in primary and secondary care and in
mental health settings frequently do not address alcohol and drug use.
• Caution should be exercised in prescribing drugs with potential for
dependence, particularly for patients who are at high risk for dependence 
or diversion.
• Management of medical emergencies related to acute symptoms of
withdrawal should be followed by longer-term medical management and
support to reduce dependence.
• It is also important to address strategies for relapse prevention after
detoxification.
• The use of naloxone for relapse prevention after opioid detoxification is of
limited value.
• Psychosocial interventions that help users to identify high-risk situations 
and use coping strategies have been shown to be helpful in managing
cannabis dependence.
• In US studies, contingency management in the form of voucher-based
reinforcement has been found to significantly improve outcomes for all
substance use disorders apart from alcohol. Couples-based therapy and
support groups are also of value.
• Brief therapist interventions and motivational interviewing have been shown
to reduce drug use among young people. Opportunistic interventions in
patients attending for HIV testing has also been shown to increase the
likelihood of abstinence and reduce arrest rates.
• Illicit drug use in pregnancy needs particular care with medical management,
to avoid harm to both the mother and her baby.
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10. Medical management of drug dependence in the context
of criminal justice: illicit drug use, courts and prison
• Many illicit drug users first present to medical practitioners via the criminal
justice system.
• Treatment of illicit drug users creates particular ethical challenges for
medical professionals, especially in relation to coercion and informed
consent within the criminal justice system. It is essential to recognise that
these individuals have the same rights to accept or refuse treatment as the
rest of the population.
• There is a high prevalence of drug use among prisoners in the UK, and high
rates of first initiation of drug use.
• The Drug Interventions Programme (DIP), introduced by the Home Office in
2003, aims to develop and integrate measures for directing adult offenders
who are illicit drug users into drug treatment and thereby reduce offender
behaviour. Most DIP referrals into treatment are achieved via drug testing in
police custody suites. This raises ethical issues about coercion to treatment.
• Methadone treatment in prisons has been shown to significantly reduce
heroin use among those treated; retention in treatment is associated with
reduced mortality, reincarceration and hepatitis C infection. It is hoped that a
research study currently in progress in the UK will provide evidence about the
most effective treatment for detoxification in prisons. Naltrexone may have a
role in this treatment.
• Safety considerations are paramount in opioid detoxification treatment,
especially in those soon to be released.
• Opioid substitution therapy has been shown to have an important role in
reducing transmission of HIV in the prison setting.
• Needle-exchange programmes are important for harm reduction and are
recommended for all illicit drug users in prison in guidance from the World
Health Organization (WHO), the United Nations Office on Drugs and Crime
(UNODC) and the Joint United Nations Programme on HIV/AIDS (UNAIDS).
Nowhere in the UK offers such programmes in the prison setting.
• Vaccination for hepatitis B in the prison setting is important but not yet
offered in every prison in England and Wales.
• The National Offender Management Service (NOMS) aims to offer all
prisoners who want to commit to leading a drug-free life access to
accommodation designated as ‘drug free’.
• There is a high risk of drug-related deaths in prison and shortly after release.
Medical management must take this into account in planning treatment.
• It is important to ensure patients are linked with community drug services
immediately on release from prison.
• The use of naloxone may reduce mortality from drug overdose.
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11. The role of healthcare professionals 
• Medical training should provide graduates with basic knowledge about the
social and personal factors increasing the risks of illicit drug use, the adverse
health consequences of the illicit use of drugs, and the role of doctors in
identifying drug-related harm and initiating intervention.
• Doctors should maintain an awareness of the non-medical facets of drug
use, and exercise caution in prescribing drugs with the potential for non-
medical use.
• Doctors should take a drug use history when indicated, undertake brief
opportunistic interventions to reduce drug-related harm, and refer to
specialist services as appropriate.
• Guidance on clinical management of drug use and dependence is provided by
‘The orange guidelines’, available to all clinicians.
• Doctors can play an essential role in refocusing debate and influencing global
drug policy, so that it is based on public health principles, and results in better
health outcomes for all illicit drug users.
• Doctors with knowledge and experience of helping patients affected by illicit
drug use are ideally placed to engage in debate to promote a rational
approach to drug policy that is evidence based and health oriented.
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Chapter 1 – Introduction
The usea of legal or illegal substances that are associated with pleasure, solace or relief
from pain, but also have the potential of harm to health, is not a new phenomenon.
These behaviours have long been accompanied by concerns about the potential impact
on the individual and on society.
As discussed in Chapter 5, most of these substances have origins as medicines but
have been, or are, used for other purposes. There have, historically, been waves of
medical enthusiasm for particular psychoactive substances, which have often been
adopted for medical use on the premise that they solved the problems of the previous
object of enthusiasm. Many then become new objects of illicit use.
Many different types of psychoactive drugs (see Glossary) are commonly used; these
include alcohol and nicotine, illicit drugs (see Glossary)b such as cocaine or heroin,
prescription drugs such as tranquillisers and over-the-counter (OTC) medications
including codeine. The use of these drugs is not always harmful and, in the case of
prescription and OTC drugs, they can dramatically improve health when used correctly.
All types of drugs can and do cause harm to the health of some individuals, as well as
affecting their family, friends and communities. The extent of harm depends on the type
of drug, how it is used, and the social context within which it is used.
As this report notes, there is evidence that alcohol is the most harmful psychoactive
drug, in terms of both harm to the individual and harm to others, although there has
been much debate about how these harms are measured (see Section 3.4).1,2 The
damaging effects of nicotine when used in the form of smoked tobacco are also well
known (see Section 3.2).1 Their use in the UK is subject to a regulatory framework
that covers various aspects of production, supply and consumption. The BMA has a
long history of supporting comprehensive tobacco control measures and policies to
reduce alcohol-related harm. While this report makes several references to alcohol and
tobacco use, its purpose is to consider illicit drugs and the reader is referred to more
detailed information about alcohol and tobacco use that can be accessed from the
BMA website.
Alcohol, nicotine and other drugs are available in the UK under various forms of legal
regulation (see Glossary), and are an accepted part of the social norm. By contrast,
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a Given the scientific and legal ambiguity regarding the distinctions between ‘use’, ‘misuse’ and ‘abuse’, only the neutral term
‘use’ is used in this report (see Glossary for further discussion of these different terms).
b An overview of the effects and addictiveness of commonly used illicit drugs is provided in Appendix 2.
the use of illicit drugs – those controlled under the Misuse of Drugs Act 1971 (see
Section 1.2) – is regulated through prohibition (see Glossary). Their possession is a
criminal offence and users are commonly portrayed as a menacing scourge on society,
despite the fact that alcohol has been shown to be at least as harmful as commonly
used illicit drugs (see Section 3.2 and Figure 3).1,2 This demonisation, coupled with the
prohibitionist approach to regulation, is argued by many to be counterproductive to
reducing the harms caused by illicit drug use (see Chapter 6).
The BMA, through its Board of Science, has a long history supporting the development
of policies to reduce and prevent the harms associated with drug use and drug control
policies.c In January 2011, the Board agreed to undertake a review of the role of the
medical profession in preventing and reducing these harms, based on an independent
and objective review of the evidence. This report aims to encourage debate on this
important topic by considering the strengths and weaknesses of current policy and
practice for the prevention, control and treatment of illicit drug use. It also considers
what the medical profession can do to improve policy and practice. This report is
intended for a wide audience, including medical professionals, policy makers,
legislators, service providers, the police, the legal profession and academics with a
particular interest or expertise in this area.
The initial chapters examine the scale of the problem (Chapter 2), the harms associated
with drug use, both for the individual user and for society (Chapter 3), and the
influences on illicit drug use (Chapter 4).
Traditionally, the medical profession had a lead role in UK drug policy (see Glossary).
Over the last few decades, policy has shifted towards a crime-prevention and law-
enforcement issue. The development of drug policy in the UK is presented in
Chapter 5.
It is important to distinguish harms associated with drug use per se from harms to the
individual and to society associated with the prohibitionist legal framework surrounding
drug use. Chapter 6 reviews the evidence for the harms associated with the regulatory
framework, for both individuals and society. It also presents the options for an
alternative legal framework.
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c The BMA has published a number of reports on drug use, including: The misuse of drugs (1997),3 which examined the range of
policies for improving services for drug users in the UK; Therapeutic uses of cannabis (1997),4 which considered the potential
medicinal uses and benefits of cannabis and cannabinoids; Adolescent health (2003),5 which examined the levels of drug use
among adolescents in the UK and identified interventions to reduce its prevalence in this age group; Over-the-counter medication
(2005),6 which discussed the use of drugs bought over the counter without prescription; Child and adolescent mental health
(2006),7 which considered the link between substance use and mental health problems in young people; Legalising illicit drugs: 
a signposting resource (2006),8 which examined the arguments for and against legalising illicit drugs; and Driving under the
influence of drugs (2009),9 which discussed the key issues related to drug-driving and ways to tackle this problem.
Interventions that prevent or delay initiation of drug use will reduce the harms
associated with dependent use, and evidence for the effectiveness of such interventions
is examined in Chapter 7.
The final chapters of this report examine the management of drug dependence as a
medical issue. Chapter 8 looks at the doctor’s role in managing heroin addiction, while
Chapter 9 reviews the role of medical practitioners in the prevention and reduction of
drug-related harm. Finally, Chapter 10 looks at the management of illicit drug use in
the context of criminal justice. By the time they come for treatment, many dependent
drug users are socially marginalised, or in prison, and specific issues arise relating to
coercion and consent to treatment in this vulnerable population. There may also be a
blurring of the distinction between punishment and treatment. These issues are also
considered in Chapter 10.
The medical profession has a vested interest in drug policy, because of the direct and
indirect health and social harms caused by illicit drug use. It has a key role in supporting
and treating the physical and mental health needs of drug users. Medical professionals
are ideally placed to encourage a refocusing of debate on these important issues and to
influence national and global drug policy. Their role in relation to illicit drug use, both as
individuals and as a profession, is examined in the closing chapter of this report
(Chapter 11).
1.1 Substance use as a medical disorder
The use of psychoactive substances is well recognised across UK society. Such use is
associated with a range of harms for some people, while for others there are few
negative consequences. As discussed in Section 3.3.7, some psychoactive drugs,
such as heroin, crack cocaine and methamphetamine, as well as alcohol and
tobacco, are highly addictive, while others, such as cannabis and ecstasy are less so.
The addictiveness (dependence potential – see Glossary) of different psychoactive
drugs is presented in Appendix 2. Attitudes towards the acceptability of substance
use vary widely, with particular debate regarding the concept of pathological
substance use and a disease model for addiction. This section examines the evidence
for considering harmful/dependent substance use as a medical disorder.
1.1.1 Background
The historical response to harmful/dependent substance use is of interest.
Internationally, different countries have either accepted a disease model and treated
harmful/dependent users as patients, and/or used the judicial system as a means to
define substance use primarily as a criminal activity. Often, particularly nowadays,
national systems combine both disease and crime models.
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The concept of addiction (see Glossary) as a disease was first widely discussed in the
19th century, in the context of alcohol use, and was later applied to the use of other
psychoactive substances that have since been classified as illicit drugs. In 1924, 
against the background of international opiate prohibition developing since 1912 
(see Chapter 5), the UK made a pioneering decision to support a disease model of
addiction. Sir Humphrey Rolleston, then President of the Royal College of Physicians,
chaired the Departmental Commission on Morphine and Heroin Addiction (commonly
known as the Rolleston Committee), whose recommendations were accepted as
Government policy. This committee described addiction as a disease and that those
suffering with addiction should receive medical treatment rather than legal sanction.10
The development of drug policy in the UK is discussed in more detail in Chapter 5.
1.1.2 Categories of use
One of the complications in understanding substance use is describing the way in which
a particular substance is used. Broadly, use can be considered in terms of recreational
use and pathological use.
Recreational use
Many people are able to use psychoactive substances in a recreational manner 
(see Glossary) that causes no problems to the individual or those around them. 
This pattern of use is usually characterised by moderate levels of consumption and
periods when the person stops using the substance without difficulty.
Harmful, dependent and hazardous use
There are clear, internationally agreed frameworks for describing harmful and
dependent patterns of substance use. These frameworks define a hierarchy of physical,
psychological and social harm to the individual.
The World Health Organization (WHO) International Classification of Diseases, currently
in its 10th edition (ICD-10),11 is a diagnostic description of all diseases. Within the
chapter on mental and behavioural disorders, a subchapter defines mental and
behavioural disorders due to psychoactive substance use. It defines a number of
categories including acute intoxication (see Glossary), harmful use, dependence and
withdrawal. The level of harm caused by a particular pattern of substance use is defined
by the categories ‘harmful’ and ‘dependent’.
• Harmful use: a pattern of psychoactive substance use that is causing damage to
health. The damage may be physical or psychological.
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• Dependent use: dependence has both psychological and physiological elements.
Psychological dependence involves a need (craving – see Glossary) for repeated
doses of the drug to feel good, or avoid feeling bad. Physiological (physical)
dependence is associated with tolerance (see Glossary), where increased doses of
the drug are required to produce the effects originally produced by lower doses, and
development of withdrawal syndrome (see Glossary) when the drug is withdrawn.
Withdrawal syndrome is characterised by physiological and psychological symptoms
that are specific to a particular drug. The term ‘dependence’ is often used
interchangeably with ‘addiction’ (see Glossary). The ICD-10 uses the term
‘dependence syndrome’ (see Glossary), to describe a cluster of behavioural, cognitive
and physiological phenomena in which the use of the substance or a class of
substances takes on a much higher priority for a given individual than other
behaviours that once had greater value, and the user may develop tolerance and a
physical withdrawal reaction when drug use is discontinued. Specific diagnostic
criteria for dependence syndrome are presented in Box 1.
Box 1 – ICD-10 diagnostic criteria for dependence syndrome11
A definite diagnosis of dependence should usually be made only if three or more of
the following have been present together at some time during the previous year:
• a strong desire or sense of compulsion to take the substance
• difficulties in controlling substance-taking behaviour in terms of its onset,
termination or levels of use
• a physiological withdrawal state when substance use has ceased or been
reduced, as evidenced by the characteristic withdrawal syndrome for the
substance, or use of the same (or a closely related) substance with the intention
of relieving or avoiding withdrawal symptoms
• evidence of tolerance, such that increased doses of the psychoactive substance(s)
are required in order to achieve effects originally produced by lower doses (clear
examples of this are found in alcohol- and opioid-dependent individuals who
may take daily doses that are sufficient to incapacitate or kill non-tolerant users)
• progressive neglect of alternative pleasures or interests because of psychoactive
substance use; increased amount of time necessary to obtain or take the
substance or to recover from its effects
• persisting with substance use despite clear evidence of overtly harmful
consequences, such as harm to the liver through excessive drinking, depressive
mood states consequent to periods of heavy substance use, or drug-related
impairment of cognitive functioning; efforts should be made to determine that
the user was actually, or could be expected to be, aware of the nature and
extent of the harm.
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The other major diagnostic framework, the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) describes a similar disorder, using the terms ‘abuse’ 
and ‘dependence’.12
WHO also uses the term ‘hazardous use’ to describe a pattern of substance use that
increases the risk of harmful consequences for the user. In contrast to harmful use,
hazardous use also refers to patterns of use that are of public health significance,
despite the absence of any current disorder in the individual user. It is not used as a
diagnostic term in the ICD-10.
These terms, and many others that are used throughout the report, are discussed in
more detail in the Glossary.
1.1.3 Dependence as a brain disorder
The neurobiology of dependence
While there is compelling evidence to demonstrate a neurobiological underpinning to
addictive behaviours,13 the relationship between the brain elements of addiction and
dependence and the characterisation of addiction and dependence at a behavioural
level is unclear. Substances have been clearly shown to affect the brain in the short and
longer term.14
In the short term, substances affect the brain through changing levels of
neurotransmitters. Some substances (eg heroin, cannabis) mimic endogenous
neurotransmitters, while others (eg cocaine, amphetamine) increase the availability
of endogenous neurotransmitter to the brain, by either increasing neurotransmitter
release or inhibiting its breakdown.
If a person uses substances over a longer period of time, the brain’s structure and
function begin to change, prompting behavioural changes in that individual.14 The
psychological effects of classical conditioning, as described in Section 4.3.2, are also
likely to be involved in reinforcing continued drug use.
The prefrontal cortex area of the brain is particularly vulnerable to the effect of
substances. This brain area is crucial for decision making, such as weighing up the pros
and cons of a certain activity. Research suggests that the prefrontal cortex is one of the
last brain areas to mature.15 This may make adolescents who use psychoactive
substances particularly vulnerable to poor decision making and impulsivity.16
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The role of dopamine
Dopamine is one of a number of neurotransmitters associated with addictive
processes. It is a naturally occurring, ‘feel good’ neurotransmitter that is important in
rewarding positive behaviours (eg eating, drinking). Some psychoactive substances
cause dopamine to be released rapidly and in huge quantities when compared to
usual brain levels. Raised levels of dopamine in the mesolimbic system lead to
intense feelings of pleasure, known to users as a ‘high’ (see Glossary).
If substance use persists, the brain responds to the dopamine overstimulation by
decreasing the amount of dopamine produced and reducing the number of
dopamine receptors (see Glossary) available. This, in turn, can lead to the user
feeling emotionally flat and exhausted once the immediate effect of the drug has
subsided. The user will often try to stimulate further additional dopamine release by
using larger quantities of the substance. This is one of the mechanisms underpinning
the clinical features of ‘tolerance’.
The role of dopamine in the effect of psychoactive drugs is considered further in
Section 4.2.3 and Section 4.3.
Genetics
There is strong evidence for a genetic component to dependence, provided by family,
twin and adoption studies (see Chapter 4).17 The evidence is particularly compelling for
alcohol dependence. Although research suggests many genes may be involved,18 there
is evidence that a single genetic variant in the aldehyde dehydrogenase 2 gene impacts
on patterns of drinking and the risk of dependence.19 Individuals who are heterozygous
for this gene are protected from the effects of heavy drinking, while a mutation in this
gene, commonly found in individuals of Far-Eastern descent, causes a reduced ability to
metabolise alcohol. The genetics of dependence is a rapidly developing area but, apart
from the studies on the aldehyde dehydrogenase 2 gene, there is little immediate
prospect of a breakthrough in genetics leading to improved patient care.
1.1.4 The role of other factors
No single factor determines whether a person will harmfully or dependently use a
particular substance. As described above, dependence can be considered primarily a
brain disorder, but one that interacts with a range of predisposing, precipitating,
perpetuating and protective factors.
These factors can best be described in a framework in which the biological, psychological
and social components are identified. This is discussed in detail in Chapter 4.
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Examples of biological factors include chronic pain, which can result in a person seeking
pain relief through the use of psychoactive substances (eg alcohol, cannabis); or
exposure to dependence-forming medications.
Psychological factors include comorbid mental health problems such as depression,
psychosis and personality disorder. Traumatic events, such as childhood sexual abuse,
may also increase a person’s vulnerability to subsequent use of psychoactive substances.
Social factors include the availability of a particular substance; the nature of, and
support provided by, a person’s social network; peer pressure; and environmental
factors such as housing and employment.
A range of evidence-based treatments are available to help people with harmful/
dependent substance use, and some of these are discussed in Chapters 8 to 10. 
Each individual is unique, and treatment of harmful/dependent use should be planned
with a clear understanding of the predisposing and protective factors.
1.2 The legal framework for illicit drugs
The development of drug policy in the UK is discussed in detail in Chapter 5.
The principal legislation regulating the control and supply of illicit drugs in the UK is the
Misuse of Drugs Act 1971. This Act classifies drugs into three groups according to the
perceived level of harm; the Act itself does not specify how certain drugs should be
classified, but created a review board, the Advisory Council on the Misuse of Drugs
(ACMD), with this purpose.d The current classification of drugs and associated penalties
is shown in Table 1.20 It is important to note that some of these controlled drugs will
also have clinical uses. Appendix 2 gives further details about the nature and
addictiveness of these drugs, and Appendix 3 gives details of health-related harms
associated with illicit drug use.
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d The ACMD makes recommendations to Government on the control of dangerous or otherwise harmful drugs, including
classification and scheduling under the Misuse of Drugs Act 1971. These recommendations are non-binding, and have, on
occasion, been ignored or rejected.
Table 1 – Classification of drugs and associated penalties for illicit (non-medical) use
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Classification Examples of drug type Maximum
penalty for
possession 
Maximum
penalty for
supply
Class A Cocaine, crack cocaine, ecstasy 
(MDMA or 3,4-methylene-
dioxymethamphetamine), lysergic
acid diethylamide (LSD), heroin,
methadone, methamphetamine,
phencyclidine (PCP), psilocybin 
(magic mushrooms) 
Up to 7 years
in prison or an
unlimited fine,
or both
Up to life in
prison or an
unlimited fine,
or both
Class B Amphetamines, cannabis,
methylphenidate (Ritalin®), codeine,
pholcodine
Up to 5 years
in prison or an
unlimited fine,
or both
Up to 14 years
in prison or an
unlimited, fine
or both
Class C Tranquillisers, some painkillers,
gamma-hydroxybutyrate (GHB),
ketamine
Up to 2 years
in prison or an
unlimited fine,
or both
Source: Science and Technology Committee. Fifth Report of Session 2005-2006. Drug classification: making a
hash of it? HC 1031. London: The Stationery Office, 2006, p8.20
Up to 14 years
in prison or an
unlimited fine,
or both
The Misuse of Drugs Act states that it is an offence to:
• possess a controlled substance unlawfully
• possess a controlled substance with intent to supply it
• supply or offer to supply a controlled drug (even if it is given away free)
• allow a house, flat or office to be used by people for taking drugs.
In December 2009, the following drugs (commonly known as ‘legal highs’ or 
‘novel psychoactive substances’) were also brought under control of the Misuse 
of Drugs Act 1971:
• synthetic cannabinoid receptor (see Glossary) agonists (including herbal smoking
mixes such as Spice) (Class B)
• gamma-butyrolactone (GBL) (Class C)
• 1-benzylpiperazine (BZP) and related piperazines (Class C)
• oripavine (Class C).
Mephedrone and related cathinone derivatives, as well as naphthylpyrovalerone
analogues, were classified as Class B drugs in 2010. The Drugs Act 2005 amended the
Misuse of Drugs Act 1971 and the Police and Criminal Evidence Act 1984, to increase
the powers of the police and courts in relation to drug control (see Glossary). It
includes stronger measures to allow police to test drug offenders on arrest rather than
at the time of charging, and requires those testing positive to undergo treatment.
In July 2011, the Government announced a ban on the importation of phenazepam 
– a harmful drug advertised as producing a ‘legal high’– as well as its intention to
control it as a Class C drug in 2012.21 In November 2012, following advice from the
ACMD, the Home Office announced its intention to classify new synthetic cannabinoids
(such as those sold under the name ‘Black Mamba’), and methoxetamine (sold as
Mexxy/MXE) and its related compounds, under the Misuse of Drugs Act 1971.22
Methoxetamine has been subject to a Temporay Class Drug Order (TCDO) since 
March 2012,23 and will remain under this regulation until its classification under the
Misuse of Drugs Act 1971 is approved. It is important to emphasise that that the
development of new agents will inevitably run ahead of the Government’s ability to
amend the legislation.
International drug policy is regulated by three United Nations (UN) conventions: the
1961 Single Convention on Narcotic Drugs, as amended by the 1972 Protocol; the
1971 Convention on Psychotropic Substances; and the 1988 Convention against Illicit
Traffic in Narcotic Drugs and Psychotropic Substances (see Box 2). As of March 2011,
183 states, including the UK, are parties to all three conventions. It is worth noting that
many provisions in national legislation are not required by these international drug
control treaties.
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Box 2 – United Nations international drug control treaties
Single Convention on Narcotic Drugs 1961
The 1961 convention established a single model for international drug control,
binding parties to limit the production, manufacture, export, import, distribution
of, trade in, use and posses sion of drugs derived from opium poppies, coca leaves
or cannabis exclusively to ‘medical and scientific purposes’. Over 100 illicit
substances are placed in four schedules, nominally based on their perceived 
harm fulness. Limited flexibility is allowed in the interpretation and implementation
in many areas of the legislation, which has allowed countries to respond to their
specific circumstances. Legalisation (see Glossary) of any narcotic drugs listed in
the convention is prohibited, and harm-reduction measures to reduce drug-related
problems have often been argued against by the International Narcotics Control
Board (INCB), which is the independent body established to oversee the UN drug
control conventions.
Convention on Psychotropic Substances 1971
This convention was developed in response to increasing concern about emerging
drugs and related behaviours during the 1960s, such as the use of amphetamine-
like stimulants, barbiturates and other sedative-hyp notics/depressants, and
hallucinogens. As with the 1961 convention, these drugs are classified into four
schedules according to perceived harm and therapeutic value, with a
corresponding hierarchy of controls to license medical, scientific or other uses.
Market and trade controls and national requirements are less onerous than those
under the Single Convention.
Convention against Illicit Traffic in Narcotic Drugs and Psychotropic
Substances 1988
The 1988 convention strengthened the existing powers for prevention of
international drug trafficking (including provisions against money laundering and
the diversion (see Glossary) of precursor chemicals). It also included provisions 
to make the intentional possession, purchase or cultivation of narcotic drugs or
psychotropic (see Glossary) substances for personal consumption a criminal
offence under domestic law.
Source: www.unodc.org (accessed 1 October 2012).
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Summary
• Substance use describes a wide range of different patterns of use, from harmless
recreational use to life-threatening dependence.
• There is evidence of a neurobiological underpinning to dependence, and an
association between biological, psychological and social factors. These factors create
a framework within which an individual’s predisposing, precipitating, perpetuating
and protective elements can be used to plan the most effective treatments.
• Drugs of dependence, such as alcohol and tobacco, are at least as harmful as some
illicit drugs, and their use in the UK is subject to a regulatory framework that covers
various aspects of production, supply and consumption.
• The Misuse of Drugs Act 1971 in the UK and the three international conventions on
international drug policy, to which the UK is a party, classify illicit drugs according to
their perceived level of harm, and regulate their control and supply. Possession,
purchase or cultivation of illicit drugs is illegal and thus a criminal offence in the UK.
• The priority of the medical profession is to support and treat the physical and mental
health needs of drug users and those affected by others’ drug use.
• Medical professionals are ideally placed to encourage a refocusing of debate 
on issues relating to dependent drug use and to influence national and global
drug policy.
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Chapter 2 – The scale of the
problem: illicit drug use in
the UK
Case study: The financial pressure of illicit drug use
The defendant was a 32-year-old man. As a teenager, he had been in a gang and had
previous convictions for possession of dangerous weapons (knives), burglaries, street
robberies (mainly mobile phones) and assault. Since the age of 22 he had kept out of
trouble with the police. He had been in employment until two years ago, when he had been
made redundant through no fault of his own. While in employment, he had frequently used
drugs (Class A and B) recreationally but this had escalated to the point where he had
become addicted. When he was made redundant he had no financial means to pay for the
drugs, so his supplier had persuaded him that if he ‘helped’ him out by couriering drugs to
users for him, he would then be given drugs for his own personal use free of charge. The
defendant was very troubled by this offer but felt that he had little option. This arrangement
continued until he was arrested in an undercover operation by a plain clothes police officer
posing as a purchaser. By this time, the defendant had not only been acting as a courier for
his supplier but had started to deal, in a modest way, on his own account. He made about
£800 per week, but a part of this was then used to pay for drugs for his own use.
He was charged with possession with the intent to supply Class A and B drugs. He pleaded
guilty and came before the Crown Court for sentencing.
The pre-sentence report from the Probation Service explained that he was a self-confessed
addict who had taken a deliberate decision to supply drugs in order to raise the funds to
satisfy his addiction. He had explained that his only real choice was either to go back to
committing burglaries and robberies to raise funds, or to cooperate with his supplier. He did
not think he had other realistic options open to him. He was desperate not to return to the
cycle of violence that had characterised his life during his youth, so he had agreed to work
with this supplier, which he viewed as the lesser of the two evils. 
No person further up the supply chain, including the defendant’s own supplier, was
prosecuted. The defendant was given 18 months’ custody.
Case study details provided by Nicholas Green QC, who has a special interest in the impact of drugs
policy upon the administration of the justice system.
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2.1 Prevalence and patterns of use
According to the UK Focal Point on Drugs,a it is estimated that in 2009-2010, 
35.9 per cent of 16 to 59 year olds in the UK had used illicit drugs in their lifetime
(ever), while 8.7 per cent had used drugs in the last year (recent use), and 
5.0 per cent had used drugs in the last month (current use).b,1 The EMCDDA defines
problem drug use as ‘injecting drug use or long duration/regular use of opioids,
cocaine and/or amphetamines’ (see Glossary).2 In 2011, it was estimated that there
were 379,262 people affected by problem drug use in the UK,c equivalent to a rate
of 9.31 per 1,000 population aged 15 to 64 years, and representing approximately
10 per cent of all UK drug users.1 In the same year, it was estimated that there were
133,112 people injecting drugs (primarily users of opioid drugs or crack cocaine).1
Data from various surveysd (see Appendix 4) provide a more detailed picture of
patterns of illicit drug use in the UK:
• cannabis continues to be the most commonly used across all recall periods,
followed by cocaine powder, ecstasy and amphetamines for recent and current
use. In England and Wales in 2011-2012, 6.9 per cent of adults had used cannabis
in the last year compared to 2.2 per cent who had used powder cocaine
• men are more likely to report drug use than women, across all age groups. 
In Scotland in 2010-2011, 5.3 per cent of men compared with 1.8 per cent of
women reported the use of one or more illicit drug in the last month
• the extent of frequent use varies between drugs, with cannabis users most likely 
to report frequent use (more than once a month in the past year). Among
respondents to the Northern Ireland Crime Survey who had reported taking
cannabis in the last year, 34.1 per cent had used it at least once or twice a week 
in 2008-2009.3-6
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a The UK Focal Point on Drugs is the national partner of the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA). It provides comprehensive information to the EMCDDA on the drug situation in England, Northern Ireland, Scotland
and Wales.
b It is worth noting that the drug-use categories used in these surveys (ever, recent and current use) are not comparable with the
the categories outlined in Section 1.1.2 that describe the level of harm associated with drug use.
c The UK Focal Point on Drugs estimate of problem drug use in the UK is based on data from England for 2009/2010 for opiate
and/or crack cocaine use; data from Scotland from 2006 for opiates and/or benzodiazepine use and drug injecting; data from
Wales from 2009/10 for the injecting of opioids, cocaine powder and/or crack cocaine; and data from Northern Ireland from
2004 for problem opiate and/or problem cocaine powder use. For further details see Department of Health (2011) United
Kingdom drug situation: annual report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2011.
London: Department of Health.1
d Data from general population surveys are subject to a number of limitations associated with self-reporting and sampling
methodology. Specifically in relation to drug use, these surveys are likely to be under-representative as they commonly miss
students and homeless people, who have a higher consumption rate than the general population. Further information on the
limitations of general population surveys can be found at www.ons.gov.uk.
The age of first use of illicit drugs varies with drug type. According to the 2011-2012
British Crime Survey (BCS), the most common age of onset for cannabis use was
16 years, compared to 18 years for powder cocaine and ecstasy.4 The 2010-2011
Scottish Crime and Justice Survey (SCJS) found that just over half of adults who had
ever used drugs (51.3%) reported that late adolescence (16 to 19 years) was the age 
at which they first did so, and 24.7 per cent had first used them before the age of
16 years.5
The data suggest that, for a large majority of users, illicit drug use is a life phase
during young years. Young adults aged under 35 years are much more likely than
older adults to use drugs, with recent and current use highest in the under-25 age
group.3-6 Data from England for 2009-2010 show that the highest prevalence of
problem drug use was in the age group 25 to 34 years, at a rate of 17.95 per 1,000
population, compared to a rate of 6.87 per 1,000 in the 15 to 24 years age group,
and 6.65 per 1,000 in the 35 to 64 years age group.7
Polydrug use (having taken two or more illicit drugs within the same time period – 
see Glossary) is also commonly reported among drug users. In England and Wales in
2009-2010, 19.7 per cent of adults aged 16 to 59 years reported polydrug use in their
lifetime, with 3.3 per cent reporting recent polydrug use, and 1.4 per cent reporting
current polydrug use.3 The drugs most commonly used by recent polydrug users were
cannabis (83%), cocaine powder (65%), ecstasy (46%) and amphetamines (26%).3
In Scotland, 34.3 per cent of adults who had used at least one illicit drug in the last
month reported some kind of polydrug use in their lifetime.5
Concurrent use of illicit drugs and alcohol (polysubstance use – see Glossary) 
has also been found to be common. In England and Wales in 2009-2010, the
proportion of recent drug users reporting concurrent harmful alcohol use was at
least 90 per cent for all drugs, and as high as 98 per cent for cocaine powder and
amyl nitrite.3
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2.2 Trends in illicit drug use
Recent years have seen an overall long-term decline in illicit drug use in the UK.
According to the BCS, the proportion of adults aged 16 to 59 years in England 
and Wales reporting current drug use decreased from 6.7 per cent in 1996 to 
5.2 per cent in 2011-2012 (see Figure 1).4 This has been mainly driven by the
decrease in cannabis use (9.5% in 1996 compared to 6.5% in 2011-2012). Over this
time period, use of opioid drugs has remained relatively stable, while use of ecstasy,
amphetamine and hallucinogens (LSD and psilocybin (magic mushrooms)) has
declined slowly.4 Cocaine use has increased slightly over the total period, but has
been in decline since 2008-2009.4
The BCS also shows that there has been a long-term downward trend in current
drug use in the 16 to 24 years age group, largely due to a significant reduction in
the use of cannabis and amphetamines (see Figure 2).4 Similar trends have been
reported in Northern Ireland and Scotland.5,6
The number of problem drug users aged 15 to 64 years in the UK is approximately
10 per cent of all drug users. It has increased from 357,160 (9.26 per 1,000
population) in 2006 to a peak of 404,884 (10.10 per 1,000 population) in 2009, 
an increase of 9.07 per cent.1 This has since declined to 379,262 people 
(9.31 per 1,000 population).1 It is worth noting that, while current use of illicit drugs
in the UK has been declining since the 1990s, trends (outlined elsewhere in this
report, see Sections 3.3, 3.4 and 5.10) in problem drug use, drug-related deaths,
recorded drug law offences and the number of people in/expenditure on drug
treatment, are not showing a long-term decline, and in many cases are increasing.
This has important policy implications, which are discussed in more detail in 
Chapter 11.
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Figure 1 – Proportion of 16 to 59 year olds reporting having used drugs in the last
month, England and Wales, 1996 to 2010-2011
Source: Home Office (2012) Drug misuse declared: findings from the 2010/11 British Crime Survey. England and
Wales (2e). London: Home Office.4 Reproduced under the terms of the Open Government Licence for public
sector information.
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Figure 2 – Proportion of 16 to 24 year olds reporting having used drugs in the last
month, England and Wales, 1996 to 2010-2011
Source: Home Office (2012) Drug misuse declared: findings from the 2010/11 British Crime Survey. England and
Wales (2e). London: Home Office.4 Reproduced under the terms of the Open Government Licence for public
sector information.
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2.3 Young people and use of illicit drugs
Use of illicit drugs among young people under the age of 16 years broadly mirrors
that of the UK adult population. According to Smoking, drinking and drug use
amongst young people in England 2011, 12 per cent of 11- to 15-year-old pupils
reported taking drugs in the last year, and 6 per cent did so in the last month.8
Similar proportions of boys and girls had ever taken drugs or used drugs in the last
year, while slightly more boys reported taking drugs in the last month compared to
girls (7% and 5% respectively).8 There has been a broad decline in drug use in 11 to 
15 year olds since 2001.8
The survey also found that:
• 11- to 15-year-old pupils were most likely to have taken cannabis (7.6% in the 
last year), or to have sniffed glue, gas or other volatile substances (3.5%)
• 2.3 per cent of pupils reported taking a Class A drug in the last year
• most pupils who took drugs did so relatively infrequently: 3 per cent had only ever
taken drugs once in the last year, 3 per cent said they had taken them on two to five
occasions, and 1 per cent reported having taken drugs on six to ten occasions.
Repeated drug use, on more than ten occasions was reported by 3 per cent of pupils
• those pupils reporting Class A drug use were more likely to take drugs at least once
a month.8
The 2005-2006 cross-national Health Behaviour in School-aged Children (HBSC) study
found that of the 41 countries and regions surveyed, use of cannabis among 15 year
olds was particularly high in North America, the UK, France, Spain and Italy, especially
among boys.9 The 2007 European School Survey Project on Alcohol and other Drugs
(ESPAD) found that in Europe, UK teenagers were among the most likely to report
recent and current use of cannabis, and were above the European average reported
level for lifetime use of illicit drugs other than cannabis.10
2.4 Emerging trends
The use of a range of new substances – commonly referred to as ‘legal highs’ – is
becoming increasingly prevalent in night-life settings and among specific populations
such as the lesbian, gay, bisexual and transgender (LGBT) community. These include
GBL, BZP, oripavine, mephedrone,11 a number of anabolic steroids and growth
promoters, and herbal smoking mixes such as Spice (see Appendix 2). As these
were only recently brought under control of the Misuse of Drugs Act 1971, there is
only limited information on their use in the general population. As a result of this
control, the term ‘legal highs’ is no longer appropriate and the ACMD favours the
term ‘novel psychoactive substances’. A significant rise in the use of mephedrone
was reported in 2009, which led to its control under the Misuse of Drugs Act 1971
in 2010.11 The 2011-2012 Crime Survey for England and Wales found that 1.1 per cent
of adults aged 16 to 50 years reported using mephedrone in the last year, compared to
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0.1 per cent for Spice and other cannabinoids and 0.1 per cent for BZP.4 The level of
reported mephedrone use (1.1%) in this age group was similar to that for ecstasy.
Younger adults (aged 16 to 24 years) were more likely to have used recently
classified drugs in the last year than adults aged 25 years and over.3 For adults aged
16 to 24 years, the level of mephedrone use (3.3%) was the same as for ecstasy, 
the third most taken drug within this age group.4
There is emerging evidence that novel psychoactive substances are increasingly being
sought as an alternative to ecstasy.1 In light of the rate at which these new substances
are coming onto the market, it is not yet clear whether they will be more or less harmful
than the psychoactive substances already commonly used.
2.5 Attitudes to illicit drug use and policy in the UK
Public attitudes to illicit drug use and policy have varied over time. While there has been
limited systematic research in this area, a number of surveys and polls provide an
indication of public opinion on drug use.
A 2004 review of the international evidence of attitudes to drug policy concluded that
support in the UK for relaxing the laws on cannabis had grown considerably over the
last decade, among the general population (particularly men) and various professional
groups (notably the police, doctors and MPs).12 It found that more than four in five
people supported rescheduling cannabis to allow medical use,e and a substantial
minority believed in reforming the laws on personal use – including up to one in two
who supported decriminalising or legalising possession (see Glossary for a detailed
description of these terms), and about one in four who endorsed some form of
legalised supply.14 Support for legalisation of any other drug was found to be no higher
than 10 per cent in general population surveys, though it has been notably higher
among surveys of some sections of the young adult population (eg dance-clubgoers,
students, drug users).14
Two recent YouGov surveys (in 2006 and 2011) have considered the attitudes of the
general public to drugs:f
• in 2011, 48 per cent of all respondents agreed that drug use was a serious problem
that affects practically the whole country, compared to 51 per cent in 2006
• in 2011, 59 per cent felt that, where individuals use drugs but have not committed
any other crime, they should be treated as people who may need medical treatment
and other forms of support, compared to 62 per cent in 2006
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e The BMA report Therapeutic uses of cannabis, published in 1997, concluded that although cannabis is unsuitable for medical
use, individual cannabinoids have a therapeutic potential in a number of medical conditions in which present drugs or other
treatments are not fully adequate.13
f The 200714 and 201115 surveys on behalf of the Royal Society for the encouragement of Arts, Manufactures & Commerce (RSA)
Commission on Illegal Drugs, Communities and Public Policy, were of 2,938 and 2,928 adults in Great Britain, respectively. 
• in 2006, 58 per cent of all respondents said that possession of ‘soft’ drugs, such as
cannabis, for personal use should be treated as a lesser offence or not treated as an
offence at all
• in 2006, 80 per cent of all respondents considered that people’s knowledge of the
ABC classification had little or no impact on their choice of which drugs, if any, to use
• in 2006, 10 per cent of drug users said they had held back from seeking treatment,
because of the stigma of illegality
• in 2011, 53 per cent of all respondents believed that the Government’s approach to
illegal drugs was totally ineffective.14,15
A number of other surveys have found that the attitudes towards illicit drug use, 
in particular opioid and cannabis use, have changed since the start of the 
21st century.16,17 There is a trend towards better understanding of the health 
harms associated with drug use and greater agreement with maintaining the illegal
nature of drugs.16,17
The 2009 Scottish Social Attitudes (SSA) survey found that 34 per cent of respondents
believed that people in possession of small amounts of cannabis should not be
prosecuted, while support for the legalisation of cannabis fell from 37 per cent in 2001
to 24 per cent in 2009.17 Similar views were found in the 2009 British Social Attitudes
(BSA) survey, which reported that 58 per cent of participants felt that cannabis should
remain illegal, compared to 46 per cent in 2001.16
This change in attitudes is also reflected in the views about the harms of illicit drug use
and its acceptability. The proportion of respondents to the 2009 BSA survey who
supported the statement ‘cannabis isn’t as damaging as some people think’ decreased
from 46 per cent in 2001 to 24 per cent in 2009.16 The 2009 SSA survey found that
the number of respondents who disagreed with the statement ‘using illegal drugs
should be accepted as a normal part of some people’s lives’ increased from 40 per cent
in 2001 to 57 per cent in 2009.17 This was particularly noticeable in the age group 18
to 24 years, where disagreement with the statement increased from 48 per cent in
2001 to 86 per cent in 2009.17 Other findings from the SSA include:
• individuals who reported ever having used drugs and/or to have had indirect
experience of drug use (through family and friends) were more liberal in their
attitudes towards drug use
• 54 per cent of respondents agreed with the statement that taking cocaine
occasionally is ‘very seriously wrong’
• 45 per cent of respondents thought that persistent heroin users themselves were to
blame for their problems with heroin
• 29 per cent of respondents agreed with the statement ‘most users come from
difficult backgrounds’.17
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In relation to young people’s attitudes to illicit drug use, this varies depending on
drug type. Smoking, drinking and drug use amongst young people in England 2011
found that relatively small proportions of pupils thought it was acceptable for
someone of their age to try cannabis (9%), sniffing glue (7%) or taking cocaine
(2%). Even smaller proportions thought it would be acceptable for someone their
age to take any of these drugs once a week (cannabis 4%, sniffing glue 2%, 
cocaine 1%).8
2.6 International perspectives
According to the UNODC World Drug Report 2012, approximately 230 million
people (5% of the population aged 15 to 64 years) worldwide used illicit substances
at least once in 2010.18 By comparison, 10 per cent of 16 to 59 year olds in the UK
had used drugs in the last year.1 Cannabis users comprise the largest number of
users of illicit drugs (119 to 224 million people and an annual prevalence between
2.6% and 5% of the global population aged 15 to 64 years), followed by users of
amphetamine-group substances (including amphetamine, methamphetamine and
ecstasy), cocaine and opioid drugs.18 It is estimated that there were 27 million
problem drug users in the world in 2010, representing between 10 and 13 per cent
of all people who used drugs that year.18 This is similar to the ratio of problem drug
users to total drug users in the UK (see Section 2.1).
Information on the global drug markets provides an indication of recent global
trends. Behind North America, Europe is the second largest cocaine market, with the
UK highest within Europe, followed by Spain, Italy, Germany and France.18 Recent
data suggest that the rapid growth of the European cocaine market is beginning to
level off in the majority of the larger markets, except in the UK, where consumption
is increasing.18 While western Europe is the second largest heroin market worldwide
– consisting predominantly of the markets in the UK, Italy and France – heroin use is
declining in most west European countries.18 There is limited information on the
international cannabis market, as much of the drug is produced locally. The most
notable global trend is the growth of indoor cultivation, in particular in Europe,
Australia and North America.18
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Summary
• There has been a long-term downward trend in illicit drug use in the UK, although
use of cocaine has increased slightly. In 2009-2010, 5 per cent of 16 to 59 year olds
in the UK population were current drug users (had used drugs in the last month).
• Men are more likely than women to report drug use and current use is highest in
the under-25 age group.
• International evidence suggests 10 to 13 per cent of all people who use drugs
worldwide are problem drug users. Problem drug use affects approximately 
10 per cent of all UK drug users, with the highest levels in the 25 to 34 years 
age group.
• Cannabis is the most commonly used drug, followed by cocaine powder, ecstasy
and amphetamines.
• After North America, Europe is the next largest cocaine market and the UK is the
largest market in Europe.
• In Europe, UK teenagers are among the most likely to report recent and current
cannabis use, and are above the European average reported level for lifetime use
of other illicit drugs.
• There are few reliable data on novel psychoactive substances, gamma-
butyrolactone (GBL), 1-benzylpiperazine (BZP), mephedrone, oripavine, anabolic
steroids, Spice, etc), which have only been controlled under the Misuse of Drugs
Act 1971 since 2009, but they appear to be used more by younger age groups
and as an alternative to ecstasy.
• Around half the UK population surveyed considers drug use is a serious problem;
and slightly more believe drug users should be treated as individuals needing
medical treatment or other support.
• A majority of those interviewed in the British Social Attitudes survey in 2011
believed cannabis should remain illegal and is harmful; this has increased 
since 2009.
• A majority interviewed for the Scottish Social Attitudes survey thought illegal drug
use should not be accepted as a normal part of some people’s lives and the
proportion has also increased from 2001 to 2009; this is particularly noticeable in
the 18 to 24 years age group. Less than 10 per cent of pupils interviewed in
England in 2010 thought use of any illicit drugs was acceptable.
• Over half the UK population interviewed in 2011 believed the Government’s
approach to illicit drug use is totally ineffective.
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Chapter 3 – The burden of
illicit drug use
3.1 Introduction
The use of illicit drugs – particularly strongly addictive drugs like heroin, cocaine and
methamphetamine – is associated with a range of physical, psychological and social
harms. This can include deaths from overdose, long-term adverse effects on health,
dependence, and harms to families and communities. This chapter considers the harms
associated with drug use per se. The harms associated with the regulatory framework
of drug prohibition are considered in Chapter 6.a
Not all illicit drugs are equally harmful and the extent of harm varies between
individuals and depends on the level and pattern of drug use, as well as the
pharmacological properties of each drug. Harm is also influenced by the setting in
which the substances are used and the combination of substances used.
The level of harm is affected by:
• the dosage of the drug – the more of a drug that is taken on a specific occasion,
the higher the risk of the user experiencing acute effects, including intoxication and
overdose. The greater the amount taken over time, the higher the risk of chronic
toxic effects. An additional risk with illicit drugs is that a user may be unaware of the
exact dose they are taking; a dose that is higher than expected will increase the risk
of harm or fatality
• the pattern of drug use – which is determined by the frequency and variability of
drug use
• the mode of administration – which depends on the way the drug is ingested 
(eg swallowed, snorted, injected, etc).1
The level of harm will also be affected by the purity of the drug. Many illicit drugs are
commonly found to contain adulterants that can increase the risk of morbidity and
mortality (see Section 3.3.4).
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a While we discuss the harms from drug use per se and those from prohibition and other social reactions to drug use separately, it
is worth noting that in practice there is often a mixture.
3.2 Measuring the level of harm
In the last two decades, there have been a number of attempts to measure and rank
the relative level of harm associated with different psychoactive substances.2-7
These have used various measures of harm, including a drug’s safety ratio 
(usual effective dose for non-medical purposes divided by the usual lethal dose),
intoxicating effect, general toxicity, social dangerousness, dependence potential and
social and healthcare costs. It is worth noting that, while these evaluations do not
directly consider the epidemiology of the respective drugs, some of the criteria 
(eg the harm that a drug causes to those other than the user) indirectly take account
of the number of users.
In 2010, a Dutch addiction medicine expert group conducted a risk assessment of 
19 recreational drugs (17 illicit drugs plus alcohol and tobacco), and ranked them on
the basis of acute and chronic toxicity, addictive potency and social harm.8 The study
ranked alcohol, tobacco, heroin, crack cocaine and methamphetamine as being most
harmful, with benzodiazepines, GHB, cannabis, ecstasy and ketamine scoring in the
moderately harmful range.8 Psilocybin (magic mushrooms), LSD and khat were
regarded as the least harmful of the drugs in the study.8
Similar conclusions were made in a 2010 study by Nutt and colleagues.2 This study
involved a multicriteria decision analysis of the level of harm associated with the 
use of different drugs in the UK. Each drug was scored out of 100 points based 
on 16 criteria, nine of which related to the individual harms, and seven to the 
harms caused to others.2 The study found that heroin, crack cocaine, and
methamphetamine were the most harmful drugs to individuals.2 Alcohol, heroin,
crack cocaine and cannabis were scored as the most harmful to others.2 Overall, 
the most harmful drug was found to be alcohol, followed by heroin, crack cocaine,
methamphetamine and cocaine (see Figure 3).2
Nutt et al and the authors of the Dutch study concluded that their findings on the
relative levels of harm for the different drugs correlated poorly with the legal
classification of drugs;2,8 legal substances such as tobacco and alcohol were found 
to be at least as harmful as commonly used illicit drugs.
It is important to note that the methodology for these studies evaluating and
ranking drug harms has been questioned by Rolles and Measham9 and Caulkins et
al.10 This primarily concerns the difficulty in quantifying the multiple and non-
comparable dimensions of harm in a single measure, and the failure to disaggregate
harms related to drug use from those related to drug user behaviours and the policy
environment.9,10 Several rebuttals were published in response to the critique by
Caulkins et al (including from the principal author of the 2010 study, Professor David
Nutt). These noted that the importance of developing new approaches to ranking
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drug harms was to progress the debate among policy makers and the public
regarding the validity of the way illicit drugs are classified.11-15
Figure 3 – Drugs ordered by their overall harm scores, showing the separate
contributions to the overall scores of harms to users and harm to others
Reprinted from Nutt DJ, King LA & Phillips LD (2010) Drug harms in the UK: a multicriteria decision analysis. The
Lancet 376: 1558-65,2 ©2010, with permission from Elsevier.
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3.3 Primary and secondary health harms
The primary health harms associated with illicit drug use result from the acute and
chronic toxic effects of individual drugs, as well as drug dependence (ie where the risk
of harm is intrinsically raised due to the chronic drug use). Acute toxicity can lead to
short-term harms, ranging from unpleasant side-effects such as vomiting and fainting,
to more serious impacts such as seizures, tissue and neural damage or death. In the
longer term, repeated drug use can lead to chronic physical and psychological health
effects, as well as dependence.
3.3.1 Drug-related deaths: overdoses, poisoning 
and suicides
While Section 2.2 notes that current use of illicit drugs in the UK has been declining
since the 1990s, the number of recorded drug-related deathsb in the UK increased by
67.5 per cent between 1996 and 2010, with year-on-year fluctuations (see Figure 4).17
In 2010, there were 1,930 drug-related deaths, equivalent to a rate of 3.10 per
100,000 population (all ages).17 The vast majority of these were among men (79.4%)
and the rate was highest in the 35 to 39 years age group. Deaths in all age groups
decreased from the previous year, with the exception of the oldest age group (60 plus
years) (see Figure 5). The largest decrease was seen among those aged 20 to 29 years
(25.6%). The difference in trends for the 20 to 29 and 40 to 49 years age groups in
Figure 5 (with an ageing trend observed among overdose deaths) suggests there may
be an ageing cohort effect.
Most of the drug-related deaths in the UK continue to be linked to the use of opioid
drugs, primarily heroin/morphine and methadone, followed by cocaine and ecstasy (see
Table 2).17 Overdoses related to opioid use are predominantly caused by respiratory
depression, while cocaine-related deaths usually result from myocardial infarction or
stroke, and ecstasy-related deaths from hyperthermia or hyponatraemia and reduced
resilience to other concurrent threats (see Appendix 3 for more details).1 It is worth
noting that some categories of illicit drugs, including cannabis, present no risk of death
by overdose.
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b Defined as deaths caused directly by the consumption of at least one illegal drug. Interpretation of these data should be treated
with caution, as death certificates do not always state specific drug types, which could lead to under-reporting, or deaths may
be counted in more than one category. 
Figure 4 – Drug-related deaths in the UK, 1996 to 2010
Source: Davies C, English L, Stewart C et al (2011) United Kingdom drug situation: annual report to the
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2011. London: United Kingdom Focal
Point at the Department of Health.17 Reproduced with the permission of the UK Focal Point on Drugs,
Department of Health.
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Figure 5 – Drug-related deaths by age group in the UK, 1998 to 2010
Source: Davies C, English L, Stewart C et al (2011) United Kingdom drug situation: annual report to the
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2011. London: United Kingdom Focal
Point at the Department of Health.17 Reproduced with the permission of the UK Focal Point on Drugs,
Department of Health.
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Table 2 – Drug mentions on death certificates in the UK, 2002 to 2010
Drug Year Percentage
change 
2002 2003 2004 2005 2006 2007 2008 2009 2010 (2002-10)
Heroin 1,118 883 977 1,043 985 1,130 1,243 1,210 1,061 –5.1
Methadone 300 292 300 292 339 441 565 582 503 +67.6
Cocaine 161 161 192 221 224 246 325 238 180 +11.8
Ecstasy 79 66 61 73 62 64 55 32 9 –88.6
Source: Davies C, English L, Stewart C et al (2011) United Kingdom drug situation: annual report to the
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2011. London: United Kingdom Focal
Point at the Department of Health.17 Reproduced with the permission of the UK Focal Point on Drugs,
Department of Health.
Various studies have estimated that the annual death rate for ‘high-risk’ drug users,
such as those who illegally inject opioid drugs, is between 1.1 per cent and 
2.0 per cent.18-21 Increased risk of death from drug overdose has also been found 
to be associated with poverty, homelessness, polydrug and polysubstance use 
(see Glossary), impaired physical health, depression and a previous history of drug
overdose.21-23 Illicit drug users are known to have higher rates of completed and
attempted suicide compared to the general population, and this is associated with
psychopathology, family dysfunction, social isolation and polydrug use.21
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3.3.2 Short- and long-term health harms
Illicit drug use can lead to a range of short- and long-term adverse health impacts.24-26
A detailed overview of the latest scientific evidence about the health-related harms of
emerging and established licit and illicit psychoactive drugs commonly used in the UK
is provided in Appendix 3.
Amphetamine and methamphetamine
Acute and chronic amphetamine and methamphetamine use is associated with a wide
range of complications, although their incidence is unclear.27 These complications
include:
• cardiovascular disorders
• central nervous system (CNS)/psychiatric complications
• pulmonary disorders
• gastrointestinal complications
• metabolic disorders.26,28,29
Deaths from amphetamine and methamphetamine use are reported, but are relatively
uncommon.30,31
Psychological dependence on amphetamine occurs in 30 to 40 per cent of repeated
users,24 but cessation of use is not associated with any physical symptoms. The use 
of methamphetamine (injected or smoked) in its crystal form (crystal meth) is also
associated with a high potential for psychological as well as physical dependence.25,32-36
Cannabis
The effects of cannabis are dependent on the strength and type used. Acute cannabis
intoxication (at high doses) can result in anxiety and panic attacks, paranoia, dysphoria,
cognitive impairment, perceptual distortions and confusion/delirium.24,26
Death caused directly by an overdose of smoked cannabis is not possible. Chronic use 
is associated with impaired pulmonary function, recurrent bronchitis, worsening of
asthma and lung cancer (from carcinogens in cannabis and tobacco smoke).c Animal
studies suggest that heavy use may cause disruption of ovulation, sperm production
and sperm function.24,26,39,40
Cannabis use is also associated with psychological harm, although there is considerable
scientific disagreement regarding the relationship between the two. There is broad
agreement in the medical community that:
• regular heavy users may suffer repeated, short episodes of psychosis and effectively
maintain a chronic psychotic state
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c The evidence for the association between cannabis and lung cancer is unclear, owing to the difficulty in ruling out tobacco use as
a confounder. Some studies report an increased risk,37 while other studies find no link.38
• cannabis use may trigger relapse or exacerbate existing symptoms in patients with
schizophrenia, and may precipitate psychotic symptoms in individuals predisposed to
developing schizophrenia. At an individual level, cannabis users have a two-fold
increase in the relative risk for later developing schizophrenia, while at a population
level, the effect size is relatively small, as eliminating its use in those at risk would
reduce the incidence of schizophrenia by 8 per cent.24,41-45
Emerging evidence also suggests that heavy cannabis use by adolescents increases
the risk of depression and schizophrenia in later life, especially in individuals who
already have a vulnerability to develop a psychiatric syndrome.46-48 Regular cannabis
use during adolescence has also been found to result in declines in intelligence
quotient (IQ). A 2012 study found that persistent regular cannabis use over 20 years
was associated with neuropsychological decline broadly across the domains of
functioning (ie executive function, memory, processing speed, perceptual reasoning
and verbal comprehension).49 This effect was concentrated among adolescent-onset
users, and the cessation of cannabis use did not fully restore neuropsychological
functioning in this group.49
Approximately 10 per cent of people who have ever used cannabis develop features
of dependence, which is associated with chronic regular use and may be physical or
psychological.24
Cocaine and crack cocaine
Cocaine use is linked to a high incidence of cardiac arrhythmias and sudden death
from overdose, mainly owing to cardiovascular and cerebrovascular complications.50-61
The risk of cocaine toxicity is influenced by concomitant use of other drugs, in
particular alcohol and heroin.61 Many deaths caused by cardiovascular complications
occur in individuals with pre-existing risk factors or conditions induced by chronic
cocaine use, such as left ventricular hypertrophy, coronary atherosclerosis or vascular
malformations in the brain.62,63
While cardiovascular and cerebrovascular complications are the most common adverse
health consequences,64 acute and chronic cocaine use can also lead to:
• respiratory disorders, either acute (pulmonary oedema, pulmonary infarction,
haemoptysis) or chronic (eg pulmonary hypertension)
• genitourinary and obstetric disorders, either acute (acute renal failure, mediated by
rhabdomyolysis or direct toxicity, testicular infarction, placental abruption,
spontaneous abortion) or chronic (premature birth, growth retardation)
• gastrointestinal complications (mesenteric ischaemia or infarction)
• psychiatric disorders (euphoria, dysphoria, agitation, anxiety, suicidal thoughts,
paranoid psychosis, depression)
• musculoskeletal and dermatological disorders.62
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Ecstasy
The incidence of serious acute adverse events related to ecstasy use is low and their
occurrence is unpredictable.65,66 Ecstasy-related deaths have received a lot of media
attention,67 but they are rare and usually result from hyperthermia or acute
hyponatraemia (where a user drinks too much water to avoid dehydration), which can
ultimately lead to cerebral oedema.66,68
In the short term, regular use of ecstasy can lead to sleep problems, lack of energy,
dietary problems and increased susceptibility to colds and flu. It is also associated with a
range of psychological effects, including anxiety, visual hallucinations and paranoia.24
In the longer term, ecstasy can cause psychological dependence as users seek the
feelings of euphoria and calmness associated with its use.24,68,69 There is little evidence
for long-term physical dependence associated with ecstasy.68
There is also little evidence of longer-term harm to the brain in terms of either its
structure or function.66 There is some evidence for a small decline in a variety of
domains, including verbal memory, even at low cumulative doses.68,70,71 The magnitude
of such deficits appears to be small and their clinical relevance is unclear.
GHB
Use of GHB at high doses can lead to overdose, which is commonly associated with
acute complications such as unconsciousness, vomiting, tremors, headache and
confusion.72-74 Severe intoxication can lead to deep coma and breathing difficulties, 
and GHB-related deaths have been reported in rare cases.75 As well as developing
psychological dependence, users can become physically dependent on GHB.76,77
Although this is rare, it can be severe, with a rapid onset of severe withdrawal
symptoms including delirium, psychosis, tremor, insomnia and severe anxiety.78
Dependence can develop from severe bingeing over a short period, or may result
from regular use over a longer period. 
Adverse effects of the related drugs GBL and 1,4-butanediol (1,4-BD) are listed in
Appendix 3.
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Heroin and other opioid drugs
As noted previously, opioid overdose is the most common cause of drug-related death
in the UK (predominantly from respiratory depression and drop in blood pressure
resulting in respiratory arrest).17 A number of common correlates of overdose fatality
have been identified, which include:
• a long history and high level of opioid dependence
• recent abstinence (eg prison, detoxification release)
• polydrug or polysubstance use (particularly with alcohol, which seems to be a factor
in approximately half of overdoses, and benzodiazepines)
• being male
• increasing age (most fatalities occur among those in their 30s)
• social isolation
• eurocognitive deficits.26
As discussed in Sections 3.1 and 3.3.4, the strength and purity of the drug also affect
the risk of overdose.
In the short term, acute intoxication causes a range of common side-effects (eg nausea,
vomiting, constipation, drowsiness and mental confusion), and in some cases
hallucinations, dysphoria, sweating and itching.26 Rare features of acute intoxication
include complications associated with non-fatal overdose (eg hypoxia causing brain
damage), and disease of the white matter of the brain (leukoencephalopathy) resulting
from inhalation of heroin vapours.26
Chronic use of opioids is associated with an increased risk of mortality (from overdose
and route-specific hazards – see Section 3.3.5), and a suicide rate that is higher than
that of the general population.26,79,80 A number of chronic complications can also occur,
which include:
• constipation, dry mouth, menstrual irregularity, malnutrition, anorexia, tooth decay,
decreased sexual desire and performance
• respiratory diseases (asthma, chronic obstructive pulmonary disease)
• modest suppression of hormone levels
• suppression of the immune system, social deprivation and malnutrition.26
Opioid dependence is characterised by profound psychological and physical
dependence and can develop through use of heroin, opium and other illicit opioids, as
well as prescribed medications such as methadone and buprenorphine. When
untreated, approximately 30 per cent of heroin-dependent individuals will have died by
10 years from overdoses,24 or as a result of secondary complications, as described in
Section 3.3.5. Those on prescribed heroin do not have a lower life expectancy.
Individuals who are opioid dependent are five times more likely than the general
population to have a depressive disorder, and three times more likely to be affected by
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an anxiety disorder.24 It is unclear whether this is a causal relationship. Withdrawal from
opioid dependence is rarely life threatening, but can lead to a range of unpleasant
symptoms (eg nasal discharge, sweating, sleep disturbance, anorexia, restlessness,
irritability, tremor, weakness, depression, nausea, vomiting, abdominal cramps, muscle
spasms and diarrhoea).
Hallucinogens (including LSD and psilocybin)
The hallucinogenic effects of LSD and psilocybin (magic mushrooms) vary, depending on
the dose, and the situation the user is in. In the short term, their use leads to an
increased risk of accidental death, violence and injuries, owing to perceptual distortions
and impaired decision making.26
A range of acute psychological/psychiatric effects are associated with the use of these
hallucinogens:
• dysphoria
• distortions in shapes and colours
• illusions, delusions
• anxiety, panic, depression
• dizziness, disorientation and impaired concentration
• frequent mood changes
• recall of psychologically troubling memories
• short-lived psychotic episode (hallucinations, paranoia)
• precipitation of relapses in schizophrenia.26
Chronic use of LSD and psilocybin (magic mushrooms) can lead to depression and
feelings of isolation or delirium, and brief flashbacks or recollection of previous
hallucinatory experience may occur days or months after use.26 In rare cases, it can 
also cause persistence of low-level hallucinations, known as hallucinogen persisting
perception disorder.26 Only a few users of hallucinogens experience signs or symptoms
of dependence.26
Adverse effects of the hallucinogens mescaline and N,N-dimethyltryptamine (DMT) are
listed in Appendix 3.
Ketamine and phencyclidine 
Ketamine and PCP are dissociative anaesthetics that can cause loss of coordination and
control.81 This can lead to an increased risk of death and injury as a result of accidents,
as well as respiratory depression, loss of consciousness and coma.26 There have been
rare reports of overdose deaths from heart attack or respiratory problems associated
with the use of ketamine, while PCP can cause death as a result of hyperthermia and
convulsions.26 The use of these dissociative anaesthetics can also lead to acute and
chronic psychological and psychiatric symptoms such as hallucinations, impaired
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attention and cognitive functioning, confusion, panic attacks and paranoia, depression,
and extreme loss of motor skills (catatonia).
Chronic heavy use of ketamine can lead to ulcerative cystitis (marked thickening 
of the bladder wall and severe inflammation)82-84 and abdominal pain.26 There is
limited evidence that ketamine dependence and tolerance may occur among regular
heavy users, but there is no evidence to suggest withdrawal symptoms. There is also
some evidence that dependence and withdrawal syndrome can develop with chronic
PCP use.26
Other psychoactive drugs
Adverse effects of nitrites; novel psychoactive substances such as substituted
cathinones, 2C series phenylalanines and tryptamine derivatives; khat; and Salvia
divinorim are all listed in Appendix 3.
Polydrug use
Polydrug use or the combination of illegal drugs with alcohol (polysubstance use) 
can lead to an increased risk of serious health harm and death. This can result from
pharmacokinetic factors (eg reduced metabolism) or drug interactions, or directly 
from the drugs’ toxic effects. The use of one psychoactive substance can also lead to
increased risk behaviour with another substance (eg alcohol use may reduce the
capacity to judge the amount of opioids consumed).
Many of the drug-related deaths that occur among problem drug users, which most
commonly involve opioid overdose, are also linked to polydrug use (including tobacco
and alcohol).85 Chronic polydrug use can also lead to increased mortality from other
diseases, as the continued use of several substances leads to longer-term toxicities in
various organs or body systems.86
A specific example of chronic health damage resulting from polysubstance use is the
high prevalence of tobacco smoking among individuals with cocaine-associated
myocardial infarction.87,88 Table 3 provides an overview of the harms associated with
the concurrent use of specific substances.
BMA Board of Science
Drugs of dependence: the role of medical professionals 49
Table 3 – An overview of the harms associated with the concurrent use of specific
substances
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Drug Effects associated with concurrent use of:
Alcohol Illicit drugs
Amphetamines • Increases perceived total
intoxication
• Increases adverse
cardiovascular effects
Cocaine
• Limited evidence; may have
adverse consequences on the
CNS
MDMA (ecstasy) and
related analogues
• Reduces subjective sedation
associated with alcohol, but
not alcohol-induced
impairments
• Increases plasma levels 
of MDMA
• Decreases blood 
alcohol levels
• May enhance the temporary
impairment of immune cells
associated with MDMA use
(transient immune dysfunction)
Cannabis
• Users may potentially
experience cumulative CNS
impairment
• May increase susceptibility to
infection
Cocaine
• Evidence from animal studies
suggests an increased risk of
neurotoxicity
Cannabis • Reduces driving performance
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Drug Effects associated with concurrent use of:
Alcohol Illicit drugs
Cocaine • Increases blood levels of
cocaine and the active
metabolite cocaethylene; users
may perceive a more intense
feeling of intoxication
• Users may perceive a
reduction in the sedating
effects of alcohol
• Combination potentially
increases adverse
cardiovascular effects
• Patients with coronary artery
disease or alcohol dependence
may be particularly vulnerable
to the combined toxic effects
of alcohol and cocaine
Ketamine
• Potential to exacerbate the
cardiovascular risks of
cocaine (crack)
Methadone
• Increases adverse
cardiovascular effects 
(eg increased blood pressure
and heart rate) 
GHB • Increases the risk of
respiratory depression
• None documented
Opioids • Increases the depressant
effects of alcohol on the
CNS; can be fatal
• Acute use of alcohol and
methadone appears to result
in lower blood-alcohol levels
– the clinical significance is
unclear
Benzodiazepines
• Increase the depressant
effects of opioids on the CNS
Nitrites • None documented Use of drugs for treating
erectile dysfunction 
(eg viagra)
• Increases the hypotensive effects
(abnormally low blood pressure)
Source: Jones L, Bates G, Bellis M et al (2011) A summary of the health harms of drugs. London: Department
of Health.26 Reproduced with the permission of the Department of Health.
3.3.3 Effects on the fetus
Fetal development can be adversely impacted by maternal drug use. The BMA has
previously considered the effects of prenatal alcohol exposure and smoking on the
unborn fetus in its 2007 report Fetal alcohol spectrum disorders – a guide for healthcare
professionals (2007)89 and its 2004 report Smoking and reproductive life – the impact 
of smoking on sexual, reproductive and child health.90
The risk of harm to the fetus from maternal drug use is generally considered to be
greatest during the first trimester (especially the first 8 weeks),24 although the second
and third trimesters remain critical periods of exposure for fetal development. Damage
may also be caused before the woman knows that she is pregnant. Evidence is
continuing to emerge on the adverse effects of a number of specific drugs:
• babies born to opioid-dependent mothers may suffer neonatal abstinence syndrome.
This can be characterised by short-term withdrawal symptoms affecting the CNS, the
respiratory system and the gastrointestinal tract24
• cocaine causes reduced blood flow to the placenta, thereby increasing the risk of
placental abruption.26,91 Maternal cocaine use is also associated with an increased risk
of spontaneous abortion and premature delivery, as well as sudden infant death
syndrome (SIDS) 24,92
• a greater risk of prematurity and intra-uterine growth retardation is associated with
multiple drug use.24
There is also likely to be an increased risk of fetal harm from pregnant drug users who
lead chaotic lifestyles (including as a result of the illegality of the drugs), as this can lead
to poor nutrition and maternal health, as well as poor antenatal attendance.
3.3.4 Adulterants
Illicit drugs are commonly found to contain substances in addition to the purported
active ingredient.93,94 These adulterants – any substance or organism found in illicit
drugs at the point of purchase other than the active ingredient – can increase the risk of
morbidity and mortality. They are commonly added to enhance or mimic the effects of
an illicit drug (eg procaine in cocaine), or to facilitate its administration (eg caffeine in
heroin).93 Contaminants such as bacteria or other biological agents may adulterate illicit
drugs, as a result of poor or unsterile manufacturing and production techniques,
substandard packaging and inappropriate storage.93
Evidence from case reports has found that the adverse health impacts and deaths
associated with adulterants commonly result from poisoning, poor manufacturing
techniques or poor storage or packaging, or occur as a result of the effects of other
substances sold as the illicit drug.93 Key findings from the case reports include:
• heroin adulteration is mostly associated with poisonings (eg by lead, scopolamine and
clenbuterol) or bacterial infections
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• cocaine/crack cocaine adulteration is mostly associated with poisonings, with a wide
range of adulterants responsible, including phenacetin, thallium, benzocaine,
scopolamine, strychnine, levamisole and anticholinergic poisoning
• methamphetamine adulterants are mostly associated with poisonings, for example
with lead, toxic fumes and talcum powder
• two case reports detail the deaths of ecstasy users as a result of consumption of
tablets adulterated with paramethoxymethamphetamine (PMMA) and/or
paramethoxyamphetamine (PMA).
A more detailed overview of the evidence of drug adulterants, including information
on the potential reasons for their inclusion and the health effects, is provided in
Appendix 5.
3.3.5 Secondary health harms associated with injecting 
drug use
In addition to the direct adverse effects of illicit drug use, there can be a number of
secondary health impacts associated with the way in which the drug is used. People
who inject drugs and share needles are at risk of transmitting and acquiring a range of
infections, including HIV, hepatitis B (HBV), hepatitis C (HCV), and, if using in unhygienic
environments with unsterilised injecting paraphernalia, bacterial infections at the
injection site.
In the UK, HIV prevalence among people who inject drugs was 1.5 per cent in 2009,
compared to 0.8 per cent in 2000.17 This is matched by the increasing total prevalence
of HIV infection. In England and Wales, the estimated number of prevalent HIV
infections in 15 to 44 year olds increased from 1.5 per 1000 in 2000, to 2.4 per 1000 
in 2008.95 The proportion of these who were injecting drug users was 2.4 per cent.95
In 2009, the prevalence of HCV among people who inject drugs was much higher, at
48 per cent for England and Wales, compared to 38 per cent in 2000.17 Around one in
six people who inject drugs have ever had an HBV infection, and in this group the
prevalence of infection in England, Wales and Northern Ireland fell from 28 per cent in
2000 to 17 per cent in 2009.17 In the general population in the UK, HBV infection has
been estimated to affect 0.3 per cent and HCV 0.4 per cent.96
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3.3.6 Other secondary health harms
Other chronic secondary health harms include:
• the long-term adverse consequences of smoking cannabis on pulmonary function
(including airways obstruction and hyperinflation)97
• smoking crack cocaine can cause chest pain and lung damage98-101
• snorting cocaine powder can lead to nasal bleeding and stiffening of the facial
muscles, while heavy users may damage the nasal membranes or perforate the
nasal septum.54
3.3.7 Dependence
The repeated use of illicit drugs can lead to dependence syndrome – a cluster of
behavioural, cognitive and physiological phenomena that typically include a strong
desire to take the drug, difficulties in controlling its use, persisting in its use despite
harmful consequences, a higher priority given to drug use than to other activities
and obligations, increased tolerance, and sometimes a physical withdrawal state (see
Glossary). As can be seen from Section 3.3.2 and Appendix 2, repeated use of
some psychoactive drugs can lead to dependence.
Dependence per se is not necessarily significantly harmful but the risk of harm is
intrinsically raised because of the chronic drug use. In the case of heroin, for example,
as noted previously, its chronic use is characterised by profound psychological and
physical dependence.26 This chronic use significantly increases the risk of mortality
from overdose and acquisition of a drug-related infectious disease.
Different drugs vary in their propensity to give rise to dependence (dependence
potential, see Glossary). Illicit drugs such as heroin, crack cocaine and
methamphetamine – as well as the licit drugs, tobacco and alcohol – rank highly 
in their tendency to encourage repeated use.2
3.4 Social harms
Illicit drug use is associated with a range of potential social harms, including deprivation
and family adversity/neglect, criminality associated with intoxication, acquisitive crime
associated with obtaining drugs, drug-impaired driving, and drug-impaired workplace
performance. Some of these social harms result from the illegality of the drugs, while
others are caused by factors such as the psychopharmacological effects of the drug.
3.4.1 The social effects of illicit drug use on families
Certain patterns of illicit drug use can adversely affect family life, in many of the same
ways that problematic levels of drinking can: through domestic violence, loss of family
income, poor role models for children, accidents and injuries, malnutrition and eating
disorders, unemployment, social exclusion, self-harm and suicide, and problems in
relationships with friends and partners.1 Illicit drug use can significantly impact on family
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economic resources through direct expenditure on drugs, increased medical expenses,
reduced household income through drug-related morbidity and mortality, lost
employment opportunities, legal costs of drug-related offences, and decreased eligibility
for loans.1,16,102,103
The children of drug users are likely to be adversely affected in a number of ways,
including suffering from poverty, abuse and neglect, exposure to violence and crime,
risks of harm from drug paraphernalia, going into care, absence of a parent, and
disrupted schooling and education.104-106
3.4.2 Harm to communities – drug-related violence 
and crime
Drug-related crime falls into two categories. Drug law offences include possession,
dealing or trafficking of drugs covered under the Misuse of Drugs Act 1971. This is
dealt with in Chapter 5. Illicit drug use is also associated with a number of other
criminal behaviours, which in turn are linked to underlying socioeconomic factors.
In the UK in 2010-2011, there were 270,045 recorded drug law offences 
(39,966 (14.8%) of which were for trafficking, 228,425 (84.6%) for possession, 
and 1,384 (0.5%) for other drug offences), which was an increase (19.7%) from
225,670 in 2005-2006.17 The vast majority of these offences were for cannabis
possession.17 This increase contrasts sharply with the long-term decline in current
drug use outlined in Section 2.2).
Dependent use of drugs is associated with increased levels of acquisitive crime – such as
theft, street robbery, car break-ins and burglary – as a means to fund habits. The link
between illicit drug use and crime is complex and multifaceted, as not all drug types are
associated with all forms of crime, and some drugs are not associated with crime at all.
In England and Wales, according to the Home Office Arrestee survey 2003-2006, 81
per cent of regular (at least weekly) users of heroin or crack reported having committed
acquisitive crime in the 12 months prior to arrest, compared to 30 per cent of
respondents who did not use heroin or crack regularly (ie did not use them weekly).107
A report from the UK Government Strategy Unit in 2003 suggested that dependent
heroin and crack users ‘commit substantial amounts of crime to fund their drug use
(costing £16bn a year)’ and that ‘Drug use is responsible for the great majority of some
types of crime, such as shoplifting and burglary’, including ‘85% of shoplifting, 
70-80% of burglaries and 54% of robberies’.108 For dependent drug users with limited
alternative sources of income, particularly women, street sex work often becomes the
most viable source of fundraising to buy drugs. The UK Home Office has estimated that
more than 85 per cent of street sex work is drug motivated.109
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In addition to the criminality and violence associated with acquisitive crime, the
psychobiological effect of drugs may directly lead to violent behaviour; the drugs
most commonly linked to psychopharmacological violence include amphetamines and
cocaine.110 There is little evidence that the psychopharmacological effects of heroin,
cannabis, ecstasy or other hallucinogens are associated with violence and crime.110
It should be noted that the evidence for the psychopharmacological causation of violent
behaviour is weak (including for amphetamines and cocaine).110,111
Other social harms associated with the law relating to drug use are considered in detail
in Chapter 6.
A high level of drug use in the community is also linked to unsafe communities,
through increases in violent incidents, antisocial behaviour, prostitution, begging,
unusable public spaces, and people sleeping rough.112 This in turn can depress house
prices, reduce investment in the neighbourhood and create or maintain areas of
deprivation.
3.4.3 Drug-driving
Data on the levels of drug-driving in the UK are limited. While drug use cannot be
causally linkedd to road crashes, a number of small-scale studies provide some
information on its prevalence:
• in 1989, random samples from a number of road traffic accident fatalities showed
that only 3 per cent of the drivers involved in accidents had been driving with drugs
in their systems, compared to 35 per cent for alcohol (25% over the legal limit)113
• a 2001 study of fatal road accident casualties found that at least one impairing
prescription or illegal drug was detected in 24.1 per cent of the 1,184 casualties, 
and that alcohol was present in 31.5 per cent of the sample (21.5% over the legal
limit).114 The study identified cannabis as the drug most frequently found among
casualties. There was a substantial increase in the incidence of cannabis in fatal road
casualties, from 2.6 to 11.9 per cent over the period between the two studies. 
The authors found that those who had consumed drugs were no more likely to have
also consumed alcohol than drivers who had not used drugs – when considering
drivers over the legal limit for blood alcohol, there was no significant difference 
(at the 5% significance level) between those with no drugs, single drug use and
multiple drug use: 20.6 per cent, 17.3 per cent and 16.1 per cent respectively
• surveys of drug use among Scottish drivers arrested under Section 4 of the Road
Traffic Offenders Act 198817 have shown that cannabinoids were consistently present,
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d A causal link cannot be stated because of poor data levels and a lack of information on the effect of various drug levels on
driving performance.
ranging from 36 per cent in 2003 to 53 per cent in 2008, while cocaine was detected
in around 15 to 25 per cent of cases.115
Limited data are available internationally. A study by the EMCDDA, published in 2008,
concluded that the prevalence of drivers under the influence of drugs on EU roads had
increased significantly since the late 1990s.116 A Dutch study conducted in the mid-
1980s found that 8.5 per cent of injured drivers were under the influence of illegal and
impairing medicinal drugs.117 A similar survey conducted in 2000-2001 found the
proportion of injured drivers under the influence of illegal or impairing medicinal drugs
had increased to 30 per cent.118
3.5 The economic and social costs of illicit drug use
Estimates for the cost of illicit drug use to society in economic terms are limited 
(see Box 3). These include costs to the individual, such as the costs related to premature
death, drug-related illness and the loss of earnings through criminality/imprisonment,
sickness, temporary or permanent unemployment and reduced educational attainment.
The costs to society can be divided into four broad categories:
• healthcare service costs: including costs to primary care services and hospital
services (A&E, medical and surgical inpatient services, paediatric services, psychiatric
services, and outpatient departments)
• costs of drug-related crime, disorder and antisocial behaviour: including costs
to the criminal justice system, costs to services (eg social work services), costs of 
drug-driving, and the human cost of drug-related harm (eg domestic abuse, assault)
• loss of productivity and profitability in the workplace: including costs to the
economy from drug-related deaths and drug-related lost working days
• impact on family and social networks: including human and emotional costs such
as breakdown of marital and family relationships, poverty, loss of employment,
domestic and child abuse, and homelessness.
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Box 3 – Estimates for the costs of drug-related harm in the UKe
The economic and social costs of Class A drug use (cocaine, crack, ecstasy, heroin,
methadone, LSD and psilocybin (magic mushrooms)), in 2003-2004 in England and
Wales were estimated by a Home Office report to be £15.4 billion, equating to
£44,231 per year per problematic drug user:
• problematic Class A drug use (opioid drug and/or crack users) accounted for 
the majority (99%) of the total costs
• health and social care costs accounted for £557 million
• the measured costs of drug-related deaths were estimated to account for 
£923 million.119
This report says that the cost estimates include two components of the cost 
of crime: expenditure by the criminal justice system in dealing with crimes
committed (with no further details supplied in the report, it is assumed this does
not include the costs associated with imprisonment) and cost consequences for
the victims of crime.
Hospital admissions arising from diseases or conditions directly and indirectly related to
substance use make a large contribution to the costs to the NHS. The most recent data
available indicate that there are around 6,400 admissions for drug-related mental 
health and behavioural disorders each year in England, and over 12,500 admissions 
for drug poisoning.120
In 2003, the Prime Minister’s Strategy Unit (PMSU) estimated that the cost in terms of
health and social functioning harms of drug use in the UK was £24 billion per year.121
This report does not specify what constitutes drug-related crime.109
The economic and social cost of drug-related harm in Scotland, which includes criminal
justice costs (extent unspecified) has been estimated as £2.6 billion per annum.122
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e It is worth noting that the costs associated with the impact on family and social networks are not included in these estimates
because of the difficultly in determining the level of cost associated with these factors.
The total economic and social cost of Class A drug use in Wales has been estimated to
be around £780 million per year, and drug-related crime accounts for 90 per cent of
this.123 Similar data are not available for Northern Ireland.
The criminal justice costs associated with illicit drug use, including prison costs, are
discussed in more detail in Section 6.4.5.
Summary
• The use of illicit drugs is associated with a range of physical, psychological and social
harms. These are affected by the dosage of drug, the pattern of drug use and the
mode of administration.
• Most drug-related deaths in the UK are related to the use of opioid drugs, followed
by cocaine. The vast majority of these deaths are in men and many are associated
with polydrug or polysubstance use. Ecstasy-related deaths are very rare and deaths
from cannabis overdose do not occur.
• The risk of death from accidental drug overdose, and from suicide, is associated with
poverty, homelessness, polydrug or polysubstance use, impaired physical health and
depression.
• While dependence per se is not necessarily significantly harmful, the risk of harm is
intrinsically raised as a result of chronic drug use. The following are associated with
physical and psychological dependence: cannabis, cocaine, gamma-hydroxybutyrate
(GHB), heroin, methamphetamine and other opioid drugs. Amphetamine and ecstasy
are associated with psychological dependence only, and there is limited evidence for
dependence with ketamine and phencyclidine (PCP). Dependence is rare with
hallucinogens.
• Fetal development can be adversely impacted by maternal drug use.
• Adverse health impacts and drug-related deaths may also be associated with
adulterants.
• Social harms of drug use include deprivation and family adversity/neglect; criminality
associated with drug intoxication or with the need to obtain drugs; and drug-
impaired performance at work or when driving. These can result from the illegality 
of the drugs, or from factors such as the psychopharmacological effects of the drug.
They have associated costs for the individual related to loss of earnings, reduced
educational attainment and damage to personal relationships. High levels of drug 
use in a community are linked to unsafe communities because of the associated
social problems.
• Studies of the level of harm associated with use of different drugs in the UK scored
heroin, crack cocaine and methamphetamine as most harmful to individuals; alcohol,
heroin, crack cocaine and cannabis as most harmful to others; and alcohol as most
harmful overall, followed by heroin, crack cocaine, methamphetamine and cocaine.
The relative levels of harm for the different drugs correlate poorly with the legal
classification of drugs.
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• Economic and social costs of drug use are related to health and social care costs and
criminality; 99 per cent of costs are linked to Class A drug use (cocaine, crack, ecstasy,
heroin, methadone, lysergic acid diethylamide (LSD) and psilocybin (magic
mushrooms)), and a large proportion is linked to crime, including crimes of illegality.
The economic and social costs of Class A drug use in 2003-2004 in England and
Wales were estimated to be £15.4 billion, which equates to £44,231 per year per
problematic Class A drug user.
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Chapter 4 – Influences on
illicit drug use
4.1 Introduction
Drug experimentation primarily begins in adolescence but only a small proportion of
those that experiment with drugs then go on to use drugs harmfully.1 Understanding
the reasons behind this and, in so doing, categorising the various theories to explain
this phenomenon, is an extensive task.
There is general consensus that drug use is a multifaceted ‘biopsychosocial’
phenomenon. This term is used to encapsulate that drug use is influenced by
biological, psychological and social factors. Although distinct theories have been
developed for each of these factors, which are discussed in this chapter, there is
often a degree of overlap between these explanations. Using only one model to
explain why people use drugs may not be appropriate to describe all types of
behaviour.
In addition to biopsychosocial influences, the extent to which drugs are obtainable
and aspirational is thought to influence their use.1 This includes their price of
purchase, the ease of access to specific drugs and their psychological attractiveness
and societal acceptance. This chapter also considers these influences.
This chapter will focus only on the influences of illicit drug use. It should be noted
that there are similarities between what influences illicit drug use and what
influences alcohol and tobacco use. Since the influences on alcohol and tobacco 
use have been widely published elsewhere by the BMA, these will not be addressed.
For further information on these topics please refer to the BMA reports:
• Under the influence: the damaging effect of alcohol marketing on young 
people (2009)
• Forever cool: the influence of smoking imagery on young people (2008).
The following case study illustrates the multifactorial aetiology of drug dependence.
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Case study: Influences on illicit drug use
Mr X is a 43-year-old man who has been using substances since he was in his teens. He has
been in treatment for the last 10 years. He is now taking 40mg of methadone, which is
dispensed daily. This has reduced from 80mg over the past two years. He has not used any
heroin or other opioid drugs for the past four years and has not injected at all for the past
eight years. He is continuing to use crack cocaine about once a month. His main problem is
his alcohol use, which has been increasing ever since he came into treatment and became
much worse when he stopped using heroin. He is now drinking about two cans of strong
lager (10 units) several days a week, although he is sometimes able to stay off alcohol for
two or three days per week. He finds it particularly difficult not to drink after work.
Ten years ago Mr X was diagnosed with hepatitis C. He was offered treatment then, but as
he did not want to have a liver biopsy did not want to be referred. Two years ago he was
admitted to hospital with jaundice and ascites and diagnosed with advanced hepatic
cirrhosis. He did well during that admission, and following medical treatment improved
substantially and was able to return to work. He was subsequently offered treatment for
HCV by his local hepatology service. This was not started though, as he continued to drink
alcohol after a short (3-month) period of abstinence.
Mr X had a difficult childhood. His alcoholic father died when he was very small. His mother
was depressed and he was taken into care when his behaviour became unmanageable as a
teenager. This followed his mother remarrying. As an older adolescent, he was caught by
the police a few times for minor acquisitive offending and served one short sentence in a
young offenders’ unit. He did enjoy school, was popular and was always interested in
computing. He left school with GCSEs in maths and computer science. He spent some time
in South America in his 20s but returned to England and started working as a computer
technician. He still works freelance and is able to get work from a friend who runs his own
business. He has a council tenancy.
He has a long-term partner who has used drugs in the past. He has two stepdaughters.
He is seen every two weeks by his local drug treatment service. He has a keyworker 
(see Glossary) but does not use the sessions well and generally just wants to collect a
prescription. He has a GP but has never been to see him. He is seen by the hepatologists
every six months.
Three months ago Mr X had another episode of ascites. Again he did well and was booked
in to see the hepatitis clinical nurse specialist to talk about interferon and ribavarin
treatment. He began to understand that he must stop drinking if he is to have successful
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treatment for his hepatitis C. The hepatologist explained to him in detail the prognostic
implications of his liver damage and the nature of the treatment. He began to use his
keywork session to discuss his fears for the future. The addiction psychiatrist assessed his
mental state and concluded that he was depressed and that he would benefit from both an
antidepressant and some cognitive-behavioural therapy (CBT), which he did attend. He was
also advised to stay on methadone (for a discussion of methadone therapy, see Chapter 8),
as further withdrawal symptoms may have jeopardised his ability to stay free of illicit drugs
and alcohol. The psychiatrist also did some joint sessions with him and his partner. He also
began to see his GP, who was able to reinforce the message that he had to stop drinking.
He was eventually able to stop drinking for three months and start treatment, while
continuing to receive support from his drug service and his GP. His goal is to become
completely drug and alcohol free.
Case study details provided by Dr Emily Finch, a consultant addiction psychiatrist.
4.2 Biological factors
4.2.1 The genetic basis for drug use
The use of drugs has a genetic component.2 This means that those with a genetic
predisposition to drug use, such as those with a direct family member with a history
of substance use, are at an increased risk of using drugs.2 The implication of this is
that variations exist at an individual neurobiological level, and this affects an
individual’s susceptibility to drug use. This means that not every person will
themselves carry the gene or become drug dependent.
Evidence for the heritability of drug use is derived from a range of research designs.
The most robust evidence for the genetic influence of drug use comes from twin
studies; research using family- and adoption-based designs has also shown an effect.
Given the breadth of high-quality research using twin studies, this section will only
briefly examine family- and adoption-based designs, before focusing on twin studies.
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As discussed earlier, a considerable part of the genetic effect may be protective
against dependence rather than raising risk. An example of this is the aldehyde
dehydrogenase 2 gene (ALDH2), which is prevalent in Asian populations and
thought to be protective against dependence on alcohol.3,a
Family-based designs
Research using family-based designs suggests that siblings of cannabis-dependent
individuals have an elevated risk of developing cannabis dependence themselves.4
Similar findings have been reported among siblings of cocaine-dependent individuals.4
Siblings of individuals with dependence on opioid drugs, cocaine and/or cannabis have
also been reported to be at an increased risk of developing drug dependence.5 These
findings were found to be largely independent of factors related to family conditions.5
The impact of the family on drug use is discussed in greater detail later in this chapter
(see Section 4.4.1).
While there is evidence that substance use disorders cluster in families, it is not clear
from family-based designs whether these can be wholly attributable to heritable factors.
This is because the family design cannot distinguish between whether the cause of
familial similarity is genetic or environmental in nature.6
Adoption-based studies
Adoption-based studies have shown a genetic basis for drug use. Adoption studies are
based on a comparison of the concordanceb between offspring behaviour and the
characteristics of both the adoptive and biological parents. Similarity between offspring
and biological parents is suggestive of genetic influences, although research studies in
this area should correct for in utero exposure to drugs.
Adoption studies have reported a strong link between biological parents’ substance use,
and their offsprings’ risk of addiction. A 1995 analysis of adoptees with substance-
dependent biological parents (parents that were alcohol and/or drug dependent)
compared with controls (adoptees with non-substance-dependent biological parents)
provided an early demonstration of the role of genetic factors in the development of
drug use and dependence.7 After controlling for in utero substance use, substance use
in biological parents was found to be significantly associated with adoptee drug use.7
These findings are suggestive of genetics having a significant influence on the
development of drug use.
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a In some drinkers, however, the ALDH2 allele (‘flushing gene’) contributes to diminished activity of the enzyme and increases
drinkers’ risk of developing some cancers.8
b In genetic terms, concordance refers to the probability that a pair of individuals will both have a certain characteristic, given that
one of the pair has the characteristic.
Twin studies
Twin studies utilise data from identical/monozygotic (MZ) and fraternal/dizygotic (DZ)
twin pairs that have been reared together. As genotypes and family environments tend
to be similar, twin studies provide greater clarity in disentangling the role of genetic and
environmental influences on drug use.6 This is because genetic influences are shared
100 per cent between members of MZ twin pairs, while DZ twin pairs only share 
50 per cent of their additive genetic influences. This means the genetic influence
between MZ twins is likely to be more apparent than in DZ twins. Thus, differences
between these two groups are suggestive of a genetic factor.
Research using twin studies has reported a large degree of heritabilityc in relation to
drug use.6 It has consistently been shown there is a higher MZ than DZ concordance for
drug dependence.2
The extent to which drug use has a genetic component appears to differ between
different types of drug. Cannabis use and dependence appear to have a large genetic
component. A 2006 review of the genetic epidemiology of cannabis use, abuse and
dependence found evidence that there is a genetic basis to each of these three
stages.9 It was estimated that the heritability of cannabis use ranged from 34 per cent
to 78 per cent.9
In terms of other drugs, research from the late 1990s among Vietnamese twins
reported that 33 per cent of stimulant use/dependence, 27 per cent of sedative
use/dependence, 54 per cent of heroin use/dependence and 26 per cent of the
use/dependence of psychedelic drugs could be attributed to genetic factors.10,11 These
findings have been replicated among female twins from the USA.12,13 Significant twin
resemblance was found for hallucinogen use, opioid use, sedative use, stimulant use
and symptoms of dependence.12,13
The convergence of findings from a range of research designs provides compelling
evidence that illicit drug use and dependence are influenced by heritable genetic
factors. Despite this, genetic factors are not exclusively responsible for the development
of drug use and dependence. If they were, the above studies would be expected to
report 100 per cent concordance between MZ twins. As is detailed in the following
sections, there are a wide range of other factors that may influence drug use.
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c Heritability refers to the extent to which genetic individual differences contribute to individual differences in observed behaviour
(also known as phenotypic variation). Individual differences in behaviour may be due to genetic or environmental factors, and/or
random chance.
4.2.2 Concurrent disorders
Psychiatric illness is thought to strongly influence the use of drugs. In recent years, a
considerable amount of research literature has documented associations between drug
use and dependence, and a range of psychiatric disorders.14-17 This comorbidityd has
been observed for a diverse range of drugs, and is associated with negative outcomes
for both the persistence and severity of drug use and psychiatric illness.2
It should be noted that a proportion of the overlap between drug use and mental illness
may be definitional. This is because of the difficulty in separating out true underlying
disorders from behaviours that develop as part of drug use. The effects of drugs on
mental health are explored in more detail in Chapter 3.
Available clinical, neurobiological and epidemiological evidence is yet to identify a
unified explanation as to why there is such a high concordance between drug use and
mental illness.2 A number of different explanations have been suggested to account for
this relationship.
It is assumed that the presence of an initial psychiatric illness may, either directly or
indirectly, increase the risk of drug use. One of the most widely cited explanations of
this causal relationship between psychiatric illness and drug use is that drugs are used to
self-medicate the negative pervasive symptoms of psychiatric illness. 2,18
It may be that the direction of this relationship is reversed, and that drug use acts as a
precursor to biological changes that are known to be involved with psychiatric illness.2
Research from the USA has suggested that high levels of cocaine use are associated
with the development of psychotic symptoms.19,20 A similar pattern has been observed
for cannabis,21-25 opioid drugs and amphetamines.26
Alternately, it may be that there is a shared aetiology to drug use and mental illness, 
in which a specific factor, such as a common genetic predisposition, increases the risk 
of both mental illness and drug use.2 Epidemiological data from the USA indicate 
the lifetime rates of major depression are 32 per cent in cocaine users, and up to 
13 per cent among non-users of cocaine, which is suggestive of some common cause.2
It may also be that shared environmental influences account for this comorbidity.2,26
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d Comorbidity refers to the co-occurrence in the same individual of more than one psychiatric disorder.
Available longitudinal investigations provide little in terms of disentangling the
relationship between mental illness and drug use. This is both because the evidence
from these investigations is considered relatively weak in determining causality, and
because they are limited in number. From available research, there is supporting
evidence for each explanation.2 It may be the case that each of these explanations is
correct, and the extent to which any one is at work is related to a complex range of
factors that are specific to the individual.
4.2.3 The psychopharmacology of individual drugs
Aside from an individual’s own biological predisposition, which may put them at an
increased risk of using drugs, the extent to which a drug can influence an individual’s
behaviour is related to a drug’s psychopharmacology (see Glossary).
Drugs alter the normal functioning of brain mechanisms that exist to regulate the
functions of mood, thoughts and motivations.2 There is considerable variation in
relation to the particular types of neural receptors (see Glossary) and neurotransmitters
that drugs affect in the brain, and consequently the extent and nature of their
physiological effects on the brain and behaviour.2 It should be noted that almost all
psychoactive substances with reinforcing properties share the common property of
activating mesolimbic dopamine, which plays a critical role in models of learning
theory.2 The role of dopamine is considered further in Section 4.3.
A component of why individuals may wish to use drugs is to elicit an alteration in
normal brain function. This may include the desire to experience pleasure or to avoid
pain (the desired effects of commonly used illicit drugs are explored in greater detail in
Appendix 2). Thus, at a biological level, both the immediate and long-term reasons for
why people may use a drug can be rationalised by understanding how that drug affects
the brain at the pharmacological level.
The repeated use of drugs may contribute to their continued re-administration through
the development of physical symptoms. These include:
• tolerance: which can be defined as a given drug producing a decreasing effect with
repeated dosing.2 Tolerance to a drug can be both physical and psychological, with
psychological tolerance often having a greater effect on influencing behaviour.
Tolerance influences repeated drug use, and as a result larger drug doses must be
administered to produce a similar effect
• withdrawal: which is the body’s reaction to absolute or relative withdrawal of a
drug. Withdrawal is associated with a range of significant negative physical and
psychological outcomes, and in certain cases can be fatal. Withdrawal can be
alleviated by readministering the drug, which contributes to its repeated use.2
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These two factors may influence the continued use of drugs but, as highlighted 
in Appendix 2, the potential to develop tolerance and withdrawal states varies
with individual drugs.
4.3 Psychological factors
4.3.1 Personality type
There is evidence that certain personality characteristics can be considered predisposing
vulnerabilities for drug use.17,27 The use of drugs is also thought to contribute to the
development in changes in personality.17, 27
Personality traits of impulsiveness, sensation seeking and negative emotionality have
been associated with an increased risk of using drugs.28-31 Sensation seeking has been
defined as a need to seek intense sensations, along with the willingness to take risks for
the sake of having such experiences. Among those with sensation seeking as a
personality trait, under-responsiveness to natural rewards and the need for greater
stimulation has been suggested as motivation for drug taking.28 Individuals with high
levels of impulsivity have a tendency to act quickly without forethought and planning.29
Evidence suggests that a lack of forethought and inhibitory control over behavioural
impulses may play a role in perpetuating drug use.27,30 Longitudinal studies have found
that impulsivity in childhood predicts experimentation with drugs in later adolescence
and early adulthood.31 High scores on measures of negative emotionality have also been
associated with future drug use.27
Continued use of drugs has been associated with behavioural, cognitive or affective
changes to personality.17,27 The social withdrawal, irritability and negative emotionality
often observed among drug-dependent groups may be better attributed to drug-
induced anxiety and depressive syndromes.27
Further perspectives have suggested a different explanation for the association between
personality type and drug use. Personality traits have been documented to have a
substantial heritable component.32 Rather than personality influencing drug use, or drug
use influencing personality, it may be that there is some common genetic factor that
predisposes an individual both to have certain personality traits and to be at an
increased risk of using drugs.32
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4.3.2 Models based on learning theory
Learning-based theories have been developed from classical and operant conditioning
paradigms of response reinforcement. These models seek to explain addictive behaviour
as pairings between a drug, drug-associated stimuli,e and the effect of taking a drug.
Enduring changes to behaviour result from, or are influenced by, these interactions.
Learning theory may be useful to understand how drug use becomes a facet of identity,
and the implications this may have on treatment. In these instances, specific
maladaptive traits may become reinforced over time, through the acquisition of drugs
or perceived protection against negative experiences (see Chapter 8 for further
information on the ‘addict identity’).27
It is necessary to recognise that drugs are rewarding. The rewarding properties of drugs
can include sensations of pleasure or relief of pain, tension or fatigue, as well as the
ability to enable the user to escape negative feelings or emotions. Thus, the drug is
used, it has rewarding effects, and this reinforces repeating this behaviour (ie it
influences the continued use of the drugs).2
This relationship can be understood at a biological level. As explored earlier, drugs
influence the normal functioning of the brain. The use of psychoactive drugs causes
activation to areas of the brain that are normally involved in motivation, such as the
mesolimbic dopamine system (see Section 1.1.3). This causes the release of dopamine,
the neurotransmitter released in response to any positive event or reward.2 Any release
of dopamine leads to a strengthening of the synaptic connections in the neural
pathways.2,33,34 This reinforces the behaviour that resulted in a reward, making it more
likely to be repeated.2 Psychoactive drugs can activate the mesolimbic dopamine
system, either directly or indirectly, and, through associative learning processes, stimuli
associated with drug use and drugs can themselves begin to influence behaviour.2
Classical conditioning
Classical conditioning (sometimes known as Pavlovian conditioning) can be simplified as
learning through association. Theories based on classical conditioning are often used to
explain complex behaviours, such as drug craving.f,2,35 Under a classical conditioning
model, drug craving arises because of the repeated pairing of environmental stimuli
with the rewarding properties of drugs.30
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e Drug-associated stimuli could include environments where drugs are taken, the presence of drug dealers or drug users, or the
sight of drug paraphernalia.
f Craving is to have a strong or incontrollable want for something (Cambridge Dictionary).
To the individual using drugs, neutral stimuli associated with drug use, such as drug use
paraphernalia, or environments where drugs have previously been consumed, can begin
to exert influences on behaviour. Research has demonstrated that after repeated drug
administration, cues that precede drug ingestion, such as the sight of a needle and
syringe, elicit craving for drugs.36 A formulation of how this process takes place is as
follows:
• a stimulus, such as a syringe, elicits no particular drug-related response, ie it is a
neutral stimulus
• when an individual uses a drug such as heroin intravenously via a syringe, it reliably
elicits a response: a drug-related high. The drug is the unconditioned stimulus, and
the drug-related high is the unconditioned response. The unconditioned response
occurs in response to the unconditioned stimulus
• the unconditioned response (heroin) is repeatedly paired with the neutral
stimulus (syringe)
• eventually, the neutral stimulus (syringe) alone is able to elicit a conditioned
response, which is to crave using heroin.
Operant conditioning
The theory of operant conditioning (also known as instrumental learning/conditioning)
has also been used to describe why people use drugs. If classical conditioning can be
seen as learning through association, then operant conditioning can be seen as learning
through reinforcement.2,35
In contrast to classical conditioning models, where the individual has no control over the
presentation of a stimulus, with operant conditioning it is the individual’s own
behaviour that produces the stimulus.2,35
Operant conditioning explains that behaviour is repeated because of the emotional
consequences attached to that behaviour.2,35 If use of a drug produces a reward, such
as a state of euphoria, or alleviates withdrawal symptoms, it is more likely to be
repeated.2,34 If use of a drug leads to an non-rewarding, aversive state, such as acute
intoxication, then a behaviour is less likely to be repeated.2,35
Social learning
Social learning theory has also been used to explain influences on drug use. Social
learning theory extends the concept of operant conditioning as a basis for addiction,
to learning through observation and communication. Social learning theory posits that
individuals may be influenced in their decision to use drugs through observing role
models in their environment and perceiving social norms in relation to drug use.35
Social learning theory explains that individuals will repeat behaviours they observe 
to have a positive outcome, and avoid behaviours they observe having a negative
outcome.35 According to social learning theory, the more frequent and intense the
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observed positive element of drug taking, the more likely it is that it will become
habitual.35 The more frequent or intense the observed negative drug-associated
experience, the greater the likelihood that it will be avoided. Social learning theory 
is often used to describe the influence of peers and family on drug use.35
4.4 Social factors
4.4.1 Family
Family conditions during childhood are associated with illicit drug use.7,37,38 Beyond the
genetic characteristics shared within a family, there are a range of familial factors
thought to influence drug use. As described in Section 4.3.2, social learning theory
suggests that one of the mechanisms by which behaviour is acquired is through
imitation and modelling of others. The role of the family’s attitudes towards drug use
may play a role in this regard. As well as this, atypical family relationships may also
influence drug use. Research has indicated that the family factors that contribute to
individual differences in drug use include:
• single-parent, or step families39-42
• substance use among family members43
• poor parent-child relationships44,45
• family conflict46
• poor parental supervision.43
It should be noted that there may be other environmental factors that influence drug
use, and it can be difficult to disentangle these factors from the influence of family
conditions. This is because families share the same environments. These confounding
variables may include social inequalities and the role of peer influence.
Family structure
A number of studies have suggested that family structure may play a role in individual
development and functionality, including drug use. Research among 14 to 15 year olds
in five European countries, including England, found that living with both biological
parents was generally associated with reduced levels of drug use.39 Similar research
reported a significant association between illegal drug use and broken family structure
among 10 to 12 year olds in Glasgow and Newcastle.47 In comparison, those living with
both biological parents had the lowest past illegal drug use.47 The highest levels of drug
use were found among those living with reconstituted families (step families).47 Similar
findings were reported in research among Scottish adolescents, with a greater level of
lifetime illegal drug use reported among those from single-parent families.48
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Family substance use
The use of drugs within the family environment may influence subsequent drug use.
Research among Scottish pupils reported that almost half of those who had used drugs
had a family member that also used drugs.49 This compares with around 10 per cent of
non-using pupils having a family member that used drugs.49 In the majority of cases, the
drug-using family member identified was a sibling or cousin.49
Family relationships
As well as family composition and behaviour, the quality of family relationships may
influence drug use. Research among British adolescents reported that those who
thought their parents’ opinions were most important were less likely to regularly use
drugs.50 In comparison, those who valued their friends’ opinions highest reported
greater drug use.50
Parenting style may also influence levels of drug use. Research has reported that
families that lack parental monitoring, that have high levels of parent–child conflict, or
where children are unwilling to disclose information to their parents, have higher levels
of drug use.48 The association between lack of parental monitoring and drug use at
the age of 15 years has been shown to be particularly strong.48 Stattin and Kerr have
posited that a lack of parental monitoring may result from children disclosing too
much information about norm-breaking behaviour to their parents.51 This knowledge
causes parents to abandon monitoring their children’s behaviour, which has
consequent impacts on drug use.51
Protective factors
The family environment may also exert effects that protect against the use of drugs.
Positive family relationships and communication may guard against future use of
drugs.39,40 Any benefit in living with both parents is thought to be undermined in
instances where drug use among peers is high.39
4.4.2 Peer influence
Peers may influence whether an individual engages in or refrains from drug use.52,53
Peers may influence individuals directly, such as by offering drugs, or indirectly through
social modelling and perceived norms.
Drug use appears to occur often within a peer-group context. Research has reported
that adolescents who spend more time with their friends are at an increased risk of
drug use.54 American research has found that youth spending five or more evenings
each week out with friends are at greater risk of drug use than those spending fewer
nights out.54 From a British perspective, research has indicated that lifetime cannabis
users are less likely to spend time regularly with their parents, and more likely to
spend free time with drug-using friends.45 Research conducted among Swiss school
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students reported a close association between pupils witnessing students coming to
school cannabis intoxicated, or taking cannabis onto school premises, and their own
cannabis use.52 It should be noted that this research does not identify the direction
of this relationship, in terms of whether cannabis-using peers influence students to
use cannabis, or whether cannabis users choose to associate more with other
cannabis users.
The relationship between peer groups and drug use is complex, and may function in
different ways. Individuals often identify themselves as a member of a group on the
basis of shared behaviours or beliefs. They may adopt behaviours to increase their sense
of belonging to a group, or to become accepted as a group member. Alternatively, the
high concordance between peer group and drug use may be a result of individuals
seeking out peers with similar interests and behaviours to their own. Consequently,
peer-group homogeneity may result from processes of selection into groups, or
conformity to existing members of a group.55 Social learning theory may explain peer
drug use, as drug use is encouraged by observing drug using among role models.
Decisions to use drugs are made on assessments of the consequences of drug use, and
the perceived punishments or rewards reinforce the decision to engage in or refrain
from the behaviour.
McIntosh et al reported that the impact of peer pressure declines with age.53 Research
involving 11 to 14 year olds in Scotland and England reported a decrease with age in
the influence of peer pressure when experimenting with drugs.53 It is suggested that the
declining role of peer pressure results from drug-using peers moving away from viewing
drug use as a form of risk taking, and instead to drug use as an enjoyable activity.53 The
decision to experiment with drugs becomes increasingly a matter of personal choice
rather than one of external influence.53
4.4.3 Social inequalities
Social inequalities refer to people in different socioeconomic groups experiencing a
different quality of life. These differences include avoidable differences in health,
wellbeing and length of life.
Cannabis use has been found to be greater among those living in areas of lower
deprivation.56 It has been suggested that this is because cannabis users more frequently
come from less-deprived backgrounds.57 Teenagers and young adults from poorer
backgrounds have less discretionary cash to purchase drugs. This suggests there is an
effect of affluence on drug use, at both the individual and neighbourhood level.58
Social deprivation does appear to influence the harmful use of drugs. The Marmot
Review suggested that, in the UK, the likelihood of problematic drug use is related to
socioeconomic status, noting a positive correlation between the prevalence of
problematic drug users aged 15 to 64 years and deprivation (see Figure 6).59 Similarly,
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hospital admission rates for drug-specific conditions for both male and female
individuals have shown a strong positive association with deprivation.59
Figure 6 – Prevalence of problematic drug users aged 15 to 64 years, by local
authority of residence and Index of Multiple Deprivation (IMD),g 2006-2007
Source: North West Public Health Observatory (2010) Indications of public health in the English regions. 10. Drug
use, p51, scatter plot 1. Liverpool: North West Public Health Observatory.57 Reproduced with the permission of
the North West Public Health Observatory.
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g The Index of Multiple Deprivation (IMD) is a measure used in UK Government statistical study of deprived areas in UK local
authorities. A low IMD score indicates an area of low deprivation.
4.4.4 Stigmatised groups
Stigmatised groups are prone to earlier, more frequent, or more problematic drug use.60
For the less affluent in particular, drug use can cause stigma, and can be how people
end up in these groups. It is thought they might also experience faster progression to
problem drug use.60 Among certain stigmatised groups, socioeconomic inequalities
appear to play a substantial role in their stigmatisation.60 Problematic drug use is just
one of a number of behaviours, such as poor diet and lack of exercise, associated with
negative health outcomes.60
Groups that are considered vulnerable include, but are not limited to:
• young people within care institutions
• sex workers
• homeless populations
• victims of traumatic experiences.
Young people within care institutions
Young people in care institutions, such as residential or foster care, face distinct
developmental challenges. In comparison to the normal population, these include
accelerated social independence, not completing formal education, and high
unemployment upon leaving care.61
Research has identified that those in care are at an increased risk of earlier initiation
into, higher levels of, and more frequent use of drugs, including heroin and crack
cocaine.61-64 Research using twin studies has shown that those using cannabis in 
care institutions before the age of 17 have an increased risk of other drug use and
dependence, when compared to their non-drug-using co-twin.65 The risk of other
drug use and dependence is estimated to be 2.1 to 5.2 times higher than that of
their co-twin.65
A range of factors are thought to explain the high proportion of drug use among 
this population. These factors include carer use and challenging life events, such as
bereavement, rejection, early independence and responsibility, sex work and the
transition from care.64 In addition, some young people within care institutions may
have grown up in homes where parental problematic drug use was evident. As has
been highlighted previously, parental use of drugs may influence their children’s drug
use.66 Parental drug use may also be a compounding factor in preventing children
from returning to the care of their parents. This separation from their parents may
further increase the risk of young people using drugs.61
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Sex workers
Sex workers are thought to be at an increased risk of using drugs. Explanations for
this increased risk include sharing environmental space on streets and in the dealing
houses, which serve as sex markets, drug markets and areas where homeless people
congregate.67 In one study, 84 per cent of those sex workers who work outdoors
reported having a current drug problem.67 This compares with just 13 per cent of 
sex workers who work indoors.67
There are few reliable data on the prevalence and patterns of drug use among this
population. Evidence on whether drug use is a cause or effect of sex work indicates that
both are possible. Research suggests that drug use is often a motive for prostitution,
but could also be a consequence and maintaining factor.67 Sex work and drug use may
be mutually reinforcing, such that ‘exiting’ either becomes more difficult. Their mutually
reinforcing potential is strengthened where individuals are exposed to ‘trapping factors’.
These include:
• involvement in prostitution and/or ‘hard drug’ use before the age of 18 years
• sex working ‘outdoors’ or as an ‘independent drifter’
• experience of at least one additional vulnerability indicator, such as being ‘looked
after’ in local authority care or being homeless.66
Homeless populations
Homelessness occurs on a continuum ranging from ‘rooflessness’ or sleeping rough, 
to living in bed and breakfast accommodation and hostels, to an inability to leave
unsatisfactory housing conditions. Homelessness has been associated with increased
use of drugs.68 In addition to drug use, homelessness is also associated with social
exclusion, which includes poor and unhealthy living conditions, unemployment, low
education, socially disadvantaged background and poor physical health. There may also
be a high level of psychiatric illness among homeless populations.61
The association between homelessness and drug use is largely recognised in the
literature. Research among homeless people in London found that 60 per cent reported
that their substance use was one of the reasons they first became homeless.69 Having
become homeless, 80 per cent reported subsequently using drugs.69 Overall, drug use,
injecting, daily use and dependence have been found to increase, the longer that
individuals remain homeless.69
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A 2003 Home Office piece of research into young homeless populations found young
homeless people reported high lifetime, last-year and last-month prevalence rates for
drug use. This included illegal drugs and illicit use of prescribed medication.70 Ninety-five
per cent of young homeless individuals had used drugs.70 Often they had begun
experimenting with illegal drugs at a young age, typically aged 14 years.70 Levels of use
of cannabis, amphetamine and ecstasy were also high among this population, and a
substantial minority reporting use of heroin and crack cocaine.70
Victims of traumatic experiences
Adverse experiences are thought to play a role in influencing drug use. Early adverse
experience, such as childhood sexual or physical abuse, have been associated with an
increased vulnerability to drug use.71
There is evidence that individuals who have experienced some form of trauma at a
young age are at an increased risk of developing problems with drug use.72 Research
among US childhood victims of physical abuse, sexual abuse or neglect estimated that
these individuals are up to 1.5 times more likely to use illicit drugs.73 Similar research
among American students demonstrated that the highest levels of drug use were found
among students who reported both physical and sexual abuse.74 In addition, victims of
any form of abuse reported initiating drug use earlier and greater multiple drug use,
when compared to their non-abused peers.74 Research has also demonstrated that
emotional abuse is associated with higher levels of drug use.75 Trauma in later life is
thought to be associated with drug use, but the evidence base for this association is not
well established.
Although clinical data confirm a relationship between adverse experiences and drug
use, it is not known whether this relationship is direct or indirect. It is thought that the
high concordance between drug use and victims of trauma may, in part, be explained
by individuals using illicit drugs to cope with negative emotions, feelings and
experiences. Among drug-using school children who have been sexually and physically
abused, explanations for use include coping with painful emotions and escaping from
their problems.74 It may also be that traumatic experiences indirectly impact on drug
use. It has been well established that childhood maltreatment may result in a number of
emotional and psychological consequences, such as depression, anxiety, suicidality, low
self-esteem and personality disorders.76 The association between mental health and
drug use has already been highlighted in Section 4.2.2.
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4.5 Access to drugs
4.5.1 Price
Price appears to influence the use of drugs. It was previously believed that the
addictive nature of drugs meant drug users were not sensitive to changes in price, but
research has demonstrated that drug users are responsive to price.1,77 This estimated
responsiveness to price (elasticity of demandh) varies by drug and user type;i in almost
all cases, the number of users and the quantity of drugs consumed declines when
prices are increased – in some cases substantially.1,77 Further evidence for how price
affects different types of drugs, and users, is presented next. It should be noted that,
given the illegal nature of drug use, the price data reported are often of low quality
(see Section 6.3.2).
Cannabis
American research has estimated that, among high school students, responsiveness 
to the price of cannabis is about –0.30.78 Research in Australia, which investigated
cannabis use among adult populations, demonstrated a much larger responsiveness 
of –0.88.j,79
Cocaine
Responsiveness to price has been shown for cocaine. Research conducted in 1999,
using data from the US National Household Survey on Drug Abuse between the years
1988 and 1991, estimated a price responsiveness of between –0.30 and –0.55.80
Among youth populations, the responsiveness to the price of cocaine was –0.89 and 
–1.28.k,80 More recent research, conducted in 2006, estimated that among US college
students, the responsiveness to the price of cocaine is as high as –0.57, depending on
age and sex.81 It is interesting in this context to note that the price of cocaine in the USA
has fallen by around 70 per cent since its peak in the late 1970s, but use has fallen by
almost the same amount.82
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h Price elasticity of demand is a measure used in economics to show the responsiveness, or elasticity, of the quantity (proportion)
demanded of a good or service, in relation to a change in its price. More precisely, it depicts the change in quantity demanded,
in response to a 1 per cent change in price. Price elasticity, or responsiveness to price, is almost always depicted as negative – a
rise in price reduces demand. Demand is described as ‘inelastic’ if it is numerically less than –1.0, but this does not mean that
there is no responsiveness to price.
i In the context of drug use, elasticity of demand comprises two components: the ‘participation response’ – the decision to use
the substance – and the ‘intensity response’ – the amount a continuing user consumes.1
j The figures –0.30 and –0.88 both refer to the participation elasticity, ie the decision to use the drug.
k The participation elasticity was –0.89 and the overall elasticity was –1.28.
Heroin
It is unclear whether the responsiveness to changes in the price of heroin is similar to
that seen with cocaine and cannabis.1 This is because the evidence base for heroin use
is poor. Responsiveness to the price of cannabis and cocaine is generally extrapolated
from general population surveys that provide information on the prevalence of cocaine
and cannabis use. General population surveys do not report on the prevalence of heroin
use. This is, in part, because heroin users generally live too chaotic a lifestyle to allow
their inclusion in such samples.
Research between 1993 and 2006 among clients in needle exchanges in Oslo,
estimated a price responsiveness of –0.77 for heroin users.83 It should be noted that
these findings are conditional on the user injecting heroin. Research among US
arrestees testing positive for heroin estimated that the responsiveness to heroin prices
was between –0.10 and –0.18.84 Research that examined the impact of US heroin
prices on admissions to emergency rooms for heroin use found that responsiveness to
price among this population was only –0.10.85 These trends underline that, at least in
the medium term, the demand for drugs is responsive to other factors besides price.
4.5.2 Physical availability of drugs
The physical availability of drugs refers to the proximity and accessibility of a drug. Logic
dictates that if a drug is not physically available, then it cannot be used. As explored
previously, a range of factors influence drug use, and while the physical availability of
drugs plays a role in their use, it cannot be considered the sole influence on whether
they are used.
Available evidence suggests that the physical availability of drugs does not impact on
levels of drug use. Research from the USA has suggested that the physical availability of
drugs is often concentrated in neighbourhoods with high levels of economic
disadvantage, greater population density and high concentrations of minority
residents.86,87 Levels of use were reported to be similar to those seen in affluent
neighbourhoods.86,87 Socioeconomic status appears to influence problematic drug use,
so the physical availability of drugs may impact use among those who are already using
drugs problematically.
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4.6 Psychological attractiveness and societal acceptance
4.6.1 Popular media
The popular media, which include film, television, music, video games and the internet,
together with increasing exposure to celebrity lifestyles, form a dimension of people’s
social environment. Available evidence suggests that popular media may influence
health behaviours. Research has demonstrated that popular media portrayals of pro-
alcohol and smoking imagery can influence the uptake of these substances.23,88-90
While research into the influence of popular media on drug use has received much 
less attention, a similar effect appears to be present.92-96 There is little evidence
demonstrating that popular media has a protective impact on drug use.97,98 The efficacy
of mass media approaches in delaying initiation into and minimising the use of illicit
drugs is explored in Chapter 7.
4.6.2 Films
Films often address and depict health-related behaviours. With the cinematic film
industry grossing billion of pounds in profits, and with the globalisation and
proliferation of home-based media technologies, there is the potential for film to
influence the behaviour of large numbers of people.
The use of illicit drugs is often portrayed in films. A content analysis of the top grossing
US films from 1999 to 2001, found nearly two out of five teen characters in films used
illicit drugs, and were unlikely to be shown suffering any consequences of their drug
use (either positive or negative, or short or long term).99 Australian research from 2005
analysed the portrayal of drug use among the most popular 200 films globally, from
1985 to 2005. It was found that cannabis was portrayed in 8 per cent of films, with
each film depicting the use of cannabis up to a maximum of 10 times.100 Cannabis 
use was only shown in a positive or neutral light, with no negative depictions or
consequences.79 This is similar to the findings related to the effects of marketing and
imagery on tobacco and alcohol use.88,101
The available evidence suggests that films have the potential to model behaviour, and
communicate normative propositions about health-related matters, such as illicit drug
use.102 Research has suggested that portrayals of drugs have an impact on drug use in
the UK. A 2011 cross-sectional study of over 1,000 13 and 15 year olds from the west
of Scotland explored incidents of witnessing drug use in films, and subsequent drug
use, and found an association between film exposure to illicit drugs and using
cannabis.92 This association persisted after adjusting for sex, social class, family structure
and levels of parental control.92 The association did not exist when controlling for 
other variables, including personal characteristics, such as risk taking, rule breaking,
achievement of school qualifications and friends’ substance use.92 It is difficult to
interpret these findings, given the cross-sectional nature of this analysis, which makes
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conclusions about the direction of any relationship problematic. One explanation is 
that young people who take drugs not only are more inclined to do this in the company
of like-minded friends, but may also share, or develop, similar tastes in cultural
representations of drug use, which may in turn determine the kinds of films they
choose to watch.92 Conversely, portrayals of drug use could directly influence an
individual’s uptake of drug use, which could itself influence the friendship groups that
an individual may choose to maintain.92
4.6.3 Television
Television watching is widespread throughout the UK. There is the potential for images
on television to reach a broad range of UK society, although the evidence that
portrayals of drug use on television influence behaviour is less well established than for
other media. Given the evidence that film influences drug use, and the obvious
similarities between these two media, it is not unreasonable to assume similar effects
occur with television.
Portrayals of drug use on UK television appear to be relatively sparse and predominantly
negative (see Box 4). A 2005 review by Ofcom, which assessed a snapshot of television
for content, including drug references, found that overt or implied drug users
comprised 0.4 per cent of the television characters included in the sample.102 Drug
scenes were most likely to provide an antidrugs message, with 57 per cent of scenes
reviewed assessed as carrying a negative message, 40 per cent a neutral message and 
3 per cent a mixed message.102 There were no drug scenes assessed as portraying a
positive message about drugs.102
Box 4 – Example of drug reference in television
Holby City
Gabby is in hospital after taking too many drugs and consequently gave birth
3 months early. The baby is on life support and unlikely to survive. Her boyfriend
Leo blames her for taking the drugs, and himself for supplying them. Gabby says
she can’t think straight and wants Leo to ask the doctors for some drugs so she
can say yes to turning off the life support machine. Leo says that he cannot believe
she is more bothered about her next fix than her dying baby.
Source: Ofcom (2005) Smoking, alcohol and drugs on television: a content analysis. London:
Ofcom.102 Reproduced with the permission of Ofcom.
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4.6.4 Music
As with other forms of media, exposure to music and the impact on drug use has
received little attention. There are a range of reasons why music may influence
health behaviours. Music is related to personal identity, and people often model
themselves after musical figures, in terms of dress, behaviour and identity.103-105
Exposure to modern music is ubiquitous.
Reference to drug use in certain types of music is common, and appears to influence
drug use. American research from 2008 found that explicit substance use is
represented in around one-third of the most popular songs in the USA, with alcohol
and cannabis referenced most frequently.106 Overall explicit substance use is
portrayed most frequently in rap music, and least frequently in pop music.106
References within music to substance use are most commonly motivated by social
pressure and sex, and are associated with partying and sex.106 The social, sexual,
emotional and financial consequences of drug use are most commonly depicted as
positive.106 The legal and physical consequences of drug use are more commonly
depicted as negative.106
Robust research on exposure to drug references in UK music has not taken place, so
it is not possible to make a reliable assessment of drug exposure in UK music. Due to
the increasingly globalised trends in music in developed countries, there is a large
degree of international crossover in styles of music. It is not unreasonable to take
figures reported in the USA as a crude estimate of what is taking place in the UK.
Research has suggested that exposure to drug references in music influences
cannabis use. American research from 2010 looked specifically at cannabis exposure
in popular music and current cannabis use among students aged 14 to 15 years.92
It was reported that high exposure to references to cannabis in popular music was
independently associated with higher levels of current cannabis use.93
4.6.5 Celebrity
The reach of entertainment media provides unprecedented public access to the lives
of celebrities. Public knowledge of the personal lives of media personalities is greater
today than it has ever been. This is particularly true among young people.107
Research from 2001 reported that of those surveyed, 59 per cent of young people
stated that their celebrity idol had influenced some aspect of their attitudes or
beliefs.108
Research has suggested that celebrities may have both a positive and negative
impact on drug use, although this is not conclusive. Research from 2010, which
examined Diego Maradona’s influence on drug use (an Argentinean footballer with 
a history of involvement with drugs), found that those who had a greater degree of
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parasocial interactionl with Diego Maradonna were more likely to have an increased
awareness of drug abuse, a greater personal concern about drug use, abstain from
drug use, and strongly support drug-use-prevention programmes.94 In contrast,
identification with Maradonna had a mitigating effect on prevention of drug use.94
These findings suggest that notable celebrities may have a role in reducing drug use,
and a conflicting role in increasing drug use.
4.6.6 Video games
Leisure activities have changed over the last 10 to 15 years, with the use of new
technologies such as video game consoles taking up a large proportion of free
time.95 This increase in video game use is set within a context of leisure time that is
increasingly being occupied by the use of electronic devices.95
The number and types of depictions of drug use in video games is less clear than 
for other forms of media. The most recent content analyses, from 2004 and 2005, 
of US teen- and mature-rated video games found that only a handful of video games
depicted drug use in any format.109,110 It should be noted that the video games industry
is a continually expanding market, and it is likely that the number and complexity of
video games on offer since these analyses were conducted has increased dramatically.96
The number of depictions and types of drug use portrayed in video games are
potentially much higher than the available figures suggest.
Given the relative paucity of evidence examining the frequency of video game use, and
how this impacts on behaviour, it is not clear whether video games affect drug use. 
One American research study has suggested that video game use is positively related to
drug use.95 The direction of this relationship, in terms of games influencing drug use, 
or drug users being more drawn to games, is unknown. It is not possible to determine
whether use of video games plays a direct role in use of drugs, or if it impacts drug use
indirectly, by taking time away from activities that have been shown to have a protective
influence on drug use.95
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l Parasocial interaction is a term used in social science to describe one-sided, interpersonal relationships in which one party knows
a great deal about the other, but the other does not.
4.6.7 The internet
Given the rapid advancement in the internet as a means of finding and disseminating
vast amounts of information, it represents a developing area in terms of drug
exposure and use. A 2009 piece of exploratory analysis on drug website viewing
among 12 to 18 year olds in America, found that 5.4 per cent of youths had visited
antidrug websites, 1.7 per cent had visited websites that discussed drug use in a
positive light and 3.2 per cent had visited a mixture of both.96 Viewing of websites
encouraging drug use was associated strongly with drug-use behaviours.96
The extent to which internet use may influence drug use is unknown. From the
limited available evidence, it appears that internet use may influence drug use in 
a more complex manner than is seen with other forms of popular media.95
This complexity appears to arise from the type of internet use engaged in by an
individual, with some use encouraging drug use, and other forms of internet use
protecting against it. When the internet is mainly used for chat rooms, shopping,
entertainment and pornography, an increase in the use of drugs has been found.95
Conversely, when the internet is used for activities such as school work, it is
associated with less drug use.95 The content or purpose of internet use may be
significant, in terms of use of illicit drugs.
Summary
• Drug use is widely held to be a multifaceted biopsychosocial phenomenon. 
No single biological, psychological or social factor is exclusively responsible for
drug use.
• Family-based, adoption and twin studies have shown a substantial genetic
component to drug use. Comorbid psychiatric illness and personality type have
also been shown to be strongly linked to drug use.
• The rewarding potential of drugs, such as sensations of pleasure or relief from
pain, may play a role in reinforcing the continued use of drugs. The use of drugs
activates the mesolimbic dopamine system in the brain, strengthening neural
connections, which influences the repetition of drug-related behaviours.
• A drug’s potential to lead to tolerance and withdrawal may influence its 
continued use.
• The environmental or social factors commonly attributed to problematic drug use
include family composition, behaviour and relationships, peer influence, social
inequalities and being a member of a stigmatised group.
• Positive family relationships and communication may guard against future use of
drugs. Living in a single-parent or step family, substance use among family
members, family conflict and poor parental supervision are all indicators for drug
use in young people.
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• Stigmatised groups are at increased risk of drug use; these include young people
in care institutions, sex workers (particularly those who work outdoors) homeless
populations and victims of traumatic experiences.
• Evidence shows price has an impact on drug use but the effect is not the same for
all types of drugs.
• Evidence of the effect of portrayals of drug use in popular media on drug use are
limited and difficult to interpret. There is some evidence that portrayals of drug
use in film have an impact on drug use in the UK. Notable celebrities may have a
role in either reducing or increasing drug use.
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Chapter 5 – Drug policy in the
UK: from the 19th century to
the present day
5.1 Introduction
The need to address problems associated with drug use is not a new phenomenon. 
As discussed in Chapter 6, a key question is what the primary aim of drug policy
and legislation should be. At one end of the spectrum, it could simply be to reduce
or eliminate illegal drug use, while at the other end it would focus entirely on the
health and social problems of the individual drug user, by considering drug
dependence as a chronic medical disorder. These are two examples of possible 
foci: the question is discussed in detail in Chapter 6.
Current policy in Britain takes account of both viewpoints, as well as the wider 
social and economic factors associated with illicit drug use (see Chapters 3 and 6).
This chapter examines the development of drug policy in Britain since the mid-19th
century and the rationale behind current policy.
5.2 The beginnings of drug control in Britain
Opium eating and laudanum (an alcoholic solution of opiates) consumption were
widespread in mid-19th century Britain. Opium, and its derivative morphine, were
available as patent medicines, in tinctures and other commercial products that were
readily accessible through chemists and herbalists. The use of these products
declined after the 1868 Pharmacy Act restricted opium sales to the pharmacist’s
shop, with the Act requiring pharmacists to keep records of the purchasers. The later
1908 Pharmacy Act moved morphine, cocaine, opium and derivatives containing
more than 1 per cent morphine into part one of the poisons schedule. At this point,
control was on availability and sale and was largely based on self-regulation by
pharmacists, with little Government intervention. There was a small population of
morphine-using addicts and some opium and cannabis smoking among artistic,
mystic and bohemian circles but the population of drug users at the beginning of 
the 20th century was relatively small. At the same time, British pharmacists and
physicians had nearly 40 years’ experience of dispensing opiates and attempting to
control their use.1,2
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5.3 Domestic policy developments and international 
drug control
Meeting Britain’s international treaty obligations set the context for the development
of British drug policy. Britain became committed to a drug control policy as a result of
the international narcotics control system established in the early 20th century. 
A series of international meetings, largely prompted by American concern about 
Far Eastern opiate use, laid the bases of the system. Britain’s involvement in the Indian
opium trade with China through the 19th century was brought to an end by the
Anglo-Chinese opium agreement. There was some domestic pressure for drug
control, with public and press concern about cocaine smuggling to India and opium
and morphine smuggling to the Far East, some of which involved British ships. 
This was of particular concern in the wartime emergency situation of 1915-1916 and
was compounded by reports of cocaine use among soldiers, especially those on leave
in London, which was seen as compromising army efficiency. In 1916, the Army
Council issued an order prohibiting the gift or sale of cocaine and other drugs to
soldiers, except on prescription. This was the first time that a doctor’s prescription was
required by law for the purchase of specified drugs. When cocaine dealers found
ways of circumventing the order, pressure from the press, anti-opium interests, the
police and the army resulted in the introduction of the Defence of the Realm Act
regulation 40B (DORA 40B) in the same year. The regulation made it an offence for
anyone except physicians, pharmacists and vets to be in possession of, 
to sell or give cocaine. The drug and its preparations could only be supplied on
prescription. The Home Office had responsibility for policing DORA 40B and now took
on the central role of initiating and shaping the restrictions of drug control policy.2
Before the First World War, Britain had been a signatory of the International Opium
Convention at The Hague in 1912. This Convention was the first global attempt at
drug control and aimed to reduce the use of morphine and cocaine by restricting the
manufacture of, trade in, distribution and use of, these drugs to ‘legitimate’ scientific
and medical purposes only. Although it did not specify limiting the use of opium to
scientific and medical purposes (and this was, essentially, not covered until 1961 –
see Section 5.7), signatories agreed to suppress the use of opium and distribution
was expected to fall as a result of the Convention. In 1920, Britain was obliged to
introduce the first Dangerous Drugs Act to meet the Hague Convention’s
requirements, while also incorporating the DORA 40B restrictions. The Dangerous
Drugs Act laid the foundation of further legislation and control policy in Britain and
consolidated the precedence of the Home Office over the Ministry of Health in the
area of drug policy. The Act generated little debate at large, with recent sensational
accounts of recreational drug use among bohemian circles prompting a political and
press demand for a penal approach to drug control.2 A penal emphasis in policy
continued with the 1923 Dangerous Drugs and Poisons (Amendment) Act, which
imposed stricter controls on doctors and pharmacists with respect to dangerous
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drugs, introduced more severe penalties and higher fines and sentences, and
expanded the search powers of the police.2
5.4 The Rolleston Committee
The 1920 Dangerous Drugs Act established that medical practitioners were allowed
to prescribe morphine, cocaine and heroin but it was not clear from either the
Hague Convention or the Act whether prescribing these drugs to addicts constituted
legitimate medical work. The population of opiate users at this time was small,
largely middle class, addicted to morphine and in the medical and allied professions,
or had become dependent in the course of medical treatment. At the suggestion of
the Home Office, the Ministry of Health convened an expert committee
(Departmental Committee on Morphine and Heroin Addiction) chaired by Sir
Humphrey Rolleston, then President of the Royal College of Physicians, to consider
and advise on the circumstances in which it was medically advisable to prescribe
heroin or morphine to addicts. The report produced by the committee (usually
known as the Rolleston Report),3 reaffirmed the doctor’s freedom to prescribe
regular supplies of opioid drugs to certain addicted patients in defined circumstances
that the committee regarded as ‘treatment’ rather than the ‘gratification of
addiction’. While the possession of dangerous drugs without a prescription was still
the subject of the criminal law, addiction to opioid drugs was recognised as the
legitimate domain of medical practice (and hence prescribing). This balance of a
medical approach within a penal framework became a hallmark of British drug
control and has been called the ‘British System’ by commentators.
5.5 Increasing international drug control
The Hague Convention had laid down domestic control obligations for its signatories
and not addressed the question of transnational controls. The League of Nations was
established after the First World War and provided a centralised body for
administration of international drug control. The second Geneva Convention of
1925 was signed under the auspices of the League of Nations and required parties
to the treaty to provide annual statistics on drug stocks and consumption, the
production of raw opium and coca, and the manufacture and distribution of heroin,
morphine and cocaine. The Geneva Convention was also notable in bringing
cannabis under international control, and restrictions on cannabis were implemented
in Britain with the 1928 Dangerous Drugs Act.
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5.6 Growth of drug use in Britain and the 1960s 
heroin crisis
Until the 1960s, prescribed heroin was the main medication used for treatment of 
those addicted to morphine and heroin; this population was predominantly aged over
30 years and middle class. This was a settled approach, as a major addiction problem
was not apparent in the British drug scene. In the early 1960s, the first reports about
the activities of young heroin users began to appear in British newspapers – a
phenomenon that was new to Britain. The Home Office convened an interdepartmental
committee under the chairmanship of Sir Russell Brain, largely prompted by concern
about whether long-term prescribing was still appropriate more than 30 years after the
Rolleston Report. The Brain Committee published its first report early in 1961,4 and
concluded that the drug problem remained small and no changes in approach were
needed. Increasing media and professional evidence of a heroin epidemic in Britain
involving younger heroin users led to a Second Interdepartmental Committee on Drug
Addiction, again chaired by Brain. Drug addiction was formulated as a ‘socially
infectious condition’, for which it was appropriate to provide treatment. The committee
concluded that the increase in heroin use had been fuelled by a small number of
doctors who were overprescribing heroin and that individual doctors were unable to
meet the demands of the new situation. As a result, the committee recommended that
restrictions should apply to the prescribing of heroin and cocaine and that new drug
treatment centres should be set up within the NHS hospital system.5 These
recommendations were enacted in the Dangerous Drugs Act 1967, which restricted the
prescribing of heroin for treatment of addiction to doctors licensed by the Home Office.
The doctors who obtained licences were mostly consultant psychiatrists in charge of
drug treatment centres. This limitation of doctors’ clinical autonomy received some
criticism from the medical profession. As this restriction of clinical freedom did not
extend to prescribing heroin for medical treatment other than addiction, and GPs were
generally reluctant to treat addicts, the change was accepted by the medical
profession.6 The committee’s recommendations also led to the introduction of a
notification system for addiction (as with infectious diseases). The drug clinics took over
the prescribing of heroin to patients who were previously prescribed by private doctors
and NHS GPs. Prescription of heroin to addicts declined in the early 1970s, as doctors at
the drug clinics were uncomfortable prescribing it. Methadone had recently been
developed in the USA as a new treatment specifically for dependence on opioid drugs,
and the clinic doctors considered oral methadone was a more suitable medication.
The 1960s also saw widespread use of other illicit drugs by young people, notably
cannabis but also LSD and amphetamines. Concern over the use of amphetamines, or
‘purple hearts’ or ‘pep pills’ as they were commonly called, led to their control under
the Drugs (Prevention of Misuse) Act 1964.7 While amphetamine use among young
people was the first to draw political reaction, cannabis-related convictions increased
steeply as use of this drug became more popular in the mid-1960s, and the issue was
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hard to ignore. A Home Office Advisory Committee (the ‘Wootton Report’) in 1968
recommended that the legal penalties for simple possession of cannabis should be
reduced and casual users of cannabis should not receive custodial sentences.8 Despite
initial hostile Government reaction, the committee’s proposals were implemented in
subsequent legislation.
5.7 The UN Single Convention on Narcotic Drugs 1961 and
the Misuse of Drugs Act 1971
Further international drug control protocols followed the Geneva Conventions of the
1920s and eventually all the existing international drug control treaties were
consolidated in the UN 1961 Single Convention on Narcotic Drugs (see Box 2,
Section 1.2).9 The Single Convention has four schedules of controlled drugs, ranging
from most restrictive to least restrictive. The Misuse of Drugs Act 1971 was
introduced to meet the treaty obligations and has an analogous scheme of drug
scheduling, with drugs considered the most harmful such as heroin and cocaine
classified as Class A drugs (see Table 1, Section 1.2). The Act also established the
Advisory Council on the Misuse of Drugs (ACMD) to keep the drug situation under
review and give advice to the Government on measures ‘which, in the opinion of the
Council ought to be taken for preventing the misuse of such drugs or dealing with
social problems connected with their misuse’.10 Among its important functions is to
recommend classification of new or existing drugs that may be misused. Further
details of drugs covered by the Misuse of Drugs Act are given in Section 1.2.
5.8 Heroin use grows in the 1980s
The 1980s brought new pressures on the treatment system and Britain’s drug control
policy, with a new epidemic of heroin use. The numbers of addicts notified to the Home
Office and the amount of heroin seized rose dramatically. There was widespread media
coverage of this new wave of heroin use, and drug use became an important and
sustained policy issue for the first time since the 1960s. The then Conservative
Government sought to encourage a coordinated response from across the range of
Government departments, by setting up an interdepartmental working group of
ministers and officials, which resulted in the first Government strategy document
Tackling drug misuse, issued in 1985.11 During the same period, new ways of tackling
drug treatment were developed following the recommendations of the Treatment and
rehabilitation report from the ACMD in 1982.12 The focus became the broader
population of ‘problem drug users’, seen as a heterogeneous group with a range of
problems beyond the use of a drug itself, encompassing social and economic as well as
medical problems. The generalist doctor was seen as key to dealing with drug-related
problems, and drug use was no longer seen as the sole province of the specialist clinic
psychiatrist. The ACMD saw an increasing role for doctors outside the specialist
treatment services, with the proviso that there were ‘strict safeguards’.12 In response to
the ACMD recommendations for safeguards, in 1984 the Department of Health and
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Social Security issued all doctors with their publication Guidelines of good clinical
practice in the treatment of drug misuse.13 Revisions of these guidelines have been
published subsequently, most recently in 2007.14
5.9 The AIDS epidemic and treatment policy
The late 1980s saw HIV and AIDS become the dominant public health concern. People
who injected drugs were seen as a potential route for the HIV virus to rapidly diffuse
into the wider community, through the sharing of contaminated injecting equipment. 
In response to the widespread concern about AIDS, HIV and those who inject drugs, the
ACMD set up an AIDS and Drug Misuse Working Group. The resulting report, AIDS and
drug misuse. Part I provided the template and rationale for a reorientation of drug
treatment practice to meet the new challenge of drug use and HIV.15 The report stated
that ‘The spread of HIV is a greater threat to individual and public health than drug
misuse’. The ACMD saw that the key aims of drug treatment were to attract
seropositive injecting drug users into treatment, where they could be encouraged to
stop using injecting equipment and move away from injecting toward oral use. 
Harm minimisation was the core principle of this policy and received support from the
Government. Harm minimisation was characterised by adopting measures that sought
to reduce the harm caused by continued drug use, through modification of using
behaviours.15 AIDS and drug misuse. Part I and the complementary report AIDS and
drug misuse. Part 2,16 continued the policy aim of involving GPs and general
psychiatrists more actively in the direct provision of services to address the more general
healthcare needs of drug users, while the specialist clinics maintained responsibility for
the more complicated needs of the more difficult drug users. Needle exchange services
rapidly became mainstream. Their early introduction, together with a range of other
harm-reduction interventions, has been seen as critical in preventing the major spread
of HIV among individuals who inject drugs that has been seen in other countries where
such approaches were not adopted.17
Around this time, maintenance prescribing re-emerged in the form of oral methadone
maintenance and became increasingly provided by GPs, either independently or in a
‘shared care’ scheme, as well as by specialist services.18
5.10 Crime and a redesign of British drug policy
Through the 1980s, there was a notable increase in use of recreational drugs among
the young, not only cannabis but also the new ‘dance drugs’ such as ecstasy, and there
was increasing public and political concern about the link between drug use and crime.
The number of drugs offenders rose from 24,000 in 1986 to 95,000 in 1996, with the
majority of these offences related to cannabis possession.19 In 1995, the Government
published Tackling drugs together: a strategy for England 1995-1998,20 in which it
sought to combine ‘accessible treatment [with] vigorous law enforcement … and a new
emphasis on education and prevention’ (see Chapter 7). The aim of the strategy was to
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increase community safety from crime and to reduce the health risks and other damage
related to drug use. This and subsequent Government drug strategies reconceptualised
drug treatment as an intervention that might lead to a reduction of criminal behaviour.
Criminals who use drugs were to be encouraged to enter treatment as a means of
altering their behaviour. The strategy also indicated a move away from the harm-
minimisation approach of the preceding years. The strategy stated that the principal
objective of treatment was to assist drug users toward abstinence and maintenance of a
drug-free state, while recognising that other approaches would continue to be taken to
reduce the spread, by drug users, of HIV and other communicable diseases. There was
to be an integrated approach coordinated by the Government but with the details of
policy determined at a local level by new drug action teams. Statutory and voluntary
sectors would work together and health and social care would be linked to the criminal
justice system.
In 1996, the Department of Health (DH) set up a review of drug treatment services and
their effectiveness, which concluded that ‘treatment works’.21 This conclusion underlay
the 10-year New Labour strategy Tackling drugs to build a better Britain,22 which
stressed the use of diversion into drug treatment from the criminal justice system. An
example of this new approach was the introduction of community sentences for
offenders, involving drug testing and treatment components called Drug Treatment and
Testing Orders (DTTOs). Treatment services within prisons expanded. The main focus of
the strategy was problematic drug users, which included those who injected drugs and
those using opioid drugs and crack cocaine. Spending on drug treatment rose
substantially. In 1994, around 67,000 people were counted as being in treatment, rising
by 26.9 per cent to 85,000 in 1998-1999 and a further 129.9 per cent to 195,400 
by 2006-2007, giving an overall rise from 1994 to 2006-2007 of 191.6 per cent.23
The treatment and rehabilitation (see Glossary) budget for 1994 was £61 million, while
the total spend on treatment in 2005-2006 was estimated to be £508 million.23
In criminality surveys conducted in England and Wales in 2000 and 2002, over one-third
of male prisoners and over a quarter of men serving community sentences reported
experiencing problematic drug use.24 Men were more likely than women to say that
they had problems staying off drugs in the last 12 months (43% versus 39%).24 The
budget for drug treatment interventions in the criminal justice system in England and
Wales was over £330 million in 2006-2007 and spending on drug treatment in prisons
increased from £7 million in 1997-1998 to £80 million in 2007-2008.25
The 2002 Updated drug strategy concentrated on the ‘most dangerous drugs’, defined
as Class A drugs, and again emphasised the objective of getting more of the estimated
250,000 problem drug users into treatment.26 The Home Office was given overall
responsibility for implementation of the drug strategy, although the DH and
Department for Education and Skills (DfES) had key roles. The 2004 Tackling drugs:
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changing lives strategy document again stressed Government policy to get as many
offenders who were drug users into treatment as possible.27 Another aim was to
enhance the quality of treatment by providing support with housing, finance, skills
training and job opportunities for drug users. The 2008 drugs strategy Drugs:
protecting families and communities28 maintained the focus on problematic drug users
and the links between drugs and crime but laid a greater emphasis on the impact of
problematic drug use on others in the user’s circle, especially children and families.29
5.10.1 Recovery and policy
As part of the NHS, the National Treatment Agency (NTA) was set up in 2001 as a
specialist health authority to monitor expenditure of the drug treatment budget and to
expand the availability and quality of treatment. As described in the previous section,
the number of people in drug treatment increased by 129.9 per cent from 85,000 to
195,400 between 1998-1999 and 2006-2007.23 Then in 2009 the NTA shifted its focus
from getting people into treatment to helping service users achieve and sustain long-
term recovery (see Glossary), with services aiming to support recovery that is shaped by
the individual drug users themselves. This focus on outcomes and an emphasis on
recovery is mirrored in the most recent Government strategy, Drug strategy 2010.
Reducing demand, restricting supply, building recovery: supporting people to lead a
drug free life.30 Policy continues to move beyond an individualistic focus, with less
emphasis on drug–crime links and a greater consideration of the wider social and
economic factors that drive problematic drug and alcohol use and that can help or
hinder recovery.
A subsequent Government document, Putting full recovery first, provides more detail of
the Government’s aim of establishing a treatment system approach that puts more
emphasis on people in drug treatment achieving recovery, rather than aiming to simply
engage and retain them in treatment.31 An Inter Ministerial Group on Drugs has been
established to direct and monitor implementation of the drug strategy. The functions of
the NTA will be transferred to a new body, Public Health England (PHE), from April
2013. PHE is being set up to provide leadership within a recovery sector that covers
both drug and alcohol dependence. A payment by results model is to be developed to
incentivise reaching outcomes that include being free of dependence and not involved
in crime and being in employment. Local areas will be supported to move local
commissioning structures toward recovery- and abstinence-based support.
It is worth noting that there are risks associated with moving to a payment by results
system where the agencies, and presumably thus the professionals, are to be paid not
for their services, but by whether the patient behaves, and lives his/her life, in the way
that Government policy prescribes. Given the poor success rates for treatment of drug
problems, particularly if the definition of success includes abstinence, this may make a
bad situation worse. Apart from that, within a medical framework, this would be a
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change in the aims of doctors: not to minimise sickness but to help the patient lead a
good life, and to be paid not for services provided but by how the patient behaves.
Under such circumstances, healthcare professionals may be reluctant to take on patients
who have failed before, as they may be at higher risk of failing again. 
The international policy framework means that all possession or marketing of illicit
drugs remains a criminal activity.
An overview of current Government strategies in the UK is provided in Appendix 6.
Summary
• Purchase of psychoactive drugs such as opium and laudanum was unregulated 
in the UK until 1868, when the Pharmacy Act was passed, restricting opium 
sales to pharmacists’ shops, with a requirement on pharmacists to keep a record 
of purchasers.
• In 1916, an Army Council order, and the Defence of the Realm Act later the same
year, made it an offence for anyone except a physician, pharmacist or vet to
possess, sell or give cocaine, and the drug and its preparations could only be
supplied on prescription.
• The first Dangerous Drugs Act passed in 1920, and a further Act in 1923, passed to
conform to the 1912 International Opium Convention at The Hague to which Britain
was a signatory, imposed stricter controls on doctors and pharmacists in relation to
dangerous drugs, in a climate with a penal emphasis on policy.
• It was not clear from these Acts or the Convention whether prescribing drugs to
addicts constituted legal medical work. The Rolleston Report in 1926 affirmed the
right of doctors to prescribe controlled drugs to addicts in defined circumstances and
set the scene for a balanced medical approach within a penal framework.
• The second Geneva Convention in 1925 brought cannabis under international
control, and restrictions were implemented in the 1928 Dangerous Drugs Act.
• As a result of increasing use of heroin, the 1967 Dangerous Drugs Act restricted
prescribing of heroin to doctors licensed by the Home Office, and set up new drug
treatment centres within the NHS hospital system. A notification system for addiction
was also introduced.
• Introduction of other drugs to the illicit market, such as amphetamines and LSD, led
to the Drugs (Prevention of Misuse) Act 1967, and recommendations that penalties
for possession of cannabis should be reduced, with no custodial sentencing for casual
use, were implemented.
• The 1961 United Nations Single Convention on Narcotic Drugs introduced four
schedules of controlled drugs and was followed in the UK by the Misuse of Drugs Act
1971, with drugs categorised in classes according to perceived harm and therapeutic
value. This Act also set up the Advisory Council on the Misuse of Drugs, to keep the
drug situation under review and advise the Government.
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• With increasing illicit drug use, Government strategies in the 1980s began to focus
on the social and economic problems of drug users, in addition to their medical
problems, and GPs became involved with the more general healthcare needs of drug
users, leaving specialists to deal with more difficult drug users.
• The spread of HIV and AIDS generated ‘harm-minimisation’ policies in relation to
drug use, by modification of using behaviours, from injecting to oral use where
possible.
• The 1995 Drug Strategy moved away from this approach to one encouraging users
to enter treatment, with the aim of moving users towards abstinence and
achievement of a drug-free state and of reducing criminal behaviour.
• Later strategies (2002, 2004, 2008) continued to emphasise the need to move drug
users into treatment and focused on the links between drugs and crime; they also
aimed to move drug treatment away from the NHS into the community and
voluntary sector.
• The 2008 strategy maintained a focus on drugs and crime but placed greater
emphasis on the impact of problematic drug use on children and families of users.
• With the 2010 strategy, policy continues to move away from drug-crime links and
towards a focus on wider social and economic factors that drive problematic drug
use. The emphasis is on people in drug treatment achieving recovery, rather than
aiming to simply engage and retain them in treatment.
• The international policy framework means that all possession or marketing of illicit
drugs remains a criminal activity.
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Chapter 6 – Controlling illicit
drug use
6.1 Introduction
This chapter reviews the current legal framework related to illicit drug use and examines
the implications for society and for health professionals.
In considering the impacts of current drug policy and law, it is important to
distinguish between harm associated with drug use per se and harm associated with,
or created or exacerbated by, the legal/policy environment. The former are discussed
in detail in Chapter 3. Sections 6.2 and 6.3 of this chapter specifically explore the
legal/policy aspects. This type of distinction may not always be clear in practice; while
the health harms associated with drug use are relatively well understood,a the
relationship between drug use, and the cultural/political response to the drug use, 
is complex. It is important to consider whether the same drug may cause different
types of harm depending upon the sociocultural context and legal framework within
which the drug use takes place.
The debate surrounding enforcement of drug policy is controversial, with strong
feelings both for and against liberalisation. These arguments are discussed in
Section 6.5 and alternative approaches to drug control are presented in 
Sections 6.6 and 6.7.
6.2 Evaluating prohibition
Reviewing both the impact and effectiveness of the legal and policy environment
relating to drug use is not straightforward and study conclusions must be interpreted
with care. A wide variety of interest groups come to the drug policy debate, with
different priorities and analytical perspectives, which can be shaped by personal,
ideological, political or professional interests. Drug policy and law influence a broad
range of social policy arenas, encompassing a range of different enforcement
interventions that may deliver success on certain indicators, but prove
counterproductive elsewhere. The choice and prioritisation of particular effectiveness
indicators can lead to very different conclusions.
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a Novel psychoactive substances are an important exception.
Separating out the impact of drug policy from the effects of wider social policy and
non-policy exogenous variables that can also affect drug-using behaviours and drug
marketsb presents an additional challenge.
A key question is what the primary aim of drug policy and legislation should be.
Specifically, should it be the reduction of illegal drug use through the use of prohibitive
and criminal legislation? Or should it be, from the medical perspective, focused upon
reducing public health and social harms? This dichotomy requires consideration of a
complex array of social, health and human rights factors. The doctor’s role is discussed
in more detail in Chapter 11.
6.2.1 A global approach
Current drug policy is underpinned by the UN drug conventions (see Box 2, Section
1.2). Their founding principle is the need to address problems associated with drug use
and is primarily concerned with protecting and improving public health. The consensus
based on these conventions is to create a framework where supply and possession of
listed drugs for non-medical/scientific use is made a criminal offence.
6.3 The benefits of a prohibitionist approach
6.3.1 Deterring use
While there is a voluminous literature on the deterrent effects of punitive enforcement
on crime generally, there is comparatively little about how the threat of sanctions and
law enforcement affects illicit drug use.1 Existing research has tended to focus on the
impacts of decriminalising, rather than criminalising, the possession and use of illicit
drugs. The 2001 US National Academy of Sciences report, Informing America’s policy
on illegal drugs: what we don’t know keeps hurting us recognised this evidential gap,2
and called for more research into the deterrent effect, noting that ‘a rational drug
control policy must take appropriate account of the benefits and costs of enforcing
sanctions against drug users’. The gap was also identified in the 2006 Science and
Technology Select Committee’s report Drug classification: making a hash of it?3
The report notes that while legal enforcement underpins the Government’s policy on
drug classification, the committee could find ‘no solid evidence to support the existence
of a deterrent effect’. The UK Government responded by acknowledging the lack of
evidence but stating that it ‘fundamentally believes that illegality is an important factor
when people are considering engaging in risk-taking behaviour’.4 The response also
stated that ‘[T]he Government will consider ways in which the evidence base in the
context of the deterrent effect can be strengthened’,4 but it has, to date, not published
any such evidence.
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b For example, demographic changes, cultural shifts, migration, medical advances, emergence of new drugs, recessions, wars, etc.
For crime more broadly, the literature indicates that generalisations about punishment
and deterrence are not useful and a differentiated approach is necessary for different
types of crimes.5 Research that specifically studies deterrence and illicit drug use is
urgently needed.
Studies that have focused on the deterrent effects of sanctions on users have produced
mixed results. Some polling evidence, for example by The Police Foundation inquiry
report Drugs and the law (1999),6 suggests that, for some, illegality is a factor in their
decision not to use drugs. The inquiry concluded that the evidence of a deterrent effect
was ‘very limited’ and found that health concerns and general disinterest played a
much greater role. There is also some evidence showing that sanctions can reduce use
of hard drugs among individuals already in the criminal justice system,7 though Babor
and colleagues caution against extrapolating these findings to more open systems.8
Comparative analysis between countries or jurisdictions with different levels or intensity
of punitive user-level enforcement provides no conclusive support for a significant
deterrent effect. A 2008 review, drawing on mental health surveys conducted in 
17 countries across the world in conjunction with the WHO, concluded that global drug
use is not simply related to drug policy, since ‘countries with stringent user-level illegal
drug policies did not have lower levels of use than countries with liberal ones’.9 As
discussed in Chapter 3, the relative levels of harm for different drugs correlate poorly
with their legal classification, and legal substances, such as alcohol and tobacco, have
been found to be at least as harmful as commonly used illicit drugs (see Figure 3,
Chapter 3).10,11 Studies comparing levels of cannabis use in different states in both
Australia and the USA have similarly failed to demonstrate any significant correlation
between punitiveness of enforcement and prevalence of use.12 Some of the groups that
are most vulnerable to drug-related health harms are likely to be among those least
deterred by punitive laws. These groups include young people with an inclination to
take risks, dependent and problematic users, those from socially deprived backgrounds,
those with existing criminal records, and those with mental health vulnerabilities (see
Chapter 4). The impact of enforcement on overall harms for these groups is likely to 
be limited.13
There may even be perverse effects associated with criminalisation. The Home Office
noted in its submission to the Home Affairs Select Committee in 2001: ‘some people
would seem to be attracted to experiment with controlled drugs because of their
illegality (eg “forbidden fruits”)’.14 Any such effects are hard to quantify.
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Following their review of the existing evidence, Babor and colleagues report that the
majority of interventions aimed at deterring drug use in the criminal justice system show
‘modest effectiveness’.8 They go on to stress that the amount of research on this issue
has been minimal, of varying quality, and concentrated in only a few countries.8 A review
published by the EMCDDA in 2010 also highlighted that the impact of legal changes on
drug use has not been consistently evaluated.15 At present, the evidence justifying the
conclusion that criminal prohibition deters use is not strong (see Chapter 7).16 While it
would be wrong to discount the effect altogether, there is little evidence that punitive
enforcement is significantly effective in ‘sending a message’ that will help reduce or
eliminate drug use. It is argued that illegality can help young people in particular to ‘say
no to drugs’: this is a credible proposition but it is hard to measure its efficacy with any
accuracy. It is unclear whether comparable prevention efforts are more effective with
illegal drugs than legal ones, ie whether the illegality itself is a key aspect of prevention
effectiveness (see Chapter 7). In addition to legal sanctions, it is also important to
consider the extent to which social, cultural and religious norms may condition and
deter use. Writing in the journal Science, Jarvik suggests that religious convictions may
account for the lower use of legal substances such as alcohol and tobacco in Amish and
Mormon communities.17 He goes on to hypothesise that such convictions, combined
with the conspicuous stigmatisation of deviant behaviour, may deter illicit drug use
more effectively than the threat of prison.17
6.3.2 Reducing use by reducing availability and 
increasing price
As discussed in Section 4.5.1, price appears to influence the use of drugs.
Availability
As discussed in Section 4.5.2, the physical availability of drugs refers to their
proximity and accessibility. In an illegal market, it is difficult to establish reliable
methods to measure availability. A series of proxy measures have been used by the
UK Government, such as drug seizures, dismantling of criminal groups, and recovery
of criminal assets. While these measures can indicate enforcement successes, they
are not measures of availability.
The reduction of availability was a priority target in the 1998 and 2002 UK drug
strategies,18,19 and the 2010 strategy takes what it describes as an ‘uncompromising
approach to crack down on those involved in the drug supply both at home and
abroad’.20 The strategies are not based upon an agreed definition of availability, and
although the 2010 strategy focuses on process measures such as breaking up criminal
gangs and seizing assets, it has not identified any targets or established measures of
impacts on availability.20
BMA Board of Science
Drugs of dependence: the role of medical professionals100
Price
The role of supply-side enforcement in raising prices is unquestioned. Products like
heroin and cocaine, which cost only pennies per gram to produce, frequently sell for
£40 or more per gram by the time they reach consumers in the UK.21 This process,
which has been described as ‘the alchemy of prohibition’,22 turns low-value
processed agricultural products into commodities that are literally worth more than
their weight in gold.23
The impact of price on levels of drug consumption is discussed in detail in 
Section 4.5.1. Drugs of dependence have more complex economics than other
products: drug use does not necessarily follow predictable economic patterns in a
simple linear way, which makes generalised conclusions problematic. Levels of use
can rise and fall independently of price24 and there is some disagreement between
commentators on the impact of price rises. Drawing on the work of Grossman25,
Babor and colleagues maintain that even users who are drug dependent cut back on
their consumption when prices rise.8 Other commentators argue that for those who
are dependent, increases in price are unlikely to have a dramatic impact on use,
particularly when compared to those whose use is more intermittent.
Enforcement can certainly create obstacles in terms of additional expense and
inconvenience, and drug markets can be locally displaced and temporarily disrupted.
There is no evidence from the experience of past decades to suggest they can be
eliminated or significantly reduced in the long term while demand remains high. 
It is evident that criminal supply has been able to keep pace with rising demand.
Inference from prevalence data (see Chapter 2), and survey data on ‘drug offers’,
indicate that drugs remain widely available to those who seek them.26
Supply and demand within a criminal market that is not regulated by the state still
has a series of checks and balances. In a market that is primarily demand driven and
supplied by profit-seeking entrepreneurs, prices are unlikely to rise to a level where
demand dries up. Even if supply-side enforcement can successfully achieve a
‘drought’ or push prices for a particular drug beyond the reach of most consumers,
the effect is likely to be displacement to other more affordable drugs, or a drop in
drug purity as a way of maintaining more consistent street prices.21 Both these
impacts have unpredictable health implications. For dependent users on lower
incomes, demand may also be less price elastic (for an explanation of price elasticity,
see Section 4.5.1), so that increasing prices lead to increased levels of criminal
activities (see Section 6.4.2) to raise the necessary funds, rather than reduced use.27 
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All of these effects were observed during the 2000 Australian ‘heroin drought’,c,27
although it is not clear how much this was related to enforcement, and how much
to external factors in global opiate production.28
6.4 The costs of a prohibitionist approach
In 2008, the executive director of the UNODC acknowledged the major negative
‘unintended consequences’ of prohibition.29 These included the creation of ‘a huge
criminal black market’; ‘policy displacement’, where ‘public health, which is clearly
the first principle of drug control … [is] displaced into the background’; and 
‘the balloon-effect’, where enforcement activity in one area does not eliminate
production, transit or use, but simply displaces it to another area.29 Other bodies,
such as the coalition of non-governmental organisations (NGOs) supporting the
2011 Count the Costs initiative,30 have produced more detailed analyses. The key
costs, or unintended consequences, of the prohibition approach are outlined next.
6.4.1 Increasing health risks associated with drug use
Prohibition has an impact on the type and quality of the specific products consumed
and on consumption behaviours. This increases health risks in a number of ways.
• Illegally sourced drugs are of unknown quality, strength and purity, lacking the
certainty of legal drugs or legally regulated equivalents for medical use. This point
was emphasised by a recent NTA guide.31 In addition to the health risks associated
with illicit drug use, the uncertainty surrounding the quality and purity of illicit drugs
creates or exacerbates risks. These include the risks of overdose, poisoning (from
adulterants, bulking agents and other contaminants), and infection from biological
contaminants among drug users who inject.32
• A fall in purity and/or rise in the cost of heroin (and some other powder-form drugs)
can encourage injecting in preference to safer methods of use such as
smoking/snorting, as a way of getting a greater effect for less money.33
• The economics of the illegal trade have tended to push markets towards increasingly
potent or concentrated (but profitable) drugs and drug preparations associated with
increased risks.34
• Criminalisation can increase risk by pushing use into marginal, unhygienic and
unsupervised environments. This is particularly true for needle sharing among drug
users who inject, in relation to transmission of HIV and hepatitis.35,36 These infections
are not a feature of injecting use in Swiss-style clinics, where injection of prescribed
heroin is supervised (see Section 6.6.4).37
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c The Australian ‘heroin drought’ was an unpredicted and abrupt reduction in heroin supply. The shortage was most marked in
New South Wales, which witnessed increases in price, decreases in purity at street level, and reductions in the ease of obtaining
the drug.
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• Criminalisation of users can discourage them from approaching drug services,
contacting paramedic services in emergency situations, or volunteering accurate or
complete information to health professionals (see Section 8.2).
6.4.2 Fuelling crime
The causal links between drug use and crime are complex and contentious among
criminologists.d,13 There is a clear and demonstrable connection or nexus between
supply-side criminalisation and actual acts of criminal behaviour.30 Conflict between
high demand for drugs and the laws that prohibit their production, supply and use
puts pressure on supply in a market that is demand led. This inflates prices, which
has two effects.
• The first is the creation of a lucrative opportunity for criminal entrepreneurs. To give
an indication of scale, the Home Office has estimated the value of the UK illicit drug
market at £4.6 billion a year,38 while the 2005 UN World Drug Report estimated the
global market at $332 billion (around £200 billion) at retail level.39 There is cogent
evidence that organised crime has exploited the opportunities created by drug
prohibition. A growing illegal trade is associated with high levels of violence,40
corruption and money laundering.41,42
• The second effect is that inflated prices encourage acquisitive crime among low-
income dependent drug users fundraising to support their habits (see Section 3.4.2).
While estimates are hard to formulate,43 volumes of such offending are substantial
(see Section 3.4.2).44 The high cost of drug use also exacerbates the social harms
discussed in Section 3.4. The specific role of illegality is underlined by an absence of
evidence for acquisitive crime associated with dependent use of alcohol,45,46 tobacco47
or prescription drugs, which are all available legally.
6.4.3 Marginalisation of human rights
In many countries, drug enforcement has resulted in serious human rights abuses,48,49
including torture and ill treatment by police, judicial corporal punishment for drug
offenders, executions and extrajudicial killings, arbitrary detention, and denial of 
basic health services. Poorly scrutinised drug-enforcement practices can additionally
exacerbate systematic discrimination against people who use drugs, impede access 
to essential medicines,50,51 and prevent access to harm-reduction and HIV-treatment
services for marginalised high-risk populations.
Many of these particular issues are of marginal or no relevance to the situation in the
UK, where concerns centre essentially around access to HCV treatment for some people
who inject drugs (see Section 10.6).52,53 There is some evidence to suggest that UK
drug users feel that they are negatively profiled by the police. Research examining drug
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users’ experiences of street policing in the UK found that the vast majority of the
sample (n=62) were known to the police and were targeted for attention. Very few
relayed stories about receiving help from the police: for most of the sample, contact
was a negative experience involving routine ‘stopping, checking, questioning, and
moving persons on’.54 Those who were subjected to this practice tended to perceive 
it as an unwarranted imposition of authority and control. When conducted in a 
busy, public place, some of the sample also felt that police actions were intended 
to shame the user by exposing their drug use to others.54 Stigmatisation of
problematic/dependent drug users, particularly those who inject drugs, remains 
a serious issue (see Section 8.2), with a series of identified negative public health
implications; this is made worse by the burden of criminalisation, in addition to the
stigma relating to addiction to legal or prescription drugs.35,55
An additional human rights issue is the discriminatory use of police powers. White
young people in an affluent neighbourhood in New York are many times less likely to
be stopped, checked and arrested by police than Black young people in a poor
neighbourhood in New York;56 the same has been documented for California57 and
elsewhere in the USA.58 Discriminatory stop-and-search patterns have also been well
documented for the UK, particularly in London and the Midlands.59
6.4.4 Negative impacts on international development,
security and conflict
Drug consumption in the developed west cannot be divorced from the regions in which
many of the drugs are produced, or through which they are transported. The illicit drug
trade has deleterious effects on development and security in many of the world’s most
fragile regions and states.60,61 Illicit drug production and transit is naturally drawn to the
most marginal and underdeveloped regions that already have poor infrastructure and
weak governance. This ensures that the threat from enforcement can be kept to a
minimum, public officials are relatively easily corrupted, and a ready supply of labour is
available from impoverished populations.
The endemic violence and corruption that accompany large-scale illicit drug operations
massively increases the challenges involved in bringing development to regions involved
in drug production, such as Latin and Central America and Afghanistan,62 or those
involved in transit, such as the Caribbean and West Africa.62 The resulting
destabilisation has disastrous knock-on impacts on a range of public health, human
rights and wider development goals, deterring investment, restricting activities of
development agencies and NGOs, and diverting limited domestic or foreign aid
resources into enforcement rather than public health and development initiatives.62
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6.4.5 Financial costs
Expenditure on the UK’s drug strategy is around £1.2 billion per annum, of which 
£300-400 million is on enforcement, with most of the rest spent on treatment.63
This figure is understated, as it includes only direct, proactive, spending on supply-side
enforcement, and does not include reactive spending dealing with drug-related crime
across the criminal justice system, including police, courts, probation and prisons. When
these costs are included, the total criminal justice expenditure is estimated at between 
£2 billion64 and £4 billion65 per annum. These criminal justice costs are in addition to 
the wider social and economic costs of drug-related crime itself (see Section 6.4.2),
which have been estimated at around £16 billion a year in England and Wales.24
The overall spend (proactive and reactive) on drug law enforcement and dealing with
the costs of drug-related crime is significantly greater than the amount spent on drug-
related health interventions (see Section 3.5).
6.4.6 Consequences for health professionals
The existing legal framework can impact on the ability of health professionals to
provide treatment for individuals who need medical intervention. It can, for example,
make access to vulnerable populations more difficult and make problematic drug
users reluctant either to come forward or to disclose information about their drug
use (see Section 8.2). It can also create political or practical obstacles to providing
certain treatments (eg for hepatitis or HIV) or harm-reduction interventions 
(eg needle exchange or methadone treatment), especially for individuals who are in
prison (see Section 10.6).51-53
6.5 Debate on the need for reform
Calls for any form of liberalisation of policy, and especially moves towards legalisation
and regulation of any currently illegal drug, remain controversial, with debate frequently
being polarised. Proposals have increasingly moved into the mainstream political arena.
The case in favour of maintaining the overarching prohibitionist status quo has also
been put by a range of individuals and agencies.
6.5.1 Maintaining the status quo
The core of the arguments against law reform is that it threatens to reduce or remove
existing barriers to availability and will thus lead to increased availability, use,
dependence and related harms. It is additionally argued that the potential for increased
use would be made worse by the removal of the deterrent effect of criminality and
the ‘wrong message’ that any such reforms would send out, particularly to young
people.66-71 The experience with some legal drugs, specifically alcohol and tobacco, is
often suggested as a potential indicator of where levels of use of currently illegal drugs
could end up, without the restraining influence of prohibition. 66-71
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While the UK Government has generally refrained from engaging in the detail of 
this debate, the Home Secretary, writing in the foreword to the 2010 drug strategy,
stated unequivocally that the ‘Government does not believe that liberalisation 
and decriminalisation are the answer’, as they ‘fail to recognise the complexity of 
the problem’.20
Similar rejections of any liberalisation of UK drug laws are regularly issued by the
Home Office in response to such calls. In 2010, for example, in response to the
Government’s drug strategy consultation paper, the ACMD recommended that:
‘[F]or people found to be in possession of drugs (any) for
personal use (and involved in no other criminal offences), they
should not be processed through the criminal justice system
but instead be diverted into drug education/awareness courses
[…] or possibly other, more creative civil punishments.’72
While recognising the harms associated with drug use and the need to support
‘those caught in the cycle of dependence’ to live drug-free lives, the Home Office
rejected the ACMD’s recommendation, stating that ‘giving people a green light to
possess drugs through decriminalisation is clearly not the answer’.73 A very similar
response was given to the Global Commission on Drug Policy’s report War on
drugs.74,75
More detailed critiques of reform proposals have been made by academics 66,77 and
NGO coalitions.67,68 The UN drug agencies have also produced clear statements. 
For example, in the preface to the World Drug Report 2009, the UNODC Executive
Director concludes that ‘transnational organized crime will never be stopped by drug
legalization’ and calls for ‘more control on crime, without fewer controls on drugs’.69
The 1997 World Drug Report also presents a more nuanced discussion in a chapter
dedicated to ‘the regulation–legalization debate’.70 The US Drug Enforcement
Agency has gone further, producing a detailed debating guide titled Speaking out
against drug legalization.71
6.5.2 Changing the status quo
Those who argue that the status quo is not working believe that reform is needed
and that the current punitive criminal justice approach to drug use has failed in its
key aim of eliminating or substantially reducing the trade and use of illegal drugs
and related health harms. They argue that the blanket prohibition of non-medical
use of drugs encompassed by the three UN conventions (see Section 1.2 and
Chapter 5) has an effect on users’ access to healthcare (see Section 8.2) and leads
to additional social and health harms associated with the illegal drug trade 
(see Section 3.4 for a discussion of part of this issue). These arguments are made
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while accepting that criminalisation might have had some, positive, deterrent effect.
The point is made that a modified and reformed system could be substantially more
effective than the status quo. The point is also made that the options for reform are
not binary: criminalisation or non-criminalisation. There is a spectrum of alternatives
and permutations of alternatives that could be used to potentially improve upon the
present system. There may well be some elements of criminalisation that should
remain but that should be coupled to other non-criminal approaches.
These broad conclusions have been repeated in a series of UK reports produced in
recent years, including those from the Police Foundation,6 the Home Affairs Select
Committee,77 The Prime Minister’s Strategy Unit,24 the Royal Society for the
encouragement of Arts, Manufacture and Commerce,78 and the UK Drug Policy
Commission (UKDPC).79 They are also endorsed by the Vienna Declaration of 2010,
which calls for evidence-based drug polices.80
A 2011 report from the Global Commission on Drug Policy, whose members
included the former Secretary-General of the UN, Kofi Annan,e and a further five
former heads of state, summarises the current situation.74 It states that the vast
expenditure and effort involved in enforcing prohibition has failed to curtail supply 
or consumption of illicit drugs. It cites the health and social harms that are linked to
drug use and those that occur as a direct consequence of prohibition and suggests
that Government expenditure on ‘supply reduction strategies and incarceration
displace more cost-effective and evidence-based investments in demand and harm
reduction’.74
Most recently, a 2012 report from the UKDPC, A fresh approach to drugs, identifies
the need for a new approach to policy that changes the ways in which Government
and society respond to drug problems, informed by a thorough analysis of the
evidence for improvements to polices and interventions.81
It calls for ‘a clear distinction between the overall goals of drug policy and the tools
to deliver it’, looking at ways to support responsible behaviour, while also focusing
on ways in which ‘society can enable and promote recovery from entrenched drug
problems’. The report advocates a ‘wholesale review’ of the Misuse of Drugs Act
1971 and the classification of drugs (see Section 1.2), with a commitment to
ensuring a strong evidence base to inform all changes to policy.
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e Following his appointment as Joint Special Envoy for Syria in April 2012, Mr Annan recused himself as a Commissioner of the
Global Commission on Drug Policy, with immediate effect.
6.6 What are the options for an alternative 
legal framework?
There is a spectrum of alternative legal frameworks available, and a useful, if incomplete,
body of evidence to draw on. This includes experience with other drugs, in other
countries, and with approaches to regulation and control of other risky products or
behaviours.82
The options for alternatives range from harshly enforced absolutist prohibition, through 
a series of regulatory market models, through to (effectively unregulated) free market
models (see Box 5).83 Between these extremes, there is a range of options for less
punitive approaches, decriminalising drug users, and potentially regulating drug markets.
Box 5 – The range of regulatory market models
Prohibition/criminalisation
Prohibiting/criminalising non-medical production, supply, possession and use, with
punitive sanctions. The intensity of enforcement and severity of penalties can vary.
Decriminalisation (see Glossary and Section 6.6.2) of personal possession and use
can operate within a prohibitionist framework.
• Examples: heroin, cocaine, cannabis, ecstasy
• Market controller: criminal entrepreneurs, corrupt officials
Regulated markets
A range of regulatory controls are deployed, covering drug production and trade,
products, gatekeepers of supply and users. Some drugs, preparations and activities
remain prohibited.
• Examples: prescription drugs, OTC drugs, alcohol, tobacco
• Market controller: moderate to intense regulation by Government agencies
Free market legislation or ‘supermarket model’
Drugs are legal and available for essentially unrestricted sale in the ‘free market’, 
like other consumer goods.
• Example: caffeinated drinks
• Market controller: corporate/private enterprise, with minimal regulation by
Government agencies and voluntary codes for retailers
Adapted from Rolles S (2009) After the war on drugs: blueprint for regulation. Bristol:
Transform Drug Policy Foundation,83 with the permission of Transform Drug Policy Foundation.
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Within each of these of these broad categorisations, there exists a range of sub-options.
As highlighted in Box 5, different drugs in the UK sit within all three categorisations.
While illegal drugs obviously come under ‘prohibition/criminalisation’, the UK’s
approach could be described as intermediate between the most punitive and most
tolerant of the prohibition models observed around the world.
As discussed in Section 6.2.1, the international consensus set out in the three UN
conventions (see Box 2, Section 1.2) means that supply and possession of classified
drugs is made a criminal offence. There are a number of legal and policy reforms that
can take place within an overarching prohibitionist framework. These are explored
below (see Sections 6.6.1 and 6.6.2) and can involve moves towards either more or
less punitive approaches. Any options that involve legally regulated production, supply
and availability of drugs that are currently illegal for non-medical use (see Sections
6.6.3 and 6.6.4) face more substantive legal, practical and political obstacles (both
domestically and internationally), as they necessarily involve crossing the line
established by the UN drug conventions that prohibits any such moves.f,g,83
6.6.1 Increasing the intensity or severity of enforcement
Relatively few policy makers, even those such as the UK and US Governments and 
UN drug agencies who argue against less punitive enforcement, call for increases in
the intensity of enforcement against drug users, even if tough talking around drug
trafficking remains a key element of the political narrative. In the USA, there has
recently been a conscious effort to move away from the ‘war on drugs’ rhetoric of past
decades.84 Some UK commentators have argued that the evident failures of UK drug
policy are not due to failure of the prohibition paradigm per se, but rather the failure
to enforce the laws with sufficient vigour and resources. These include members of the
police and academia and some media commentators and think tanks.h,85
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f See After the war on drugs83 Appendix 1 page 165.
g There is the option of denouncing the treaty, withdrawing from the convention, and requesting reaccession with a reservation.12
Bolivia is part way through this process and has asked to be re-admitted if the UN removes the statute that classifies the coca
leaf as illegal.
h Including the Social Justice Policy Group,85 and the Centre for Policy Studies.
6.6.2 Sentencing reform, including options for non-criminal
sanctions for certain drug offences
Various options exist for reforming sentencing for drug offences. The UK has recently
concluded a consultation process and review of sentencing guidelines for drug
offences under the auspices of the Sentencing Council. Its primary aim has been to
improve guidelines to ensure consistency of sentencing, while leaving the average
severity of sentencing unchanged.86 Potential sentencing reforms beyond the remit
of this review could consider the severity of sentencing more broadly and examine
options for raising or lowering average penalties, or alternative non-criminal
disposals for some offences.
This concept of maintaining certain drug offences but reforming sentencing to
empower judges to impose more non-custodial sentences, or enabling law enforcement
agencies to use administrative (non-criminal) sanctions, is usually explored in reference
to possession of small quantities of drugs for personal use. Small-scale production,
usually of cannabis, or not-for-profit supply among peer networks, is also occasionally
included in such discussions. This is often referred to as decriminalisation, although
the term is inaccurately and confusingly used in some of the literature.
‘Decriminalisation’ only describes a process, rather than an actual policy or legal
framework, and it is often mistakenly either confused with legalisation (which
usually includes regulation, see Section 6.6.4), or assumed to mean the removal 
of any sanctions, or removal of an offence from law entirely. These terms are defined
in more detail in the Glossary.
Decriminalisation of usei is widespread across the world (see Glossary and below),
and there is a clear trend of growing support and adoption for such approaches.87,88
It is difficult to generalise about these experiences, as there are many variations
between countries (and often between local Government jurisdictions within
countries), as well as different legal structures and definitions of civil and criminal
offences and sanctions.89 There are also significant variations in the threshold
quantities used to determine the user/supplier distinction,90 as well as the non-
criminal sanctions adopted. Variations include fines, warnings, treatment referrals
(sometimes mandatory) and confiscation of passports or driving licences. The key
point is that decriminalisation does not mean deregulation; it means adopting a
different (and it is hoped), more effective response than the use of the criminal
courts and process.
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i Dutch coffee shops go beyond decriminalisation of use. They operate within a regime where a drug (cannabis) can be
purchased within a highly regulated retail system, as well as used and possessed.8 New legislation has been introduced
prohibiting sales to non-Dutch residents; however, local authorities have been given the power to determine how the laws
will be implemented/enforced. A number of cities have enforced the law (eg Maastricht and Tilburg), while others (including
Amsterdam) have not.
A distinction is also made between de jure decriminalisation, which involves specific
reforms to the legal framework, and de facto decriminalisation, which involves a
similar outcome, but is achieved through ‘turning a blind eye’ tolerant policing –
effectively non-enforcement of criminal laws that technically remain in force.
Confiscation of drugs also characterises most decriminalisation policies, with the
exception of discretionary approaches adopted by police under some of the more
tolerant cannabis policy models (in the Netherlands, Belgium and Spain for example).89
There is considerable variation in the approaches operating within the regulatory
framework in different countries. Box 6 presents a list of countries that have adopted
some form of non-criminal disposals for possession of small quantities of some or all
drugs, and an example case study is set out below.
Box 6 – Countries that have adopted non-criminal disposals for possession
of small quantities of drugs
Europe
Austria, Portugal, Spain and the Czech Republic have decriminalised all drugs 
(de jure decriminalisation), while the Netherlands and Switzerland effectively have
similar but de facto decriminalisation policies. Luxembourg, Belgium and Germany
have adopted similar approaches for cannabis (in some German Lander this is
applied to all drugs).91
Latin America
Argentina, Mexico, Paraguay, Peru and Uruguay have decriminalised all drugs,
Ecuador and Brazil have decriminalisation laws pending, Chile and Ecuador have
partial decriminalisation, and in Colombia the Government and Supreme Court are
involved in an ongoing legal and constitutional dispute over a 1994
decriminalisation law. j,92,93
Elsewhere in the world
Four Australian states and 14 US states have decriminalised cannabis possession.
Russia has made possession of small amounts of any drugs for personal use an
administrative offence, and Kyrgyzstan has administrative responses to small-scale
possession offences.94
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j A 1994 Supreme Court ruling effectively made criminalisation of possession unconstitutional. The constitution was amended in
2009 to recriminalise possession.92 This has recently been challenged again in the Supreme Court.93
Case study: The Portugal experience 
The publication in 2009 of a report by the US-based CATO Institute95 on Portugal’s 2001
decriminalisation policy has made the country a focus of global drug debate. The
Portuguese policy decriminalised the possession of small quantities of any drug for
personal use, alongside expanding drug-treatment and harm-reduction interventions.
The volume of data collected on numerous indicators over 10 years provides many useful
lessons but has also provided scope for cherry-picking and filtering through different
political and ideological perspectives.96 Some of Portugal’s prohibitionist ‘antidrug’
organisations, for example, present the data as indicating an unmitigated disaster,97
in contrast to the arguably rose-tinted perspective of the libertarian-leaning 
CATO Institute report.95
A comprehensive academic study of the Portugal experience has now been published 
in a peer-reviewed journal. What can we learn from the Portuguese decriminalization 
of illicit drugs?98 summarises that since decriminalisation, the following changes have
been observed:
• small increases in reported illicit drug use amongst adults
• reduced illicit drug use among problematic drug users and adolescents, at least 
since 2003
• reduced burden of drug offenders on the criminal justice system
• increased uptake of drug treatment
• reduction in opiate-related deaths and infectious diseases
• increases in the amounts of drugs seized by the authorities
• reductions in the retail prices of drugs.
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In conclusion, this publication notes:
‘[The Portugal experience] disconfirms the hypothesis that
decriminalization necessarily leads to increases in the most harmful
forms of drug use. While small increases in drug use were reported
by Portuguese adults, the regional context of this trend suggests that
they were not produced solely by the 2001 decriminalization. 
We would argue that they are less important than the major
reductions seen in opiate-related deaths and infections, as well as
reductions in young people’s drug use. The Portuguese evidence
suggests that combining the removal of criminal penalties with the
use of alternative therapeutic responses to dependent drug users
offers several advantages. It can reduce the burden of drug law
enforcement on the criminal justice system, while also reducing
problematic drug use.’
A more recent Drug Policy Profile of Portugal produced by the EU’s European Monitoring
Centre on Drugs and Drug Addiction has supported these conclusions.99 It observed that
the model might be best described as a public health harm-reduction policy rather than a
first step towards legalisation of drug use.
6.6.3 Unregulated ‘free market’ model
While only advocated by a small group of free market libertarians, the free market
model has remained a feature of the debate, although more as a thought experiment
than a serious proposition. Under this model, a clear description of which can be found
in Nadelmann,100 all aspects of drug production and supply are legalised. Regulation is
essentially left to market forces and self-regulation among vendors, with a minimal level
of Government intervention (trading standards, contract enforcement and so on) that
might be associated with standard consumer products available in a supermarket.100
There is an argument that tax revenue from sales of drugs could be used to fund the
public health costs associated with dependent drug use.100 
Given the negative health outcomes that under-regulated markets for alcohol and
tobacco have produced historically,46,101 this is a model that is unlikely to be supported
by health professionals working to proven public health principles.
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6.6.4 Options for legal regulation of drug production 
and availability
While the UN conventions clearly mandate that the supply of drugs must remain an
offence, this section examines models that cannot currently operate for use of drugs
classified within this framework. In theory, the conventions can be revisited and
changed; Room and colleagues identify four ways in which the 1961 Convention could
be altered:
1. by amendment under Article 47. This Article states that ‘[A]ny Party may propose
an amendment to this Convention’ and requires either unanimous consent or the
convening of a Conference of the Parties by action of the Economic and Social
Council of the United Nations (UN ECOSOC)
2. by termination of the convention, resulting from a sufficient number of
denunciations (withdrawals) from the convention to reduce the number of parties
below 40
3. by removing particular drugs from any of the convention’s schedules. This would
have to be based on the recommendation of a WHO expert committee, and would
require a majority vote in the Commission on Narcotic Drugs (CND), and in the UN
ECOSOC if any party appealed the CND decision
4. the convention could theoretically fall out of use as conditions change, without any
formal termination or denunciation.12
These methods highlight that there is scope – in theory at least – to change the drug
conventions. Proposals for how post-prohibition models of drug market regulation
(legalisation) could function have been published relatively recently.102-104 In the UK, 
the Transform Drug Policy Foundation’s 2009 Blueprint for regulation83,105 presents a
range of potential regulatory models for different drugs that are currently illegal.
Options are explored for controls over:
• products (dose, preparation, price, and packaging)
• vendors (licensing, vetting and training requirements, marketing and promotions) 
and outlets (location, outlet density, appearance)
• who has access (age controls, licensed buyers, club membership schemes)
• where and when drugs can be consumed.83
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Five basic models for regulating drug availability are proposed:
1. a medical prescription model: or supervised venues for the highest-risk drugs
(injected drugs including heroin and more potent stimulants such as
methamphetamine) and problematic usersk
2. a ‘specialist pharmacist’ retail model: for moderate-risk drugs such as
amphetamine, powder cocaine and ecstasy. A trained and licensed pharmacist
would act as both gatekeeper and provider of health/risk information. Systems for
named/licensed user access and rationing of volume of sales could be added
3. licensed retailing: including tiers of regulation appropriate to product risk and
local needs. This could be used for lower-risk drugs and preparations such as lower-
strength stimulant-based drinks
4. licensed premises for retail and consumption: similar to licensed alcohol
venues and Dutch cannabis ‘coffee shops’, potentially also for smoking opium or
drinking poppy tea
5. unlicensed retail: minimal regulation for the least risky products, such as caffeine
drinks and coca tea.
In making the case for such an approach, Transform has additionally noted that:83
• rather than a universal model, a flexible range of regulatory tools would be available
with the more restrictive controls used for more risky products and less restrictive
controls for lower-risk products
• differential application of regulatory controls could additionally encourage use of
safer products, behaviours and environments
• commercialisation of markets would be strictly controlled, with default bans on most
or all forms of promotion, branding and marketing
• the oversight and enforcement of new regulations would largely fall within the remit
of existing public health, regulatory and enforcement agencies. Activities that take
place outside the regulatory framework would naturally remain prohibited and
subject to civil or criminal sanctions
• such models would also need to be phased in cautiously over several years, under
close evaluation
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k Existing examples include Swiss-style heroin ‘clinics’ where prescribed heroin can be injected in a supervised quasi-clinical setting.
UK law already allows for maintenance prescription of cocaine, (injectable) heroin, and amphetamines to dependent users,
although only heroin and amphetamines are prescribed in practice (in a similar fashion to methadone) and numbers are small,
around 400 and 2,000 individuals respectively.37
• the costs of developing and implementing a new regulatory infrastructure would
represent a fraction of the resources currently directed towards supply. There would
also be potential for translating a proportion of existing criminal profits into tax
revenue. It is important to note that there is no clear assessment as to what level of
revenue this could generate.83
6.7 Call to consider alternative options for drug policy
In 2010, Anand Grover, the UN’s Special Rapporteur on the Right of Everyone to 
the Enjoyment of the Highest Attainable Standard of Physical and Mental Health,
presented a thematic report on drug policy to the UN Secretary-General.106 As well 
as calling for the decriminalisation of possession and use of drugs, the report’s
concluding recommendation was to: ‘Consider creation of an alternative drug
regulatory framework in the long term, based on a model such as the Framework
Convention on Tobacco Control’.107 This was attempted in 2010 by Room and
colleagues who adapted the tobacco model and used it as the basis for a ‘draft
Framework Convention on Cannabis Control’.12
The Framework Convention on Tobacco Control contains a series of UN-mandated
recommendations specifically for the public-health-based regulation of a non-medical
drug.107 Transform has noted that this convention encompasses the same types of
regulation proposed in its own blueprint,83 and has a similar number of signatories (168)
to the three UN drug treaties, ‘which define parallel contrasting systems for the
absolute prohibition of almost all other non-medical drug markets’.83
As noted in Section 6.5.1 the Government’s ACMD has expressed interest in exploring
non-criminal sanctions for drug possession72 and many of the UK’s leading drug service
providers have expressed support for exploration and debate around the legal
framework relating to drug use.108-113 Internationally, support for such moves is far wider
– as demonstrated by initiatives such as the Vienna Declaration in 201080 and the Beirut
Declaration in 2011.114 The UKDPC report in 2012, A fresh approach to drugs, proposes
a new approach to the ways in which Government and society respond to drug
problems.81 It provides an analysis of the evidence for how policies and interventions
could be improved, with recommendations for policy makers and practitioners to
address the new and established challenges associated with drug use.
While support for moves in this direction has gathered increasingly mainstream
intellectual, political and public support, the current legal framework presents 
an impassable obstacle. The law is absolutist in nature; it does not allow for
experimentation with any forms of legally regulated non-medical drug production
and supply.
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6.8 Conclusions
This chapter highlights the shortage of robust evidence relating to the benefits of the
present prohibitionist framework in terms of deterring use or reducing availability and
presents some evidence that the effects are, at best, modest (see Sections 6.2 and 6.3).
The evidence suggests that the costs of enforcement are high (see Section 6.4.5) and
prohibition has created a range of unintended health, social and economic costs (see
Section 6.4).
Some commentators have gone on to argue that the benefits of the UK’s current
system are questionable and that there is a pressing need to explore whether a new
and/or modified legal and policy framework is required. The assumption is that a
different policy framework holds the potential to be more effective than the status quo.
Other commentators have been more cautious: for this group, the lack of research into
the effects of criminalising illicit drug use and possession does not, in itself, lead to the
position that new or amended regulations are required.
Doctors have a key role to play in taking this debate forward and this is discussed in
Chapter 11.
Summary
• For the last half century, prohibition and criminalisation has been the dominant policy
for drug control, both nationally and internationally.
• It is very difficult to separate the impact of drug policy from the wider effects of social
policy and environmental factors on drug-using behaviour.
• Levels of drug consumption do not necessarily follow predictable economic patterns
in a linear way, where an increase in price leads to decreased use.
• It is difficult to predict supply and demand of illicit drugs, as all trade is illegal;
decreased availability of one drug may result in users turning to other drugs that are
more readily available.
• Illegally sourced drugs are of variable quality and purity, with clear adverse health
implications for users.
• Criminalisation increases the health risks of illicit drugs by encouraging use in unsafe
environments and through dangerous methods of administration. It also deters users
from approaching health professionals for treatment.
• A prohibitionist approach creates a lucrative opportunity for criminality and leads to
high levels of acquisitive crime among dependent users.
• The stigmatisation of vulnerable populations of drug users also has significant public
health implications.
• The illicit drug trade has deleterious effects on development and security in many of
the world’s most fragile regions and states.
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• The national budget required for law enforcement, the criminal justice system and
dealing with the costs of drug-related crime is several times higher than the amount
spent on drug-related health interventions.
• The existing legal framework directly impacts on the ability of medical professionals
to gain access to and treat problematic drug users.
• Debate on liberalisation of drug policy is contentious, with strong feelings on both
sides of the argument.
• There is widespread confusion about the use of terms such as ‘decriminalisation’ and
an insufficient understanding that criminalisation can operate in tandem with other
forms of regulation, supervision and intervention.
• Alternative legal frameworks include decriminalisation (eg sentencing reform),
regulation (within a legislative framework), and free market legalisation.
• There is a shortage of robust evidence relating to the benefits of the present
prohibitionist framework in terms of deterring use or reducing availability.
• The evidence suggests that the costs of enforcement are high and that prohibition
has created a range of unintended health, social and economic costs.
• While some commentators argue that the benefits of the UK’s current system are
questionable, and that there is a pressing need to explore whether a new and/or
modified legal and policy framework is required, other commentators have been
more cautious. Among this latter group of commentators, the lack of research into
the effects of criminalising illicit drug use and possession does not, in itself, lead to
the position that new or amended regulations are required.
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Chapter 7 – Delaying
initiation and minimising
the use of illicit drugs
7.1 Introduction
Drug dependence, even after successful treatment, can impact on the lives of
individuals and their families. Reducing the number of people using drugs by delaying
their initiation into drug use and preventing the transition from experimental 
or recreational drug use to problematic or dependent use has a role to play in 
drug prevention.
At present, strategies that aim to reduce the use of drugs fall broadly under two
categories:
• reducing the number of people who are dependent on drugs, mainly by means of
treatment and other forms of support
• undertaking activities to improve people’s knowledge about the risks of using
drugs, to influence their attitudes and behaviour and to encourage the
development of skills to resist.
Treatment and other forms of support are discussed in Chapters 8-10. Section 9.2
specifically examines evidence on strategies that aim to reduce use in those who are
already using drugs. This chapter will explore the efficacy of interventions that aim to
delay the onset of drug use. A focus on young people has been chosen because the
volume of research among this population is much larger than for prevention in
adults.1 Adolescence is recognised as the period in life when drug use is most likely
to begin.1 While the majority of drug initiates do not progress to harmful use or
dependence, for a minority this timeframe represents a crucial period when harmful
drug-taking habits can be formed.1 A large number of interventions are targeted at
this population.
7.2 Interventions for preventing drug use
Prevention strategies are recognised as the main policy area aiming to reduce drug
initiation and continued use. Traditionally, two main aims of prevention initiatives are
recognised. These are:
• primary prevention: where the aim is to avert or delay the initial use of a drug
• secondary prevention: where the aim is to minimise hazards, or actual harms,
among those who have already begun using drugs.
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Secondary prevention measures, such as interventions based on harm-reduction
strategies, are yet to receive much in the way of attention, in terms of interventions that
aim to influence people’s knowledge attitudes and behaviour. In relation to alcohol use,
available evidence suggests that harm-reduction approaches show considerable promise
in reducing alcohol-related harm.2 Similar research for drug use is not available.
Most preventative drug interventions, known as universal interventions, are directed at
unselected populations. A small minority of target groups are known, or believed, to be
at a heightened risk of involvement with drug use; targeted interventions are known as:
• selective interventions: these strategies target subsets of the total population who
are thought to be at an increased risk of using drugs. These approaches are intended
for entire groups of people considered at risk, regardless of the degree of risk for any
one individual in the group
• indicated interventions: rather than affecting groups, indicated interventions focus
on identifying individuals who are exhibiting early signs of drug use. The emphasis is
placed on identification, intervention, support and, in some cases, referral.
When considering the evidence base for prevention programmes, there are two
limitations. Firstly, researchers have studied a fairly narrow band of strategies.1
Commonly used strategies, such as supporting grassroots coalitions that organise
against drug use, have rarely been evaluated.1 Few conclusions can be drawn by policy
makers on the efficacy of the vast majority of interventions for preventing drug use.
Interventions that take place in school-based settings have received the greatest
amount of attention, usually because of the ease of conducting research in these
settings, compared to community-based or mass media interventions.1 Secondly, while
drug prevention strategies are used widely internationally, research into their efficacy
has mainly taken place in the USA.
There is no clear evidence that drug education and prevention strategies have an effect
on reducing total drug use in the UK.3,4 Even for programmes that are delivered
effectively, these seem to have little impact on preventing future drug use.3,4 Drug
prevention programmes may have some benefit in terms of delaying the initial onset of
drug use. Drug use at an early age is associated with future drug use, particularly for
harmful drugs such as heroin or cocaine, and is correlated with a range of other
negative behaviours.1,5-7
Midford reported in 2000 that the cost-effectiveness of drug education compares
favourably with the cost-effectiveness of most law-enforcement approaches.8 In 1999,
Caulkins et al used modelling to indicate that the US drug education programmes led to
an average drop in cocaine use of 3.8g per person.9 The modelling went on to show
that for every million dollars spent on drug education, consumption of cocaine would
reduce by 26kg, which compared favourably with US law enforcement, but was not as
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cost effective as drug treatment programmes.8,9 Available research indicates that
soundly conceptualised and rigorously implemented programmes that are
comprehensively provided are likely to produce a net social cost saving to society.8
7.2.1 Universal prevention strategies
Universal prevention strategies aim to prevent, delay or reduce drug use and drug-
related harms at a general population level. These types of interventions can include
programmes that address an entire school population through drug education lessons,
parents through parenting programmes, or communities through community-wide
prevention efforts.
The vast majority of universal prevention initiatives take place in an educational setting.
This is because schools represent the most systematic and efficient way of reaching a
substantial number of young people.
Types of school-based interventions
The history of drugs education in UK schools, outside the factual content taught in
science lessons, has taken place under a number of conceptual models. Despite the
widespread international use of drug prevention programmes in schools, there is limited
high-quality evidence about the effect of school-based interventions on drug use.
In the 1970s, drug education and prevention interventions in schools were primarily
aimed at reducing drug use through giving young people information about the risks
associated with drugs.10 These interventions operated under the rationale that increased
knowledge about the effects of drug use would impact on young people’s attitudes 
to illicit drugs, with a consequent influence on behaviour, and therefore drug use.10
These programmes generally sought to instil fear of the consequences of
experimentation with drugs. Evaluation of this intervention shows that this approach
did not reduce young people’s drug-taking behaviour.10 It is posited that the
introduction of these interventions at a time when drug use, or at least cannabis use,
was becoming more prevalent, led to difficulties for campaigns aiming to convince a
population with extensive first-hand knowledge of drug use that it invariably led to
serious harm.1 A 2005 Cochrane review of school-based interventions to reduce illicit
drug use found that approaches that simply convey didactic information about drugs
and their effects have no impact on drug use.11
The early 1980s saw the development of what are termed ‘affective programmes’.
The theory behind these interventions is that drug use is caused by lack of self-esteem,
as opposed to a lack of knowledge about the adverse effects of drug use. Affective
programmes aimed to prevent or reduce the scale of drug use, through enhanced
personal and social development.10 While there is some evidence that these
interventions improve drug knowledge, attitudes and self-efficacy, there is no evidence
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that this type of programme impacts on drug use or behaviour.10 The 2005 Cochrane
review of school-based interventions, noted that programmes that teach social and
coping skills were shown to reduce drug use marginally.4,11 There was no evidence of a
long-term impact from these interventions, and it was unclear what elements of skills-
based approaches contribute to their effectiveness.4,11
The late 1980s saw the growing use of social influence programmes. These were based
on the hypothesis that drug use stems from direct or indirect social influences from
peers and the media.10 These programmes aim to strengthen young people’s resistance
skills. There is little evidence of reduction in the use of illicit drugs as a result of these
programmes.10
Most recent programmes have attempted to marry elements of all previous approaches
into programmes designed to ensure that young people have the knowledge, skills and
attitudes to make safe and sensible decisions about drug use. Research, including the
2005 Cochrane review,11 has found that these high-quality school-based multifaceted
programmes show a marked improvement in young people’s knowledge and skills,
which can have a small impact on illicit drug use, and drug behaviour, most notably in
delaying the onset of use.7-9,12
Whole-school approaches, involve addressing a school’s values and ethos, as well as
considering staff training and the involvement of pupils, staff, parents, carers, governors
and the wider community. Programmes that change the environment of a classroom 
or school are thought to be more effective than those that try to change individual
behaviour. Research from the USA in 2008, which included interventions on improving
classroom behaviour management, demonstrated a 50 per cent reduction in lifetime
drug use among young males (aged 14) but no effect on young females. Stronger
effects were found in boys who were identified as aggressive and disruptive at a young
age.13 This programme included no discussion of drugs, instead targeting changes in
the school environment that promote consistency and reward positive behaviour. The
long-term effects of this intervention appear to compare well with the best school-
based programmes aimed specifically at drug prevention.1 A possible explanation for
this is the inter-relatedness of drug use and other aspects of young people’s lives.
Research has demonstrated that factors that predict development of a drug problem
are also predictive of school failure, social isolation, aggression and other problems.1
It should be noted that, of the 32 studies included in the above Cochrane review, none
achieved the highest-quality rating for their research methods, and 28 of these were
conducted in the USA.11 This demonstrates the scarcity of high-quality reliable evidence,
and presents difficulties in generalising any findings on the efficacy of school-based
interventions from within the USA to the UK. It should be noted that, despite this
limited evidence base, large amounts of pupil and staff time are invested in these types
of intervention.
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The current situation in the UK
The most recent guidance on drugs education in schools, published by the DfES in
2004,14 states that all schools should have a drug education programme that should
cover all drugs, and specifically cannabis, volatile substances and Class A drugs, and, to
be effective, be supported by a whole-school approach.
This guidance also states that all schools should have a drug policy that sets out the
school’s role in relation to all drug matters, which includes the content and organisation
of any drug education programme. This was reiterated in joint guidance published in
2012 by the Department for Education (DfE) and The Association of Chief Police
Officers (ACPO).15
In the overwhelming majority of schools, drug education forms part of personal, social
and health education (PSHE) programmes.16 In terms of providing drugs education
through PSHE lessons, in recent years the PSHE curriculum has expanded to include new
modules (see Box 7). With no additional time provided for PSHE, this has had an
immediate and negative impact on the time allocated to the provision of drugs
education in some schools.16 This is of concern, given the range of drug-promoting
influences that exist (as identified in Chapter 4).
Box 7 – Combating the psychological attractiveness and social acceptance 
of drugs
As identified in Chapter 4, heavy exposure to substance use in popular media may
influence drug use. Universal interventions aimed at reducing the use of drugs may
need to be rethought by policy makers. This is because currently accepted health
education usually takes place under the wider umbrella of PSHE in schools. These
lessons take place for finite number of hours a year, with information on health
behaviours such as drug use often competing with other modules. Over the same
time period, the average person is likely to be exposed to a larger number of hours
of drug-promoting references in film, television, popular music, video games and
the internet. This large disparity between the exposure to drugs in popular media,
and interventions to reduce the use of illicit drug use, may result in the efficacy of
interventions to reduce the use of drugs being diluted by the widespread exposure
to drug imagery. Appendix 7 explores current and possible policy options to
counter the psychological attractiveness and social acceptance of drug use within
popular media.
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The quality of provision of drug education in UK schools differs across age ranges. 
The most recent assessment of drugs education in the UK, conducted by Ofsted in
2005, found that the quality of teaching is good in around 80 per cent of lessons at 
key stages one and two (primary school)16 and in around 65 and 75 per cent of lessons
at key stages three and four, respectively (secondary school).16 The review also noted
that the evidence base for school-based drug programmes is poor, particularly with
reference to primary school education.16,17
While the majority of young people of school age have never used an illicit drug, a
proportion may experiment with illicit drug use, some of whom may then go on to
become problem drug users.18 In 2010, 9 per cent of pupils aged 11 years reported
having ever taken drugs, with the prevalence increasing to 40 per cent among 15 year
olds.18 Further information on the prevalence and patterns of drug use can be found 
in Chapter 2.
From a UK perspective, there is a paucity of evidence for the efficacy of school-based
drug prevention programmes. The Home Office’s Blueprint drugs education
programme,19 which ran from 2003 to 2007, was the largest drugs education
programme that has ever been run in Britain. The programme provided drug
education lessons to school children aged 11 and 12 years, across 23 different
schools in England. It aimed to equip pupils with the knowledge and experiences
necessary to make informed choices about drug use.19 The efficacy of the
programme is not known, as the study design meant it was not possible to draw 
any conclusions from this research.
Despite a lack of evidence that UK school-based prevention programmes affect drug
use, perception studies suggest that the messages taught in these programmes are
reaching pupils, although the extent to which these are affecting behaviour, and
therefore drug use, is less strong. The 2011 NHS Information Centre survey of
smoking, drinking and drug use among secondary school pupils, surveyed 6,519
pupils aged 11 to 15 years across 219 schools in England.20 It found that in relation
to school-based prevention programmes, most pupils recalled lessons about drugs
(60%), and felt they helped them think about the risks of taking drugs (96%).20
Pupils also believed that lessons helped them realise that taking drugs was against
the law (88%), think about what they would do if they were offered drugs (77%)
and find out where they could get advice or information about drugs (71%).20 Fewer
pupils reported that the lessons helped them understand that not as many young
people take drugs as they previously believed (38%).20
Boys were more likely than girls to say they had learnt messages from lessons about
drugs.20 Younger pupils were more likely in general to indicate they had learnt
lessons from drug education programmes.20 A more complex pattern was reported in
BMA Board of Science
Drugs of dependence: the role of medical professionals124
relation to pupils’ previous experiences with drug use. Those who had never taken
drugs were more likely to say that lessons had helped them to avoid drugs, and to think
about what to do if they were offered drugs.20 This contrasts with pupils who had taken
drugs, who were more likely to say they had been helped to understand why people
took drugs, and to see that not as many people as they thought took drugs.20
Drug testing
Drug testing in schools has been suggested as an alternative school-based policy
intervention to reduce the use of illicit drugs. This policy has not been extensively
evaluated in the UK. Drug testing in schools, whether random or on suspicion, is
more common in the USA, albeit in a minority of schools.
In the UK, the DfES guidance on drug testing in schools states that the implementation of
drug testing should be considered carefully.14 It recommends that schools should
formulate their own appropriate drugs policies and practices in consultation with staff,
parents, governors, local drug services and the police. The guidance also advises that drug
testing should be placed within the wider context of educating children about the risks,
effects and consequences of drug use. Since the publication of this guidance in 2004, the
uptake of drug testing in schools has been limited. It is recommended by the ACPO that
drug testing should not be used in cases where there is no evidence of drug use.15
Drug testing in schools does not appear to affect the use of illicit drugs. Research has
demonstrated that drug use does not differ between schools with and without drug
testing.21 A 2005 review of school-based prevention programmes found no
convincing evidence to support random drug testing in schools.22 It was also
speculated that such programmes could have negative effects, which include
reduced trust between pupils and staff.22
Non-school settings
Non-school settings for universal interventions that aim to reduce drug use can
include youth clubs, primary care centres, colleges, and work with families and in the
community. In 2006, the Cochrane Collaboration published a systematic review of
interventions for the prevention of drug use delivered to young people in non-school
settings.23 The interventions included:
• multicomponent community studies
• family intervention studies
• education and skills training.
The lack of research in this area meant the authors were unable to carry out a meta-
analysis and pool results across similar interventions. It was suggested that further
high-quality research was needed before any conclusions could be made on the
efficacy of non-school-based prevention strategies.23
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Some evidence of efficacy was found in individual studies but this was not constant
across the different study modalities. Significant effects on reducing drug use were
detected for individual family interventions.23 There was insufficient evidence that any
of the multicomponent community studies for reducing illicit drug use that had been
considered had any advantage over the school-based programmes. Education and
skills training were found to have little effect on reducing drug use.23 Overall, the
findings suggest that community-based programmes offer little for reducing the use
of drugs, although family interventions may have some impact.
Mass media and social marketing approaches
Mass media campaigns are commonly used as part of universal strategies to reduce
drug use. They often involve the use of television, radio and other advertising media.
In the UK, the Talk to FRANK initiative (now called Frank. Friendly confidential drugs
advice) is the most recent example of a mass media prevention initiative. This was
established by the Department of Health and the Home Office in 2003 and included an
online information source. It is advertised and promoted through television, radio and
the internet.24 As part of the 2010 drug strategy,25 the UK Government affirmed its
commitment to continue enhancing this service.
In 2002, WHO undertook a thorough analysis of mass media approaches for the
prevention of psychoactive substance use. An analysis of 13 review papers concluded
that the use of mass media alone improved awareness of drug harms in some cases,
but overall was not effective in reducing illicit drug use.26 This was particularly true in
countries where the presence of countervailing influences, such as drug club cultures,
drug imagery within music, drug-using role models and exposure to images of drug use
was high.26 These influences are common to the UK. Large-scale research, which
evaluated the efficacy of the US National Youth Antidrug Campaign between 1999 and
2003 showed exposure to campaign materials had no effect on youth drug use.27 The
widespread use of mass media approaches to reduce drug use may need to be
rethought by policy makers.
Using social marketing to enhance mass media approaches may be a useful way of
increasing the efficacy of mass media campaigns. 28 Social marketing programmes are
designed to bring about social change using concepts from commercial advertising and
marketing. Social marketing differs from commercial marketing, in that it tries to sell
‘ideas’ to consumers, as opposed to products. Social marketing seeks to influence social
behaviours and benefit the target audience.
Using social marketing to deliver health messages presents a developing area in
reducing the uptake of drugs. An evaluation of social marketing to reduce alcohol
and cannabis use found a significant effect in terms of lifetime cannabis use.28
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Cannabis initiation was shown to be between 10 and 72 per cent less likely two years
after exposure to the social marketing. This research has yet to be robustly replicated.
7.2.2 Selective and indicated prevention strategies
Aside from broader questions surrounding the impact of universal prevention strategies
on drug use, universal strategies can also be inefficient, as they may address those who
are not at risk of using illicit drugs, while not concentrating on those at highest risk.
Selective and indicated prevention strategies overcome this by targeting specific groups
at heightened risk of using drugs. Research has demonstrated that these groups
commonly include the homeless, those looked after by local authorities or in foster care,
sex workers, truants and those excluded from school, young offenders, children from
substance-using families, and young people with conduct or depressive disorders 
(see Section 4.4.4).29 There are benefits of these approaches but since selective and
indicated prevention programmes are specifically targeted at those at risk of drug use,
identifying these individuals also risks stigmatising or labelling those involved in these
strategies.30,31 This in itself is a risk factor for subsequent drug use.30,31
Despite the large amount of information concerning risk and protective factors for drug
use, relatively little is known about what works to reduce the use and uptake of illicit
drugs among high-risk groups. There is a limited amount of high-quality research in this
area, but the evidence that is available suggests these interventions have some effect 
at reducing drug use among vulnerable groups. A 2005 review of US research of the
effectiveness of drug use prevention programmes found that selective prevention
programmes appear to be effective in reducing short-term drug use among vulnerable
young people, although this was not found across all the studies reviewed.32 A number
of school-based programmes that provided life skills training to at-risk groups
demonstrated positive effects on drug use, whereas similar studies did not.32 Results
from studies of the effectiveness of counselling services for at-risk groups were mixed,
with some showing positive results, some showing negative results, and some showing
no change at all.32 Multicomponent studies also produced similarly mixed reports.32
While interventions targeted at vulnerable groups appear to have some effect on
reducing drug use, it is not clear what type of intervention works best, and what
format these interventions should take. It should be noted that all research from the
above review is from the USA, raising issues of comparability to the UK.32 There is a
need for outcome evaluations of targeted drug prevention programmes that take
place in the UK.
The age at which interventions take place among vulnerable young people appears to
have a significant impact on illicit drug use. The 2005 review discussed above identified
the age range 11 to 13 years as a crucial period for interventions.32 This is a time when
young people at high risk start to experiment with drugs.32 This appears to be an
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earlier age of onset than for the general population.33,34 In the UK, this period
traditionally marks the time of transition to secondary school, and it may be that
interventions should be targeted at this age range among vulnerable groups within the
school setting. For vulnerable children at high risk, interventions in non-school settings
may need to be explored, as these children may have higher levels of school truancy.
Targeting preventative interventions to those at heightened risk of problematic drug
use relies on accurate identification of those groups that are susceptible to drug use. 
It is essential that all necessary agencies are provided with the appropriate resources to
identify at-risk groups.
7.3 Evaluation of prevention strategies: conclusions
Prevention strategies have a relatively small impact on reducing drug use, other than
delaying the initiation of use. There is little international evidence, and only a small
amount of UK evidence, to suggest that such strategies have any impact on future
drug use. Government policy currently focuses on providing universal and selective
prevention programmes. While these interventions may have some benefit, this is
limited and there is a lack of robust evidence to support their use. The question
remains whether alternative policy options should be explored, which could
potentially have greater benefit.
Prevention strategies that focus on positive social and behavioural development appear
to be effective. Programmes that only provide drug-relevant information, or try to
boost self-esteem, are less likely to be effective at reducing demand. Taking action on
preventing the underlying causes of drug use may be as effective as, or more effective
than, preventing drug use directly.
Summary
• Current prevention strategies aim to reduce drug use by influencing attitudes and
behaviour, in order to prevent or delay the initiation of drug use.
• Primary prevention aims to avert or delay initial use, while secondary prevention aims
to minimise the harms in those already using drugs. Secondary prevention
interventions, such as harm-prevention strategies, are yet to receive much in the way
of attention.
• There is no clear evidence that drug education and prevention strategies have an
effect on reducing total drug use in the UK. Drug treatment programmes are more
cost effective.
• All schools in the UK are required to have a drug education programme. These
programmes improve young people’s knowledge about drug use, and have a small
impact, notably in delaying the onset of use.
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• There is evidence that most pupils recall the content of their drug-education lessons
and report that it helps them to make decisions about what to do if offered drugs.
Those who had taken drugs said lessons helped them understand why people take
drugs and that not as many people as they thought take drugs.
• Programmes that also address classroom behaviour management have been shown
to reduce lifetime drug use in boys but not girls in the USA.
• Drug testing in schools does not appear to affect the use of illicit drugs; random
testing in schools may have a negative effect.
• There is insufficient research on interventions outside the school setting to prevent
drug use to provide evidence on their effectiveness.
• The use of mass media can improve knowledge but is not effective at reducing illicit
drug use; social marketing may be a useful way of increasing the efficancy of mass
media campaigns.
• Selective prevention strategies target at-risk groups and often address multiple and
complex risk factors. There is conflicting evidence about their efficacy in reducing
drug use among vulnerable groups, and there is a risk that they further stigmatise
already marginalised individuals. The age range 11 to 13 years has been identified as
a crucial period for effective intervention.
• Groups that are most susceptible to drug harm should be identified. Taking action on
preventing the underlying causes of drug harm rather than preventing drug harm
directly may be more effective.
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Chapter 8 – Medical
management of drug
dependence: the doctor’s
role in managing heroin
addiction
8.1 Introduction
This chapter examines management of drug dependence by medical practitioners. 
It then presents a detailed description of opioid substitution therapy (OST), the evidence
for its effectiveness, and an analysis of the ingredients of effective treatment. This
analysis provides a model for the components of effective medical management 
of drug dependence.
OST has been extensively researched, and evidence that it can reduce the adverse
effects of heroin addiction has led to its widespread use internationally.1 OST has always
generated disquiet, as it challenges the intuitive notion that the best way to overcome
addiction is to stop using drugs, and become drug free.2 This chapter provides a brief
overview of the extensive research evidence indicating that OST is as effective, or more
effective, than short-term treatments aimed at ‘cure’ of heroin addiction, and describes
the factors that have been identified as improving the outcomes of treatment.
In Chapter 9, medical responses to the use of other illicit drugs and drug-related harms
are considered, while Chapter 10 examines medical management of illicit drug use
within the criminal justice system.
8.2 Managing drug dependence as a medical issue
Among people seeking treatment, heroin addiction tends to be a chronic, relapsing and
remitting disorder, with few people achieving stable, sustained abstinence after an
episode of care. The notion of medical management of chronic disease seems more
useful than episodes of care.3 The medical management of dependence is usually more
difficult and challenging than for other chronic disorders. By the time they come for
treatment, many dependent drug users are socially marginalised, or in prison, lacking
access to the rewards arising from employment, personal relationships and family
participation. As a result, there is little in their lives motivating them towards recovery.
Treating heroin addiction frequently involves the social reintegration of marginalised
individuals lacking in skills and having few and often tenuous social connections. 
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As outlined in Section 4.4, there is a positive correlation between the prevalence of
problematic drug users aged 15 to 64 years and deprivation. Hospital admission rates
for drug-specific conditions have also shown a strong positive association with
deprivation. Deprivation appears to be a strong predictor of drug-related harm.
8.2.1 Tackling stigma and the ‘addict identity’
The stigma surrounding drug use further complicates management. Drugs, especially
illicit drugs, are viewed with fear and disapproval (see Sections 2.5 and 6.4). 
The stigma associated with addiction is a significant barrier in providing healthcare 
to people misusing drugs, as negative attitudes – on the part of both practitioners
and patients – can compromise effective care (see Sections 2.5 and 6.4).
Stigma may have a public health benefit, in making certain risky or harmful behaviours
less attractive, and the stigma associated with illicit drugs probably discourages many
people from using them. Stigma can also attract troubled young people; which
probably explains why many drug prevention programmes paradoxically lead to more,
rather than less, drug use.4 Breaking rules, and experiencing the disapproval of family
and peers, confirms their sense of badness, while providing a self-defeating sense of
autonomy and independence (see Section 6.3.1).5 Drug use is reinforcing, producing
wellbeing and relaxation and relieving negative mood states such as pervasive guilt
and shame, or alleviating painful conditions. Repeated use can lead to the
development of dependence syndrome (see Section 1.1.2 and Glossary), with
physical and psychological symptoms that include characteristic narrowing of the
individual’s range of interests and activities, as drug use comes to displace other
activities. This can progress to increasing isolation, disrupted relationships with
family, and loss of social supports. All these factors contribute to the development of
the ‘addict identity’ – someone who has become conditioned to see himself existing
outside of normal society, isolated and defiant.
For people with an ‘addict identity’, seeking treatment can seem like a defeat. 
Once in treatment, and able to stop compulsive drug use, it is not rare for the
patient to sabotage his own treatment, for example by dropping out, or missing
scheduled appointments, taking refuge in the familiar experience of failure,
disapproval and conflict.6 This desire for the familiarity of experience, and the
associated learned behaviour, can be understood as a form of conditioning (see
Section 4.3.2). There is a major element of behavioural treatment in how doctors,
nurses and pharmacists respond to the challenge of disaffected, impulsive behaviour.
Clinics delivering the same ‘treatment’ often achieve dramatically different
outcomes, and the quality of the therapeutic relationship is one factor contributing
to the greater effectiveness observed in some settings.7
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8.2.2 Staff attitudes
Managing a chronic disease is based on a partnership between doctor and patient, 
and the patients’ self-efficacy and responsibility for their own wellbeing are critical
determinants of outcome. Managing addiction involves long-term support, educating
patients about their condition, promoting engagement in and compliance with
treatment, monitoring symptoms and dealing with complications.
Practitioners treating drug-dependent patients require not just skills and knowledge, but
also a positive attitude towards treatment and recovery. Negative attitudes on the part
of drug-dependent patients may sabotage treatment, but so too can negative attitudes
on the part of practitioners. Four decades ago, Dole and Nyswander, pioneers of
methadone treatment (MT) for opiate addiction, recognised the critical importance of
changing the addict identity,8 a change encapsulated in Marie Nyswander’s phrase
‘from drug addict to patient’. Their theme was that, freed from the cycle of addiction
and treated with respect and dignity, heroin users can develop a different image of
themselves, and behave with self-respect and dignity. They emphasised that negative
assumptions about drug users need to be balanced by a belief in their capacity to
change, and a sense of the practitioner’s role in fostering that change.8
8.2.3 Shifting opinion: is drug dependence ‘sickness’ 
or ‘badness’?
A shift in viewing dependence, from ‘sickness’ to ‘badness’, has been documented in
the USA, and labelled the ‘demedicalisation’ of treatment.9 The result was widespread
delivery of treatment out of line with research evidence,10 and a proliferation of
programmes oriented to abstinence rather than medical maintenance treatment of
opioid addiction (see Section 8.4). In response to the weight of evidence that OST can
reduce the harms of heroin addiction, there has been a ‘remedicalisation’ of treatment
of addiction in the USA over the last 15 years. From the mid 1990s, neuroscience
research has been promoted as showing that addiction is a ‘chronic relapsing brain
disease’ (see Section 1.1).11 In 2000, the passage by Congress of the Drug Abuse
Treatment Act liberalised regulations surrounding treatment, permitting the use of
office-based treatment of addiction for the first time in the USA.12
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8.3 Example of managing drug dependence as a medical
issue: OST
The following case study illustrates an example of heroin addiction.
Case study: Treatment of heroin addiction with injectable diamorphine
Mr HT is a 42-year-old man who has been receiving injectable diamorphine treatment
since March 2010.
Mr HT was adopted at the age of six months. He found school challenging, and truanted
from mid primary school. The secondary school he attended recognised that he had
learning difficulties and he was sent to a boarding school for children with special needs.
His behavioural problems worsened there. At the age of 14 he began using drugs, and
he was expelled at the age of 15. He had not learned to read and write.
Instead of returning to his home, Mr HT went to live in a ‘hippy compound’, supporting
himself with occasional manual work, busking and some begging. Aged 22 he came to
London, sleeping on the streets and squatting. He was to live on the streets for most of
the next two decades. Within two years he was addicted to heroin, spending £150 to
£200 daily on the drug, gaining the money by begging, thieving and raiding phone boxes
and parking meters. He acquired an extensive criminal history, including five periods of
imprisonment. The first thing he would do on release from prison was ‘score’ heroin.
In 2004, a community drug project found Mr HT sleeping on the streets and offered 
him a bed in a hostel. He began an MT programme, but continued to inject heroin and
crack cocaine. He lost his place in this hostel during one of his spells in prison. In 2007,
again homeless, he was picked up by another community drug project and placed in a
hostel. He restarted an MT programme, but continued to inject street heroin, and to
smoke crack cocaine and cannabis. His health and personal hygiene were poor. When his
peripheral veins were scarred and difficult to inject, he began injecting street heroin into
his neck, and his hostel referred him to an NHS injectable opioid clinic in 2010. Here,
diamorphine (pharmaceutical heroin) is prescribed for patients not responding to oral
methadone. Administration of diamorphine is all supervised by trained staff, and the
service users attend twice daily and engage in frequent reviews and keyworking 
(see Glossary) sessions.
When first assessed for diamorphine treatment, Mr HT expressed doubt that he would be
able to attend the clinic twice daily seven days per week. For the first several months he
remained chaotic and disorganised, often missing doses and continuing to use street
drugs. His dose was progressively increased, until he was stabilised on 200mg
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diamorphine intramuscularly twice daily and 70mg of methadone once a day. In August
2011, although continuing to smoke crack about twice per month, he had ceased illicit
heroin use, and his personal hygiene, mood and outlook had improved dramatically. He
acquired a publicly funded flat, and began occupational therapy sessions to improve his
literacy.
Mr HT presented as someone who, having lived on the streets for most of his adult life,
lived ‘for the moment’, with little capacity for planning, and little motivation or hope that
his life might be different. His primary reaction is surprise that he has made such a vast
improvement in his life.
Case study details provided by Dr James Bell, Consultant in Addictions Medicine.
The case history starts with a story that is not rare. Mr HT was a vulnerable adolescent
with limited education and a disadvantaged background, and went on a downward
spiral as a result of dependence on drugs. Criminal sanctions were no deterrent to his
drug-using career, and he did not respond to methadone. At present, his downward
spiral has been interrupted and reversed by diamorphine treatment. The continuing
challenge is to build a sustainable recovery, based on self-care in stable housing and
gaining employment. That would provide a basis for progressively reducing his
frequency of injecting, and eventually returning to oral medication.
Prescribing diamorphine for heroin addicts is a poorly understood, often
controversial, modality of treatment. Diamorphine has been shown to reduce heroin
use and improve self-reported quality of life in those who are not responding to
MT,13-15 but there has been little reflection on why injectable treatment has
advantages over oral medication. This case history is presented to illustrate some of
the reasons why prescribing diamorphine can have advantages over other treatment
approaches. This is discussed further in Section 8.4.
Opioid substitution therapy is the prescribing and administration of a pharmaceutical
opioid as a ‘substitute’ for illicit opioids, to patients who have become dependent.
The most common form of OST is MT, but there is a rapidly increasing experience
with buprenorphine, and a small experience with prescribed diamorphine
(pharmaceutical heroin) in the management of heroin addiction.
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In the 1980s, recognition that injecting drug use represented an important mode of
transmission of HIV and other blood-borne viruses led to increasing provision of 
OST internationally.16 Methadone is the most commonly used OST medication, and
has the most extensive literature surrounding it. There has been increasing delivery 
of MT in primary care worldwide, placing medical practitioners in the frontline in
delivering treatment.
Although it is thought of primarily as a pharmacological treatment, OST has important
behavioural and interpersonal elements that contribute to outcome.7 Opioid
substitution requires ritualised, daily attendance for administration in a predictable,
safe, non-punitive and non-judgemental treatment space, and establishment of a 
long-term therapeutic relationship with a keyworker (see Glossary) or doctor 
(see Section 8.4.3).7 For a small proportion of people, the respite from withdrawal
offered by MT is not sufficient to allow them to move away from repetitive heroin
use.7,17 For many marginalised individuals with little sense of purpose or planning
beyond short-term survival, prescribed diamorphine is sufficiently reinforcing to
motivate them to attend and comply with the requirements of treatment. Daily
attendance provides a structure and routine in a previously chaotic life. Clear rules 
and expectations of behaviour, enforced consistently, offer a new (and sometimes
challenging) experience for previously asocial or antisocial individuals.
The cornerstone of treatment is an adequate dose of opioid – in the words used by
patients on prescriptions, the dose that ‘holds’ them. Psychodynamic psychotherapy
involves ‘holding’ clients with the experience of empathy, while allowing them to
come to terms with their own unacceptable thoughts and impulses. Prescribing
opioids ‘holds’ patients with medication, while allowing them to explore the
challenging possibility that they are acceptable, and capable of social reintegration.
8.3.1 The effectiveness of OST
Traditionally, treatment of dependence on alcohol and drugs has been based on 
two premises – that recovery from addiction requires abstinence from drugs, and
that it requires a change of attitude and identity. The principle of OST – that people
can recover while still dependent on an opioid – has challenged the assumption 
that the objective of treatment should be abstinence from all drugs (including
methadone).This is currently re-emerging as an issue in the UK, as there are
proposals in the Drug strategy 2010 that the funding of drug treatment services
should reward abstinence from all drugs.18
A comprehensive Health Technology Assessment undertaken in the UK in 2007
reviewed the evidence for the effectiveness of methadone and buprenorphine, 
and concluded that both drugs were effective in treating opioid dependence.17
This finding was based on a synthesis of randomised trials, observational evidence
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and expert opinion. This section seeks to go beyond the finding that OST is effective,
and investigate how well it achieves the many different objectives of treatment of
drug dependence.
8.3.2 Is OST effective in promoting abstinence from all
drugs, including OST medications?
International studies suggest that for opioid-dependent persons in the criminal
justice system, and those seeking treatment, addiction is a chronic, relapsing and
remitting condition. People cycle through differing episodes, and differing modalities
of treatment. In 2001, Hser et al reported on a group of heroin addicts in the USA,
followed up 33 years after entering treatment.19 Forty per cent were dead; 
many remained addicted. Among those who achieved prolonged abstinence, one-
quarter had eventually relapsed in subsequent observations. Relapse was observed
even among patients abstinent for as long as 15 years. Long-term follow-up studies
documenting the natural history of heroin addiction estimate that among subjects
who seek treatment, 2 to 5 per cent per year achieve stable abstinence from
opioids.20,21
It has been argued that this view is overly pessimistic, and many more people can
and do recover from dependence on drugs. The phenomenon of spontaneous
recovery from addiction has been well documented.22 Community surveys (notably,
the Epidemiological Catchment Area (ECA) study from the USA), have identified a
number of respondents who report previous dependent use of drugs, but are no
longer dependent, confirming that many people do ‘recover’ from dependence. 
The prognosis for people who seek treatment for drug dependence is consistently
worse than in non-treatment samples. Among people seeking treatment for
addictive disorders, whether alcohol dependence23 or heroin addiction,22 the course
of dependence tends to be chronic and relapsing, and recovery is less likely in this
group than among people who never seek treatment. The reason for this disparity 
is most likely that people who present seeking treatment have more severe problems
– ‘problems that will not be resolved just by getting them off drugs’.22
This is not to suggest that individuals cannot leave MT and remain abstinent. 
People leaving MT are less likely to relapse if they have ceased injecting heroin, and
have achieved a degree of social reintegration – employment, a stable relationship,
or community connections – before they attempt to withdraw from methadone.24
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To optimise the effectiveness of OST, the NTA’s Recovery Orientated Drug Treatment
Expert Group has drawn attention to the importance of delivering OST in line with
National Institute for Health and Clinical Excellence (NICE) clinical guidance. In their
2012 report, the group advised doctors and health professionals working with heroin
addicts to:
• review all existing patients to ensure they are working to achieve abstinence 
from problem drugs
• ensure treatment programmes are dynamic and support recovery, with the 
exit visible to patients from the moment they walk through the door
• integrate treatment services with other recovery support such as mutual aid
groups, employment services and housing agencies.25
A recent study from Scotland confirmed the protective effect of methadone
treatment on mortality, but also found that longer duration of methadone treatment
was associated with less likelihood of achieving abstinence from heroin.26 This has
been interpreted as showing that treatment with methadone may actually impede
recovery from dependence, but a simpler explanation is that people with more
severe problems tend to remain in treatment longer, and have a poorer prognosis.26
The implication of the chronic, relapsing nature of heroin addiction is that
responding to an individual seeking help for heroin addiction is best conceptualised
as management of a chronic disease, characterised by exacerbations and remissions
(see Glossary), variable levels of disability, and risk of complications. The objectives
of long-term management are reduced risk of death and disease, suppression of
drug use, improvement in mental health and outlook, and restoration of impaired
social roles. These are the key elements of ‘recovery’, and each element – cessation
of heroin use, reduction in other drug use, improvements in health and social
functioning – supports each other element in a holistic, biopsychosocial approach 
to chronic disease management.
8.3.3 How effective is OST in suppressing the use of 
illicit drugs?
Three major large-scale observational studies from different countries provide a
reasonably clear indication of the effectiveness of OST in suppressing use of heroin,
use of illicit drugs such as cannabis and cocaine, and misuse of alcohol and
benzodiazepines.27-29 These studies compared the effectiveness of OST with that of
residential rehabilitation (RR), a drug-free approach to treatment involving prolonged
residential treatment in a highly structured environment based on self-help and
mutual support (see Glossary). Some observational studies have also compared 
OST to short-term detoxification (see Glossary).
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The Treatment Outcome Prospective Study (TOPS) followed a large sample of US
patients treated in RR and on MT.27 The National Treatment Outcome Research Study
(NTORS) was undertaken in the UK, using a similar methodology to TOPS,28 and the
Australian Treatment Outcome Study (ATOS) followed samples of heroin users
entering RR, MT, detoxification or no treatment.29
These studies provide surprisingly consistent results. Over time, heroin use was
reduced, with 25 to 35 per cent of heroin users reporting continuing heroin use 
3-5 years after beginning their index treatment. Many were still in treatment at
follow-up, and the majority of subjects had been though several episodes of
treatment, making it difficult to attribute outcomes to any particular treatment
modality – and emphasising that treating heroin addiction is best conceptualised 
as chronic disease management.
Three-quarters of subjects were using other drugs, mainly cannabis and alcohol. 
This is important, as there are few ‘pure’ heroin users, and most people entering 
MT have used, or are using, multiple drugs.22 Results of large-scale, observational
studies suggest both OST and residential, drug-free programmes seldom result in
long-term abstinence from all drugs, and that alcohol misuse and cannabis use 
are common.27,29
The NTORS demonstrated that for every pound spent on treatment in the UK, a
reduction of £3 in public costs was observed.30 Economic benefits were largely
accounted for by reduced costs of crime. Among clients recruited to NTORS 
(549 in total, recruited from 54 residential and community treatment programmes),
criminal behaviour costs were estimated to fall by £16.1 million during the first year
of treatment, and by £11.3 million during the second year.31 The findings
demonstrate that there are clear economic benefits to directly funding treatment 
of drug users, which far outweigh the costs.
8.3.4 How effective is OST in improving physical and 
mental health?
Opioid substitution reduces the risk of death by overdose, the commonest cause of
death among active heroin users. There is a long-recognised risk of death during
induction into MT, and an increased risk of death by overdose after leaving any form
of treatment. Clausen and colleagues had the opportunity to follow risk of death in
subjects entering MT, and in subjects placed on a waiting list for MT.32 This study
demonstrated the protective effect of entry to treatment; despite risks during
induction and an increase in mortality after leaving treatment, subjects entering MT
had a lower risk of death than those placed on a waiting list for treatment. There is
some indirect evidence that the reduction in risk for those entering treatment
translates into a public health benefit. In France, in 1994, there were only 52 people
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in treatment with methadone, and an estimated 160,000 people injecting illicit
opioids. Five years later, there had been an expansion in MT to 7,000 people, and
60,000 people were being prescribed buprenorphine. Deaths from heroin overdose
in France fell from 505 in 1994 to 92 in 1999.33 A similar observation was made in
Sweden following liberalisation of access to OST, particularly buprenorphine.34 The
number of patients in treatment increased more than threefold from 2000 to 2006,
with the greatest increase for buprenorphine, which was introduced in 2000. There was
a significant 20 to 30 per cent reduction in opioid-related mortality and inpatient care
between 2000-2002 and 2004-2006 but not of other drug-related mortality and
inpatient care. A small but significant increase in buprenorphine- and methadone-
related mortality occurred. The authors concluded that liberalisation of Sweden’s drug
policy, and expanded access to OST, contributed to a decrease in overall opioid-related
mortality and inpatient care.
Opioid substitution also reduces the risk of transmission of blood-borne viruses 
(HCV and HIV), particularly in conjunction with availability of clean needles and
syringes.35,36 There is considerably less data on which to assess mental health outcomes.
Residential rehabilitation programmes usually place emphasis on attitude change and
growth of a new consciousness. In TOPS, at five years post treatment, improvements in
depression were identical in the MT and RR cohorts.27 The ATOS study reported
substantial self-reported reductions in risk taking and injection-related health problems,
and improvements in general physical and mental health.29 Positive outcomes were
associated with more time in maintenance therapies and RR and fewer treatment
episodes.
A 2010 review of studies of quality of life among opioid-dependent individuals
identified 38 articles addressing the topic.37 The results were quite mixed, but a few
conclusions emerged. The subjective quality of life (QoL) and health-related quality of
life (HRQoL) of opioid-dependent individuals is relatively low compared to the general
population, and is most comparable with the QoL of individuals with psychiatric
problems. Users of opioid drugs reported lower scores on mental health in particular,
while their physical wellbeing was less affected. Entry to substitution treatment
generally had a prompt beneficial effect on QoL, although this may reflect the fact 
that people enter treatment in very poor condition.38
The influence of drug use on HRQoL was inconsistent, although a negative impact of
excessive alcohol use on the HRQoL of opioid users was shown in various studies.37
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8.3.5 How effective is OST in improving social reintegration
of marginalised heroin users?
One of the primary reasons for public support of treatment for heroin addiction is
that treatment is associated with reduced acquisitive crime. To the extent that people
in treatment reduce their use of illicit drugs (and reduce expenditure on illicit drugs),
the level of acquisitive crime diminishes in individuals in treatment.39 An Australian
analysis of community rates of offending has demonstrated a statistically significant
link between increased numbers in MT and falling levels of acquisitive crime in 
the community.40
There are very few quantitative data available on which to assess the extent to which
people in MT are able to achieve social reintegration. One early randomised trial
comparing MT to drug-free treatment included intensive psychosocial input,
comprising vocational retraining and limit setting in relation to continued drug use. 
It is one of few studies demonstrating that MT can dramatically improve social
reintegration.41 The control group received no treatment, as none accepted drug-free
treatment. At two years, 12-17 MT subjects were not using heroin regularly, and
were employed or undertaking education. The remaining five subjects had been
discharged from the programme for continuing drug use. These impressive results
were dramatically better than the outcomes observed in subjects randomised to
drug-free treatment, and, although the sample size was small, the study provides
clear evidence that, with appropriate resources and policies, MT can contribute to
social reintegration.
8.4 What are the components of effective OST?
There has been a proliferation of models of MT, with clear evidence that some
treatment programmes are more effective than others.7,42,43
Ball and Ross investigated what actually occurred in treatment in six clinics in the
USA, and compared the outcomes of patients treated in these clinics.7 They reported
that clinics achieving better outcomes had an ‘orientation to maintenance’ 
(as opposed to an orientation to abstinence; see Section 8.4.4), had on-site medical
services, and were better managed, with stable clinic leadership. They reported that
patients who did better had received higher methadone doses, and reported a good
relationship with at least one clinic staff member.
8.4.1 Drug and dose – the pharmacology of OST
Drug use starts out primarily as pursuit of the euphoric effects of drugs, but
dependent drug use comes to be primarily driven by the compulsion to avoid
withdrawal. The appeal of OST for dependent heroin users is that a daily dose of
methadone (or buprenorphine) will abolish withdrawal symptoms (see Section 8.3).
A dose of methadone means opioid-dependent individuals are no longer sick when
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they are not using heroin, and this increases their control over their heroin use.44
Methadone doses of 30-50mg/day are sufficient to block withdrawal for 24 hours 
in the majority of dependent heroin users. For around 10 per cent of heroin users
seeking treatment, respite from withdrawal is sufficient to enable them to cease
drug seeking and drug use.25
Heroin use is a powerfully reinforcing and motivating factor shaping the behaviour
and consciousness of people who have been addicted. Dependence and the
additional conditioning (see Section 4.3.2) associated with injecting drug use mean
that in the first months of treatment, people maintained on low doses of methadone
tend to continue injecting. By increasing the daily methadone dose, patients’
tolerance to opioids is progressively increased, and high tolerance attenuates the
individual’s response to injected heroin. Heroin becomes less reinforcing, helping to
extinguish the habit. This explains why high-dose methadone is far more effective in
suppressing heroin use than low doses. A reasonable approach to dose setting is
that after entry to treatment, the methadone dose should be progressively raised
until patients cease heroin use, or reach a dose of 100mg/day. Once patients have
ceased use of heroin for a period, it may be reasonable to lower the dose of
methadone if side-effects are problematic, but there is a significant likelihood that, 
as doses are lowered, patients will return to heroin use.45
Not everyone responds to adequate doses of methadone. Up to one-third of heroin
users metabolise methadone sufficiently rapidly that they experience low-grade
withdrawal symptoms in the latter half of the dosing interval, when their blood
concentration of methadone is falling. These patients experience withdrawal
dysphoria, low mood and craving, and are more likely to persist in heroin use and 
to use other drugs.46,47 Increasing the methadone dose in these subjects is unlikely to
be effective, as the problem is not the absolute blood concentration of methadone,
but the rate at which the concentration is falling.46 In patients who have continued
to use heroin despite receiving doses of methadone of 100mg/day, it may be that
buprenorphine, or slow-release oral morphine, would be more effective in
suppressing withdrawal symptoms and heroin use.
Qualitative interviews with a group of patients maintained on methadone provide an
idea of the role of medication in enhancing social reintegration.44 Gaining control
over one’s life and daily functioning and no longer being sick when no heroin is
available, were only some of the frequently mentioned benefits of following a MT
programme. The respondents emphasised that methadone did not cause changes 
in their lives, but allowed change to occur in important areas such as relationships.
Methadone treatment can create the necessary preconditions to deal with a number
of issues (eg developing one’s skills to practise a job) that can enhance individuals’
quality of life. Opiate-dependent individuals valued methadone’s ability to help them
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function normally, overcome their psychological problems and dependence on illicit
opioid drugs, and support them in achieving certain life goals.44 Stigmatisation,
discrimination, dependence on methadone and the drug’s paralysing effects on 
their emotions were mentioned as common negative consequences. A number of
consequences (difficulty and unpleasantness of withdrawing from methadone, and
stigmatisation) were mentioned as having a negative impact on important aspects 
of being in treatment.44
Buprenorphine
Buprenorphine is a partial opioid agonist, with different pharmacological properties
to methadone. It has high mu-receptor affinity, remaining bound to opioid receptors
for longer periods than drugs such as morphine or methadone. While receptors are
occupied, they can no longer be activated. At low doses, buprenorphine is a potent
opioid agonist, but as doses are increased, opioid receptors remain occupied and
blocked, meaning that the effects of buprenorphine are self-limiting. Above quite
low dosage levels, increasing doses prolong opioid actions, but do not produce
increased sedation or respiratory depression. Buprenorphine has greater safety than
other opioids in overdose.
Buprenorphine has a prolonged half-life, and a single daily dose produces sufficient
opioid activity to block withdrawal for 24 hours or longer. Through prolonged
receptor occupancy, buprenorphine also attenuates the response to heroin. It is thus
a useful drug in treatment of addiction, and it has been used in OST for many years.
A Cochrane review examined trials comparing buprenorphine and placebo, and
reported that buprenorphine was statistically significantly superior to placebo in
retaining patients in treatment and suppressing heroin use (although low doses of
buprenorphine were not effective in suppressing heroin use).47 Comparisons with
methadone were reported as showing that methadone was more effective than
buprenorphine in retaining patients in treatment.48
Buprenorphine is an important treatment option, for two reasons. Firstly, some patients
tolerate methadone poorly, and the availability of buprenorphine provides a valuable
alternative. More importantly, buprenorphine treatment is associated with a lower risk
of death by overdose than that associated with MT.49
Diamorphine
For a small proportion of patients, relief from withdrawal is not sufficient to motivate
them to comply with treatment. In this group of ‘poorly motivated or treatment-
resistant’ patients, who persist in heroin use despite other forms of treatment, injectable
diamorphine has been shown to be effective in reducing street heroin use and
improving self-reported quality of life.13,15
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The rationale for this treatment is that, as illustrated by the case study at the start of
the chapter, and discussed in Section 8.3, diamorphine is a more reinforcing drug
than methadone, and provides a greater incentive to comply with treatment than
methadone. Most of these participants have lost family support, and are so
entrenched in a daily cycle of drug seeking and drug use that they have little other
reward in life, and little capacity to hope or imagine that things might ever be
different. Injectable diamorphine treatment is highly structured, requiring twice-daily
(or more frequent) attendance to administer diamorphine under medical supervision.
These onerous requirements deter many individuals who are addicted to heroin 
from participating in this treatment, but for others, access to diamorphine provides
sufficient motivation to comply with the requirements of treatment. For many
demoralised trial participants, the transition (not always smooth) from addict to
patient begins a process of social reintegration that is made possible because
sufficient incentive is offered to participate in structured treatment.
8.4.2 Supervised administration
The randomised trials establishing the effectiveness of methadone, buprenorphine
and diamorphine treatment have all involved supervised administration.13-15,48,50 
There has been a substantial deviation from the model of care supported by
evidence, namely a reduction in the requirement for supervision of administration.
Although the benefits of supervised administration of OST are recognised and
understood by patients,51 they have received relatively little study. There is only one
randomised controlled trial (RCT) comparing supervised and unsupervised treatment,
and it showed no difference in effectiveness.52 Entry criteria for the study were
restrictive, and only 22 per cent of new entrants to treatment were eligible for
randomisation. The main reason for excluding potential subjects was homelessness.
For people in chaotic circumstances, it is plausible that structured treatment is more
likely to be effective (see Section 8.2), while for those who are reasonably high
functioning, the requirement to attend daily for treatment may well be a deterrent to
participating. By only randomising relatively stable patients, this study would have
missed the main potential benefit of supervised treatment, which is to treat
marginalised individuals living in chaotic circumstances. At present, all that can be
concluded is that for patients who have stable housing and no active mental health
problems, treatment without direct observation of administration was as effective as
supervised treatment.
Reports from France have shown that less clinical monitoring was associated with more
heroin use and more injecting or prescribed buprenorphine,53 and that less supervision
of administration was associated with worse retention and more heroin use.54
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There have been a variety of studies confirming that clear policies and expectations
of behaviour produce better treatment outcomes. The most recent (2010) came from
the USA, demonstrating that structured treatment (delivered according to protocol),
is more effective than treatment that does not follow protocol.55
8.4.3 Counselling
There have been two randomised trials, both from the USA, comparing the
effectiveness of differing levels of counselling in MT. The first reported that the
provision of counselling and support improved outcomes – several counselling
sessions were more effective than few, and few were more effective than none.a,56
The second showed no difference in outcome between new entrants to MT offered
no counselling, monthly counselling or weekly counselling.57
Interpretation of these trials is compromised by the fact that neither could be
conducted double blind. Treatment is more likely to be effective when staff believe 
in the treatment they are delivering. In a trial to demonstrate the potential value of
interim methadone (without counselling), it is probable that staff believed this
approach would be effective – and it was.58 In the McLellan trial,56 staff probably
believed that those who were randomised to minimal counselling were receiving
suboptimal care – and found they were. The most plausible interpretation is that
when staff believe in the treatment they are providing, it works better.58
The McLellan study,56 finding benefit from formal counselling, is also at odds with 
the experience of Dole and Nyswander, who reported that although counselling was
offered to their patients, very few availed themselves of it.8
Consistent with these observations, a recent Cochrane review analysed the results 
of trials of psychosocial interventions in conjunction with OST, and found no
significant benefit of psychosocial services in terms of retention, non-prescribed
opioid use, psychiatric symptoms, compliance or depression.59
This finding does not negate the possibility that some individuals can benefit from
psychological interventions, but in randomised trials no benefit was shown overall.
While there is little evidence for formal counselling, there is substantial evidence that
the quality of interaction between a patient and staff is an important ingredient of
treatment (see Section 8.2.2).7
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a One treatment group received no counselling; the second group received counselling on a weekly or biweekly basis; and the
third group received the same as the second but could also access additional sessions with a psychiatrist, an employment
counsellor and a family therapist.
It is worth reiterating that daily interaction with health professionals, in a non-
judgemental, non-punitive environment in which there are clear rules and expectations
of behaviour, enforced consistently, offers safety and structure to previously
marginalised and chaotic individuals.
8.4.4 Orientation to maintenance
Longer periods in MT (and in RR)b are associated with better treatment outcomes 
– the duration of treatment is a linear, non-threshold predictor of outcome, with better
outcomes from longer treatment.61 After leaving treatment, relapse is usual.26
Time-limited MT is not effective.62,63 For these reasons, there are risks associated 
with encouraging or pressuring patients to withdraw from treatment, and OST is 
best regarded as a maintenance intervention.
The majority of patients aspire to an opioid-free life without methadone,44 and an
orientation to maintenance does not mean that people should be discouraged from
seeking to withdraw from treatment if they are doing well, and have sufficient ‘recovery
capital’ (social supports such as a relationship, job, family support, affiliation with
mutual support groups – see Glossary) to sustain long-term abstinence. People who
achieve good social reintegration, particularly employment, are more likely to be able 
to leave treatment without relapse.24
While, in general, individuals should be encouraged to remain in treatment, patients
who are deriving no observable benefit from treatment, or who are compromising 
the safety of the treatment space, may need to be discharged. An unstructured
environment without enforced expectations is unlikely to be a therapeutic environment.
8.4.5 Patient education and relapse prevention
The controlled withdrawal from an opioid is termed detoxification (see Glossary).
Patients should be given detailed information about detoxification and the associated
risks, including the loss of opioid tolerance following detoxification; the ensuing
increased risk of overdose and death from illicit drug use; and the importance of
continued support to maintain abstinence and reduce the risk of adverse outcomes.64
Following detoxification, rehabilitation, or other periods of abstinence from opioid use,
relapse is common.65,66 Relapse prevention is discussed in more detail in Section 9.5
and is likely to require continued community support in addition to the teaching of
relapse prevention skills.
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b The therapeutic community (TC) (see Glossary) for the treatment of drug abuse and addiction has existed for about 40 years. In
general, TCs are drug-free residential settings (residential rehabilitation) that use a hierarchical model with treatment stages that
reflect increased levels of personal and social responsibility. Peer influence, mediated through a variety of group processes, is
used to help individuals learn and assimilate social norms and develop more effective social skills.60
Long-term favourable outcomes are more likely in those who remain in some kind of
treatment, whether this includes OST with community support, or abstinence with
community support, for example participation in Alcoholics Anonymous (AA), 
Narcotics Anonymous (NA) or other mutual-help programmes (see Glossary for 
further information on AA, NA and mutual-help groups).67
8.4.6 The role of naltrexone in relapse prevention
The opioid antagonist naltrexone is licensed in its oral form for use as an adjunct in
relapse prevention for people who have undergone opioid detoxification, to help them
remain abstinent. An essential safety precaution for the medical professional to be
aware of and educate patients about is the risk of a fatal overdose if they return to
heroin use after naltrexone treatment, because of loss of tolerance to heroin.68
While pharmacologically it is consistent that naltrexone would be an effective preventive
strategy, the use of oral naltrexone requires significant motivation to remain compliant,
and thus for it to be an effective therapeutic strategy. The results of studies have not
been favourable, except in cases where there are added significant external motivating
factors, such as might be the case for an opioid-dependent health professional.69
Long-acting naltrexone preparations, in the form of an implant or depot, are not
currently licensed in the UK. In a series of small trials, and one large study from Russia,
implants were demonstrated to be superior to oral naltrexone and to placebo 
in reducing the risk of relapse.68
8.5 The limitations of treatment for heroin addiction
Like all forms of treatment for drug dependence (and like management of most chronic
diseases), OST relies on patient motivation – willingness to accept treatment and, more
importantly, the willingness, personal resources and social opportunities to take
advantage of the respite from dependence to take steps towards sustained recovery.
8.5.1 Patient choice and motivation
The importance of patient choice and motivation was illustrated in an early randomised
trial reported by Bale et al in 1980, in which 457 patients completing inpatient
detoxification for heroin addiction were randomised to either MT or RR.70
Based on a retained-in-treatment analysis, both methadone and a long-term TC 
were more effective than no treatment or short-term treatment, but – as in other
comparisons between these modalities – did not differ significantly in terms of heroin
use, other drug use, crime or employment.70
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The important aspect of this study was the failure of most subjects to accept any
ongoing treatment, and especially failure to accept allocation to a treatment that they
did not want.70 It is an important illustration about the treatment of heroin addiction.
The assumption underlying most clinical trials in medicine, that people will accept
allocation if there is a reasonable expectation that the alternative treatments will be 
safe and effective, does not apply to people seeking treatment for addiction. Individuals
who are addicted to heroin only enter treatment if it is perceived to offer some
advantage over their drug-using state.71 Often this means entering treatment during
crisis, and only remaining in treatment until the crisis is past.
In the Bale study,70 methadone attracted a significantly higher proportion of patients
than RR. Methadone treatment is as effective as other modalities of treatment, and the
public health rationale for supporting OST is that it attracts and retains in treatment a
higher proportion of heroin users than other treatment modalities.72 Participation in
treatment is often patchy, with people cycling in and out of treatment, having periods
of heavy drug use, periods of treatment, periods of abstinence or controlled drug use,
relapse to dependent use, and return to treatment.73 The ATOS study established that
the best outcomes were associated with people remaining in continuous treatment for
prolonged periods, rather than cycling through treatment episodes.29
8.5.2 The need for alternative rewards
A second limitation of OST is that people need alternative rewards in their lives if they
are to recover from drug dependence. The rewards of everyday life – for most people, 
a stable, intimate relationship, employment, and family life – are less accessible for
people who are marginalised by drug dependence, and lacking in interpersonal and
vocational skills. Employment is a key step in social reintegration, and in settings in
which unemployment is high, and social cohesion low, prospects for sustained recovery
are compromised. There is some evidence that participation in training and employment
can be fostered by treatment. In the Swedish trial described earlier,41 two-thirds of
patients receiving methadone were in employment or training two years after
programme entry (compared to none in the group randomised to no treatment). 
Social reintegration in two-thirds of subjects receiving MT is an impressive outcome. 
This occurred in a programme providing ‘intensive’ psychosocial input, including
vocational retraining. The programme also involved limit setting – subjects persisting in
heroin use were discharged. It is not possible without further research to ascertain
whether it was psychosocial support, limit setting, or both, that contributed to better
outcomes. This is an issue for further investigation.
BMA Board of Science
Drugs of dependence: the role of medical professionals148
8.5.3 Subtherapeutic dosing
The greatest limitation on the effectiveness of MT is that subtherapeutic dosing remains
common, even among patients who persist in daily heroin use. Evidence suggests
subtherapeutic dosing is common in the UK, where the mean methadone dose is 
56mg per day,74 below the 60-120mg range recommended in national guidelines.75
This low dosing is associated with high levels of persisting heroin use, with more than
60 per cent of patients in treatment reporting heroin use within the preceding month.76
Indeed, it is common for people who prefer to use heroin to enter MT as a protection
against the daily experience of withdrawal, but to remain on low doses in order to 
be able to use heroin and experience the reinforcing effect. The evaluation of 
‘low-threshhold’ methadone in Amsterdam showed that failure to suppress heroin 
use did not protect against blood-borne virus transmission.77
8.5.4 Opioid dependence as a chronic medical condition
Part of the problem is that methadone is not really seen as medical treatment – 
by patients, or by health professionals. Patients and practitioners reflect community
assumptions that drug use is a matter of personal responsibility, rather than a
disease, and many heroin users are reluctant to see themselves as ill. Adopting the
role of ‘patient’ involves relinquishing their ‘addict identity’, and they may prefer to
see participation in treatment as taking advantage of the supports available to them
rather than seeking to recover.78 Practitioners who prescribe methadone have been
noted to have polarised assumptions about the nature of treatment.79 Some see it as
a way to control deviance and reduce crime, others as support and palliation for
disadvantaged patients. It is uncommon for doctors to think of it as management 
of a chronic medical condition.
8.6 The safety of OST
Heroin addiction is associated with increased risk of death, predominantly by overdose.
While in MT, heroin users are substantially protected against the risk of death by
overdose. The overall protective effect is diminished by two factors.
The first is the risk of death of individuals not in treatment, as a result of diversion 
(see Glossary) of methadone. The primary mechanism for reducing diversion is
supervised administration. In the UK, increased supervised administration has been
associated with a reduced number of deaths relative to the total amount of methadone
dispensed.80 As discussed earlier, there is evidence that buprenorphine is associated with
fewer overall deaths proportionate to the amount prescribed.81
The second is that there is an increased risk of death during the first two weeks of
treatment, and in the month after leaving treatment.75 Induction into MT involves
inducing a high level of tolerance to opioids, such that usual doses of street heroin
cease to be reinforcing. This must be undertaken gradually, starting with doses in the
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range 20-30mg/day – doses that would be safe in non-tolerant individuals. There is
consistent evidence that during induction into MT, there is an increased risk of death
by overdose. This is the basis for clinical guidelines recommending slow induction
and close monitoring during the first week of MT.75
Overall, as elegantly demonstrated by a Norwegian study, the risk of death for heroin
users is diminished by entering treatment.32 In the short term, the risk of death
appears lower for people entering MT than for people entering abstinence-oriented
treatment, particularly detoxification.82
Offsetting the protective effects on mortality among people who enter treatment 
is the risk of fatal overdoses resulting from diversion of medication prescribed in
treatment programmes. Diversion is an inevitable accompaniment of OST, and
around two-thirds of methadone-related deaths occur in people who were not in
receipt of a prescription.83 In the UK, guidelines on increasing supervision of dosing
appear to have reduced the rate of fatal methadone overdoses.80
8.6.1 Reducing drug-related deaths at times of 
increased risk
In doses that exceed an individual’s tolerance at any one time, opioid drugs can
cause respiratory depression and death. Experiencing or witnessing an overdose is a
common occurrence among users of illicit opioid drugs,84 but prescribed opioid
drugs also carry these risks. It is essential that the medical professional understands
the process of careful and safe assessment and prescribing, as well as recognising
the times when a patient is most at risk. While OST has a greater than 85 per cent
chance of reducing overall mortality among users of opioid drugs if the average
duration approaches or exceeds 12 months,66 in the first two weeks of OST, the
mortality rate has been found to be three times higher (after adjustment for sex, age
group, calendar period, and comorbidity) than that during the rest of the time on
treatment.66 Overdose may occur if the initial dose is too high or if patients continue
to use non-prescribed opioid drugs during this time.66,85 Although further research is
needed on which to base better and safer management of OST, closer supervision of
induction of treatment is important.66 This requires careful titration, but may also
include repeated urinary drug screens, clear safety and educational advice to the
patient, and frequent reviews. All patients starting an MT programme must be
informed of the risks of toxicity and overdose, and the necessity for safe storage of
any take-home medication;64,86-88 and supervised daily consumption is recommended
for new prescriptions, for a minimum of three months.75
Overdose in heroin users is common,84 with intravenous drug use, polydrug use,
early heroin use, not being in MT, and the initiation of substitution treatment all
being periods of increased risk, in addition to being early in a period of abstinence
BMA Board of Science
Drugs of dependence: the role of medical professionals150
following opioid use, whether the abstinence is voluntary (such as detoxification in
the community) or involuntary (such as in the prison setting).84,89 The mortality rate is
increased by eight- to nine-fold in the first four weeks after MT has stopped.66
Strategies to reduce the mortality rates from opioid overdose at these high-risk times
are essential. One important strategy is training users of opioid drugs themselves,84
and also healthcare staff and carers,90 in the recognition of opioid (and other drug)
overdose in the community and prison setting, and how to respond, including
administration of the opioid antagonist naloxone. The possibility of prescribing take-
home naloxone to high-risk groups was first suggested in the literature in 1996,91
and has been proposed by others in the USA.92 A national programme of naloxone
provision and training has recently been rolled out in Scotland to those deemed to be
at risk of opioid overdose (and their family, friends, carers and partners), including
prisoners who use opioid drugs on release from prison.93 An ongoing trial in England of
supplying naloxone to newly released prisoners with a history of heroin use is described
in Section 10.11.94
8.7 Research, training and resources for effective delivery
of OST
8.7.1 Research needs
The foundation of OST remains suppression of illicit heroin use; currently 63 per cent of
people in MT in the UK report continuing heroin use.74 The immediate challenge for
researchers and service providers is to find more effective ways to reduce heroin use.
Ensuring delivery of a supervised, adequate dose of OST medication is the key to
suppressing heroin use. In the UK at present, there is a substantial group of people on
low or moderate doses of methadone, who continue to use heroin regularly.74 Such
people have settled into a pattern of treatment and are very resistant to change,
whereas if, from the outset, treatment is approached with the objective of suppressing
heroin use, outcomes tend to be better. Alternative methods of treatment for people
not responding to methadone, such as slow-release oral morphine, could enhance
consumer choice. Little is known about the efficacy of such approaches and research is
needed in this area.
8.7.2 Training needs
The implication of delivering OST in primary care is that medical practitioners who
choose to engage in this practice need the skills, knowledge and attitudes to work with
heroin addicts. In order to deliver such care, doctors report that they need not just initial
training, but ongoing supervision, support and reflection.73
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8.7.3 Resource needs
Drug-dependent people, in particular those who inject heroin, are among the most
challenging and disadvantaged of patients. Treatment requires structure, support 
and monitoring, and has been operationalised into clinical guidelines.89 Compliance
with guidelines is more expensive. A recent US study demonstrated that effective
implementation of guidelines results in better outcomes, but is also considerably more
expensive.51 The authors reported that, after 12 months, treatment of new clients of
highly staffed, guideline-concordant sites cost $10,252, which is significantly more than
the $6,476 cost for less-concordant programmes.
In a climate of fiscal austerity, re-tendering of drug treatment programmes has become
common, with a view to reducing costs in an already squeezed system. Quite apart
from the financial pressure to provide minimalist services, re-tendering in itself risks
compromising the quality and continuity of treatment. As reported by Ball and Ross,7
more effective programmes are characterised by stable management, and frequent
restructuring of services may compromise effectiveness. Clinical leadership, with well-
understood, protocol-driven treatment and support and supervision for staff, are
important ingredients of treatment.
Summary
• Medical management of drug dependence is more difficult and challenging than for
other chronic disorders. Many users who present for treatment are socially
marginalised, lead chaotic lifestyles and have little to motivate them towards recovery.
• Stigma and staff attitudes may also complicate management.
• Traditional methods for treating opioid addiction were based on two approaches 
– encouraging abstinence and a change of attitude on the part of the user.
• Although some individuals do recover spontaneously from opioid dependence, it is
usually a chronic relapsing–remitting condition.
• The principle of opioid substitution therapy (OST) is to prescribe and administer a
pharmaceutical opioid as a substitute for heroin. This attenuates the symptoms of
withdrawal from heroin and allows the user to gain control over other aspects of
their life, thereby creating the necessary preconditions to cease drug seeking and use.
• Substitution therapy provides a structured routine through daily attendance for
administration in a safe non-punitive and non-judgemental treatment space, which
may benefit users in restructuring a chaotic lifestyle.
• The basis of effective OST is suppression of opioid withdrawal.
• High-dose methadone is more effective than a low dose, because it progressively
increases the patient’s tolerance to opioids, making heroin less reinforcing and
cessation of use more likely.
• For some users, the respite from withdrawal offered by methadone is insufficient to
allow them to move away from heroin use; treatment with diamorphine is more
reinforcing and successful in these individuals.
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• Long-term studies suggest OST may reduce use of opioid drugs (in a relapsing–
remitting manner), but seldom results in long-term abstinence from all drugs.
Continued alcohol misuse and cannabis use are common.
• Opioid substitution has been shown to reduce deaths from opioid overdose and 
the risk of blood-borne viruses.
• Evidence on the effects of OST on mental health and quality of life is limited 
and equivocal.
• The National Treatment Outcome Research Study (NTORS) demonstrated that for
every pound spent on treatment in the UK, a reduction of £3 in public costs was
observed. Economic benefits were largely accounted for by reduced costs of crime.
• Opioid substitution has been shown to reduce rates of acquisitive crime and there 
is some evidence that it contributes to social reintegration.
• There has been little research on the effectiveness of supervised administration of
OST, but limited evidence suggests it is more effective at reducing heroin use than
non-supervised treatment.
• Randomised trials have shown no benefit overall of additional psychological
interventions in terms of retention, non-prescribed opioid use, psychiatric symptoms,
compliance or depression. There is substantial evidence that good-quality staff
interactions are of benefit for recovery.
• Opioid substitution is associated with a risk of diversion of methadone to other
individuals, as well as an increased risk of death during the first two weeks of
treatment and in the month after leaving treatment. Overall, the risk of death is
reduced by entering OST.
• Subtherapeutic dosing is a serious limitation on the effectiveness of OST.
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Chapter 9 – Medical
management of drug
dependence: reducing
secondary health harms
9.1 Provision of healthcare and identification of drug 
use as a health issue
This chapter considers the scope of medical practitioners’ involvement in the reduction
of drug-related harm, through the provision of healthcare to people using drugs, and
the identification of users, provision of information, and monitoring where drug use is 
a risk factor for health problems.
Some people who use drugs report experiencing disapproval and frustration in their
interaction with healthcare services,1 and this can be a significant barrier to accessing
healthcare. As discussed in Chapter 8, health professionals who adopt a non-
judgemental, non-stigmatising empathic stance are most likely to be effective in
delivering healthcare for these patients.
There is consistent evidence that in primary care settings, in hospitals, and in mental
health settings, doctors frequently do not address alcohol and drug use.2-5 A history of
alcohol or drug use is seldom documented, even where presenting symptoms or signs
provide an index of suspicion that alcohol or drugs may be involved.2,3 There has been
difficulty engaging doctors in the treatment of problems with addiction in Australia,4
and reports of similar problems in the UK.5 Possible explanations for the reluctance to
explore alcohol and drug use include some doctors’ sense of pessimism about being
able to do anything, avoidance of antagonising patients, and, possibly, reluctance to
work with stigmatised patients (see Section 8.2).
The medical frame of reference is a useful one in which to approach drug use – 
non-judgemental, factual, professional, accurate diagnosis and provision of information
and referral, monitoring the response. Contrary to pessimism and reluctance to address
drug use as a health issue, there is evidence that, in relation to the legal drugs alcohol
and tobacco, medical management can have significant impact,6-9 but it is unclear how
far this can be extrapolated to illicit drugs. Opportunistic identification of drug use, 
and provision of brief health advice, may be useful in triggering individuals to reflect on,
and sometimes to modify, their use of drugs.
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If a doctor finds a patient is using illicit drugs, the response should be to undertake
an assessment of the extent to which this use is impacting on the person’s health
and their life and the lives of others around them, while acknowledging the
importance of patient autonomy and choice. The appropriate response may involve
provision of information about health risks and harms, or referral for management.
Referral to a specialist service is not always indicated. Screening and brief advice
from physicians can affect the motivation for change among patients, including
those with substance dependence.10,11
It is important to identify whether the patient perceives that their health, or other
aspects of their life or that of those around them is negatively impacted by their drug
use, whether their family members perceive this to be so, and whether the doctor, on
the basis of the patient’s symptoms and presentation, has identified negative effects of
their drug use on the person’s life. The doctor must also consider the impact the drug
use may be having on children and young people. Guidance published by the General
Medical Council (GMC) in 2012 on Protecting children and young peoplemakes it clear
that, while the adult patient must be the doctor’s first concern, the doctor also has a
responsibility to consider whether the patient poses a risk to children or young people.12
The new guidance also stresses that, when responding to requests for information for
child protection purposes, the doctor should:
‘include information about the child or young person, 
their parents and any other relevant people in contact with 
the child or young person. Relevant information will include
family risk factors, such as drug and alcohol misuse, or
previous instances of abuse or neglect, but you should not
usually share complete records.’12
9.2 Opportunistic brief intervention
In the medical response to addictive disorders, prevention is probably better than
treatment – ie opportunistic interventions with people identified as using drugs in
ways that place them at risk. Strategies to prevent drug use are discussed in detail in
Chapter 7. This section looks at strategies to reduce use in those who are already
using drugs.
9.2.1 Young people and drug use
A review of randomised trials that evaluated an intervention targeting drug use by
young people under 25 years of age, delivered in a non-school setting, noted that
overall there is a lack of evidence in this area, so further research is still needed to
determine which interventions can be recommended and which are cost effective.13
Some larger studies show promising results, suggesting that, for medical
professionals (and other healthcare workers), brief interventions using motivational
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interviewing provide an important means of reducing drug use in young people,
including in those who are most vulnerable or most at risk. Some authors have
shown positive impact of brief interventions for use of individual drugs in young
people,9,14 while one UK study showed these benefits simultaneously derived across
a number of different drugs,15 which may also have useful implications for the busy
primary care or emergency department setting.
McCambridge and Strang tested brief interventions in young people,16 and found that 
a single session of motivational interviewing (including discussing illicit drug use) led
successfully to reduction in use of these drugs among young people. The intervention
took place across 10 further education colleges across inner London, with 200 young
people aged 16-20 years who were currently using illegal drugs. Those randomised to
motivational interviewing reduced their use of cannabis (and cigarettes and alcohol).
Those most at risk benefited the most: for cannabis, the effect was greater among
heavier users. The effect of reduction in cannabis use was also greater among youth
usually considered vulnerable or high risk according to other criteria – for example
young male individuals who smoked cannabis the most frequently, were in receipt of
benefits, and had a prior history of selling drugs.
9.2.2 Cannabis
Relapse prevention CBT (see Section 9.5.2) appears to be effective for cannabis
dependence, compared with a control group awaiting treatment. It appears that
individual therapy may be more effective than group therapy.17
9.2.3 Stimulant use
Contingency management (see Section 9.5.2) is associated with much longer
continuous periods of abstinence for cocaine compared with control groups, in both
prize and voucher reinforcement studies.18 This intervention has not been widely used 
in the UK, possibly due to training needs.18 Couples-based interventions have also been
found to be effective.18
9.2.4 Use of opioid drugs
Individuals with opioid dependence who are in close contact with a non-drug-using
partner have been found to benefit from behavioural couples therapy, both during
treatment and at follow-up.19
In order to reduce relapse and the associated increased risk of fatal overdose, services
providing residential opioid detoxification should prepare people for admission, strive to
retain them in treatment for the full admission period, and actively support their entry
into planned aftercare, in order to improve outcome.20
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9.2.5 Intravenous drug use and associated risks
Opportunistic brief interventions in intravenous drug users have also been shown to
have significant impact. A randomised trial across 15 cities and 4,000 participants
examined the effect of three sessions of motivation interviewing for intravenous drug
users attending healthcare services for other purposes (HIV testing) compared to HIV
testing alone. The study found that those who received additional counselling had
better outcomes than those randomly assigned to receive just HIV testing. In the 
group that received additional counselling, there was half the rate of drug injection at
6-month follow-up, four times the likelihood of abstinence (confirmed by urinalysis),
and significantly lower arrest rates.10,11
9.3 Safe prescribing
Management of illicit drug users is multifaceted. It requires medical management of the
drug use and its sequelae, but also includes referring to other disciplines, such as social
services, that can help with the wider aspects of improving quality of life. Medical
management of dependent drug use focuses directly on treating physical and mental
health issues and may involve prescribing. This section presents some of the safety
issues that are important in this context. It considers the appropriate and safe
prescribing of drugs of dependence and ways to minimise the risks of diversion, misuse
and iatrogenic dependence.
Misuse of, and dependence on, prescribed drugs (in particular opioids and
benzodiazepines) is a rapidly growing public health problem in many jurisdictions
internationally.21,22 There have been well-documented periods in the past when
diversion and misuse of pharmaceuticals was the primary source of street drugs in some
UK cities.23 Caution in prescribing, particularly in patients with histories of drug
dependence and misuse, is an essential part of minimising diversion and delivering safe
and effective medical management. The most effective deterrent to diversion and
misuse is supervised consumption.22 There is clear evidence from the UK that increasing
the level of supervision in patients receiving methadone has been associated with a
marked reduction in deaths due to diverted methadone.24
In assessing patients seeking analgesics and/or hypnosedatives, it is appropriate to seek
a history and family history of drug use, and to examine for any objective signs of use of
injected drugs (such as scarred veins), with the patient’s consent. Urine toxicology is also
useful, to enhance the accuracy of self-report. In addition to minimising misuse,
diversion and iatrogenic dependence, the medical professional must consider the
physical safety of the prescribed drugs, as is the case in all prescribing. The impact of
injudicious prescribing is illustrated in a study from Melbourne, Australia, where
researchers investigated the medical attendances of young people who had died of
opioid overdoses.25 In the months leading to their deaths, these young people exhibited
a pattern of increasing presentations to doctors, obtaining escalating prescriptions for
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opioids and benzodiazepines – the drug combination that led to their deaths.
In a UK-wide 17-year GP dataset of patients also prescribed OST, over one-third of
prescriptions for benzodiazepines exceeded 8 weeks (twice the maximum timeframe
recommended by the NICE guidelines).26 In other cases, some patients who may initially
be prescribed a short-term z-drug or benzodiazepine prescription for sleep problems or
an episode of anxiety, but whose symptoms continue, may be at risk of developing
dependence.27,28 It is important for medical professionals to conduct regular reviews and
consider the broader care plan options, including a stepped care approach and
psychological interventions.26
9.4 Management of withdrawal
It is not unusual for patients to present to emergency departments, or sometimes to
primary care, in acute drug withdrawal. Occasionally withdrawal from drugs that
activate the GABA (gamma-amino butyric acid) system – alcohol, barbiturates and
GHB/GBL can present with very severe and potentially life-threatening seizures. 
Such withdrawal is characterised by autonomic overactivity (tachycardia, hypertension,
tremor and sweating), cognitive changes (confusion, agitation, sometimes psychosis)
and perceptual disturbances (formication – a tactile hallucination of insects crawling on
or in the skin, illusions, visual hallucinations). Fits may also occur. One role of therapeutic
detoxification from illicit drugs is management of a clinical emergency, stabilising 
the individual and slowing the rate of change to allow their physiology to adapt. 
A second role is to decrease the distressing or uncomfortable symptoms of withdrawal,
and, through this, a third role is to enhance engagement and increase the likelihood 
of continued abstinence. It is also essential that the medical professional promotes
continued engagement and continues to provide support after the detoxification
process is complete. Relapse prevention is discussed in Section 9.5.
9.4.1 Benzodiazepine withdrawal
Fits or a paranoid psychosis may also occur on abrupt withdrawal of benzodiazepines.
This is relevant in considering illicit drug use, as it is usual for people who become
dependent on illicit drugs to misuse a range of drugs, including alcohol and
benzodiazepines. Where withdrawal from most illicit drugs is not associated with severe
morbidity, withdrawal from benzodiazepines often poses a greater risk. It is more
difficult to recognise, as the onset of withdrawal is often delayed. Withdrawal
symptoms come on within two to three half-lives of the particular benzodiazepine 
(eg 2-3 days after short- and medium-acting compounds and 7-10 days after long-
acting compounds) and usually subside within a few weeks.28,29 Some patients report
symptoms that have persisted for months or indefinitely.30 This has been described as 
a ‘post-withdrawal syndrome’,31 and may complicate management of withdrawal 
from illicit drugs.
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9.4.2 GBL withdrawal
As with benzodiazepine withdrawal, those with chronic heavy GHB or GBL use can
experience severe withdrawal,32 including delirium and the need for urgent inpatient
care or, in some cases, transfer to an intensive therapy unit. Others can be managed by
specialists, with high-dose diazepam and baclofen, titrated against withdrawal severity
in ambulatory settings, but this needs to be backed up with access to inpatient
treatment if required, because of the possible severity of the withdrawal symptoms.33
9.4.3 Opioid withdrawal
The distressing symptoms of opioid withdrawal can include dysphoric mood, nausea or
vomiting, muscle aches, lacrimation, rhinorrhoea, sweating, diarrhoea and insomnia.34
In those patients who wish to detoxify from all opioids, withdrawal symptoms are
minimised by the process of opioid detoxification, using the same drug or another
opioid in decreasing doses. This is discussed in more detail in Chapter 8. Methadone or
buprenorphine are offered as the first-line treatment in opioid detoxification.34 As with
other withdrawal syndromes, adjunctive medications at low doses may also be
considered where clinically indicated (for example, to treat diarrhoea), and where the
medication does not interact with the other medications prescribed.
Following successful opioid detoxification, patients should be offered and engaged in
continued support and monitoring designed to maintain abstinence.19 This important
topic is covered in Section 9.5.
The medical professional must also educate the patient regarding the loss of opioid
tolerance following detoxification, and the ensuing increased risk of overdose and
death if opioids are used again during this period. This is addressed in greater detail in
Sections 8.4.5 and 8.6.1.
9.4.4 Stimulant withdrawal
When chronic heavy users abruptly discontinue amphetamine or cocaine use, a
withdrawal syndrome occurring within hours to days of their last dose is commonly
reported. While the two syndromes are distinct, they share symptoms, including
dysphoric mood, fatigue, vivid or unpleasant dreams, insomnia or hypersomnia,
increased appetite and psychomotor agitation or retardation.33 The degree of severity 
is a relapse predictor in some individuals.35 This is a distressing experience, and there 
are reports of suicidal ideation in some during this period.36-38
Research on pharmacotherapies for amphetamine detoxification36,39 and cocaine
detoxification35,40,41 are currently ongoing but, as yet, no medications are licensed for
detoxification in stimulant withdrawal. The medical professional’s current focus should
be on assessment; engagement; safe means of alleviating distressing symptoms, such as
adjunctive medications where appropriate; relapse prevention strategies (discussed in
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Section 9.5); and monitoring for the use of other potentially harmful substances the
patient may be using to self-medicate.
9.4.5 Cannabis withdrawal
In managing cannabis withdrawal, the medical professional should be aware of the
frequency and presentation of withdrawal symptoms, which are newly listed in the
forthcoming Diagnostic and Statistical Manual of Mental Disorders (DSM-V), scheduled
for publication in 2013. The medical professional should also be aware of the possible
responses of patients aiming to reduce their withdrawal symptoms, including
relapsing42 and self-medication with other substances.42,43
Symptoms of cannabis withdrawal in those who are dependent include anxiety,
irritability, appetite changes, restlessness, sleeping difficulties, tension, thoughts and
cravings for cannabis, and twitches and shakes, in both adults42,44 and adolescents,45
and commencing typically within hours to days of ceasing cannabis use. From a 
US general population study, of a sample of 2,613 individuals using cannabis on three
or more days per week, 57.7 per cent (and 59.4% among the subset who did not use
other substances) experienced at least one symptom of cannabis withdrawal on
cessation, with feeling weak or tired, hypersomnia, anxiety, psychomotor retardation
and depressed mood being the commonest symptoms. There was a strong, significant
correlation between distress experienced during withdrawals and the use of other
substances to relieve the distress.43
Research on pharmacotherapies for the management of cannabis detoxification is also
ongoing.46,47 In terms of management of withdrawals, the medical professional should
monitor patients for withdrawal; address ways to alleviate significant symptoms to help
avoid relapse and self-medication;42 and engage the patient in other relapse prevention
strategies (see Section 9.5).
9.5 Relapse prevention
Drug dependence, in particular in users of heroin, other opioids and cocaine, often
presents as a chronic condition with periods of relapse and remission.48 In the case of
dependence on opioid drugs, relapse after a period of abstinence is associated with an
increased risk of death from overdose due to decreased tolerance (see Section 8.6).49,50
The medical professional has a key role in educating the opioid user51 and their carers52
about these risks and how to respond to them. The medical professional must also
address relapse prevention strategies with those undergoing detoxification.51
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9.5.1 The role of medication in relapse prevention
The use of naltrexone for relapse prevention after opioid detoxification is described in
Section 8.4.6. Its use requires significant motivation for compliance and thus its use 
as an effective therapeutic strategy is limited.53
Prescribed OST (described in detail in Chapter 8) is used as treatment in opioid
dependence, to maintain abstinence from illicit opioid use.
A Cochrane review addressing the use of psychostimulants to maintain abstinence 
from cocaine use found studies in this area to be currently inconclusive.54
9.5.2 The role of psychosocial interventions in relapse
prevention
Relapse prevention CBT focuses on helping drug users to develop skills to identify
situations or states where they are most vulnerable to drug use, to avoid high-risk
situations, and to use a range of cognitive and behavioural strategies to cope more
effectively with these situations.18,55
Relapse prevention CBT appears to be effective for cannabis dependence, with
individual relapse prevention CBT lasting between four and nine sessions associated
with greater levels of abstinence and reductions in drug use for people who use
cannabis.18,55
In a meta-analysis, contingency management (CM), in the form of voucher-based
reinforcement in the treatment of use and dependence on licit and illicit drugs, has
been shown to significantly improve treatment outcomes for all substance use disorders
apart from for alcohol.56
Contingency management has not yet been widely used in the UK,18 but has been
shown to increase the likelihood of abstinence in cocaine dependence, using either
prize- or voucher-based reinforcement,57,58 while relapse prevention CBT and standard
CBT have not been shown to be effective for the treatment of cocaine dependence.18
As Stulza et al highlight,59 cocaine users are a heterogeneous group, so studying the
impact of psychological therapies on this population as though they are psychologically
uniform is likely to underestimate the effect size of therapies, which could be more
effective when tailored to individual cases or if subgroups with shared characteristics are
studied together instead of whole populations.
Individuals with cocaine and/or opioid dependence and who are in close contact with 
a non-drug-using partner benefit from behavioural couples therapy, both during
treatment and at follow-up.18
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Narcotics Anonymous (NA) and Cocaine Anonymous (CA) are mutual-help groups 
that offer a recovery programme based on the 12-step approach that began with 
AA – ‘a non-profit fellowship or society of men and women for whom drugs had
become a major problem’, which ‘encourages its members to abstain completely 
from all drugs’.60 Although there are still only very few UK studies in this area,61
a longitudinal, prospective cohort study of 142 drug-dependent clients interviewed 
at intake to residential treatment in the UK, and again at 1-year, 2-year and 4-5-year
follow-up, found that those who attended NA/AA, in particular those who attended at
least weekly, were more likely to be abstinent of opioid drugs at all follow-up points
than those who did not.15 This study showed reduced stimulant use at 1-year follow-up
in those who attend NA/AA following residential treatment, but not at other follow-up
points.61 Other studies have shown that active participation rather than just attendance,
at 12-step groups was associated with reduced cocaine use.15 This is consistent with
findings that the efficacy of certain psychosocial treatments, including 12-step
programmes, is dependent on individual patient characteristics of cocaine-using
populations, which can be subdivided based on personal characteristics, such as 
belief in the 12-step programme.59 This emphasises the importance of the medical
professional tailoring a treatment package to the individual patient in order to 
optimise outcomes.
9.6 Illicit drug use in pregnancy
Medical professionals have a responsibility to identify pregnant women who are using
illicit drugs, and to engage them in treatment. The earlier members of this population
are able to access treatment services, the better the outcome will be for their general
physical health, the pregnancy and the neonate.
A sensitive, non-judgemental approach is essential in engaging this population and
optimising treatment effectiveness. Medical professionals have a role to play not only in
portraying this through their own clinical care and manner, but in leading their clinical
teams to be approachable, non-judgemental and patient centred in this situation. This
will include attention not only to physical healthcare and management of drug use, but
sensitive attention to the coexistent psychological difficulties and social concerns that
the patient may be experiencing. The medical professional and the full multidisciplinary
team will need to address the woman’s fears about the involvement of children’s
services; anxiety and guilt about the potential impact of their drug use on their baby;62
and concerns the patient may have about finances, support networks, and coping
strategies during pregnancy and their forthcoming parenthood. The NICE guidelines on
Pregnancy and complex social factors62 recommend that the first time a woman who
uses substances discloses that she is pregnant, she should be offered referral to an
appropriate substance use programme. They also recommend that a variety of methods
(eg text messaging) should be used to maintain contact and engagement, and to
remind women of upcoming and missed appointments.62
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The medical professional must ensure high-quality effective interagency
communication. Multiagency team work is also essential, working with social care
professionals and ensuring seamless communication between general practice and
the specialist services involved in the patient’s antenatal care, including obstetrics,
specialist drug services and any other specialist healthcare services. Multiagency case
conferences, with prospective parents invited as participating attendees, will
facilitate good inter-team communication and optimise clinical care.63
The following case study illustrates some of the additional issues to be considered 
in pregnancy.
Case study: Illicit drug use in pregnancy
Ms B is 23 years old. She is smoking about £30 of heroin and £10 of crack per day. 
She does not drink any alcohol. She has presented for treatment and is 14 weeks
pregnant for the second time.
Ms B was brought up in a small isolated community and was one of six children. Her
family were very strict and she was not allowed to have friends outside the community.
Between the ages of 10 and 13 she was subjected to regular sexual abuse by an uncle
who lived with the family. She once told her mother about the abuse but was told to
keep it quiet and not tell anyone, as it would bring shame on the family. Her mother had
been seriously depressed when she was a child.
She did well at school and started work in a local estate agent’s office when she left
school. She began to see Mr Y, who was the brother of one of her school friends. 
Mr Y was a heroin user and eventually she started smoking cigarettes that he gave her.
She thought these were cannabis. After a few months, she noticed that she felt very
unwell if she did not smoke and Mr Y told her that the cigarettes had heroin in them.
She started rowing with her family and left home to live with Mr Y in a squat. Their drug
habits were funded by Mr Y’s shoplifting.
When she was 19 she found she was 28 weeks pregnant. She presented to a local GP,
who prescribed her methadone and referred her for antenatal care. Social services were
involved. She had very little antenatal care and avoided the appointments with the social
worker, who she only met once. She continued to use heroin on top of her prescription.
She went into labour at 36 weeks and had a baby boy. For a few weeks she went back,
with her baby, to live with her parents (with the support of social services) and stopped
using heroin but the rows with her mother were so bad she eventually left the baby with
her mother and went to live with Mr Y in a big city.
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For the next three years she lived in a series of squats with Mr Y and continued to use
drugs. Ms B’s son lived at home with her mother. She occasionally slept with men to get
drugs. Mr Y started drinking alcohol and started hitting her when they argued.
She came into treatment when Mr Y was arrested for aggravated burglary and went to
prison. He was sentenced to four years.
Ms B was engaged in treatment by the city’s drug services. She registered with a GP. 
She was prescribed buprenorphine and managed in an antenatal liaison clinic, where she
received antenatal care and drug treatment. Social services were involved from the
beginning and found her a place in a local women’s hostel.
Ms B was able to stop using heroin and begin to think about some of the problems 
she had with her abusive relationship and her history of sexual abuse. Her second baby, 
a little girl, was born at full term and was immediately subject to child protection
proceedings and taken into foster care but Ms B had regular contact with the baby. 
She subsequently went, with the baby, to a mother and baby rehabilitation centre where
her parenting could be assessed and she could reduce her buprenorphine. Ms B was clear
she wanted to stop using all drugs, keep her daughter and re-establish a relationship
with her son and her family.
Case study details provided by Dr Emily Finch, a consultant addiction psychiatrist.
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9.6.1 Use of opioid drugs during pregnancy
For opiate use in pregnancy, the focus is on stability. It is safest to prescribe opiate
substitution (see Chapter 8) ‘at a dose that stops or minimises illicit use’.62
Detoxification may be considered, if requested, during the second trimester, as long
as this does not precipitate a relapse in illicit drug use; but it should be avoided
during the first and third trimester because of the risk to the fetus.63,64
Buprenorphine is not licensed for use with pregnant women, but research suggests
no adverse effects on the pregnancy or neonatal outcomes.65,66 The UK guidelines 
on the clinical management of drug misuse and dependence63 advise that if a
pregnant woman is stable on buprenorphine and informed of the risks, it is
reasonable to leave her on a prescribed dose of buprenorphine, rather than risk
inducing withdrawal in the fetus or destabilising the patient’s treatment by
transferring to methadone, unless otherwise needed. The treatment focus again 
is on stability and maintaining engagement.
In all pregnant women using or prescribed opioid drugs, particular consideration will
also need to be given to their birthing plan, including pain management and the risk
of fetal distress at birth.64,65
9.6.2 Cocaine use during pregnancy
As in the case of the non-pregnant woman, there is currently no substitution
treatment for cocaine. In view of the potential harms to the fetus and to the
mother’s health, the pregnant woman should be given support to stop using cocaine
during pregnancy. A non-judgemental, sensitive approach, with clear and effective
multidisciplinary communication and team working are again essential, addressing
the full spectrum of psychosocial and physical health needs. Psychological therapies,
including family therapy where possible, may be offered.63 Relapse prevention CBT
should be offered, and marked efforts made to ensure continued engagement of 
the patient.
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Summary
• Consistent evidence shows that doctors in primary and secondary care and in
mental health settings frequently do not address alcohol and drug use.
• Caution should be exercised in prescribing drugs with potential for dependence,
particularly for patients who are at high risk for dependence or diversion.
• Management of medical emergencies related to acute symptoms of withdrawal
should be followed by longer-term medical management and support to reduce
dependence.
• It is also important to address strategies for relapse prevention after detoxification.
• The use of naloxone for relapse prevention after opioid detoxification is of 
limited value.
• Psychosocial interventions that help users to identify high-risk situations 
and use coping strategies have been shown to be helpful in managing 
cannabis dependence.
• In US studies, contingency management in the form of voucher-based
reinforcement has been found to significantly improve outcomes for all 
substance use disorders apart from alcohol. Couples-based therapy and 
support groups are also of value.
• Brief therapist interventions and motivational interviewing have been shown 
to reduce drug use among young people. Opportunistic interventions in patients
attending for HIV testing has also been shown to increase the likelihood of
abstinence and reduce arrest rates.
• Illicit drug use in pregnancy needs particular care with medical management, 
to avoid harm to both the mother and her baby.
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Chapter 10 – Medical
management of drug
dependence in the context
of criminal justice: illicit drug
use, courts and prison
10.1 Introduction
The criminalisation of possession and supply of illicit drugs, and acquisitive crime
associated with drug use, result in many illicit drug users being imprisoned. The
maximum penalty is life imprisonment for supply of Class A drugs, with seven years
for possession, but sentences between two and 14 years are used for possession or
supply of Class B or C drugs (see Chapter 1). This has implications for the medical
professional, as many illicit drug users first come into contact with the medical
profession via the criminal justice system.1
The general principles of medical ethics apply to all individuals who come into contact
with medical professionals through the criminal justice system.2 This includes their right
to confidentiality; the right to choose their own doctor (although this is not a right for
convicted prisoners); the requirement for informed consent to medical treatment; 
the right to refuse treatment; and, for those detained or in prison, the right of access 
to the same treatments that are available outside the detention setting. This can create
particular challenges for medical professionals working within the criminal justice
setting, which are highlighted throughout this chapter.2 These issues are discussed in 
a recent joint publication by the Royal College of General Practitioners, Royal
Pharmaceutical Society and The Secure Environment Pharmacist Group, Safer
prescribing in prisons.3
The controlled environment of prison is, nevertheless, more likely to ensure compliance
with drug treatment programmes than is possible after discharge. It offers a valuable
opportunity for effective medical treatment of drug use disorder and ultimately the best
chance for many dependent drug users to be rehabilitated. This is illustrated by the case
study that follows.
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Case study: Drug-related crime resulting in drug treatment in prison
A young woman aged 19 years appeared in the Crown Court charged with a series of
offences that she had committed while on bail granted in relation to other earlier
offences. A report from the Probation Service explained that she had been picked up by
police after having collapsed in the stairwell of a housing estate in east London. It also
explained that she was homeless; she had been living in a local authority hostel but had
been thrown out of it for taking men back into the hostel for the purpose of prostitution
in order to raise funds to feed her drug habit. She was barely conscious at the time that
she was found by the police and was high on drugs. She was due to be sentenced for a
series of offences, which included attempted robberies of mobile phones from young
women whom she had threatened with a knife, and attempts to snatch handbags, also
from young women leaving a tube station late at night. All the attempts had failed.
The probation report explained that she committed these offences to raise funds to 
buy drugs and that she was so dependent that, unless she was taken off the streets 
(and in effect given a lengthy prison sentence), there was a real risk that she would die.
She had two children. The oldest was a six-year-old girl, who had been taken away by
the grandmother to Belgium (it was said that she had, in effect, abducted the
granddaughter to save her from her mother) and she also had a two-year-old child 
who was in care.
After hearing evidence from the Probation Services, the court imposed a prison sentence
at the maximum end of the scale for offences of that nature. The court discussed the
possible range of sentences with defence and prosecution counsel and the discussion
proceeded upon the basis that it was, in effect, common ground that, for her own good,
she needed to be given a custodial sentence of the longest duration that was proper in
the circumstances. This would give the defendant the best chance of receiving drug
treatment in prison. The case was unusual in that the Probation Service was able to make
enquiries about which prison the defendant would be sent to, and about the availability
of drug treatment courses in that prison. This was exceptional, since it is very rare indeed
for a sentencing judge to know anything about the prison to which a defendant is to be
sent, or about the availability of drug rehabilitation courses in that prison.
Case study details provided by Nicholas Green QC, who has a special interest in the impact of drugs
policy upon the administration of the justice system.
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10.2 Drug use prior to, during and after incarceration
The prevalence of problem drug use among prisoners in the UK is high. While drug
treatment programmes delivered in a controlled prison environment may offer some
prisoners the opportunity to be rehabilitated, rates of drug use during incarceration
remain high. A survey of nearly 1,500 new UK prisoners in 2005-2006 found lifetime
use of heroin, crack cocaine, cocaine powder, amphetamines or cannabis was reported
by 79 per cent of prisoners, with approximately one-third having used heroin or crack
cocaine during the year before custody.4 These figures mirrored findings from a 1997
National Survey of Prisoners in England and Wales,5 showing high rates of drug use
prior to and during incarceration. It has been estimated that up to half of all recorded
crime is drug related.1
Rates of first initiation of use of drugs in prison are also high. Analysis of the findings of
the 1997 National Survey found that over a quarter of the men who had used heroin
reported first initiating use in prison.6 A study across 13 prisons in England and Wales
found that prisoners were also much more likely to continue to use heroin than either
cocaine or amphetamines while in prison.7
10.2.1 The Drug Interventions Programme
The bidirectional links between drug use and offending have already been highlighted.
The Drug Interventions Programme (DIP) was introduced by the Home Office in 
April 2003, with the aim of developing and integrating measures for directing adult
drug-using offenders into drug treatment and thereby reducing offender behaviour.8
The majority of DIP referrals into treatment are achieved via drug testing in police
custody suites. The DIP also provides for interventions at other stages in the criminal
justice process, such as during an initial bail hearing or sentencing. DIP also has links
with treatment-related community sentencing and the provision of treatment in prison.
Each person entering the DIP is unique and their care needs and treatment will be
tailored to them. Care planning is integral to the process; this is an agreed plan of
action between the service user and the Criminal Justice Intervention Team worker,
which involves setting goals based on the individual needs identified. This plan
documents and enables routine review of the service user’s needs, goals and progress
across four key domains:
• drug and alcohol use
• physical and psychosocial health
• offending
• social functioning (including housing, employment and relationships).9
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Research by the Home Office has found the DIP to be effective in reducing reoffending
behaviour.8 Each person completing a DIP had a care plan with medical treatment at
one or four levels or tiers dependent upon their individual needs, for example, the
nature of their drug use (frequency of use, and number and types of drugs used). The
different levels/tiers of treatment reflected their intensity and ranged from non-specialist
general healthcare through open drugs treatment and community-based drug
treatment to residential drug treatment.8 The overall volume of offending of a cohort 
of 7,727 individuals was 26 per cent lower following identification through a positive
DIP test. Around half the cohort showed a decline in offending of around 79 per cent
post DIP.8 Earlier research by the Home Office, conducted before the introduction of DIP,
lent support to the idea that drug-using offenders who are not directed towards
treatment are unlikely to change in their pattern of drug use.10
10.2.2 Drug Rehabilitation Requirement
The Drug Rehabilitation Requirement (DRR) was introduced as a sentencing option
under the Criminal Justice Act 2003. This requirement is one of a menu of 12
requirements to which offenders can be sentenced. The DRR involves drug treatment
and testing and is a rehabilitative as opposed to a punitive requirement. The period
of treatment can last between 6 months and 3 years. There are three levels of
intensity of contact, which include, but do not entirely consist of, medical treatment.
These levels correspond to the criteria of low, medium and high seriousness.
Before making the requirement, the court must be satisfied that:
• the offender is dependent on or has a propensity to use any controlled drug
• he or she would benefit from treatment
• the necessary arrangements can be made for the treatment
• the offender agrees to comply with the requirement.
Arrangements for treatment are available through the Probation Trusts, which operate
at a local level. Several private or charitable organisations also work in partnership 
with the Probation Trusts/the National Probation Service to deliver DRR programmes 
and testing.
There is provision for the court to review the progress of the offender during the order,
and to agree changes in the treatment.
The treatment can be residential or non-residential, which is decided by the court, 
and must be supervised by a suitably qualified person. The type of treatment and the
treatment provider must be written in the order.
In 2009-2010 there was an 11 per cent decrease in the number of DRR
commencements in England and Wales, while the completion rate increased from 
BMA Board of Science
Drugs of dependence: the role of medical professionals172
47 per cent to 56 per cent.11 The 11 per cent reduction was partly due to police
initiatives which diverted offenders from charge, and a change in focus so that targets
were more focused on completion and not commencement.11
Accessing treatment, however, can be problematic for drug users subject to a DRR. 
A review of the National Drug Rehabilitation Requirement found a variation in
treatment delivery across England and Wales.12 In some cases this was due to 
‘local service level agreements or communication protocols not being set up between
probation and treatment agencies, so that only a minimum number of agencies were
seen as “DRR friendly”‘.12
10.2.3 Drugs courts
Since 2004, six pilot Dedicated Drug Courts (DDCs) specialising in dealing with
offenders who are illicit drug users were introduced in magistrates’ courts in England
and Wales. Building on existing arrangements available through the drug treatment 
and testing order and DRR, a pilot model for England was launched in 2005 in Leeds
and London, while a further four pilots (in Barnsley, Bristol, Cardiff and Salford) 
opened in 2009.
The DDC pilots in England and Wales were aimed at reducing illicit drug use and
reoffending amongst drug-using offenders who commit low-level crime to fund their
addiction.8 The DDC model introduced a new framework in magistrates’ courts for
dealing with such offenders. Sessions were set aside in existing magistrates’ courts 
for dedicated panels of magistrates or particular district judges to sit for sentencing. 
A drug-using offender who was convicted of a low-level ‘acquisitive’ offence, for
example shoplifting, could be referred to the DDC for sentencing.
Appropriate sanctions and other rehabilitation services that could be included in
community sentences were available to all courts in England and Wales. The DRR
included conditions such as: increasing the offender’s likelihood of successful
rehabilitation through early, continuous and intense judicially supervised treatment;
mandatory periodic drug testing; and community supervision.
In January 2011, the Ministry of Justice published The Dedicated Drug Courts Pilot
Evaluation Process Study.13 The evaluation did not attempt to measure the actual
impact of the DDC on reducing reoffending through decreased drug use. Instead, it
focused on identifying the factors that may have had an impact on the effectiveness of
the DDC, such as the structure of the court and the styles of engagement used by staff.
The findings indicated that the DDC model was perceived to be a useful addition to the
range of initiatives aimed at reducing drug use and offending.13 Continuity of judiciary
when working with drug-using offenders was seen to be a key element of the model:
offenders reported that they felt accountable to the DDC through seeing the same
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judicial panel and through the formal monitoring of drug use, and that this continuity
helped to reduce drug use and offending.
10.2.4 Ethical issues
Referrals for treatment from police custody suites, as in the DIP, and the power of
courts to ‘sentence’ an offender to receive medical treatment rather than a custodial
sentence or other type of punishment raise concerns about informed consent to
treatment. It also leads to a blurring of the distinction between judicial and
therapeutic strategies, with the result that a drug user may view the doctor treating
them as part of the judicial system and be confused about whether they are being
punished, or treated as a patient. Effective communication is essential to ensure that
those undergoing treatment fully understand their rights as outlined in Section 10.1.
Issues that arise for health professionals include the following:
• high rates of illiteracy and learning disability in offenders, often coupled with a
lack of time and/or privacy for consultations, which raise serious questions about
their freedom to give informed consent
• the perception of offenders that the doctor is not impartial but is working for the
police or prison
• the ethics of providing treatment when the patient has effectively been coerced 
to consent.2
It should additionally be noted that:
• it is unlawful to give compulsory mental health treatment in a setting other 
than a hospital
• all patients are owed a duty of confidentiality but this is never an absolute duty
• when governors or managers need information in order to protect the safety of
other detainees or patients, doctors must make decisions about whether to
disclose health information in the public interest, on a case by case basis and,
where disclosure is necessary, only the minimum amount of information should be
shared.14 People detained in police custody have a right to request examination by
their own doctor, and individuals held on remand have a right to consult a doctor
of their choice; convicted prisoners have no general freedom of choice regarding
the doctor that they see.2
It is paramount to build up trust between the doctor and patient, and to reassure all
patients that the doctor is impartial and not working for the judicial system.2
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10.3 Reducing the supply of drugs entering prisons
Drugs are introduced into prisons through a variety of means,15 including being
smuggled into prisons with prison visitors, being projected or catapulted (quite
literally) ‘over the wall’,15 being hidden in items sent to prisoners in the post and in
parcels, by prisoners themselves when they return from day release, and through
corrupt staff.15 The precise quantification of the problem is very difficult. It has been
estimated that the value of illicit drugs within prison is about £100 million.15 The
incentive to supply drugs into prisons is exacerbated by the fact that the value of
drugs in prison is greatly inflated relative to outside prices.15 Controlling illicit
supplies is very difficult; when the authorities succeed in curbing one supply route,
this serves to increases supplies through other routes.
There is disagreement as to which of the routes of illicit supply is the most
prominent. A report in 2008 by Blakey,16 commissioned by the Director General of
the National Offender Management Service (NOMS), did not differentiate between
the frequency and extent of different routes of supply.a,15 Recent analysis suggests
that the major problem is staff corruption. A Policy Exchange report in 2010
contends that the majority of drug dealing within prison is highly organised and
involves the collusion of around 1,000 corrupt staff, which equates to around seven
prison officers per prison.b,15 It is reported that they are able to introduce drugs into
prisons due to lax security arrangements.15 Given the inflated value of drugs in
prison, it is suggested that prison officers are able to make substantial profits,
effectively without fear of detection;c a prison officer bringing a gram of heroin into
prison every week (about the size of two paracetamol tablets) could expect to more
than double their basic salary.15
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a This was the essential criticism made of the Blakey Report16 by the Policy Exchange Report;15 see the latter report pages 14,15,
21-5.
b The figure of 1,000 is based upon a ‘leaked’ internal Metroplitan Police investigation report conducted in 2006.
c Ministry of Justice data provided on 4 May 2011 (to a Channel 4 programme on illicit drug supplies in prison) indicates that
between 2008 and 2011, 92 prison staff had been dismissed, 78 had been convicted and 167 staff who worked for other
agencies within prisons had been excluded as a result of illicit drug supplies.
10.4 How effective are current treatment modalities?
It is important that medical professionals are able to make independent clinical and
ethical decisions about the most appropriate treatment for individuals in prison, 
in exactly the same way as for those living in the community outside prison. It is also
important to fulfil the requirement for informed consent to any treatment, including
OST and opioid detoxification. This includes the right of patients to refuse any
treatment offered.2
The Integrated Drug Treatment System (IDTS), jointly developed by the NOMS and
the DH, aims to increase the volume and quality of drug treatment available in
prisons, and the NOMS Drug Strategy 2008-2011 lists as one of its aims to ‘Increase
the access to and quality of drug interventions, matched to individual needs’.17
A national evaluation of the prison IDTS programme is now taking place, assessing
post-release outcomes, including whether there are increased numbers of people
remaining in treatment on release, and reduced offending.18
The effectiveness of MT (see Chapter 8) in prisons can be measured by key
outcomes, including its impact on continued heroin use by those in treatment,
continued levels of drug use in prisons, and the impact on drug-related harms,
including blood-borne virus transmission and overdose (described in more detail in
Sections 10.5 and 10.6). Treatment with methadone in prison has been shown to
significantly reduce heroin use among those treated.19 Lasting benefits of continued
engagement with treatment services after release into the community have also
been shown – those initiated in MT in prison in the USA have been shown to be
significantly less likely to have urine drug screen results that are positive for either
heroin or cocaine at 12 months after release.4,20 A 4-year follow-up study after the
initiation of MT in New South Wales, Australia showed that retention in MT was
associated with reduced mortality, reduced reincarceration rates and reduced
hepatitis C infection.19
10.5 Opioid detoxification in the prison setting
In 2005, the predominant method of clinically managing the majority of problem
drug users in prison was detoxification (see Chapter 8),21 while the following year,
the IDTS sought to increase the available treatment options, akin to those available
in community treatment settings.21 As in the community, medical professionals
managing opioid dependence in the prison setting must consider in each case the
most appropriate treatment pathway or the individual’s needs and circumstances.
Treatment options will include continued opioid prescribing or slow reduction or
detoxification if appropriate, with regular reviews, and clinical decisions based on a
careful and full assessment, including risk assessment, in collaboration with the full
team and the patient.
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For those with shorter sentences, or soon to be released back into the community,
an additional factor to consider is the reduced opioid tolerance following a break in
opioid use, and the well-documented increased risk of drug-related death soon after
release from prison.22,23
In addition to safety considerations (see Section 8.6), the medical professional will
need to consider effectiveness. There is a paucity of research evaluating the most
effective treatment for opiate detoxification in prisons. The Leeds Evaluation of
Efficacy of Detoxification Study (LEEDS) Prisons Project Study, an RCT comparing
methadone and buprenorphine for opiate detoxification, is currently under way,24
and will help to provide an evidence base for medical professionals in considering
detoxification care plans in the prison setting.
A randomised trial of the long-acting opioid antagonist oral naltrexone for treating
opioid-dependent offenders after release from prison (6 months of either 300mg per
week oral naltrexone plus standard psychosocial treatment as usual or standard
psychosocial treatment as usual without naltrexone) in the USA reported large drop-out
rates in both groups,25 emphasising the limitations of giving oral naltrexone without
supervision. A study in which prison volunteers were randomly allocated to naltrexone
implants or methadone before release showed reductions in both groups in the
frequency of use of heroin and benzodiazepines, as well as criminality, six months 
after prison release.26 With the emphasis on patient choice and safety, clinicians may
consider the option of naltrexone in their discussions around opioid detoxification with
prison patients.
10.6 Reducing blood-borne virus transmission
It is important that detainees have full access to information about transmissible
diseases, including TB, hepatitis and HIV; an ethical requirement is that they have the
same access as those outside prison to harm-reduction measures and treatment.2
As emphasised in Section 8.3.4, OST reduces the risk of transmission of blood-borne
viruses (HCV and HIV), particularly in conjunction with the availability of clean needles,
syringes and other injecting paraphernalia.27,28
Opioid substitution has been found to play an important role in reducing the
transmission of HIV in the prison setting.29 The high prevalence of problem drug use
by the prison population4,5 is accompanied by high rates of blood-borne viruses. In
one meta-analysis, the pooled odds ratio of being positive for HCV was 24 times
higher among inmates who were currently or formerly using drugs intravenously,
compared with inmates who were not doing so.30 Rotily et al found the HIV
prevalence among users of intravenous drugs was 4 per cent (versus 1% among
those not injecting drugs intravenously).31
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10.6.1 Needle exchange
A cross-sectional survey carried out in six European prisons (including in Scotland),
found that 27 per cent of respondents had ever injected drugs and 49 per cent of these
reported they had injected while in prison.31 Stark et al assessed the impact of a needle-
exchange programme in a prison in Berlin.32 They found baseline seroprevalences for
HIV, HBV and HCV of 18, 53 and 82 per cent, respectively, among the prisoners. 
The seroprevalence of HIV and HCV at baseline was significantly associated with drug
injection in prison prior to the introduction of a needle-exchange facility.32 The provision
of needle-exchange facilities was linked to a decrease in syringe sharing from 71 per
cent during a 4-month period of previous imprisonment to 11 per cent during the first
4 months of follow-up, and to virtually zero thereafter. No HIV and HBV seroconversions
occurred during the study period after the introduction of the needle-exchange facility,
although four HCV seroconversions occurred.32 (Although not the focus of this chapter,
this emphasises the importance of also involving other coordinated approaches in the
prevention of blood-borne virus transmission, such as the provision of condoms and
sterile tattooing equipment.)
For those who use drugs intravenously, the provision of needle- and syringe-exchange
facilities in the prison setting is an important harm-reduction measure, just as it is in the
community (see Chapter 9). The provision of such needle-exchange programmes in
prisons is part of the guidance from the WHO, the UNODC and the Joint United
Nations Programme on HIV/AIDs (UNAIDS).33 Proposals for such programmes in prisons
have also been met with concerns about staff safety.34 The 2011 DH document Tackling
blood-borne viruses in prisons: a framework for best practice in the UK comments,
‘nowhere in the UK currently offers needle exchange to prisoners’.35
In Scotland, plans to pilot an in-prison injecting equipment initiative in the Scottish
Prison Service as one of a range of harm-reduction measures to reduce the transmission
of HCV were raised in the Hepatitis C Action Plan for Scotland Phase II: May 2008-
March 2011.36 The Scottish Prison Service also carried out its own review of the
literature on prison-based injecting equipment provision (IEP) services in 2005. They
reported on 46 prisons in four European countries with IEP schemes in operation for
around 10 years, and found that these schemes resulted in lower transmission rates of
HIV and HCV, and no increase in drug use or injecting among prisoners. They also noted
that, since the introduction of the schemes, there had been no attacks on staff or other
prisoners with injecting equipment.37,38
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10.6.2 Hepatitis B vaccination
Screening and vaccination can reduce the likelihood of infection and transmission,
and therefore need to be considered along with harm-reduction strategies. 
The overall improvement in uptake of the HBV vaccine probably reflects improved
provision through drug services and the prison vaccination programmes.39-41
There has been a marked increase in the number of injecting drug users receiving
the hepatitis B vaccine, with over two-thirds now reporting vaccination.41 In 2009,
80,762 doses of hepatitis B vaccine were reported to have been delivered to
prisoners in England and Wales.42 Medical professionals play an educative role in
ensuring that staff and prisoners are aware of the importance of HBV vaccination in
the prison setting.
10.7 ‘Drug-free’ wings
According to its 2008-2011 strategy, the NOMS will aim ‘within existing resources,
subject to a detailed needs assessment, to offer to every prisoner who wants to
make the commitment to lead drug-free lives, access to accommodation designated
as drug-free’, also offering engagement in prison treatment, and interventions such
as the 12-step programme (see Section 9.5.2).17
10.8 Reducing drug-related deaths in custody and 
after release
Some authors warn against the risks of death from methadone prescribing in the
prison setting, in particular where the same dose is prescribed as that reportedly
used in the community, where it may not have been consumed under supervised
conditions, and some may have been diverted over a period of time, so the tolerance
of the patient may be far lower than assumed.43 There is evidence that ‘...in the past
patients have died as a consequence of uncontrolled vomiting during detoxification
in prison’,21 so careful assessment is essential.
The 2006 DH report on the clinical management of drug dependence in the adult
prison setting makes recommendations to reduce this risk,20 which include the
following:
• clinical drug testing to include morphine, methadone and buprenorphine
• use of an opioid withdrawal assessment scale (eg short opiate withdrawal scale,44
and intoxication monitoring)
• ensure the patient is fully alert, responding appropriately and that there are 
no signs of drowsiness/sedation; withhold medication in the event of any concern
• gradual dose induction, with divided doses
• a minimum of twice-daily monitoring of withdrawal and intoxication during
stabilisation
• staff training in the administration of naloxone.21
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The role of the medical professional includes careful assessment and careful prescribing,
taking into account the unknown tolerance of the patient whose medication may not
have been supervised in the community, and the possibility of polydrug use increasing
their risk of overdose, balanced against the importance of engagement of the patient
and minimising their seeking to engage with illicit drug use in prison.
The information in Section 8.6.1 on reducing drug-related deaths at times of increased
risk is particularly relevant for individuals who are newly released from prison.
Prevention of relapse is discussed in Section 9.5.
10.9 Seamless transfer to community services from 
prison release
A meta-analysis of drug-related deaths soon after release from prison confirmed that
there is an increased risk during the first 2-4 weeks after release from prison,26 as found
by other authors.19 Drug-related deaths among men were more likely to involve heroin,
and deaths among women were more likely to involve benzodiazepines, cocaine and
tricyclic antidepressants.22 The increased risk of drug-related death soon after release
from prison is well documented.22,45 A database linkage study covering 48,771 prisoners
found that, relative to the general population, male prisoners were 29 times more likely
to die during the week following release, while female prisoners were 69 times more
likely to die during this period, with the prime cause of death being overdose of heroin
or other opioids.22
Authors have highlighted the importance of ensuring that drug-dependent prisoners
are linked with community drug services on release from prison,46,47 and the DH
gives guidance in this, including the role of CARAT (counselling, assessment, referral,
advice and throughcare) workers in directly linking the patient with community
clinical teams.21 In cases where the patient-prisoner is being released late on a Friday
and it has not been possible to link them directly with a pharmacist (although most
pharmacists are also available for contact on Saturdays) or community drug service,
the medical professional may play a role in carrying out a risk assessment in terms of
the doses to be prescribed and taken home during the period before the patient will
be reviewed in the community.21
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10.10 Take-home naloxone
As described in Chapter 8, overdose in heroin users is common and is a particular risk
with involuntary abstinence, as may occur in the prison setting.48,49
Strategies to reduce mortality rates from opioid overdose are described in detail in
Chapter 8. A national programme of naloxone provision and training recently rolled
out in Scotland for those deemed to be at risk of opioid overdose (and their family,
friends, carers, and partners) includes prisoners who use opioid drugs on release from
prison.50 In England, a large randomised trial is currently under way,51 in which naloxone
is given on release to prisoners with a history of heroin use by injection. It is
hypothesised that this will reduce heroin overdose deaths in the first 12 weeks after
release by 28 per cent.
10.11 Promoting recovery after release from prison
While social integration is an important part of the purpose and function of prison, in
many cases,52 for those with drug dependence, the challenge of social reintegration, of
moving away from drug use and to ‘personal health and citizenship’53 continues after
prison release. Liaison with community teams is essential at this crucial stage. In a
primary care clinic setting, MT is effective in reducing convictions, cautions and
incarceration over an extended period.54 A study of 382 imprisoned male heroin users
who had participated in an RCT of prison-based MT in 1997-1998 followed up subjects
over a 4-year period, either in the general community or in prison, and found, among
other benefits, that the risk of reincarceration was lowest during MT episodes of 
8 months or longer.19 A key role that treatment of drug use and drug dependence can
play in promoting social reintegration is by reducing the likelihood of reincarceration.
Recovery is about much more than avoiding harms, and while there is still debate about
its definition,55 it is generally agreed to be about positive elements – positive
development, achieving potential, contributing to the social milieu, and accessing and
benefiting from the rights of that shared society. Recovery capital has been described as
the ‘breadth and depth of internal and external resources that can be drawn upon to
initiate and sustain recovery’ from substance use.56 Medical professionals are an
essential external resource, who may also help the patient identify some of their internal
resources and access other external resources to utilise these, in their recovery journey.
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10.12 Research, training and resource needs
10.12.1 Research needs
As discussed in this chapter, there are many gaps in evidence on the treatment of drug
dependence in the prison setting. Robust research evidence is particularly required in
the following areas:
• study of the impact of drug rehabilitation availability on drug-related harms in the
prison setting and after release, including drug-related deaths after release
• study of the impact of drug rehabilitation in prisons on decreased recidivism and
social reintegration
• continued work on improving systems for prompt and accurate communication with
community services pre and post incarceration, with a view to limiting overdose in
custody and after prison release
• study of the impact of increased treatment choices on the demand for and availability
of illicit drugs in prisons and/or in the rates of initiation of drug use in prisons and the
rates of relapse in prison of those in MT or post detoxification
• audit of the provision of HBV vaccination programmes and needle-exchange facilities
in high-risk environments, including prisons.
10.12.2 Training needs
Medical professionals have an important role in day-to-day communication with 
non-medical colleagues in the prison setting, to enhance their understanding of issues
in the management of problem drug users. They also have an important role in
educating patients in the prison setting about reducing risks associated with drug use.
In addition to the needs identified at the end of Chapter 8, training needs include:
• training on the beneficial impacts of harm reduction on increasing treatment choices,
including opioid maintenance treatment
• training for all staff in recognising opioid and other drug overdose in custody and in
the prison setting, and training in how to respond to this, including contacting
emergency medical services and administration of naloxone
• training for prisoners in overdose recognition and use of naloxone
• training in the importance of needle exchange in reducing blood-borne virus
transmission and the importance of HBV vaccination in this population.
10.12.3 Resource needs
The needs identified at the end of Chapter 8 are relevant here. Optimising the response
of hospitals to drug problems requires the presence of consultation-liaison services to
support staff in the management of withdrawal. This is particularly important for the
prison population and for those newly released from prison.
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Summary
• Many illicit drug users first present to medical practitioners via the criminal justice
system.
• Treatment of illicit drug users creates particular ethical challenges for medical
professionals, especially in relation to coercion and informed consent within the
criminal justice system. It is essential to recognise that these individuals have the same
rights to accept or refuse treatment as the rest of the population.
• There is a high prevalence of drug use among prisoners in the UK, and high rates of
first initiation of drug use.
• The Drug Interventions Programme (DIP), introduced by the Home Office in 2003,
aims to develop and integrate measures for directing adult offenders who are illicit
drug users into drug treatment and thereby reduce offender behaviour. Most DIP
referrals into treatment are achieved via drug testing in police custody suites. This
raises ethical issues about coercion to treatment.
• Methadone treatment in prisons has been shown to significantly reduce heroin use
among those treated; retention in treatment is associated with reduced mortality,
reincarceration and hepatitis C infection. It is hoped that a research study currently in
progress in the UK will provide evidence about the most effective treatment for
detoxification in prisons. Naltrexone may have a role in this treatment.
• Safety considerations are paramount in opioid detoxification treatment, especially in
those soon to be released.
• Opioid substitution therapy has been shown to have an important role in reducing
transmission of HIV in the prison setting.
• Needle-exchange programmes are important for harm reduction and are
recommended for all illicit drug users in priosons in guidance from the World Health
Organisation (WHO), the United Nations Office on Drugs and Crime (UNODC) and
the Joint United Nations Programme on HIV/AIDs (UNAIDS). Nowhere in the UK offers
such programmes in the prison setting.
• Vaccination for hepatitis B in the prison setting is important but not yet offered in
every prison in England and Wales.
• The National Offender Management Service (NOMS) aims to offer all prisoners who
want to commit to leading a drug-free life access to accommodation designated as
‘drug-free’.
• There is a high risk of drug-related deaths in prison and shortly after release. Medical
management must take this into account in planning treatment.
• It is important to ensure patients are linked with community drug services
immediately on release from prison.
• The use of naloxone may reduce mortality from drug overdose.
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Chapter 11 – The role of
healthcare professionals
11.1 Introduction
There are three levels at which doctors are involved in responding to illicit drugs.
All doctors in clinical practice will encounter patients whose health is affected by use 
of psychoactive drugs. The basic competence required of all practitioners is the ability 
to recognise when drug use is contributing to health risks. This is achieved by history
taking and examination, provision of appropriate advice, diagnosis of drug-related
harm, and prescribing safely in a way that minimises the contribution of prescribed
drugs to drug-related harm.
Some doctors, particularly GPs and psychiatrists, will have greater involvement,
requiring additional competence in treating drug dependence, in managing withdrawal
and relapse prevention and in maintenance prescribing. The specific competencies
required are discussed in more detail in a recent report from the Royal College of
Psychiatrists and Royal College of General Practitioners, Delivering quality care for drug
and alcohol users: the roles and competencies of doctors. A guide for commissioners,
providers and clinicians.1
Many doctors involved in public health, and in specialist management, will also have a
further role in advocating policies to minimise drug-related harm in the community.
Medical practitioners’ knowledge and experience of the biological, psychological and
social factors predisposing to illicit drug use, and of the direct and secondary health
harms of illicit drug use, have an important contribution to the development of
prevention and treatment programmes.1
This chapter reviews the current situation in the UK and the competencies required of
doctors to fulfil the responsibilities associated with these levels of involvement in
responding to illicit drug use.
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11.2 Current trends in the UK
As noted in Chapter 2, current use of illicit drugs has been declining in the UK 
since the 1990s, but this is not reflected in a long-term decline in problem drug 
use, drug-related deaths, recorded drug law offences or the number of people
in/expenditure on drug treatment. These trends should inform medical professionals’
response to illicit drug use in the UK.
The following list summarises the data related to drug use, offences and treatment
presented in various parts of this report.
• It has been estimated that in 2009-2010, 35.9 per cent of 16 to 59 year olds in
the UK had used drugs in their lifetime (ever), while 8.7 per cent had used drugs 
in the last year (recent use), and 5.0 per cent had used drugs in the last month
(current use) (see Section 2.1).
• Current drug use in adults aged 16 to 59 years in England and Wales was reported
to be 6.7 per cent in 1996, and fell to 5.2 per cent in 2011-2012 (see Section 2.2).
• This has largely been driven by a decrease in cannabis use. Over this time period,
opiate and ecstasy use has remained relatively stable, amphetamine and
hallucinogen use has declined slowly, and use of any cocaine has increased slightly
(see Section 2.2).
• A survey of nearly 1,500 new UK prisoners in 2005-2006 found lifetime use of
heroin, crack cocaine, cocaine powder, amphetamines or cannabis was reported
by 79 per cent of prisoners, with approximately one-third having used heroin or
crack cocaine during the year before custody (see Section 10.2).
• Rates of first initiation of use of drugs in prison are also high. In a 1997 survey,
over a quarter of the men who had used heroin reported first initiating use in
prison (see Section 10.2).
• The number of problem drug users aged 15 to 64 years in the UK has increased
from 357,160 (9.26 per 1,000 population) in 2006 to a peak of 404,884 (10.10
per 1,000 population) in 2009, an increase of 9.07 per cent. This has since
declined to 379,262 people (9.31 per 1,000 population), and represents
approximately 10 per cent of all UK drug users (see Section 2.2).
• There were 1,930 (3.1 per 100,000 population) drug-related deaths in the UK in
2010, an increase of 67.5 per cent from 1996, although there are year-on-year
fluctuations (see Section 3.3).
• The rate of drug-related deaths in 2010 was highest in the 35-39 years age group
and 79.4 per cent of the deaths were men and most continue to be related to use
of opioid drugs (see Section 3.3).
• The data from 2010 show a reduction in drug-related deaths for all age groups
except the oldest (60 plus years), suggesting there is an ageing cohort effect 
(see Section 3.3).
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• From 2005-2006 to 2010-2011, recorded drug law offences in the UK increased
by 19.7 per cent from 255,670 in 2005-2006 to 270,045 in 2010-2011. Of the
offences in 2009, 15.7 per cent were for trafficking and 83.8 per cent for
possession (see Section 3.4).
• In 1994, around 67,000 people were counted as being in treatment, rising by 
26.9 per cent to 85,000 in 1998-1999 and a further 129.9 per cent to 195,400 
by 2006-2007, giving an overall rise from 1994 to 2006-2007 of 191.6 per cent
(see Section 5.10).
• There is a positive correlation between the prevalence of problematic drug users
aged 15 to 64 years and deprivation. Hospital admission rates for drug-specific
conditions for both male and female individuals have shown a strong positive
association with deprivation (see Section 4.4).
• The most recent data available indicate that there are around 5,800 NHS hospital
admissions for drug-related mental health and behavioural disorders each year in
England, and over 11,500 admissions for drug poisoning (see Section 3.5).
• The budget for drug treatment interventions in the criminal justice system in
England and Wales was over £330 million in 2006-2007 and spending on drug
treatment in prisons increased from £7 million in 1997-1998 to £80 million in
2007-2008 (see Section 5.10).
• Expenditure on the UK’s drug strategy is around £1.2 billion per annum, of which
£300-400 million is on enforcement, with most of the rest spent on treatment. It is
estimated that at least as much again is spent each year dealing with drug-related
offences in the criminal justice system and prisons, while the wider social and
economic costs of drug-related crime are estimated at around £16 billion a year in
England and Wales (see Section 6.4).
• The economic and social costs of Class A drug use (cocaine, crack cocaine, ecstasy,
heroin, methadone, LSD and psilocybin (magic mushrooms)) in 2003-2004 in
England and Wales were estimated to be £15.4 billion, equating to £44,231 per
year per problematic drug user (see Section 3.5). The costs of drug-related deaths
were estimated to be £923 million.
11.3 Issues arising from these trends
In the general population in the UK, around 10 per cent of adults have ever used
drugs and a little over half this number are current users. Of these, only around 
10 per cent are problematic drug users (see Glossary). The level of use of opioid
drugs has remained relatively unchanged over the last 15 years and most
problematic drug use and drug-related deaths are associated with opiate use. Use of
opioid drugs is an important area to target.
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These population figures do not reflect the findings in socially deprived groups and
those who are in prison, where rates of problematic drug use and treatment are
many times higher. The problem of illicit drug use in the UK requires a multifaceted
approach that tackles social deprivation and inequality, alongside dealing with the
health consequences of drug use.
11.4 Basic medical competence
Doctors have a responsibility to treat all their patients. Many patients who use illicit
drugs come from the most marginalised sectors of society, and present with distinct
and complex medical and social issues. By the time they present for treatment, they
are likely to be socially marginalised or in prison. Their presenting complaints can be
either directly or indirectly related to their drug use, but often mean that each
patient requires a high level of care and attention. These patients are likely to be
difficult to treat, as a result of feeling they have little to lose. It is essential that they
are offered treatment in a non-judgemental way that includes aspects to support
their social reintegration. As set out by the GMC in Good Medical Practice:2
‘You must not refuse or delay treatment because you believe
that a patient’s actions have contributed to their condition. 
You must treat your patients with respect whatever their life
choices and beliefs. You must not unfairly discriminate against
them by allowing your personal views [including your views
about a patient’s lifestyle] to adversely affect your professional
relationship with them or the treatment you provide or
arrange.’
11.4.1 Maintain an awareness of the non-medical facets 
of drug use
Drug problems (and even more so, alcohol problems) are common, and although 
they often bring individuals into contact with the health system, they are frequently
overlooked or ignored (see Section 9.1).3-6 Failure to address underlying factors
contributing to ill health is suboptimal care. Maintaining an awareness of the non-
medical facets of drug use, taking a drug use history, and providing personalised
health advice regarding drug use, are the three basic responsibilities of medical
practitioners.
Patients are often defensive, and are not always open or truthful about drug use 
(see Section 8.2.1). History taking is more effective if undertaken in a neutral, 
non-judgemental manner, framing drug use as a medical rather than an ethical issue.
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11.4.2 Undertake opportunistic brief interventions
Brief interventions are intended to prevent or reduce drug use, through getting
patients to think differently about drug use and possible treatment. These
interventions aim to increase the motivation of drug users to change their behaviour.
The spectrum of advice ranges from stopping drug use to using drugs in ways that
are less risky (see Section 9.2). Interventions that attend to the immediate priorities
of people who inject drugs, such as advice on vein care for injecting drug users, have
the potential to engage individuals and set them on a path towards treatment and
social reintegration.
11.4.3 Prescribe safely
Doctors have the power to exert an immediate and powerful influence on drug use
through their prescribing practices. Prescription regimes are the control structures
that enable psychoactive substances to be consumed for approved medical purposes
while preventing their use for non-approved purposes.7 As indicated in Section 9.3,
the non-medical use of, and dependence on, prescribed drugs is a rapidly growing
public health concern. Prescribing safely in a way that minimises the contribution of
prescribed drugs to drug-related harm is thus crucial. It also raises many issues for
health professionals. Prescribing doctors accept absolute clinical and legal
responsibility for their prescribing decisions,8 and must exercise particular caution
when prescribing to patients with a history of, or predisposition to, illicit drug use
and dependence. Medications used for the relief of pain, including opioid drugs and
certain sedatives, have the potential to trigger a relapse in recovering addicts,
reactivating the original addiction or precipitating an addiction to a previously
unknown substance.9 Avoiding stimulating or exacerbating existing addictive
disorders requires a rigorous assessment of the patient. The GMC’s Good practice in
prescribing medicines states that doctors must:
‘Be in possession of, or take, an adequate history from the
patient,including: any previous adverse reactions to medicines;
current medical conditions; and concurrent or recent use of
medicines, including non-prescription medicines.’10
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This can be particularly challenging to those in primary care, who operate under
immense time constraints. It is important to refer to the British National Formulary as
appropriate, to inform prescribing behaviour. When prescribing for a patient, doctors
should also consider whether ongoing monitoring and supervision are required, such as:
‘...further consultations; blood tests or other investigations;
processes for adjusting the dosage of medicines, changing
medicines and issuing repeat prescriptions.’10
Supervision is particularly important when OST is prescribed. This tends to be provided
by the dispensing pharmacist. Good communication between the prescriber and the
pharmacist is essential: the DH recommends that prescribers liaise with the pharmacist
when first prescribing controlled drugs for a patient, to ensure that the pharmacist is:
• introduced to the new patient
• part of a suitable local scheme and can provide supervised consumption of the
prescribed medicine if requested by the prescriber
• able to confirm that the prescriber and prescription are genuine.11
Ongoing communication can also help to alert the prescriber to any concerns the
pharmacist may have about the patient’s health and wellbeing, as well as their
treatment compliance.11 Sharing information in this way should be conducted in line
with locally determined confidentiality agreements.
Other interventions aimed at minimising the contribution of prescribed drugs to
drug-related harm focus on preventing the diversion of psychoactive substances
from the medical system into the illicit marketplace. Control strategies adopted in
the UK include restricting the type and quantity of medicines that can be sold over
the counter, enforcing prescription guidelines (including requirements for detailed
record keeping), restricting the settings in which the drug in question can be
administered (eg hospitals, specialist clinics) and withdrawing a drug from the legal
market.7 There are also limitations placed on the number of doctors who have the
authority to prescribe particular drugs. Under the Misuse of Drugs (Supply to
Addicts) Regulations 1997, doctors must hold a general licence that is issued by their
relevant health department in order to prescribe, administer or supply diamorphine,
dipipanone or cocaine in the treatment of drug addiction.12
The control strategies outlined above do not eliminate non-medical use of
psychoactive drugs, since they can be sourced through other channels, including
theft, prescription forgery/alteration, and via the internet.13,14 In addition, doctors 
are increasingly advised to be vigilant for ‘doctor shoppers’ – individuals visiting
numerous physicians to obtain multiple prescriptions, often for the same drug.14
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11.4.4 Lobbying medical schools for improved training on
drugs of dependence in the medical curriculum
Those who use drugs will inevitably be seen by doctors. For this reason, it is vital
that, as a part of the undergraduate medical curriculum, medical students have the
core skills and knowledge to identify and understand the complexities of drug use.
Medical students receive very limited training in issues of drug use and dependence
at an undergraduate level. Surveys of medical schools’ curricula from the mid-1980s
onwards have all indicated that the education of medical students about drug use is
typically patchy and uncoordinated.15-19 Although medical schools currently include
some teaching and learning about drug use, this topic is often taught within
psychiatry or public health,19 with the result that drug use is often seen by students
as a specialised, or peripheral subject, rather than the common pervasive problem
that it is in reality.19 It is essential that medical schools and medical students are
encouraged to place a greater emphasis on the care of those who use drugs.
11.5 Managing patients with drug-related health problems
There is wide variation in the extent to which primary care physicians become
engaged in managing illicit drug users.20 As identified in Chapter 9, this may be
because of a sense of pessimism about being able to effectively treat drug-using
patients, avoidance of antagonising patients and, possibly, reluctance to work with
stigmatised patients.
A 2005 joint report from the Royal College of Psychiatrists and Royal College of
General Practitioners estimated there were around 130 consultants in addiction
psychiatry in the UK.21 In 2005, a random sample of GPs in England and Wales,
found that over half of those surveyed provided treatment to users of opioid drugs.20
The findings published suggest that during the time of the survey, between 41,000
and 62,000 users of opioid drugs were receiving GP treatment.20 The previous survey
of opioid treatment in general practice settings, which took place in the mid-1980s,
found only 19 per cent of GPs were treating patients who used opioid drugs.22,23
Over two-thirds (61%) of these patients were approaching their GP for help with
withdrawal, rehabilitation, or both, indicating a demand by users of opioid drugs for
help with initiating abstinence from drugs.22 The findings suggest that not all drug
users are receiving treatment in general practice settings, especially given recent
estimates of there being over 260,000 users of opioid drugs in the UK.24
Both GPs and addiction psychiatrists provide services such as drug-related
information and advice, screening, brief psychosocial interventions and harm-
reduction interventions.1,21,25 Community-based drug assessment, coordinated care
planned treatment and drug specialist liaison can be conducted or arranged by GPs,
but more complex patients are best managed by practitioners with specialist
BMA Board of Science
Drugs of dependence: the role of medical professionals 191
experience and knowledge.1,21,25 Inpatient specialised drug-treatment settings are
usually headed by consultant psychiatrists, although this is often with the support of
supervised junior medical staff.1,21,25
In 2007, NICE, in association with the National Treatment Association for Substance
Misuse and the four UK health departments, published Drug misuse and
dependence: UK guidelines on clinical management.11 These guidelines, commonly
known as ‘The orange guidelines’, provide guidance to all clinicians on the treatment
of drug use and dependence, at all levels of interaction with drug users.
While ‘The orange guidelines’ have no specific statutory status, the standards and
quality of care set out in the guidelines are taken into account in any formal
assessment of clinical performance in this area. There are also separate defined legal
obligations in relation to the prescribing of controlled drugs published in both 
‘The orange guidelines’11 and the British National Formulary.26,27 Clinicians should act
in accordance with these. They include ensuring that prescribers act within Home
Office licensing arrangements for the prescription of restricted medications such as
diamorphine for the management of illicit drug use.
Chapter 8 discusses in detail the logistics of managing opioid-dependent patients
using OST. Chapter 9 details how patients may present to either primary or
secondary care in states of acute withdrawal. In these instances, healthcare
professionals have a responsibility to manage the clinical emergency, stabilise the
individual, and slow the rate of change so that their physiology can adapt and the
distressing and uncomfortable symptoms of withdrawal are reduced.
Doctors are also responsible for addressing the individual healthcare needs of
patients who use drugs. As noted in Chapters 8-10, blood-borne viruses, such as
hepatitis B and C as well as HIV, are common among drug users, especially those
who use drugs intravenously. In addition to harm-reduction measures, an essential
part of managing this aspect of drug use should include offering immunisation
against hepatitis to patients who want it.
Harm reduction focuses on the safe use of drugs, and includes provision of clean
injecting equipment and education on how to use drugs safely. There have been
arguments over the ethics of harm reduction,28 and there is a perception among
some healthcare professionals that harm-reduction techniques may lead to an
increase in drug use by individuals who would otherwise be deterred. Those who
support harm reduction assert that, rather than encouraging drug use, it offers a
realistic way to help keep drug users safe, as well as respecting their choice and
individual freedoms.28 Chapters 5 and 6 also highlight some of the public health
benefits for society at large that arise from harm-reduction and prevention methods.
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The most serious potential harms associated with illicit drug use are overdose and
death. Chapter 8 details how this is particularly true for use of opioid drugs.
Maintaining patients in high-quality treatment is the most effective preventative
measure for these risks. Clinicians can also prevent the risk of drug overdose by
providing education to drug users on the risks of overdose, the dangers of
combining drugs, and how to respond effectively if overdose takes place. In the
event of an overdose at a healthcare facility, all services working with drug users
should have an emergency protocol in place that covers the management of drug
overdoses (see Section 8.6.1).11
Chapter 4 explores the high comorbidity between drug use and mental health
problems; this comorbidity is associated with complex factors that often impact
negatively on treatment.11 To ensure the needs of the individual patient are met,
medical professionals should undertake a comprehensive assessment, produce an
individual care plan and ensure appropriate care pathways are in place.
11.6 Promoting public health policies and practices to
reduce drug-related harm
Doctors can play an essential role in refocusing debate and influencing global drug
policy, so that it is based on public health principles, and results in better health
outcomes for all illicit drug users.
The drug debate, both nationally and internationally, has been influenced by
emotions and ideologies, when, in reality, a subject as important as the use of drugs
should be based on rationality and scientific evidence. What is needed is a solid and
pragmatic approach to drug use, which is informed by the best available evidence
and puts health at the centre of any decisions.
As highlighted in Chapter 6, there are strong views in this debate. There is a widely
held view within the drugs field that the prohibition of production and supply of
certain drugs has not only failed to deliver its intended goals, but has been
counterproductive.29 This is especially so with regard to health.30 Stringent user-level
enforcement does not necessarily reduce levels of drug use,31,32 as many other factors
are also involved (see Chapter 6). It may be that a new approach is required. Before
this can occur, rational debate is needed to inform an understanding of what is, and
what may not be, working with the current approach to drug use, and options for
change. As emphasised by the 2012 UKDPC report, A fresh approach to drugs,33 such
deliberations must be independent, evidence based, and centred on the health and
wellbeing of all. An essential component of this will be ensuring that all relevant
parties, including health professionals, and the organisations that represent them, are
consulted, so that a clear, unbiased and effective approach is achieved.
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These conclusions are echoed by the 2012 Home Affairs Select Committee report,
Drugs: breaking the cycle, which is based on a year-long inquiry into national and
international aspects of drug use.34 It focuses on the need to ‘break the cycle’ of drug
addiction and concludes that ‘…there is now, more than ever, a case for a
fundamental review of all UK drugs policy in an increasingly globalised world’. The
report recommends establishment of a Royal Commission – to be set up immediately
and report in 2015 – to ‘consider the best ways of reducing the harm caused by
drugs’ and ‘instigate a public debate on all of the alternatives to the current drug
policy’. It presents strong arguments for focusing on problem drug users, with
interventions that are ‘tailored to the individual’, and calls for the setting of
measurable targets that are based on evidence of what works. Recognising the lack
of reliable data in some areas, it further recommends allocation of ring-fenced
funding to drugs policy research.
11.7 Conclusion
Medical practitioners responding to drug dependence need a frame of reference 
that helps them to respond empathically and effectively to challenging patients.
Dependent drug users have the same rights to medical treatment as any other
individuals with a chronic disorder, and effective medical management is likely to
include harm reduction, maintenance treatment and support to eventually abstain
from drug use.
An effective drug policy must take account of the complex biological, psychological
and social factors involved in illicit drug use and aim to distinguish the harms
associated with drug use from the unintended adverse consequences of attempts to
minimise drug use.
An effective policy that significantly reduces the harms associated with illicit drug use
would have enormous benefit for individuals and generate large savings to society in
terms of the cost of medical treatment and the financial and social costs of
associated crime.
There is a widely held view within the drugs field that the current legal framework
has failed to deliver its intended goals of reducing illicit drug use. There are strong
views on both sides of this debate, but it should be informed by the best evidence.
While it must be accepted that international consensus dictates that supply and
possession of illicit drugs must remain a criminal offence, this framework deserves to
be re-examined in a way that takes account of all the evidence available.
Doctors are ideally placed to play a key role in refocusing debate and influencing
global drug policy, so that it is based on public health principles, and founded on
rigorous scientific evidence.
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Summary
• Medical training should provide graduates with basic knowledge about the social
and personal factors increasing the risks of illicit drug use, the adverse health
consequences of the illicit use of drugs, and the role of doctors in identifying 
drug-related harm and initiating intervention.
• Doctors should maintain an awareness of the non-medical facets of drug use, and
exercise caution in prescribing drugs with the potential for non-medical use.
• Doctors should take a drug use history when indicated, undertake brief
opportunistic interventions to reduce drug-related harm, and refer to specialist
services as appropriate.
• Guidance on clinical management of drug use and dependence is provided by
‘The orange guidelines’, available to all clinicians.
• Doctors can play an essential role in refocusing debate and influencing global drug
policy, so that it is based on public health principles, and results in better health
outcomes for all illicit drug users.
• Doctors with knowledge and experience of helping patients affected by illicit drug
use are ideally placed to engage in debate to promote a rational approach to drug
policy that is evidence based and health oriented.
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Appendix 2: The nature and
addictiveness of commonly
used illicit drugs
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Drug What is it? Desired effect Addictiveness
Amphetamine A synthetic drug that
can easily be
produced on a small
scale. It can be
snorted, swallowed
or smoked or, less
frequently, injected.
Stimulant used for a
‘buzz’ of alertness
and energy and the
sense that anything
is possible. Relieves
boredom and
tiredness. Effects last
for about 6 hours.
People can become
dependent on the
psychological effects
and although
amphetamines do
not create physical
withdrawal, stopping
can produce strong
feelings of
depression and
anxiety.
BZP A synthetic stimulant
derived from
piperazine, often
seen as an
alternative to ecstasy
or amphetamine,
although usually
considered to be less
potent than these
drugs. It is sold as a
tablet, capsule, or
off-white powder.
BZP pills are
marketed under a
huge variety of
names and the
tablets come in many
different shapes.
Provides a sense of
euphoria and
increased alertness,
enhanced senses and
a raised heart rate.
Depending on the
dose taken, the
effects of the drug
can last for up to 
6-8 hours.
Early studies have
suggested that
people can become
dependent, as is the
case with
amphetamine use.
Cannabis Naturally occurring
plant used as leaves
(‘grass’, ‘ganja’,
‘marijuana’, ‘weed’),
resin (‘hash’,
‘hashish’) or oil that
can be smoked or
eaten. There are
many different
varieties of varying
strengths. Around
100 varieties have
high levels of the
psychoactive
component
tetrahydrocannabinol
(THC). These are
often given the
generic name
‘skunk’.
A mild hallucinogen
that also has some
sedative and
disinhibiting
properties. It induces
relaxation and
heightens the senses.
Positive uses to
relieve symptoms in
chronic illnesses like
multiple sclerosis and
glaucoma are being
actively researched.
There is some
evidence of physical
dependence
associated with
cannabis use, which
can lead to
withdrawal
symptoms. It may be
psychologically
addictive if people
depend on it as part
of a coping strategy
or as a way to relax.
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Drug What is it? Desired effect Addictiveness
Cocaine Derived from natural
coca leaves. Usually
snorted as a powder
but can be injected
or smoked.
A powerful stimulant
to the central
nervous system (CNS)
and a local
anaesthetic. It gives a
powerful physical
and psychological
rush of exhilaration
and excitement,
alertness, confidence
and strength within 3
minutes of ingestion
and the effects last 
15-40 minutes.
High. Produces
psychological
dependence, owing
to changes in the
brain. Does not
produce physical
dependence to the
same degree as
heroin, but its
physical effects are
powerful and
withdrawal creates
very unpleasant
symptoms.
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Drug What is it? Desired effect Addictiveness
Crack cocaine Smoked version of
cocaine, derived by
‘freebasing’: heating
cocaine powder with
water and a reagent
such as baking soda.
It is called crack after
the crackling sound it
makes when smoked
using a pipe, glass
tube, plastic bottle 
or foil.
Stimulant. Has the
same effect as
cocaine, but far more
intense: crack makes
users feel alive,
exhilarated,
confident and wide
awake. It kills all
feelings of pain,
tiredness and hunger.
Potentially very high.
The very steep high
and ‘come-down’
can produce strong
and immediate
cravings, which can
rapidly develop into a
‘binge’ pattern of
drug use.
Ecstasy Synthetic drug,
derived from the
chemical 3,4-
methylenedioxymeth
amphetamine
(MDMA). Usually
taken in tablet form.
Stimulant. Gives a
rush of alertness and
energy and a feeling
of being in tune with
one’s surroundings
and other people.
The effects can last
3-6 hours.
Not considered to be
physically addictive,
but it is possible to
build up a tolerance
and require larger
doses to achieve the
same effect. It may
be psychologically
addictive.
GHB/GBL Synthetic chemicals.
Once GBL enters the
body, it is rapidly
converted to GHB.
Depressant and
anaesthetic. Lowers
inhibitions and
increases libido. Used
as a club drug.
Associated with date
rape.
May produce
physical and
psychological
dependence.
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Drug What is it? Desired effect Addictiveness
Heroin Painkiller derived
from the morphine
from the opium
poppy. It is injected,
smoked or snorted.
When pure, it is a
white powder, but it
is usually brownish-
white by the time it
is sold on the street.
Depressant. Acts to
depress the nervous
system and slow
down body
functioning. Users
experience a rush, a
warm sensation and
sense of being cut
off from physical and
psychological pain.
Very high. No instant
dependency, but
physical dependence
will develop if it is
used for a number of
days consecutively,
even at relatively 
low levels.
Ketamine Synthetic chemical,
ketamine
hydrochloride, found
as liquid or tablets.
Anaesthetic. Can
produce euphoria at
lower doses,
hallucinations and
out-of-body
experiences at higher
doses.
May produce
psychological
dependence.
Tolerance develops
quickly.
LSD Synthetic chemical
known as LSD or
acid. Usually sold as
tiny squares of paper,
often with pictures
on them, but also
found as a liquid or
as tiny pellets.
Hallucinogen, mind
and mood altering
effects, which may
last up to 8-12
hours, include
heightened and
altered perception.
Not addictive. Very
dose sensitive.
Psilocybin 
(magic mushrooms)
Mushrooms growing
in the wild. There are
two main types:
Psilocybe/liberty cap
and Amanita
muscaria/fly agaric.
Can be eaten raw,
cooked in food or
made into tea.
Hallucinogens,
producing much the
same effects as LSD,
only milder.
Not addictive, but
tolerance may
develop, resulting in
increasing use during
the short growing
season.
Methamphetamine Synthetic drug. Can
be swallowed as pills,
snorted as powder or
smoked as crystals.
Stimulant. Produces
euphoric effects
similar to those of
cocaine, but longer
lasting.
Highly addictive.
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Drug What is it? Desired effect Addictiveness
Spice 
(synthetic
cannabinoids)
A collection of herbs
or plant material that
has been sprayed
with synthetic
cannabinoid receptor
agonists, and that
mimic the
psychoactive effects
of THC.
When smoked, they
produce cannabis-
like mild
hallucinogenic
effects, sedation and
relaxation.
Not known to induce
physical dependence.
As with cannabis,
they may be
psychologically
addictive if people
depend on them as
part of a coping
strategy or as a way
to relax.
Source: www.drugscope.org.uk and Royal Society for the encouragement of Arts, Manufactures and
Commerce (2007) Drugs – facing facts. London: Royal Society for the Encouragement of Arts, Manufactures
and Commerce.
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Appendix 3: Health-related
harms of emerging and
established licit and illicit
drugs commonly used in 
the UK
Source: Jones L, Bates G, Bellis M et al (2011) A summary of the health harms of drugs. London: 
Department of Health.
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Physical Psychological/psychiatric
Mortality Morbidity
Amphetamines* 
Acute adverse effects associated with the use of amphetamines
Excitation syndrome
• Abnormal heart rhythms
(arrhythmias) associated
with collapse/cardiac arrest
leading to sudden death
Vascular accidents
• Increase in blood pressure
(hypertension)
• Stroke
• Heart attack (myocardial
infarction)
• Cardiovascular shock
Acute intoxication
• Agitation/aggression
• Pupil dilation
• Headache
• Tremors and writhing
movements of the body
and limbs (dyskinesia)
• Nausea, abdominal cramps
• Dry mouth
• Sweating
• Anorectic effects,
decreased appetite
• Increase in body
temperature (hyperthermia)
• Increased breathing rate,
blood pressure and heart
rate (possible arrhythmia)
• Dizziness, tremor, irritability
and confusion
• Hallucinations
• Convulsions
Methamphetamine
Acute intoxication
• More pronounced CNS
stimulant effects and longer
duration of effect than
amphetamine sulphate
Lifestyle factors
• Use strongly associated
with risky sexual practices
Organic/neurological
• Toxic delirium with amnesia
• As stimulant effects
dissipate, users may
experience drowsiness,
reduced ability to
concentrate and/or
judgement and learning
impairment
Personality/mood
• Low mood (dysphoria)
• Anxiety, depression
• Irritability, aggression
Acute paranoid psychosis
• Psychotic reaction similar to
acute paranoid
schizophrenia (vivid visual,
auditory, or tactile
hallucinations, paranoid
ideation possibly resulting
in aggressive behaviour)
• May develop after single or
repeated ingestion of
amphetamines
• People with underlying
mental problems are at
greatest risk
* Including amphetamine sulphate and methamphetamine.
Chronic adverse effects associated with the use of amphetamines
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Excitation
syndrome
• Abnormal heart
rhythms
(arrhythmias)
associated with
collapse/cardiac
arrest leading to
sudden death
Cardiovascular
complications
• Inflammation of
the blood vessels
(vasculitis)
• Aortic dissection
• Cardiovascular
shock
Other
complications
• Depression leading
to suicide
Cardiovascular
complications
• Cumulative risk of
cardiac and
coronary artery
disease
• Abnormally high
blood pressure in
the arteries of the
lungs (pulmonary
hypertension)
• Inflammation of
the blood vessels
(vasculitis)
• Bleeding into and
along the wall of
the aorta (aortic
dissection)
Lifestyle factors
• Negative health
effects from lack of
food and sleep,
such as lower
resistance to
disease
Organic/
neurological
• Cognitive deficits
associated with
damage to the
nervous system and
brain (eg
impairment of
memory, learning
and monitoring of
complex goal-
directed behaviour
[executive
function])
• Behaviour
stereotypes –
mechanical
hyperactivities,
repetitive actions,
stereotype motor
phenomena (eg
teeth grinding)
Dependence
• High abuse
potential due to
mood-elevating
properties
• Good evidence for
an amphetamine
dependence
syndrome
• Typically occurs
after a period of
sustained regular
use
Withdrawal
• Rarely life
threatening
• Symptoms may
include depression
(increasing risk of
suicide),
seclusiveness,
craving,
fatigue/exhaustion,
weakness, lack of
energy and sleep
disturbance
• Psychotic
symptoms may also
be a feature of the
methamphetamine
withdrawal
syndrome
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Complications in
pregnancy
• Use in pregnancy
has been
associated with low
birth weight,
prematurity and
increased fetal
morbidity
• Confounded by the
impact of other
situational, health
and lifestyle
factors, and
polysubstance use
Chronic paranoid
psychosis
• Psychotic reaction
similar to paranoid
schizophrenia –
hallucinations,
paranoid ideation,
possibly resulting 
in aggressive
behaviour,
potentially reversible
• Incidence and
severity of
methamphetamine
psychosis is related
to the frequency of
use and injection or
smoking as the
route of
administration
• Symptoms usually
resolve with
abstinence, but
case reports
suggest some
methamphetamine
users may
experience
prolonged or
recurrent psychosis,
even after 
stopping use
Tolerance
• Users may become
tolerant to the
euphorigenic,
anorectic,
hyperthermic and
cardiovascular
effects
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Personality/mood
• Irritability
• Suspiciousness
• Dysphoria
• Anxiety
• Paranoid psychosis
• Depression
• Restlessness
• Delirium
• Depersonalisation
• Feelings of
persecution
• Lethargy
Methamphetamine
Personality/mood
• User reports 
of physical
aggression
Cannabis
Acute adverse effects associated with the use of cannabis
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Physical Psychological/psychiatric
Morbidity Mortality 
• No cases of fatal overdose
have been reported
• No confirmed cases of
human deaths
Acute intoxication
• Irritant effects of smoke on
the respiratory system
(coughing, sore throat and
bronchospasm among
people with asthma)
• Facial flushing
• Abdominal pain, nausea,
vomiting
• Can cause an increase in
heart rate (tachycardia) and
in some cases increased
blood pressure
(hypertension)
• Difficulty in motor
coordination and
performance
Synthetic cannabinoids
• Not documented, limited
evidence base
Organic/neurological
• Perceptual distortion
(hallucinations)
• Amnesia/forgetfulness
• Confusion of thought
processes, impaired
judgement
Personality/mood
The effects of cannabis 
upon mental state vary
considerably between
individuals; they are
determined by dose, 
route of administration,
expectations, concomitant use
of other drugs, emotional
state and psychiatric illness:
• temporary psychological
distress (especially naive
users)
• low mood (dysphoria)
• anxiety
• confusion
• drowsiness
• depression
• panic attacks
• agitation
• symptoms indicative of a
persistent and pervasive
elevated (euphoric) or
irritable mood (hypomanic
symptoms)
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Physical Psychological/psychiatric
Morbidity Mortality 
• short-lived and reversible
psychotic reaction
Synthetic cannabinoids
Organic/neurological
• Suggestion that overdose
could include significant
alterations in mental state
with paranoia and 
perceptual distortions
Chronic adverse effects associated with the use of cannabis
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Cancers
• No conclusive
evidence that
cannabis causes
cancer
• Cannabis use may
be an important
risk factor for the
development of
respiratory cancers
but the relationship
is uncleara
Chronic respiratory
diseasea
• Chronic bronchitis
• Lung damage
• There are a number
of reports in the
literature of an
association
between cannabis
use and bullous
lung disease in
relatively young
users
Cancers
• No conclusive
evidence that
cannabis causes
cancer
Immune function
• Evidence for the
effects of cannabis
on human immune
function is limited
Complications in
pregnancy
• Like tobacco,
cannabis use in
pregnancy may be
harmful to fetal
development;
studies show a
consistent
association
between cannabis
use in pregnancy
and reduced birth
weight – though
less so than as a
result of tobacco
smoking during
pregnancy
Organic/
neurological
• No evidence of
structural change in
the brains of heavy
long-term cannabis
users
• No severe or grossly
debilitating
impairment in
cognitive function
(subtle impairment
in higher cognitive
functions of
memory, learning
processes,
attention and
organisation and
the integration of
complex
information – may
or may not be
reversible after
abstinence)
Dependence
• Good evidence 
for a cannabis
dependence
syndrome
• Frequent, heavy
users are at the
greatest risk of
dependence
Withdrawal
• Irritability
• Anxious mood
• Physical changes
(tremor, perspiration
and nausea)
• Sleep disturbance
Tolerance
• Tolerance to
psychoactive and
physical effects is
unlikely to occur
unless there is
sustained heavy
exposure
a Studies of the harms associated with cannabis use are limited by confounding factors, as many users smoke
tobacco as well as cannabis, or use tobacco as a vehicle for smoking cannabis resin. Although tobacco smoke
and cannabis smoke are known to contain a similar range of mutagens and carcinogens, actual exposure to
these compounds may differ between tobacco and cannabis users in terms of the frequency and duration of
use, and because of factors such as the depth of inhalation.
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
• There are some
reports that children
born to women
who have used
cannabis in
pregnancy may face
mild developmental
problems; however,
the evidence is
mixed and
confounded by the
other situational,
health and lifestyle
factors and
polysubstance use in
this population, eg
cannabis users are
more likely to use
tobacco, alcohol
and other illicit
drugs during
pregnancy
Reproductive
disorders
• Use may inhibit
reproductive
functions and
disrupt ovulation,
sperm production
and sperm function
Other complications
• Persistent sore
throat
Personality/mood
• Evidence that early
initiation and
regular, heavy
cannabis use is
associated with a
small but
significantly
increased risk of
psychotic
symptoms and
disorders in 
later life
• Complex
association
between cannabis
use and
schizophrenia –
some evidence that
use may
exacerbate
psychotic
symptoms and is
linked with relapse
but it is unknown
whether this is a
universal risk or
due to differences
in individual
vulnerability
• Insomnia,
depression,
aggression, anxiety
Synthetic
cannabinoids
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
• Inconsistent and
mixed evidence for
whether heavy,
chronic cannabis
use is associated
with a persistent
‘amotivational
syndrome’
characterised by
social withdrawal
and apathy
Withdrawal
• Some evidence of 
a withdrawal
syndrome among
heavy users
Tolerance
• Suggestion that
users may develop
tolerance quickly
Cocaine*
Acute adverse effects associated with the use of cocaine 
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Physical Psychological/psychiatric
Mortality Morbidity
Acute complications
• Toxic reactions 
(eg cardiovascular
complications) are not
predictable from the route
of administration, quantity
taken, an individual’s
pattern of drug use, or
blood concentrations of
cocaine (or its metabolites)
• Injection of cocaine
powder or crack cocaine is
associated with a greater
risk of death than
infrequent, intranasal use
of cocaine powder alone;
this appears to be linked to
factors associated with
injecting (such as more
frequent use and higher
levels of cocaine
dependence) rather than
the route of administration
per se
Vascular complications
• Abnormal heart rhythms
(arrhythmias)
• Heart attack
• Inflammation and injury to
the intestines (mesenteric
ischaemia)
• Stroke
Cardiovascular
complications
• Increase in blood pressure
• Accelerated heart rate
• Abnormal heart rhythms
(supraventricular/ventricular
tachycardia, torsade de
pointes)
• Increased risk of heart
attack, particularly in the
first hour after use
Respiratory complications
• Chest pain
• Shortness of breath
• Rapid breathing
Neurological
complications
• Stroke
• Convulsions
Other complications
• Hyperthermia
• Muscle spasms, tremor
• Abdominal pain, nausea,
vomiting
• Insufficient blood flow
(ischaemia)
• Bleeding (haemorrhage)
• Liver damage
Personality/mood
• Sleep disturbance
• Anxiety
• Paranoia
• Grandiosity
• Transient psychotic reactions
• Hallucinations (visual,
auditory and tactile) after
large doses
• Aggression and possible
violence (especially
associated with crack
cocaine use)
* Cocaine hydrochloride (eg cocaine powder) and cocaine base (eg crack cocaine and freebase cocaine).
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Physical Psychological/psychiatric
Mortality Morbidity
Genitourinary
• Increased sexual appetite 
and desire
Allergic reaction from
intravenous use of
cocaine
• Based on anecdotal
citations – possibly caused
by additives in street
cocaine
Excited delirium
syndrome
• Characterised by
hyperthermia, delirium and
agitation
• Associated with
cardiac/respiratory arrest
and subsequent death
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Chronic adverse effects associated with the use of cocaine
Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Cardiovascular
complications
• Increased risk of
cardiovascular
disease through
toxic effects on the
cardiovascular
system (including
premature
atherosclerosis,
vasospasm and
thrombus
formation)
• Heart attack
• Heart failure
• Abnormal heart
rhythms
(arrhythmias)
• Aortic dissection
• Inflammation and
injury of the heart
muscle
(endocarditis,
cardiomyopathy)
• Sudden death
Vascular
complications
• Increased risk of
cardiovascular
disease through
toxic effects on
the cardiovascular
system
• Abnormally high
blood pressure in
the arteries of the
lungs (pulmonary
hypertension)
• Inflammation and
injury of blood
vessels (vasculitis)
Neurological
complications
• Stroke
• Inflammation and
injury of the blood
vessels of the brain
(cerebral vasculitis)
Renal
complications
• Kidney failure 
– commonly
associated with
rhabdomyolysis
Personality/mood
• Anxiety, depression
• Obsessional rituals/
preoccupation,
repetitive
behaviours
• Sleep disturbance
(decrease in
quantity and
quality of sleep)
• Irritability,
restlessness
• Auditory
hallucinations
• Paranoid delusions
and psychosis
• Hyperexcitability
• Exhaustion
• Aggression and
possible violence
(especially
associated with
crack cocaine use)
Dependence
• Good evidence for a
cocaine dependence
syndrome
• A minority of users
may exhibit cocaine
dependence soon
after onset of
cocaine use (in the
first 1-2 years of use)
– risk is greater
among those who
smoke crack cocaine
and those who
begin use at an
earlier age
Withdrawal
Symptoms may be
mild to moderate but
the type and severity
vary from person to
person:
• craving
• exhaustion/lack of
energy, fatigue
• over-eating
• depression
• low (dysphoric)
mood
• unpleasant dreams
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Lifestyle factors
• Anorectic effect –
may contribute to
malnutrition and
weight loss
• Chronic use
diminishes sexual
appetite and ability
– reversible on
stopping use
Localised effects
• Dental erosions
• Perforation of the
nasal septum
• Chronic rhinitis
• Loss of sense of
smell
• Nosebleeds
Complications in
pregnancy
• Premature rupture
of the membranes
and placental
abruption are
associated with
use during
pregnancy
Toxic syndrome
• Psychotic reaction
similar to acute
paranoid
schizophrenia and
psychoses with
vivid auditory and
tactile
hallucinations,
picking and
excoriation of skin,
delusions of
infection from
parasites, paranoid
ideation
Neurological
• Studies have shown
that chronic
cocaine use may
contribute to
cognitive
impairments in the
group of processes
involved in the
learning, control
and monitoring of
complex goal-
directed behaviour
(executive function)
• May include deficits
in memory function
and inhibitory
control
• insomnia or
hypersomnia,
psychomotor
retardation
• agitation, irritability
• anxiety, restlessness
• aggression
Substance specific
Withdrawal
• Craving – possibly
of a greater
magnitude for
crack cocaine as
compared to that
for cocaine powder
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
• Effects of cocaine
exposure may
persist into
childhood;
suggestion that
this may impact on
behaviour
problems,
attention,
language and
cognition
• Situational, health
and lifestyle
factors and
polysubstance use
in this population
may also affect
pregnancy
outcomes
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Physical Psychological/psychiatric
Morbidity Mortality 
Dissociative anaesthetics*
Acute adverse effects associated with the use of dissociative
anaesthetics
Acute complications
• Death is more often a
result of accidents due to
loss of coordination/
control, disassociation and
analgesia (eg jumping from
heights, road traffic
accidents, drowning)
• Risk of respiratory
depression
Ketamine
Acute complications
• The evidence base is
limited, but there is a low
risk of mortality associated
with the medicinal use of
ketamine
• Rare reports of overdose
deaths from heart attack or
respiratory problems
• The majority of fatalities
have been attributed to
polysubstance use (multiple
drug toxicity)
Acute intoxication
• Increased heart rate and
respiration
• Loss of consciousness,
coma
•Muscle jerking, repetitive
movements, outbursts
(automatic behaviour)
• Gastric/stomach pain
• Many effects are polarised
among users (ie reports of
opposing responses in
different individuals)
Ketamine
Injury
• Increased risk of injury
from jumping from
heights, road traffic
accidents and drowning;
associated with loss of
coordination/temporary
paralysis and/or 
dissociative effects 
(eg depersonalisation,
derealisation and reduced
perception of pain)
Organic/neurological
• Hallucinations, distorted
sensory perception
• Impaired attention,
memory and learning
• Altered body perception
• Impairments of cognitive
function and verbal fluency
Personality/mood
• Confusion
• Depersonalisation
• Derealisation
• Panic attacks, agitation,
paranoia
• Delirium
• Depression
• Night terrors
• Behavioural effects
resembling certain
symptoms of schizophrenia
• Extreme loss of motor 
skills (catatonia)
* Ketamine and phencyclidine (PCP).
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Physical Psychological/psychiatric
Morbidity Mortality 
PCP
Acute complications
• Substantially more toxic
than ketamine
• Death as a result of
hyperthermia, convulsions
PCP
Acute intoxication
• Increase in body
temperature (hyperthermia)
• Stroke
• Respiratory arrest
• Nausea, vomiting
• Loss of coordination
(ataxia)
• Hypersalivation
PCP
Organic/neurological
• Toxic psychosis (catatonia
or paranoia)
Chronic adverse effects associated with the use of 
dissociative anaesthetics
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
• Very low risk of
mortality
Ketamine
Chronic
complications
• Ketamine-induced
ulcerative cystitis
(marked thickening
of the bladder wall
and severe
inflammation) has
been described in
clinical case
reports; only
following heavy
use
• Vague abdominal
pains (gastritis)
PCP
Chronic
complications
• No human
evidence to
suggest long-term
physical damage
• Evidence from
animal studies of
congenital
malformations and
reproductive
disorders
Organic/
neurological
•Memory
impairment
• Prolonged
hallucinations,
flashbacks,
persistent
perceptual changes
Personality/mood
• Night terrors
• Evidence of
triggering
depression, post-
traumatic stress
disorder, or mania
in susceptible
individuals
•May aggravate
psychotic
symptomatology
Ketamine
Dependence
• There have been
few published
reports of
ketamine
dependence;
however, cases
have been noted
among regular,
heavy users
Withdrawal
• No evidence to
suggest
withdrawal
symptoms or
syndrome
Tolerance
• Evidence to
support the rapid
development of
tolerance over
regular repeated
dosing
PCP
Dependence
• Evidence to
suggest a
dependence
syndrome for PCP
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Ketamine
Organic/
neurological
• Evidence from
animal studies
suggests that
ketamine may
accelerate nerve 
cell death in the
brain – no evidence
that such an effect
occurs in humans
• Some evidence 
of cognitive
impairments among
regular, heavy users
PCP
Personality/mood
• Anorexia
• Insomnia
• Auditory
hallucinations
• Disorientation
• Paranoid delusions
Withdrawal
• Some evidence to
suggest withdrawal
syndrome
• Craving
• Increased appetite
• Hypersomnia
• Depression
Gamma-hydroxybutyrate and gamma-butyrolactone*
Acute adverse effects associated with the use of GHB, 
GBL or 1,4-BD
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Physical Psychological/psychiatric
Mortality Morbidity
Acute complications
• Loss of consciousness –
difficult to get dose right
and solutions of GHB often
vary in concentration
• Deaths solely caused by
GHB appear to be rare –
fatalities appear to be
mostly in combination with
alcohol or other CNS
depressants
Acute intoxication
• Loss of consciousness
• Coma
• Respiratory and cardiac
depression, bradycardia
• Hypothermia
• Nausea, vomiting
• Seizures
• Confusion
• Involuntary muscle
twitching or spasm
(myoclonus, dystonia)
• Breathing difficulties
• Agitation
• Limited evidence for the
psychological/psychiatric
effects of GHB, GBL and
1,4-BD
Personality/mood
• Agitation
• Combativeness
*Gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD).
Chronic adverse effects associated with the use of GHB, 
GBL or 1,4-BD
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Withdrawal
• Severe cases of
withdrawal,
including fatalities
have been reported
• Not documented • Not documented Dependence
• Evidence of a
dependence
syndrome associated
with heavy, frequent
use
• No dependence
syndrome has been
observed at low doses
of GHB
Withdrawal
• Examples in the
literature of physical
dependence
evidenced by a
withdrawal syndrome
• Anxiety
• Insomnia
• Increased heart rate
(tachycardia)
• Hallucinations,
delirium and psychosis
• Sweating
• Aches
• Abdominal pain
• Impotence
• Severe depression
• Reports of severe
withdrawal symp-
toms (eg rapid onset
of delirium) associated
with unplanned
detoxification
Khat and Salvia divinorum
Acute adverse effects associated with the use of khat and
Salvia divinorum
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Physical Psychological/psychiatric
Morbidity Mortality 
• Not documented, limited
evidence base
Khat
Acute complications
• Dry mouth
• Hyperthermia
• Sweating
• Aching
Cardiovascular
complications
• Transient facial and
conjunctival congestion
• Increased heart rate
(tachycardia)
• Raised blood pressure
• Heart palpitations 
(extra-systoles)
• Myocardial insufficiency
and cerebral haemorrhage
through stimulation of
adrenergic pathways
Gastrointestinal
complications
• Constipation
Genitourinary
complications
• Increased libido
Khat
Personality/mood
• Insomnia
• Transient confusional states
Salvia divinorum
Organic/neurological
• Hallucinations
• Giddiness/dizziness
• Confusion/disorientation
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Physical Psychological/psychiatric
Morbidity Mortality 
Salvia divinorum
Acute complications
• Some users report
experiencing physical and
mental tiredness
• Flushed sensation
• Tachycardia
Chronic adverse effects associated with the use of khat and
Salvia divinorum
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
• Not documented,
limited evidence
base
Khat
Personality/mood
• Anxiety
• ‘Mood swings’
(lability of mood)
• Nightmares
• Irritability,
aggressive
behaviour
• Psychotic
phenomena
• Khat psychosis
cases have been
reported in the
literature;
individuals had
recorded family
histories of
psychotic disorders
Organic/
neurological
• Cognitive
dysfunction
including disturbed
perceptual-visual
memory function
Salvia divinorum
• Not documented
Khat
Dependence
• Limited evidence
for a khat
dependence
syndrome
• Elements of ICD-10
stimulant
dependence have
been described
among users
including:
compulsive
consumption;
tolerance;
borderline
withdrawal
syndrome of
tiredness, fine
tremors and
nightmares; craving
and the urge to
seek out khat are
well known
Salvia divinorum
Dependence
• Limited evidence
base but one survey
found little
evidence of
dependence
among users
Khat
Cardiovascular
complications
• Transient facial and
conjunctival
congestion
• Increased heart rate
and raised blood
pressure
• Heart palpitations
(extra-systoles)
• Myocardial
insufficiency and
cerebral
haemorrhage
through stimulation
of adrenergic
pathways
Gastrointestinal
complications
• Brown staining of
the teeth,
periodontal disease
• Inflammation of the
mouth and
digestive system
• Anorectic effect
and delayed
intestinal
absorption; may
contribute to
malnutrition
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/psychiatric
Dependence/
withdrawal/
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Mortality Morbidity
• Constipation – may
lead to laxative
abuse
• Liver cirrhosis
Respiratory
complications
• Increased
prevalence of
respiratory diseases
including
tuberculosis may be
related to
secondary
malnutrition and
heavy tobacco
smoking
Reproductive
disorders
• Limited evidence
suggests that khat
chewing during
pregnancy may
have an impact on
fetal growth and
development; low
mean birth weights
have been reported
in some studies
• No published
evidence that khat
causes teratogenic
effects in humans
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Dependence/
withdrawal/
tolerance
Mortality Morbidity
• Limited evidence
base for effects on
male reproductive
health but
suggestion that use
may be associated
with decreased
fertility
Salvia divinorum
• Not documented
MDMA and related substances*
Acute adverse effects associated with the use of MDMA and
related substances 
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Overheating/heat stroke
(hyperthermia)
• Major acute symptom of
MDMA-related toxicity that
can lead to death
• Associated with serotonin
syndrome, and
complications including
rhabdomyolysis, abnormal
blood clotting
(disseminated intravascular
coagulation), kidney failure
and liver failure
Swelling of the brain
(cerebral oedema)
• Caused by low sodium
levels (hyponatraemia)
secondary to water
intoxication
• Propensity for women to be
disproportionately affected
Acute intoxication
• Elevated blood pressure
and increased heart rate
(palpitations)
• Nausea, vomiting
• Fatigue, dizziness and/or
vertigo
• Overheating, dehydration
• Headache
• Dry mouth and throat
• Loss of appetite
• Difficulty with bodily
coordination, muscle aches
or tightness
• Agitation/aggression
• Convulsions
Personality/mood
• Anxiety, panic attacks
• Confusion
• Depressive symptomatology
• Insomnia
• Restlessness
• Fatigue
• Anorexia
• Paranoia
• Visual and auditory
hallucinations are rare –
tend to be associated with
high doses
• Suggestions that use may
have mild and transient
effects on cognition after
acute administration
• Individual or unpredictable
psychotic episodes may
occur
• Incorrect interpretation of
emotions and other social
cues
* 3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) and related analogues, including 
3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDEA),
methylbenzodioxolylbutanamine (MBDB), 3-methoxy-4,5-methylenedioxyamphetamine (MMDA), 
4-methylthioamphetamine (4-MTA).
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Other complications
• Fatal cases of liver damage
are rare
• A small number of case
reports have linked the use
of ecstasy with
cerebrovascular accidents
(eg stroke)
• A few fatalities have been
reported in the literature
associated with the use of
‘counterfeit ecstasy’
containing
paramethoxymethampheta
mine (PMMA) and/or
paramethoxyamphetamine
(PMA)
• Many MDMA-related
fatalities are attributable to
polysubstance use (multiple
drug toxicity)
Other complications
• May inhibit orgasm in 
men and women, 
and male erection
• Examples of acute liver
injury reported in the
literature – may be
secondary to hyperthermia
or caused by direct drug
toxicity
• Associated with risk taking
in general, and sexual risk
taking in particular
• Teeth grinding and
clenching (bruxism)/teeth
problems
4-Methylthioamphetamine
(4-MTA)
Personality/mood
• 4-Methylthioamphetamine
(4-MTA) has a greater
propensity to cause visual
hallucinations than MDMA
Chronic adverse effects associated with the use of MDMA and
related substances
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Dependence/
withdrawal/
tolerance
Mortality Morbidity
• Not documented,
limited evidence
base
Organic/
neurological
• Unclear whether
long-term use is
associated with
memory and
learning (cognitive)
impairment
• Growing evidence
that chronic, heavy
use is most strongly
associated with
subtle cognitive
effects
• Unclear whether
deficits reflect the
use of MDMA or
the combination of
MDMA and other
substances
Personality/mood
• Repeated use may
have long-lasting
effects on mood
and personality
characteristics, such
as depression and
anxiety, but
evidence is
inconsistent
Immune function
• Emerging evidence
that MDMA 
may have
immunosuppressive
properties – users
report increased
susceptibility to
minor ailments
including colds, flu
and sore throats
Other
complications
• Possible liver
damage
Dependence
• Evidence for a
dependence
syndrome is limited
• In cases of
dependence, the
psychological
aspects of
dependence appear
to predominate
Withdrawal
• Features of a
withdrawal
syndrome are not
clearly defined and
are mainly based on
user reports
Tolerance
• Tolerance potential,
but evidence is
based on self-report
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Dependence/
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Mortality Morbidity
Animal studies
• An excess of
serotonin in the
CNS (serotonergic
toxicity) has been
demonstrated in
experimental
animal studies 
of MDMA
• Inconsistent effects
in humans – may
result in increased
risk of depression or
other mental illness
later in life but the
equivalence is
uncertain
Nitrites*
Acute adverse effects associated with the use of nitrites
BMA Board of Science
Drugs of dependence: the role of medical professionals 243
Physical Psychological/psychiatric
Mortality Morbidity
Acute complications
• Death may be caused by a
lack of oxygen (hypoxia)
resulting in severe injury to
red blood cells and
reduction in the supply of
oxygen to vital organs
• Users may lose
consciousness and die
through choking on own
vomit
• ‘Sudden sniffing death
syndrome’ fatality caused
by abnormal heart rhythms
(cardiac arrhythmia)
• Some cases of death have
been reported from direct
oral consumption of nitrites
Acute intoxication
• Nausea
• Headache
• Loss of consciousness,
sedation, anaesthesia
• Loss of coordination
(ataxia), weakness (less
common)
Lifestyle factors
• Associated with high-risk
sexual practices
Cardiovascular
complications
• Profound hypotension 
(low blood pressure)
• Rebound tachycardia
• Flushed skin followed by
vasoconstriction
Other complications
• Rash around the nose and
mouth and contact
dermatitis
• Irritation of the nose 
and throat
• Increased ocular pressure,
blurred vision
Personality/mood
• Disorientation
• Distorted perceptions
• Delirium
* Amyl nitrite, butyl nitrite and isobutyl nitrite.
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Physical Psychological
/psychiatric
Dependence/
withdrawal/
tolerance
Mortality Morbidity
Carcinogenic
properties
• Use produces
nitrosamine which
is carcinogenic –
however it is still to
be determined
whether this is
formed in sufficient
quantities to make
the risk clinically
significant
Lifestyle factors
• Some evidence
that, by facilitating
unsafe sexual
practices, use
indirectly increases
susceptibility to
Kaposi’s sarcoma in
people who are HIV
positive
Immune function
• Limited evidence
that immunologic
function may be
suppressed – use of
nitrites has been
associated with
facilitating the
transmission of HIV
Chronic medical
problems
• Rash and irritation
around the nose,
mouth or other
exposed areas
• Sinusitis
Blood-related
(haematological)
complications
• Anaemia
• Difficulty circulating
oxygen through the
blood stream
(methaemoglobin-
aemia)
Organic/
neurological
There is some
evidence to suggest
impairment to:
• cognition
• movement
• vision
• hearing
Dependence
• No evidence for a
dependence
syndrome
Withdrawal
• No withdrawal
syndrome
documented
Tolerance
• Evidence to suggest
chronic, regular
users may develop
tolerance
Novel psychoactive substances*
Acute adverse effects associated with the use of novel
psychoactive substances
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Acute complications
• Substituted cathinones
(primarily mephedrone)
have been implicated in
deaths in England and
Scotland – however, with a
limited evidence base, the
exact role of cathinones in
causing or contributing to
death is still to be
determined
• One case of fatal overdose
has been reported in the
international literature
relating to the use of 2C
series phenethylamines
• One case of fatal overdose
has been reported in the
international literature
relating to the use of
tryptamine derivatives
Acute intoxication
• Few clinical data are
available for novel
psychoactive substances,
most data regarding
harms are self-reported
• Chest pain is a common
feature of acute
intoxication
Substituted cathinones and
piperazines
Acute intoxication
Consistent with
sympathomimetic toxicity:
• agitation
• palpitations
• seizure
• vomiting
• sweating
• headache
• reduced appetite
• severe vasoconstriction of
the extremities, leading to
bluing of the fingers or
hands (cathinone users)
Substituted cathinones and
piperazines
Personality/mood
Consistent with
sympathomimetic toxicity:
• mood swings
• anxiety
• strange thoughts
• irritability, confusion
Substituted cathinones
Organic/neurological
• High doses may be
associated with
hallucinations and
psychosis
2C series phenethylamines
Organic/neurological
• One case of acute
intoxication associated
with psychosis has been
reported in the
international literature
Tryptamine derivatives
Organic/neurological
• Hallucinations
`
* Substituted cathinones, piperazines, 2C series phenethylamines and tryptamine derivatives.
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2C series phenethylamines
Neurological
complications
• One case of damage to
the blood vessels in the
brain associated with
persistent neurologic
deficits has been reported
in the international
literature
Tryptamine derivatives
• Not documented, limited
evidence base
Chronic adverse effects associated with the use of novel
psychoactive substances
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Dependence/
withdrawal/
tolerance
Mortality Morbidity
• Not documented • Not documented • Not documented Substituted
cathinones and
piperazines
Dependence
• Suggestion that
they are similar to
amphetamine in
terms of abuse and
dependence
potential
Tolerance
• Some evidence to
suggest that
substituted
cathinone users
may develop
tolerance quickly
Opioid drugs*
Acute adverse effects associated with the use of illicit opioids
and abuse of prescription opioids
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Overdose
• Respiratory depression and
drop in blood pressure
resulting in respiratory
arrest
• Illicit opioid use is
associated with the majority
of illicit drug-related deaths
in the UK, primarily from
overdose
Common correlates of
overdose fatality
• Long history of opioid
dependence
• High level of opioid
dependence
• Recent abstinence (eg
prison, detoxification
release)
• Polydrug use (particularly
with alcohol and
benzodiazepines)
• Being male
• Increasing age (most
fatalities occur among
those in their 30s)
• Social isolation
• Neurocognitive deficits
Common features of acute
intoxication
• Nausea, vomiting
• Depressed nervous system
activity
• Constipation
• Drowsiness, decreased
consciousness
• Sedation, mental confusion
Infrequent features of
acute intoxication
• Sweating
• Facial flushing
• Itching (pruritus)
• Dry mouth
• Hallucinations
• Dysphoria
• Difficulty in passing urine
(urinary retention)
Rare features of acute
intoxication
• Complications associated
with non-fatal overdose 
eg hypoxia causing brain
damage
• No acute psychological
adverse effects
• Cause little psychomotor or
cognitive impairment in
tolerant users
* Including illicit (ie heroin) and prescription (eg methadone, buprenorphine, tramadol, dihydrocodeine and
oxycodone) opioids.
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•While drug treatment
generally provides a
protective effect, there is a
significantly enhanced risk in
the first 2 weeks of
methadone treatment,
following detoxification
treatment and on cessation
of naltrexone treatment
• Recent abstinence on
release from prison
• Disease of the white 
matter of the brain
(leukoencephalopathy)
resulting from inhalation of
heroin vapours, which does
not seem to occur with
injection; there are sporadic
reports of cases in the
literature
Prescription drugs
Serotonin syndrome
• A few cases of tramadol use
associated with serotonin
syndrome, a potentially life
threatening condition, have
been reported in the
literature
Chronic adverse effects associated with the use of illicit opioids
and abuse of prescription opioids
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withdrawal/
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Mortality Morbidity
Overdose
• Increased mortality
risk from overdose
and route-specific
hazards
Suicide
• Suicide rate higher
than in the general
population;
associated with
situational, health
and lifestyle factors
Chronic
complications
• Non-injected
opioids carry little
risk of chronic
adverse health
effects
• Chronic
constipation
• Dry mouth
• Menstrual
irregularity
• Malnutrition,
anorexia; associated
with situational,
health and lifestyle
factors
• Tooth decay
• Decreased sexual
desire and
performance
Respiratory
complications
• Respiratory diseases
(asthma, chronic
obstructive
pulmonary disease)
Personality/mood
• Depressive disorder
is common among
those who are
dependent on
opioid drugs but it
is difficult to
attribute causality
• Instability of mood
• Lethargy
• Opioid drugs are
not causally linked
to chronic
psychiatric disorder
Dependence
• Characterised by
profound
psychological and
physical
dependence
• Develops after
repeated
administration over
a period of time,
which varies
according to the
quantity, frequency
and route of
administration –
factors of individual
vulnerability and
the context of drug
use also play a role
Withdrawal
• Rarely life
threatening
• Dependent on
opioid used, dose,
route of
administration, the
interval between
doses, duration of
use, and users’
physical and
psychological
health
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Hormones and
immune function
• Modest suppression
of hormone levels
• Suppression of
immune system;
social deprivation
and malnutrition
may also be factors
Complications in
pregnancy
• Intra-uterine
growth of the fetus
may be inhibited
• Neonates exposed
to illicit opioid
drugs may have
low birth weight
compared to non-
exposed children,
be born
prematurely, and
experience
respiratory
depression and
withdrawal
symptoms – these
symptoms may
contribute to the
increased risk of
perinatal mortality
associated with use
of illicit opioid
drugs in pregnancy
• Symptoms include
watery eyes, nasal
discharge, yawning,
sweating, sleep
disturbance, dilated
pupils, anorexia,
gooseflesh,
restlessness,
irritability, tremor,
sneezing,
weakness,
depression, nausea,
vomiting,
abdominal cramps,
muscle spasms and
diarrhoea
Tolerance
• Characterised by
shortened duration
and decreased
intensity of the
drug’s depressant
effects; there is
marked elevation in
the average lethal
dose
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• Evidence for a
direct effect of illicit
opioids is
confounded by
other situational,
health and lifestyle
factors (eg use of
other drugs,
mother’s nutritional
status, lifestyle,
infections and
exposure to
trauma) that may
be at least as
decisive for the
outcome of the
pregnancy
• Suggestion that a
deprived social
environment may
also contribute to
problems with
neurological
development
Serotonergic hallucinogens*
Acute adverse effects associated with the use of 
serotonergic hallucinogens
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Acute complications
• Risk of injury and accidental
death owing to perceptual
distortions and impaired
decision making
LSD
Acute complications
• One case of fatal overdose
has been reported in the
literature; associated with a
high dose of LSD
Psilocybin
Acute complications
• Fatal poisoning owing to
mistaken identity of
mushrooms
Violence and injuries
• Self-harm, accidents or
violence while intoxicated
LSD
Common effects
• Adrenergic ‘fight or flight’
effects
• Tachycardia
• Flushing
• Dry mouth
• Sweating
• Exhaustion, tiredness,
weakness
Rare effects
• Ataxia
• Convulsions
• Hyperpyrexia
Psilocybin
Acute intoxication
• Nausea, vomiting, stomach
pains – commonly owing to
mistaken identity of
mushrooms
• Dizziness
DMT
Acute intoxication
• Nausea and vomiting
Personality/mood
• Dysphoria
• Unpleasant distortions in
shapes and colours
• Frightening illusions,
delusions; ‘true
hallucinations’ in psychiatric
terms (ie indicative of
psychiatric morbidity) are
very rare
• Anxiety, panic, depression
• Dizziness, disorientation
• Impaired concentration
• Frequent mood changes
(emotional lability)
• Recall of psychologically
troubling memories
• Depersonalisation and
derealisation at high doses
• Short-lived psychotic
episode (hallucinations,
paranoia)
• Precipitates relapses in
schizophrenia
* Lysergic acid diethylamide (LSD), psilocybin, mescaline and N,N-dimethyltryptamine (DMT).
Chronic adverse effects associated with the use of 
serotonergic hallucinogens
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• Limited evidence
base
• No known physical
dangers associated
with long-term LSD
use
Personality/mooda
• Persistence of low-
level hallucinations,
known as
hallucinogen
persisting
perception disorder
– rare
• Brief flashbacks or
recollection of
previous
hallucinatory
experience may
occur days or
months after use
• Depression
• Feelings of isolation
• Delirium
Psychosis
• It is uncertain
whether this is a
drug-induced
condition or
unmasking of a
latent mental illness
Dependence
• Evidence suggests
that few users of
hallucinogens
experience signs or
symptoms of
dependence
Withdrawal
• A withdrawal
syndrome has not
been identified
Tolerance
• Tolerance develops
rapidly to
behavioural effects,
and sensitivity
returns after a
comparable drug-
free interval;
tolerance to
cardiovascular
effects is less
pronounced
• Cross-tolerance
between
serotonergic
hallucinogens
a Post-exposure.
Appendix 4: UK illicit drug
usage data 
Percentage of 16 to 59 year olds reporting lifetime, last year
and last month use of individual drugs in England and Wales,
2009/2010, by sex
Lifetime use Last year use Last month use
Men Women Total Men Women Total Men Women Total
Any drug 42.8 29.9 36.4 11.9 5.4 8.6 7.3 2.6 5.0
Amphetamines 14.6 8.7 11.7 1.4 0.6 1.0 0.5 0.2 0.3
Cannabis 36.7 24.5 30.6 9.3 4.0 6.6 5.7 2.0 3.9
Cocaine 11.5 6.0 8.8 3.6 1.5 2.5 1.7 0.6 1.1
Ecstasy 11.4 5.2 8.3 2.4 0.8 1.6 1.0 0.3 0.6
LSD 7.5 3.1 5.3 0.3 0.1 0.2 0.1 0.0 0.1
Magic mushrooms 10.7 4.1 7.4 0.6 0.2 0.4 0.1 0.0 0.1
Opioid drugs 1.2 0.5 0.9 0.2 0.1 0.2 0.2 0.0 0.1
Source: Home Office (2010) Drug misuse declared: findings from the 2009/10 British Crime Survey. England and
Wales. London: Home Office.
Percentage of 16 to 64 year olds reporting lifetime, last year
and last month use of individual drugs in Scotland, 2008/2009,
by sex
Lifetime use Last year use Last month use
Men Women Total Men Women Total Men Women Total
Any drug 37.2 25.6 31.3 13.4 5.5 9.4 8.0 3.0 5.5
Amphetamines 12.2 6.6 9.3 1.8 0.7 1.3 0.6 0.3 0.4
Cannabis 34.3 22.6 28.4 11.2 4.3 7.7 6.5 2.2 4.4
Cocaine 11.8 5.1 8.4 5.5 1.5 3.5 2.6 0.6 1.6
Ecstasy 12.1 6.0 9.0 3.6 1.0 2.3 1.5 0.4 0.9
LSD 9.2 3.0 6.1 0.8 0.1 0.5 0.3 0.0 0.2
Magic mushrooms 10.4 3.4 6.8 0.7 0.1 0.4 0.4 0.0 0.2
Opioid drugs 1.7 0.9 1.3 0.6 0.2 0.4 0.4 0.2 0.3
Source: The Scottish Government (2010) 2008-09 Scottish Crime and Justice Survey: drug use. Edinburgh: The
Scottish Government.
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Percentage of 16 to 64 year olds reporting lifetime, last year
and last month use of individual drugs in Northern Ireland,
2008/2009, by sex
Lifetime use Last year use Last month use
Men Women Total Men Women Total Men Women Total
Any drug 32.0 21.3 26.3 8.3 4.5 6.2 4.9 2.5 3.6
Amphetamines 8.8 5.6 7.1 0.4 0.7 0.5 0.1 0.1. 0.1
Cannabis 23.7 15.6 19.4 6.5 2.9 4.6 3.9 1.4 2.6
Cocaine 5.9 3.2 4.5 1.4 0.6 1.0 0.7 0.4 0.5
Ecstasy 9.1 5.9 7.4 1.0 1.0 1.0 0.6 0.4 0.5
LSD 5.5 3.0 4.2 0.4 0.4 0.4 0.2 0.1 0.2
Magic mushrooms 7.0 2.8 4.8 0.2 0.1 0.2 0.1 0.1 0.1
Opioid drugs 1.1 0.9 1.0 0.2 0.0 0.1 0.2 0.0 0.1
Source: Department of Justice (2010) Experience of drug misuse: findings from the 2008/09 Northern Ireland
Crime Survey. Belfast: Department of Justice.
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Illicit drugs Sucrose
Lactose
Dextrose
Mannitol
Sugars To dilute/add bulk
Legally and readily
available
Inactive adulterants Minimal risk of
adverse health
effects. Can cause
nasal irritation
Lead Soft, malleable metal Heroin
Potentially a by-
product of the use of
lead pots in illicit
drug manufacture
Methamphetamine
Sometimes used in
methamphetamine
manufacture. Poor
manufacturing can
result in lead residue
in drug product
In low dosages lead
poisoning can have
mild effects.
Injecting of illicit
drugs adulterated
with lead causes
severe adverse health
effects
• Abdominal pain
and cramping
• Headaches
• Anaemia
• Dizziness
• Nausea/vomiting
• Muscle weakness
• Seizures
• Coma
• Renal injury
• CNS damage
Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Caffeine Psychoactive
stimulant drug
Caffeine is legal,
cheap and more
readily available than
illicit drugs
Heroin
Vaporizes heroin at
lower temperature
when smoked –
slightly increases
efficiency
Cocaine/
amphetamine/
methamphetamine/
ecstasy
Stimulant properties
of caffeine can create
similar, although
usually milder, effects
to the primary drug
In small doses there
are few serious
health repercussions
Moderate to large
doses can cause
considerable harms
• Mood disturbances
• Induces anxiety
• Addictive
• Sleep disturbance
• Increases risk of a
range of health
problems
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Procaine Local anaesthetic Heroin
Facilitates smoking of
heroin and may
relieve the pain of
intravenous injection
due to anaesthetic
properties
Cocaine
Similar anaesthetic
and subjective effects
as cocaine
Risk of toxicity at
high doses
• CNS problems
• Nausea
• Vomiting
• Dizziness
• Tremors
• Convulsions
• Anxiety
Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Paracetamol/
acetaminophen
Over-the-counter
pain-relief
medication
Easily available,
relatively cheap
Heroin
Analgesic effects and
bitter taste of
paracetamol may
disguise poor-quality
heroin
May be used
because it has similar
melting point to
heroin
Low dosages should
have minimal impact
Risk of toxicity at
high doses
• Liver damage
• Gastrointestinal
effects
• Adverse effects
when mixed with
alcohol
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Strychnine Pesticide A fine motor
stimulant. Low doses
act as a muscle
stimulant
Heroin
Enhances retention
of heroin when
volatised. Has only
been found at non-
life threatening
quantities
Cocaine
Reason for inclusion
unknown. May have
been unintentional
While it has only
been reported in
non-life threatening
quantities, small
increases could
potentially be fatal
• Muscle spasm
• Opisthotonos
(holding of body in
awkward rigid
position)
Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Heroin Phenobarbital Barbiturate Psychoactive drug
that facilitates
smoking of heroin
Risk of overdose in
intravenous drug
users who are
hypersensitive
• Overdose
• Death
Quinine Antimalarial
medication
Bitter taste similar to
heroin and may be
used as a diluent
Also mimics the
respiratory ‘rush’ felt
by injecting heroin
users shortly after
administration
Can cause overdose
and a host of other
adverse health
reactions
• Acute renal failure
• Cinchonism
• Gastric
disturbances
• Thrombosis and
hypotension
(intravenous use)
• CNS
overstimulation
• Visual disturbances
(blindness)
• Death
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Clenbuterol Asthma
decongestant and
bronchodilator drug
Reason for inclusion
unknown but may
have been
unintentional
contamination
Can cause overdose
and poisoning at
moderate to high
dosages
Low doses typically
cause adverse
cardiovascular effects
• Cardiovascular
effects
• Neuromuscular
syndrome
• Mydriasis (excessive
pupil dilation)
• Agitation
Scopolamine Anticholinergic
alkaloid
Colourless, odourless
and tasteless and
therefore not easily
detectable
Low doses cause
sleepiness and
drowsiness
High doses can cause
euphoria
• Anticholinergic
toxicity
• CNS depressant
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Diazepam A benzodiazepine
derivative drug used
to treat anxiety
disorders, muscle
spasms, and alcohol
withdrawal
To enhance the
euphoric effects of
heroin by increasing
its depressant effects
on the CNS
Can cause overdose
– increased risk of
coma, respiratory
depression and death
associated with use
in combination with
CNS depressants
Risk of injury arising
from sedative
properties
• Low rates of
mortality but
implicated in a
significant
proportion of
opioid overdose
• Mood disturbances
• Dependence
syndrome and
withdrawal
symptoms (eg
convulsions,
dysphoria, anxiety,
tremors, nausea
and vomiting)
Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Cocaine Lidocaine Local anaesthetic Similar, but stronger,
anaesthetic effects
than cocaine and
gives the impression
of higher-quality
cocaine
Adverse
cardiovascular and
CNS reactions can
occur at low doses
Overdose can occur
at excessive doses; it
increases the toxicity
of cocaine
• CNS problems
• Nausea
• Vomiting
• Dizziness
• Tremors
• Convulsions
Hydroxyzine Sedative, anxiolytic,
used as an
antihistamine
Unknown, but
potentially used in
the final processing
stages of cocaine
manufacture
Use in combination
with sedative drugs
can cause
unconsciousness
Rare cases of
overdose resulting in
CNS problems
• Dizziness
• Drowsiness
• Gastrointestinal
effects
• Tinnitus
• Headaches
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Phenacetin Analgesic substance Pain-relieving
properties and similar
physical properties to
cocaine
Phenacetin is banned
in many countries
due to links with
renal failure and
suspected
carcinogenicity
• Analgesic
nephropathy
• Haemolytic
anaemia
• Methaemoglobin-
aemia
• Kidney cancer
• Bladder cancer
Levamisole An anthelmintic
medication (used for
expelling parasitic
worms)
Unknown; however,
it is theorised that it
gives a more intense
‘high’
Generally no longer
used with humans,
but still available as a
veterinary medicine
Highly toxic
• Fever
• Agranulocytosis
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Methamphetamine Methylsulfonyl-
methane (MSM)
Naturally occurring in
some foods and also
marketed as a dietary
supplement
MSM is readily
available and is
physically similar to
methamphetamine
(odourless, white,
crystalline powder)
Methamphetamine
adulterated with
MSM creates the
impression of 
high-purity
methamphetamine
None identified None identified
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Ecstasy Dextromethorphan Antitussive drug
(cough suppressant)
A high dose can
cause an individual
to feel ‘high’ in a
similar way to ecstasy
Dextromethorphan is
legal and therefore
cheaper and easier to
obtain than MDMA
High doses can cause
adverse health
effects
• Lethargy
• Tachycardia
• Ataxia
• Nystagmus
• Heatstroke
Amphetamine/
methamphetamine
Illicit stimulant drugs Amphetamines have
similar properties to
the stimulant effects
of ecstasy, although
these adulterants are
not entactogens
Amphetamine
substances are often
sold as, or in
combination with,
MDMA
Moderate doses can
cause a range of
adverse health
effects and high
doses can cause
overdose and death
• Mood disturbance
• Induce anxiety
• Addictive
• Sleep disturbance
• Increases risk of a
range of health
problems
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Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Paramethoxymetham
phetamine (PMMA)
and paramethoxyam-
phetamine (PMA)
Illegal psychoactive
chemical
Purposefully added
to ecstasy due to
stimulant properties
Relatively unknown,
but high dosages
have caused death
Cannabis Lead Soft, malleable metal To increase weight Lead poisoning • Abdominal cramps
• Anaemia
• Nausea
• Fatigue
• Polyneuropathy
• Toxic effects
• Seizures
• Coma
• Death
Aluminium Soft, malleable metal Unknown, but
aluminium
contamination may
have resulted from
impure water supply
Contribute to
smoking-related
diseases
Smoking-related
adverse health
effects
BM
A
 Board of Science
D
rugs of dependence:the role of m
edical professionals
270
Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Drug Adulterant(s) Licit use Potential reason
for presence as
adulterant
Public health risks Health
consequences
Glass Unknown, but
p tentially to
improve apparent
quality and increase
weight
Inhalation of hot
glass fumes
• Sore mouth
• Mouth ulcer
• Chesty persistent
cough
• Tight chest
Source: Cole C, Jones L, McVeigh J et al (2010) CUT: a guide to adulterants, bulking agents and other contaminants found in illicit drugs. Liverpool:
Centre for Public Health, Liverpool John Moores University; and Jones L, Bates G, Bellis M et al (2011) A summary of the health harms of drugs.
London: Department of Health.
Appendix 6: UK government
strategies for reducing illicit
drug use 
England
In England, the 2010 Home Office drug strategy, Reducing demand, restricting supply,
building recovery: supporting people to live a drug-free life,a sets out two overarching
aims: to reduce illicit and other harmful drug use, and increase the numbers recovering
from their dependence. This includes action in the following three areas:
1. reducing demand: creating an environment to discourage people from starting to
take drugs and making it easier for those that do to stop, through measures that
will:
• break intergenerational paths to dependency by supporting vulnerable families
• provide good-quality education and advice so that young people and their
parents are provided with credible information to actively resist substance use
• use the creation of Public Health England (PHE) to encourage individuals to take
responsibility for their own health
• intervene early with young people and young adults
• consistently enforce effective criminal sanctions to deter drug use
• support people to recover
2. restricting supply: making the UK an unattractive destination for drug traffickers,
through a coordinated response across Government and law enforcement to make
the country a more challenging environment for organised crime. This includes the
cross-Government organised crime strategy, Local to global: reducing the risk from
organised crime, published in July 2011b
3. building recovery in communities: the Government will work with people who
want to take the necessary steps to tackle their dependency by creating a recovery
system that focuses not only on getting people into treatment and meeting
process-driven targets, but getting them into full recovery and off drugs for good.a
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a Her Majesty’s Government (2010) Drug strategy 2010: reducing demand, restricting supply, building recovery: supporting
people to live a drug free life. London: Her Majesty’s Government.
b Her Majesty’s Government (2011) Local to global: reducing the risk from organised crime. London: Her Majesty’s Government. 
Wales
The Welsh Assembly Government’s substance misuse strategy for 2008-2018, Working
together to reduce harm,c sets out action in the following areas:
1. preventing harm: through the provision of information about the damage that
substance use can cause to health, families and the wider community, and where
to seek help and support. This includes raising awareness among parents and
carers, and targeting young people
2. support for substance users to improve their health and aid and maintain
recovery: the provision of support for substance users, through improved access
to basic harm minimisation, outreach, treatment and social services
3. supporting and protecting families: engaging substance-using parents in
effective treatment programmes, developing a multiagency approach to identifying
and supporting vulnerable families, and supporting greater use of family
intervention projects and the role of carers
4. tackling availability and protecting individuals and communities via
enforcement activity: focusing on tackling the supply of drugs to children and
young people, through improved local intelligence gathering in communities and
stronger links between drug enforcement activities at a local and regional level.c
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c Welsh Assembly Government (2008) Working together to reduce harm. The substance misuse strategy for Wales 2008-
2018. Cardiff: Welsh Assembly Government.
Scotland
The 2008 Scottish Government strategy, The road to recovery: a new approach to
tackling Scotland’s drug problem,d set out the following priorities:
1. better prevention of drug problems, with improved life chances for children and
young people, especially those at particular risk of developing a drug problem
2. to see more people recover from problem drug use so that they can live longer,
healthier lives, realising their potential and making a positive contribution to society
and the economy
3. having communities that are safer and stronger places to live and work because
crime, disorder and danger related to drug use have been reduced
4. ensuring that children affected by a parental drug problem are safer and more able
to achieve their potential
5. supporting families affected by drug use
6. improving the effectiveness of delivery at a national and local level.
BMA Board of Science
Drugs of dependence: the role of medical professionals 273
d Scottish Government (2008) The road to recovery: a new approach to tackling Scotland’s drug problem. Edinburgh: 
Scottish Government.
Northern Ireland
In 2006, the Department of Health, Social Services and Public Safety published the 
New strategic direction for drugs and alcohol 2006-2011,e which set out the following
overarching long-term aims to:
1. provide accessible and effective treatment and support for people who are
consuming alcohol and/or using drugs in a potentially hazardous, harmful or
dependent way
2. reduce the level, breadth and depth of alcohol- and drug-related harm to users,
their families and/or their carers and the wider community
3. increase awareness on all aspects of alcohol- and drug-related harm in all settings
and for all age groups
4. integrate those policies that contribute to the reduction of alcohol- and drug-
related harm into all Government department strategies
5. develop a competent skilled workforce across all sectors that can respond to the
complexities of alcohol and drug use and misuse
6. promote opportunities for those under the age of 18 years to develop appropriate
skills, attitudes and behaviours to enable them to resist societal pressures to drink
alcohol and/or use illicit drugs, with a particular emphasis on those identified as
potentially vulnerable
7. reduce the availability of illicit drugs in Northern Ireland.
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Belfast: Department of Health, Social Services and Public Safety.
Appendix 7: Societal
measures to restrict 
drug influences
A range of measures exist for ensuring inappropriate popular media, including those
that make reference to drug use, are less accessible by young people. The efficacy of
these measures is currently unknown.
Film
The British Board of Film Classification (BBFC) is responsible for classifying film works in
relation to their content, with a particular emphasis on protecting children from harm.
In relation to drugs, the 2009 BBFC guidance sets out that no film taken as a whole
may promote the use of illicit drug use, and any detailed portrayal of drug use likely to
promote or glamorise the drug use may be cut.a Any film that shows drug use while
emphasising the dangers may receive less restrictive classifications, in comparison to
films presenting drug use in a more neutral manner (see table on page 276).a
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Film/video game
classification
U: 
Universal
PG: 
Parental 
guidance
12A/12
15
18
R18
Description Guidance in classifying
film/video game
Suitable for all No reference to illegal drugs or
drug use unless they are
infrequent and innocuous, or
there is a clear educational
purpose or antidrug message
suitable for young children
General viewing, but some
scenes may be unsuitable for
young children
Suitable for 12 years and over.
The 12A category only exists for
cinema films, where children
under 12 must be accompanied
by an adult to enter. Films
classified as 12A are not
recommended for children
under 12
Any use of drugs must be
infrequent and should not be
glamorised or give instructional
detail
Reference to illegal drugs or drug
use must be innocuous or carry a
suitable antidrug message
Suitable only for 15 years 
and over
Drugs may be shown but the
film as a whole must not
promote or encourage drug use.
The misuse of easily accessible
and highly dangerous
substances (for example,
aerosols and solvents) is unlikely
to be acceptable
Suitable only for adults No specific guidance on drugs
To be shown only in specially
licensed cinemas, or supplied
only in licensed sex shops, and
to adults of not less than 18
years
No specific guidance on drugs
Source: British Board of Film Classification (2009) The guidelines. London: British Board of Film Classification.
In addition to adhering to film classifications, policy makers may also wish to consider
requiring all films portraying drug use to be preceded by a warning message advising
on drug-related harms. This is because evidence suggests that warning messages
displayed ahead of films portraying pro-smoking imagery may mitigate some of the
effects these images have in terms of encouraging uptake of smoking.b It is not
unreasonable to assume similar beneficial effects may be seen with the portrayal of
drug use.
Given that evidence suggests film images can influence drug behaviour, film producers
should consider the impact that depicting drug use may have on individuals.c-e Any such
inclusions should only be used when editorially justified. To aid in this process, policy
makers may wish to consider informing those involved in the production of film of the
potential damage done by the depiction of drug use in film.
Television
Governance of television is relatively strong. On television, the watershed operates to
protect young people from materials that may be unsuitable for them, which may
include drug use. The watershed begins at 9pm on standard television and runs until
5.30am. The most recent guidance from Ofcom on the UK television watershed, states
that material unsuitable for children should not be shown before or after this time
period.f As well as these restrictions, Ofcom encourages programme makers to consider
the potential harm that displaying the use of illegal drugs to younger viewers may have,
and that any inclusion of drug use pre-watershed, or at times when children are
particularly likely to be viewing, must be editorially justified.f
Music
Similar to classification ratings used by the BBFC in film, the Recording Industry
Association of America uses parental advisory warning messages to inform consumers
that a recording contains explicit material that is not suitable for children. Many retailers
in America limit the sale of such albums to adults only. While similar warnings are
commonly used in the retail of UK music, sale restrictions do not apply. Policy makers
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b Edwards CA, Harris WC, Cook DR et al (2004) Out of the smokescreen: does an anti-smoking advertisement affect young
women’s perception of smoking in movies and their intention to smoke? Tobacco Control 13: 277-82.
c Hunt K, Sweeting H, Sargent J et al (2011) Is there an association between seeing incidents of alcohol or drug use in films
and young Scottish adults’ own alcohol or drug use? A cross sectional study. BMC Public Health 11: 259.
d Stern SR (2005) Messages from teens on the big screen: smoking, drinking, and drug use in teen-centered films. 
Journal of Health Communication 10: 331-46.
e Gunasekera H, Chapman S & Campbell S (2005) Sex and drugs in popular movies: an analysis of the top 200 films. 
Journal of the Royal Society of Medicine 98: 464-70
f Ofcom (2009) Guidance notes section one: protecting the under 18s. London: Ofcom.
may wish to consider the classification of music, in restricting the influence of drug-
promoting references to young people. Given that a large proportion of music sales
now take place online, where assessments of age is not easily verifiable, policy makers
should also consider the difficulties in enforcing controls in this market. Taking action to
inform major artists and musicians of the potential harm of depicting drug use in music
should also be considered by policy makers.
Celebrity
Available evidence suggests celebrities can have both a role in reducing drug use, and
also a conflicting role in increasing drug use.g Informing and educating celebrities, as
well as encouraging them to act as spokespeople for drug-related harm, may be an
interesting area for policy makers to consider.
Video games
The BBFC is also responsible for classifying video games in relation to their content. 
As with film, any video game glamorising drug use is likely to receive a more restrictive
classification, in comparison to a game emphasing the danger, or presenting drug use in
a more neutral manner.h
The efficacy of video game classifications may not go far enough. Research has
demonstrated that parents are less likely to supervise video games, compared to other
forms of media, suggesting there is potential for young people to ignore classifications.i
It may be necessary to supplant video games that have drug references with advisory
messages informing about the harms of drug use.
Internet
Content-control software is a form of software designed for controlling what content
is permitted to a user on the internet. The restrictions on which web pages can be
accessed can be applied at various levels. While research has not investigated the
impact of these forms of software on reducing illicit drug use, they may represent useful
tools in restricting exposure of drug influences to young people. Further research in this
area is needed.
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g Brown WJ & de Matviuk MAC (2010) Sports celebrities and public health: Diego Maradona’s influence on drug use
prevention. Journal of Health Communication 15: 358-73.
h British Board of Film Classification (2009) The guidelines. London: British Board of Film Classification.
i Haninger K & Thompson KM (2004) Content and ratings of teen-rated video games. The Journal of the American Medical
Association 291: 856-65.
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